NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS

Title: NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS

Abstract: The present invention relates novel 6-6 bicyclic aromatic ring substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(a))

Published:

— with international search report (Art. 21(3))
Field of the Invention

The present invention relates to novel 6-6 bicyclic aromatic ring substituted nucleoside analogues useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Background of the invention


PRMT5 is a member of the type II PRMT subfamily that utilises S-adenosylmethionine (SAM) to generate symmetric dimethylated arginine on histones and non-histone protein substrates and S-adenosylhomocysteine (SAH). The crystal structure of the human heter-octameric complex (PRMT5)₄(MEP50)₄ co-crystallised with SAH and a histone H4 peptide substrate illustrated the mechanism of methylation and substrate recognition [Antonymsamy, S. et al, Proc Natl Acad Sci U S A, 2012. 109(44): p. 17960-5]. The regulation of PRMT5 activity occurs through a vast number of different
binding partners, post-translational modification cross talk, miRNAs and subcellular localisation.


Non-histone methylation can occur either in the cytoplasm or nucleus dependent on the cellular localisation of PRMT5. The methylation of the Sm proteins D1 and D3, which are required for the assembly of the nuclear splicesome, takes place in the cytoplasm as part of the PRMT5 containing "methylosome" [Friesen, W.J. et al., Mol Cell Biol, 2001. 21(24): p. 8289-300]. Further evidence for PRMT5 involved in splicing has been provided by the conditional PRMT5 knockout in mouse neural stem cells. Cells that lack PRMT5 showed a selective retention of introns and skipping of exons with weak 5' donor sites [Bezzi, M. et al, Genes Dev, 2013. 27(17): p. 1903-16].


Since PRMT5 is one of the major sym-Arg methyltransferases and involved in a multitude of cellular processes, an increased protein expression appears to be an important factor in its tumourigenicity. Interestingly, the translation of PRMT5 in mantle cell lymphoma (MCL) seems to be regulated by miRNAs. Although MCL cells show less mRNA and a slower transcription rate of PRMT5 than normal B lymphocytes, the PRMT5 level and the methylation of H3R8 and H4R3 are significantly increased [Pal, S. et al, EMBO J, 2007. 26(15): p. 3558-69]. Re-expression of miRNAs that binds the 3'UTR region of PRMT5 decreases PRMT5 protein level [Wang, L. et al, Mol Cell Biol, 2008. 28(20): p. 6262-77]. Strikingly, a prmt5 antisense RNA has been found within the human prmt5 gene that supports the hypothesis of a specific translational regulation rather than high mRNA expression level [Stopa, N. et al, Cell Mol Life Sci, 2015. 72(11): p. 2041-59].
Although PRMT5 is considered as a clinical relevant target, very few selective PRMT5 inhibitors have been published, yet. Very recently, a novel sub-nanomolar potent PRMT5 inhibitor (EPZO15666) with anti-tumour activity in multiple MCL xenograft models has been described to be the first chemical probe suitable for further validation of PRMT5's biology and role in cancer [Chan-Penebre, E. et al, Nat Chem Biol, 2015. 11(6): p. 432-7].

Further development of specific small molecule inhibitors of PRMT5 may lead to novel chemotherapeutic approaches for cancer.

WO20 14 100695 A discloses compounds useful for inhibiting PRMT5 activity;

Methods of using the compounds for treating PRMT5-mediated disorders are also described.

WO2014100730A discloses PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof.

Devkota, K. et al., ACS Med Chem Lett, 2014. 5: p. 293-297, describes the synthesis of a series of analogues of the natural product sinefungin and the ability of these analogues to inhibit EHMT1 and EHMT2.

WO2003070739 discloses partial and full agonists of A1 adenosine receptors, their preparation, and their therapeutic use.

WO2012082436 discloses compounds and compositions as modulators of histone methyltransferases, and for treating diseases influenced by modulation of histone methyltransferase activity.

WO20 14 1007 19 discloses PRMT5 inhibitors and uses thereof.

WO2014074083 discloses combination therapies that selectively kill methylthioadenosine phosphorylase deficient cells. Analogos of MTA are described herein as anti-toxicity agents.


WO20 12075500 discloses 7-deazapurine modulators of histone methyltransferase.

WO20 14035 140 discloses compounds and compositions for modulating histone methyltransferase activity.

WQ20 15200680 describes PRMT5 inhibitors and uses thereof.

There is thus a strong need for novel PRMT5 inhibitors thereby opening new avenues for the treatment or prevention of cancer, such as e.g. mantle cell lymphoma. It is accordingly an object of the present invention to provide such compounds.
The compounds of the present invention are structurally different and may have improved properties such as for example improved potency, or improved pharmacokinetics (PK) and oral bioavailability, compared with compounds disclosed in the prior art.

Summary of the invention

It has been found that the compounds of the present invention are useful as PRMT5 inhibitors. The compounds according to the invention and compositions thereof, may be useful for the treatment or prevention, in particular for the treatment, of diseases such as a blood disorder, metabolic disorders, autoimmune disorders, cancer, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection, lung injuries, and the like.

The present invention concerns novel compounds of Formula (I):

![Chemical structure](image)

wherein

R\(^1\) represents hydrogen or -C(=0)-Ci\(_4\)alkyl;
R\(^2\) represents hydrogen or -C(=0)-Ci\(_4\)alkyl;
Y represents -O-, -CH\(_2\)- or -CF\(_2\)-;
Z represents -CH\(_2\)-, -X-CR\(^a\)=CR\(^d\)-, -CR\(^c\)=CR\(^d\)-, -CR\(^c\)=CR\(^d\)-CR\(^c\)=CR\(^d\)-, or -C≡C-;
and when Y represents -CH\(_2\)- or -CF\(_2\)-, then Z can also represent -O- or -CR\(^a\)-CR\(^b\)-X-;
R\(^a\), R\(^b\), R\(^c\), R\(^d\), R\(^e\), R\(^f\), and R\(^g\) each independently represent hydrogen or Ci\(_4\)alkyl;
X represents -O-, -S-, or -NR\(^1\)-;
R\(^1\) represents hydrogen, Ci\(_4\)alkyl, or Ci\(_4\)alkyl substituted with one substituent selected from the group consisting of -OH, -OCi\(_4\)alkyl, R\(^2\), -NH\(_2\), -NH-Ci\(_4\)alkyl, and -N(C\(_1\)=alkyl)\(_2\);
R\(^2\) represents a 4-, 5-, 6- or 7-membered heterocyclic ring containing one nitrogen atom and optionally one oxygen atom; said 4-, 5-, 6- or 7-membered heterocyclic ring being attached to the remainder of the molecule via a ring nitrogen atom;
Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;

Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, -OH, -NH₂, -NH-Cᵦ₋₄alkyl, -N(C₁₋₄alkyl)₂, -NHR¹⁰d, -NR¹⁰d⁻¹⁰d, cyano, -CF₃, -C(=0)-NH₂, -C(=0)-NH-C₁₋₄alkyl, -C(=O)-C₁₋₄alkyl, Ci₄alkyloxy, -C(=0)-0-Ci₄alkyl, C₃₋₆cycloalkyl, -0-C₃₋₆cycloalkyl, -NH-C₃₋₆cycloalkyl, -N(C₃₋₆cycloalkyl)₂, C₂₋₆alkenyl, Ci₄alkyl substituted with one Ci₄alkyloxy, and Ci₄alkyl optionally substituted with one -NR¹⁰a⁻¹⁰b⁻¹⁰b; R¹⁰a and R¹⁰b each independently represent hydrogen or Ci₄alkyl; R¹⁰d and R¹⁰d⁻¹⁰d each independently represent C₃₋₆cycloalkyl; R¹³; and R¹⁴; C₃₋₆cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH and -0-Ci₄alkyl; Ci₄alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH and -0-Ci₄alkyl; or Ci₄alkyl substituted with one substituent selected from the group consisting of C₃₋₆cycloalkyl, R¹³ and R¹⁴;

R¹³ represents a 4- to 7-membered monocyclic aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(=0) and N; or a 6- to 11-membered bicyclic fused aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(=0) and N;

said 4- to 7-membered monocyclic aromatic ring or 6- to 11-membered bicyclic fused aromatic ring is optionally substituted with one or two substituents selected from the group consisting of Ci₄alkyl;

p represents 1 or 2;

R¹⁴ represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;

Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2), (a-3), (a-4) and (a-5):
R\textsuperscript{a}, R\textsuperscript{b}, R\textsuperscript{c}, R\textsuperscript{d} and R\textsuperscript{e} each independently represent hydrogen, halo, -NR\textsubscript{a}R\textsuperscript{7b}, Ci\textsubscript{4} alkyl, C\textsubscript{2-4} alkenyl, C\textsubscript{3-6} cycloalkyl, -OH, or -0-Ci\textsubscript{4} alkyl;
R\textsuperscript{7a} represents hydrogen;
R\textsuperscript{7b} represents hydrogen, C\textsubscript{3-6} cycloalkyl, or Ci\textsubscript{4} alkyl;
R\textsuperscript{4a}, R\textsuperscript{4b}, R\textsuperscript{4c}, R\textsuperscript{4d}, R\textsuperscript{4e}, R\textsuperscript{4f} and R\textsuperscript{4g} each independently represent hydrogen, halo, -NR\textsuperscript{4b}R\textsuperscript{4b}, or Ci\textsubscript{4} alkyl;
R\textsuperscript{3a} and R\textsuperscript{3b} each independently represent hydrogen or Ci\textsubscript{4} alkyl;
Q\textsuperscript{1} represents N or CR\textsuperscript{6a};
Q\textsuperscript{2} represents N or CR\textsuperscript{6b};
Q\textsuperscript{3} represents N or CR\textsuperscript{6c};
Q\textsuperscript{4} represents N or CR\textsuperscript{6d};
provided that maximum one of Q\textsuperscript{3} and Q\textsuperscript{4} represents N;
Q\textsuperscript{5} represents N or CR\textsuperscript{6e};
Q\textsuperscript{6} represents N or CR\textsuperscript{6f};
Q\textsuperscript{7} represents N or CR\textsuperscript{6g};
Q\textsuperscript{8} represents N or CR\textsuperscript{6h};
Q\textsuperscript{9} represents N or CR\textsuperscript{6i};
Q\textsuperscript{10} represents N or CR\textsuperscript{6j};
Q\textsuperscript{11} represents N or CR\textsuperscript{6k};
Q\textsuperscript{5} represents CR\textsuperscript{3d}; Q\textsuperscript{6} represents N; and Q\textsuperscript{7} represents CR\textsuperscript{4f}; or
Q\textsuperscript{5} represents CR\textsuperscript{3d}; Q\textsuperscript{6} represents CR\textsuperscript{4c}; and Q\textsuperscript{7} represents N; or
Q\textsuperscript{5} represents N; Q\textsuperscript{6} represents CR\textsuperscript{4g}; and Q\textsuperscript{7} represents CR\textsuperscript{4d}; or
Q\textsuperscript{5} represents N; Q\textsuperscript{6} represents CR\textsuperscript{4e}; and Q\textsuperscript{7} represents N; or
Q\textsuperscript{5} represents N; Q\textsuperscript{6} represents N; and Q\textsuperscript{7} represents CR\textsuperscript{4f}; or
Q\textsuperscript{5} represents N; Q\textsuperscript{6} represents N; and Q\textsuperscript{7} represents N;
R\textsuperscript{6a}, R\textsuperscript{6b}, R\textsuperscript{6c}, R\textsuperscript{6d}, R\textsuperscript{6e}, R\textsuperscript{6f}, R\textsuperscript{6g}, R\textsuperscript{6h}, R\textsuperscript{6i} and R\textsuperscript{6j} each independently represent hydrogen, halogen, Ci\textsubscript{4} alkyl, -NR\textsubscript{a}R\textsuperscript{7b}, or Ci\textsubscript{4} alkyl substituted with one, two or three halo atoms;
R\textsuperscript{3a} and R\textsuperscript{3b} each independently represent hydrogen or Ci\textsubscript{4} alkyl;
and pharmaceutically acceptable addition salts, and solvates thereof; provided that the following compounds, and pharmaceutically acceptable addition salts, and solvates thereof are excluded:

![Compounds](image)

The present invention also concerns methods for the preparation of compounds of the present invention and pharmaceutical compositions comprising them.

The compounds of the present invention were found to inhibit PRMT5 per se or can undergo metabolism to a (more) active form in vivo (prodrugs), and therefore may be useful in the treatment or prevention, in particular in the treatment, of diseases such as a blood disorder, metabolic disorders, autoimmune disorders, cancer, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection, lung injuries, and the like.

In view of the aforementioned pharmacology of the compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, it follows that they may be suitable for use as a medicament.

In particular the compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, may be suitable in the treatment or prevention, in particular in the treatment, of any one of the diseases or conditions mentioned hereinbefore or hereinafter, in particular cancer.

The present invention also concerns the use of compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for the manufacture of
a medicament for the inhibition of PRMT5, for the treatment or prevention of any one of the diseases or conditions mentioned hereinbefore or hereinafter, in particular cancer.

The present invention will now be further described. In the following passages, different aspects of the invention are defined in more detail. Each aspect so defined may be combined with any other aspect or aspects unless clearly indicated to the contrary. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being preferred or advantageous.

Detailed description

When describing the compounds of the invention, the terms used are to be construed in accordance with the following definitions, unless a context dictates otherwise.

When any variable occurs more than one time in any constituent or in any formula (e.g. Formula (I)), its definition in each occurrence is independent of its definition at every other occurrence.

Whenever the term "substituted" is used in the present invention, it is meant, unless otherwise is indicated or is clear from the context, to indicate that one or more hydrogens, in particular from 1 to 3 hydrogens, preferably 1 or 2 hydrogens, more preferably 1 hydrogen, on the atom or radical indicated in the expression using "substituted" are replaced with a selection from the indicated group, provided that the normal valency is not exceeded, and that the substitution results in a chemically stable compound, i.e. a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into a therapeutic agent.

When two or more substituents are present on a moiety they may, unless otherwise is indicated or is clear from the context, replace hydrogens on the same atom or they may replace hydrogen atoms on different atoms in the moiety.

The prefix "C_{x-y}" (where x and y are integers) as used herein refers to the number of carbon atoms in a given group. Thus, a C_{1,4}alkyl group contains from 1 to 4 carbon atoms, a C_{1,2}alkyl group contains from 1 to 3 carbon atoms and so on.

The term "halo" as a group or part of a group is generic for fluoro, chloro, bromo, iodo unless otherwise is indicated or is clear from the context.

The term "C_{1,4}alkyl" as a group or part of a group refers to a hydrocarbyl radical of Formula C_{i+1}H_{3n+1} wherein n is a number ranging from 1 to 4. C_{i,4}alkyl groups comprise from 1 to 4 carbon atoms, preferably from 1 to 3 carbon atoms, more preferably 1 to 2 carbon atoms. C_{1,4}alkyl groups may be linear or branched and may be substituted as indicated herein. When a subscript is used herein following a carbon atom, the
subscript refers to the number of carbon atoms that the named group may contain. 

\( \text{Ci}_4 \text{alkyl} \) includes all linear, or branched alkyl groups with between 1 and 4 carbon atoms, and thus includes methyl, ethyl, \( \text{-propyl} \), \( \text{-isopropyl} \), 2-methyl-ethyl, butyl and its isomers (e.g. \( \text{n-butyl} \), \( \text{iso-butyl} \) and \( \text{n-tri-butyl} \), and the like.

The skilled person will realize that the term \( \text{Ci}_4 \text{alkoxy} \) or \( \text{Ci}_4 \text{alkyloxy} \) as a group or part of a group refers to a radical having the Formula \( -\text{OR} \) wherein \( R \) is \( \text{Ci}_4 \text{alkyl} \). Non-limiting examples of suitable \( \text{Ci}_4 \text{alkyloxy} \) include methyloxy (also methoxy), ethyloxy (also ethoxy), propyloxy, isopropyloxy, butyloxy, isobutyloxy, sec-butyloxy and \( /\text{er}/- \text{butyloxy} \).

The term \( \text{\text{C}_2\text{alkenyl}} \) as used herein as a group or part of a group represents a straight or branched chain hydrocarbon group containing from 2 to 4 carbon atoms and containing a carbon carbon double bond such as, but not limited to, ethenyl, propenyl, butenyl, 1-propen-2-yl, and the like.

The term \( \text{\text{C}_3\text{cycloalkyl}} \) as used herein as a group or part of a group represents cyclic saturated hydrocarbon radicals having from 3 to 6 carbon atoms such as cyclobutyl, cyclopentyl or cyclohexyl.

In case \( Z \) is \(-\text{X-}\text{CR}^5\text{R}^6\text{-.} \), it is intended that \( X \) is attached to \( \text{Ar} \).

In case \( Z \) is \(-\text{CR}^5\text{CR}^6\text{-.} \), it is intended that the \( C \)-atom with the \( R^5 \) substituent is attached to \( \text{Ar} \).

In case \( Z \) is \(-\text{CR}^5\text{CR}^5\text{R}^6\text{-} \), it is intended that the \( C \)-atom with the \( R^5 \) and \( R^6 \) substituents is attached to \( \text{Ar} \).

In case \( Z \) is \(-\text{CR}^5\text{X-} \), it is intended that the \( C \)-atom with the \( R^5 \) substituent is attached to \( \text{Ar} \).

The skilled person will realize that the 4-, 5-, 6- or 7-membered heterocyclic ring being attached to the remainder of the molecule via a ring nitrogen atom (in the definition of \( R^6 \)) particularly is a saturated ring. Non-limiting examples of \( R^1 \) are 1-piperidyl, 1-pyrrolidinyl, 1-morpholinyl, 1-azetidinyl, and the like.

It will be clear for the skilled person that, unless otherwise is indicated or is clear from the context, a substituent on a 4- to 7-membered monocyclic aromatic ring containing one, two or three heteroatoms (as in the definition of \( R^3 \)) (non-limiting examples are pyrolyl, pyridinyl, furanyl, and the like), may replace any hydrogen atom on a ring.
carbon atom or where possible on a ring nitrogen atom (in which case a hydrogen on a nitrogen atom may be replaced by a substituent). It will be clear for the skilled person that the same is applicable to the 6- to 11-membered bicyclic fused aromatic ring containing one, two or three heteroatoms (as in the definition of $R^{13}$) (non-limiting examples are indolyl, quinolinyl, and the like).

A 4- to 7-membered monocyclic aromatic ring containing one, two or three heteroatoms (as in the definition of $R^{13}$), may be attached to the remainder of the molecule of Formula (I) through any available ring carbon or nitrogen atom as appropriate, if not otherwise specified. It will be clear for the skilled person that the same is applicable to the 6- to 11-membered bicyclic fused aromatic ring containing one, two or three heteroatoms (as in the definition of $R^{13}$).

In case a nitrogen atom replaces one of the two fused carbon atoms in the $Ar$ group, a carbonyl group is present in said bicyclic aromatic ring system as exemplified by the structure shown below:

\[
\begin{array}{c}
\text{O} \\
\text{[structure diagram]}
\end{array}
\]

which is optionally substituted according to any of the embodiments. It will be clear this example is non-limiting.

Other, non-limiting, examples of the $Ar$ group being a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom, are shown below:

\[
\begin{array}{c}
\text{[structure diagrams]}
\end{array}
\]

each of which are optionally substituted according to any of the embodiments.
The skilled person will understand that the 10 members of the 10-membered Ar group (the 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom), are 10 carbon atoms, 9 carbon atoms and 1 nitrogen atom, or 8 carbon atoms and 2 nitrogen atoms. Ar is optionally substituted according to any of the embodiments.

Whenever substituents are represented by chemical structure, "—" represents the bond of attachment to the remainder of the molecule of Formula (I). Lines drawn from substituents into ring systems indicate that the bond may be attached to any of the suitable ring atoms.

For example covers any one of the following ring systems:

[Diagram]

is an alternative representation for

The term "subject" as used herein, refers to an animal, preferably a mammal (e.g. cat, dog, primate or human), more preferably a human, who is or has been the object of treatment, observation or experiment.

The term "therapeutically effective amount" as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medicinal doctor or other clinician, which includes alleviation or reversal of the symptoms of the disease or disorder being treated.

The term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.
The term "treatment", as used herein, is intended to refer to all processes wherein there may be a slowing, interrupting, arresting or stopping of the progression of a disease, but does not necessarily indicate a total elimination of all symptoms.

The term "compounds of the (present) invention" as used herein, is meant to include the compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof.

Some of the compounds of Formula (I) may also exist in their tautomeric form. The term "tautomer" or "tautomer form" refers to structural isomers of different energies which are interconvertible via a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via migration of a proton, such as keto-enol and imine-enamine isomerisations. Valence tautomers include interconversions by reorganisation of some of the bonding electrons. Such forms in so far as they may exist, although not explicitly indicated in the above Formula (I), are intended to be included within the scope of the present invention.

As used herein, any chemical formula with bonds shown only as solid lines and not as solid wedged or hashed wedged bonds, or otherwise indicated as having a particular configuration (e.g. $R$, $S$) around one or more atoms, contemplates each possible stereoisomer, or mixture of two or more stereoisomers. Where the stereochemistry of any particular chiral atom is not specified in the structures shown herein, then all stereoisomers are contemplated and included as the compounds of the invention, either as a pure stereoisomer or as a mixture of two or more stereoisomers.

Hereinbefore and hereinafter, the term "compound of Formula (I)" is meant to include the stereoisomers thereof and the tautomeric forms thereof. However where stereochemistry, as mentioned in the previous paragraph, is specified by bonds which are shown as solid wedged or hashed wedged bonds, or are otherwise indicated as having a particular configuration (e.g. $R$, $S$), then that stereoisomer is so specified and defined. It will be clear this also applies to subgroups of Formula (I).

It follows that a single compound may, where possible, exist in both stereoisomeric and tautomeric form.

The terms "stereoisomers", "stereoisomeric forms" or "stereochemically isomeric forms" hereinbefore or hereinafter are used interchangeably.

Enantiomers are stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a racemate or racemic mixture.

Atropisomers (or atropoisomers) are stereoisomers which have a particular spatial configuration, resulting from a restricted rotation about a single bond, due to large
steric hindrance. All atropisomeric forms of the compounds of Formula (I) are intended to be included within the scope of the present invention.

Diastereomers (or diastereoisomers) are stereoisomers that are not enantiomers, i.e. they are not related as mirror images. If a compound contains a double bond, the substituents may be in the E or the Z configuration. Substituents on bivalent cyclic (partially) saturated radicals may have either the cis- or trans-configuration; for example if a compound contains a disubstituted cycloalkyl group, the substituents may be in the cis or trans configuration. Therefore, the invention includes enantiomers, atropisomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers and mixtures thereof, whenever chemically possible.

The meaning of all those terms, i.e. enantiomers, atropisomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers and mixtures thereof are known to the skilled person.

The absolute configuration is specified according to the Cahn-Ingold-Prelog system. The configuration at an asymmetric atom is specified by either R or S. Resolved stereoisomers whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which they rotate plane polarized light. For instance, resolved enantiomers whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which they rotate plane polarized light.

When a specific stereoisomer is identified, this means that said stereoisomer is substantially free, i.e. associated with less than 50%, preferably less than 20%, more preferably less than 10%, even more preferably less than 5%, in particular less than 2% and most preferably less than 1%, of the other stereoisomers. Thus, when a compound of Formula (I) is for instance specified as (R), this means that the compound is substantially free of the (S) isomer; when a compound of Formula (I) is for instance specified as E, this means that the compound is substantially free of the Z isomer; when a compound of Formula (I) is for instance specified as cis, this means that the compound is substantially free of the trans isomer.

For therapeutic use, salts of the compounds of Formula (I) and solvates thereof, are those wherein the counterion is pharmaceutically acceptable. However, salts of acids and bases which are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.
Pharmaceutically-acceptable salts include acid addition salts and base addition salts. Such salts may be formed by conventional means, for example by reaction of a free acid or a free base form with one or more equivalents of an appropriate acid or base, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. in vacuo, by freeze-drying or by filtration). Salts may also be prepared by exchanging a counter-ion of a compound of the invention in the form of a salt with another counter-ion, for example using a suitable ion exchange resin.

The pharmaceutically acceptable addition salts as mentioned hereinabove or hereinafter are meant to comprise the therapeutically active non-toxic acid and base addition salt forms which the compounds of Formula (I) and solvates thereof, are able to form.

Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic (i.e. ethanedioic), malonic, succinic (i.e. butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluensulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids. Conversely said salt forms can be converted by treatment with an appropriate base into the free base form.

The compounds of Formula (I) and solvates thereof containing an acidic proton may also be converted into their non-toxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases.

Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. primary, secondary and tertiary aliphatic and aromatic amines such as methylamine, ethylamine, propylamine, isopropylamine, the four butylamine isomers, dimethylamine, diethylamine, diethanolamine, dipropylamine, diisopropylamine, di-n-butylamine, pyrrolidine, piperidine, morpholine, trimethylamine, triethylamine, tripropylamine, quinuclidine, pyridine, quinoline and isoquinoline; the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like. Conversely the salt form can be converted by treatment with acid into the free acid form.

For the purposes of this invention prodrugs are also included within the scope of the invention.

The term "prodrug" of a relevant compound of the invention includes any compound that, following oral or parenteral administration, in particular oral administration, is
metabolised *in vivo* to a form that compound in an experimentally-detectable amount, and within a predetermined time (e.g. within a dosing interval of between 6 and 24 hours (i.e. once to four times daily)). For the avoidance of doubt, the term "parenteral" administration includes all forms of administration other than oral administration, in particular intravenous (IV), intramuscular (IM), and subcutaneous (SC) injection.

Prodrugs may be prepared by modifying functional groups present on the compound in such a way that the modifications are cleaved, *in vivo* when such prodrug is administered to a mammalian subject. The modifications typically are achieved by synthesising the parent compound with a prodrug substituent. In general, prodrugs include compounds of the invention wherein a hydroxyl, amino, sulfhydryl, carboxy or carbonyl group in a compound of the invention is bonded to any group that may be cleaved *in vivo* to regenerate the free hydroxyl, amino, sulfhydryl, carboxy or carbonyl group, respectively; in particular wherein a hydroxyl group in a compound of the invention is bonded to any group (e.g. \(-\text{C}(=\text{O})-\text{C}_1-\text{alkyl}\)) that may be cleaved *in vivo* to regenerate the free hydroxyl. Within the context of this invention, prodrugs in particular are compounds of Formula (I) or subgroups thereof wherein \(R^1\) and/or \(R^2\) represent \(-\text{C}(=\text{O})-\text{C}_1-\text{alkyl}\).

Examples of prodrugs include, but are not limited to, esters and carbamates of hydroxy functional groups, esters groups of carboxy! functional groups, N-acyl derivatives and N-Mannich bases. General information on prodrugs may be found e.g. in Bundegaard, H. "Design of Prodrugs" p. 1-92, Elsevier, New York-Oxford (1985).

The term solvate comprises the hydrates and solvent addition forms which the compounds of Formula (I) are able to form, as well as pharmaceutically acceptable addition salts thereof. Examples of such forms are e.g. hydrates, alcoholates and the like.

The compounds of the invention as prepared in the processes described below may be synthesized in the form of mixtures of enantiomers, in particular racemic mixtures of enantiomers, that can be separated from one another following art-known resolution procedures. A manner of separating the enantiomeric forms of the compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, involves liquid chromatography using a chiral stationary phase. Said pure stereochemical isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound would be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
The present invention also embraces isotopically-labeled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature (or the most abundant one found in nature).

All isotopes and isotopic mixtures of any particular atom or element as specified herein are contemplated within the scope of the compounds of the invention, either naturally occurring or synthetically produced, either with natural abundance or in an isotopically enriched form. Exemplary isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine and iodine, such as $^2$H, $^3$H, $^4$C, $^{13}$C, $^{14}$C, $^{15}$N, $^{17}$O, $^{18}$O, $^{32}$P, $^{33}$P, $^{35}$S, $^{18}$F, $^{36}$Cl, $^{122}$I, $^{123}$I, $^{125}$I, $^{125}$I, $^{75}$Br, $^{76}$Br, $^{77}$Br and $^{82}$Br. Preferably, the radioactive isotope is selected from the group of $^3$H, $^4$H and $^{18}$F. More preferably, the radioactive isotope is $^2$H. In particular, deuterated compounds are intended to be included within the scope of the present invention.

Certain isotopically-labeled compounds of the present invention (e.g., those labeled with $^3$H and $^{14}$C) are useful in compound and for substrate tissue distribution assays. Tritiated ($^3$H) and carbon-14 ($^{14}$C) isotopes are useful for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., $^2$H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Positron emitting isotopes such as $^{15}$O, $^{15}$N, $^{13}$C and $^{18}$F are useful for positron emission tomography (PET) studies to examine substrate receptor occupancy.

In all embodiments below, the following compounds, and pharmaceutically acceptable addition salts, and solvates thereof are excluded:
In an embodiment, the present invention concerns novel compounds of Formula (I), wherein

R¹ represents hydrogen or -C(=O)-C₁₋₄alkyl;

R² represents hydrogen or -C(=O)-C₁₋₄alkyl;

Y represents -0-, -CH₂- or -CF₂-;

Z represents -CH₂-, -X-CR₅aR₅b-, -CR₅c=CR₅d-, -CR₅eR₅f-, -CR₅bR₅h-, or -C≡C-;

and when Y represents -CH₂- or -CF₂-, then Z can also represent -O- or -CR₅aR₅b-X-;

R₅a, R₅b, R₅c, R₅d, R₅e, R₅f, R₅g, and R₅h each independently represent hydrogen or Ciᵣ₋₄alkyl;

X represents -0-, -S-, or -NRᵣᵣ⁺⁻;

Rᵣ⁺ represents hydrogen or Ciᵣ₋₄alkyl;

Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;

Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, -OH, -NH₂, -NH-Cᵣ₋₄alkyl, -N(C₁₋₄alkyl)₂, -NHR₁₀⁻, -NR₁₀⁺⁻, cyano, -CF₃, -C(=0)-NH₂, -C(=0)-NH-C₁₋₄alkyl, -C(=0)-Cᵣ₋₄alkyl, -Cᵣ₋₄alkoxy, -C(=0)-0-Cᵣ₋₄alkyl, C₃₋₆cycloalkyl, -0-C₃₋₆cycloalkyl, -NH-C₃₋₆cycloalkyl, -N(C₃₋₆cycloalkyl)₂, C₂₋₆alkenyl, Ciᵣ₋₄alkyl substituted with one Ciᵣ₋₄alkyl, and Ciᵣ₋₄alkyl optionally substituted with one -NR₁₀⁺⁻R₁₀⁻;

R₁₀⁻ and R₁₀⁺ each independently represent hydrogen or Ciᵣ₋₄alkyl;

substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH and -0-Cᵣ₋₄alkyl; Ciᵣ₋₄alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH and -0-Cᵣ₋₄alkyl; or Ciᵣ₋₄alkyl substituted with one substituent selected from the group consisting of C₃₋₆cycloalkyl, and R₁⁴⁺⁻;

R₁⁴ represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;

Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2), (a-3), (a-4) and (a-5):
R\(^a\), R\(^b\), R\(^c\), R\(^d\) and R\(^e\) each independently represent hydrogen, halo, -NR\(^a\)R\(^b\), Ci\(_4\)alkyl, C\(_2\)-\(_4\)alkenyl, C\(_3\)-\(_6\)cycloalkyl, -OH, or -0-Ci\(_4\)alkyl;
R\(^f\) represents hydrogen;

5
R\(^b\) represents hydrogen, C\(_3\)-\(_6\)cycloalkyl, or Ci\(_4\)alkyl;
R\(^4a\), R\(^4b\), R\(^4c\), R\(^4d\), R\(^4e\), R\(^4f\) and R\(^4g\) each independently represent hydrogen, halo, -NR\(^a\)R\(^b\), or Ci\(_4\)alkyl;
R\(^3a\) and R\(^3b\) each independently represent hydrogen or Ci\(_4\)alkyl;
Q\(^1\) represents N or CR\(^6a\);

10
Q\(^2\) represents N or CR\(^6b\);
Q\(^3\) represents N or CR\(^6c\);
Q\(^4\) represents N or CR\(^6d\);
provided that maximum one of Q\(^3\) and Q\(^4\) represents N;
Q\(^5\) represents N or CR\(^6e\);

15
Q\(^9\) represents N or CR\(^6h\);
Q\(^10\) represents N or CR\(^6i\);
Q\(^11\) represents N or CR\(^6j\);

Q\(^5\) represents CR\(^3d\); Q\(^6\) represents N; and Q\(^7\) represents CR\(^4f\); or
Q\(^5\) represents CR\(^3d\); Q\(^6\) represents CR\(^4c\); and Q\(^7\) represents N; or

20
Q\(^5\) represents N; Q\(^6\) represents CR\(^4c\); and Q\(^7\) represents CR\(^4f\); or
Q\(^5\) represents N; Q\(^6\) represents CR\(^4c\); and Q\(^7\) represents N; or
Q\(^5\) represents N; Q\(^6\) represents N; and Q\(^7\) represents CR\(^4f\); or
Q\(^5\) represents N; Q\(^6\) represents N; and Q\(^7\) represents N;
R\(^6a\), R\(^6b\), R\(^6c\), R\(^6d\), R\(^6e\), R\(^6f\), R\(^6g\), R\(^6h\), R\(^6i\) and R\(^6j\) each independently represent hydrogen, halogen, Ci\(_4\)alkyl, -NR\(^a\)R\(^b\), or Ci\(_4\)alkyl substituted with one, two or three halo atoms;
R\(^9a\) and R\(^9b\) each independently represent hydrogen or Ci\(_4\)alkyl;
and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I), wherein

5 \( R^1 \) represents hydrogen or \( -C(=O)-C_{1-4} \)alkyl; \( R^2 \) represents hydrogen or \( -C(=O)-C_{1-4} \)alkyl; \( Y \) represents \( -O-, -CH_2- \) or \( -CF_2- \); \( Z \) represents \( -CH_2-, -X-CR^{5a}R^{5b}, -CR^{5c}=CR^{5d}, -CR^{5e}R^{5f}-CR^{5g}R^{5h}, \) or \( -C≡C-; \) and when \( Y \) represents \( -CH_2- \) or \( -CF_2- \), then \( Z \) can also represent \( -O- \) or \( -CR^{5a}R^{5b}-X-; \)

10 \( R^{5a}, R^{5b}, R^{5c}, R^{5d}, R^{5e}, R^{5f}, R^{5g}, \) and \( R^{5h} \) each independently represent hydrogen or \( \text{Ci}_{4} \)alkyl; \( X \) represents \( -O-, -S-, \) or \( -NR^{11-}; \) \( R^{11} \) represents hydrogen, \( \text{Ci}_{4} \)alkyl, or \( \text{Ci}_{4} \)alkyl substituted with one substituent selected from the group consisting of \( -OH, -0-\text{Ci}_{4} \)alkyl, \( R^{12}, -NH_2, -NH-\text{Ci}_{4} \)alkyl, and \( -N(\text{Ci}_{4} \)alkyl)\(_2; \)

15 \( R^{12} \) represents a 4-, 5-, 6- or 7-membered heterocyclic ring containing one nitrogen atom and optionally one oxygen atom; said 4-, 5-, 6- or 7-membered heterocyclic ring being attached to the remainder of the molecule via a ring nitrogen atom;

Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused

20 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system; \( \text{Ar} \) is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, \( -OH, -NH_2, -NH-\text{Ci}_{4} \)alkyl, \( -N(\text{Ci}_{4} \)alkyl)\(_2, \)

25 \( -NHR^{10a}, -NR^{10a}R^{10d}, \) cyano, \( -CF_3, -C(=0)-NH_2, -C(=0)-NH-\text{Ci}_{4} \)alkyl, \( -C(=0)-\text{Ci}_{4} \)alkyl, \( \text{Ci}_{4} \)alkyloxy, \( -C(=0)-0-\text{Ci}_{4} \)alkyl, \( C_{3-6} \)cycloalkyl, \( -0-C_{3-6} \)cycloalkyl, \( -NH-C_{3-6} \)cycloalkyl, \( -N(C_{3-6} \)cycloalkyl)\(_2, \) \( C_{2-6} \)alkenyl, \( \text{Ci}_{4} \)alkyl substituted with one \( \text{Ci}_{4} \)alkyloxy, and \( \text{Ci}_{4} \)alkyl optionally substituted with one \( -NR^{10a}R^{10b}, \)

30 \( R^{10a} \) and \( R^{10b} \) each independently represent hydrogen or \( \text{Ci}_{4} \)alkyl; \( R^{10e} \) and \( R^{10d} \) each independently represent \( C_{3-4} \)cycloalkyl; \( R^{13}, R^{14}, C_{3-4} \)cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, \( -OH \) and \( -0-\text{Ci}_{4} \)alkyl; \( \text{Ci}_{4} \)alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, \( -OH \) and \( -0-\text{Ci}_{4} \)alkyl; or \( \text{Ci}_{4} \)alkyl substituted with one substituent selected from the group consisting of \( C_{3-4} \)cycloalkyl, \( R^{13} \) and \( R^{14}; \)
R^1 represents a 4- to 7-membered monocyclic aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(=0), and N; or a 6- to 11-membered bicyclic fused aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(=0), and N;
said 4- to 7-membered monocyclic aromatic ring or 6- to 11-membered bicyclic fused aromatic ring is optionally substituted with one or two substituents selected from the group consisting of Ci_4alkyl;
p represents 1 or 2;
R^{4} represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2), (a-3), (a-4) and (a-5):

\[
\begin{align*}
\text{(a-1)} & \quad N=O^1=O^2 \quad R^{3a} \\
\text{(a-2)} & \quad \begin{array}{c}
N=O^3 \\
\end{array} \quad R^{4a}, R^{4b}, R^{3d}, R^{3e} \quad \text{each independently represent hydrogen, halo, } -NR^5aR^7b, \\
\text{(a-3)} & \quad \begin{array}{c}
N=O^4 \\
\end{array} \quad R^{4a}, R^{4b}, R^{4c}, R^{4d}, R^{4e}, R^{4f} \quad \text{each independently represent hydrogen, halo, } -NR^5aR^7b, \text{ or Ci}_4\text{alkyl;} \\
\text{(a-4)} & \quad N=O^8 \quad R^{4a}, R^{4b}, R^{4c}, R^{4d} \quad \text{each independently represent hydrogen or } \text{Ci}_4\text{alkyl;} \\
\end{align*}
\]

R^{3a}, R^{3b}, R^{3c}, R^{3d} and R^{3e} each independently represent hydrogen, halo, -NR^5aR^7b, Ci_4alkyl, C_2_4alkenyl, C_3_6cycloalkyl, -OH, or -0-Ci_4alkyl;
R^3 represents hydrogen;
R^7b represents hydrogen, C_3_6cycloalkyl, or Ci_4alkyl;
R^{4a}, R^{4b}, R^{4c}, R^{4d}, R^{4e}, R^{4f} and R^{4g} each independently represent hydrogen, halo, -NR^5aR^7b, or Ci_4alkyl;
R^{3a} and R^{3b} each independently represent hydrogen or Ci_4alkyl;
Q^1 represents CR^6a;
Q^2 represents CR^6b;
Q^3 represents N or CR^6c;
Q^4 represents N or CR^6d;
provided that maximum one of Q^3 and Q^4 represents N;
Q^8 represents N or CR^6e;
Q^9 represents N or CR^6f;
Q^{10} represents N or CR^{6i};
Q^{11} represents N or CR^{6j};
Q^{5} represents CR^{3d}; Q^{6} represents N; and Q^{7} represents CR^{4f}; or
Q^{5} represents CR^{3d}; Q^{6} represents CR^{5e}; and Q^{7} represents N; or
Q^{5} represents N; Q^{6} represents CR^{4f}; and Q^{7} represents CR^{4f}; or
Q^{5} represents N; Q^{6} represents CR^{4f}; and Q^{7} represents N; or
Q^{5} represents N; Q^{6} represents N; and Q^{7} represents N;
R^{6a}, R^{6b}, R^{6c}, R^{6d}, R^{6e}, R^{6f}, R^{6g}, R^{6h}, R^{6i}, and R^{6j} each independently represent hydrogen, halogen, Ci_{4}alkyl, -NR^{3a}R^{3b}, or Ci_{4}alkyl substituted with one, two or three halo atoms;
R^{9a} and R^{9b} each independently represent hydrogen or Ci_{4}alkyl; and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
R^{1} represents hydrogen or -C(=0)-Ci_{4}alkyl;
R^{2} represents hydrogen or -C(=0)-Ci_{4}alkyl;
Y represents -0-, -CH_{2}- or -CF_{2}-;
Z represents -CH_{2}-, -X-CR^{5a}R^{5b}, -CR^{5c}=CR^{5d}, -CR^{5e}R^{5f}-CR^{5g}R^{5h}, or -C≡C-; and when Y represents -CH_{2}- or -CF_{2}-, then Z can also represent -O- or -CR^{3a}R^{3b}-X-;
R^{5a}, R^{5b}, R^{5c}, R^{5d}, R^{5e}, R^{5f}, R^{5g}, and R^{5h} each independently represent hydrogen or Ci_{4}alkyl;
X represents -0-, -S-, or -NR^{11}-;
R^{11} represents hydrogen, Ci_{4}alkyl, or Ci_{4}alkyl substituted with one substituent selected from the group consisting of -OH, -0-Ci_{4}alkyl, R^{12}, -NH_{2}, -NH-Ci_{4}alkyl, and -N(C_{4}alkyl)_{2};
R^{12} represents a 4-, 5-, 6- or 7-membered heterocyclic ring containing one nitrogen atom and optionally one oxygen atom; said 4-, 5-, 6- or 7-membered heterocyclic ring being attached to the remainder of the molecule via a ring nitrogen atom;
Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, -OH, -NH_{2}, -NH-Ci_{4}alkyl, -N(Ci_{4}alkyl)_{2}.
-NHR<sub>10d</sub>, -NR<sub>10c</sub>R<sub>10d</sub>, cyano, -CF<sub>3</sub>, -C(=0)-NH<sub>2</sub>, -C(=0)-NH-C<sub>1-4</sub>alkyl, -C(=0)-Ci<sub>4</sub>alkyl, Ci<sub>4</sub>alkyloxy, -C(=O)-O-C<sub>1-4</sub>alkyl, C<sub>3-6</sub>cycloalkyl, C<sub>2-alkenyl</sub>, Ci<sub>4</sub>alkyl substituted with one Ci<sub>4</sub>alkyloxy, and Ci<sub>4</sub>alkyl optionally substituted with one -N<sub>R</sub><sup>10a</sup>.

R<sub>10a</sub> and R<sub>10b</sub> each independently represent hydrogen or Ci<sub>4</sub>alkyl;
R<sub>10c</sub> and R<sub>10d</sub> each independently represent C<sub>3-6</sub>cycloalkyl; C<sub>3-6</sub>cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH and -0-Ci<sub>4</sub>alkyl; Ci<sub>4</sub>alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH and -0-Ci<sub>4</sub>alkyl; or Ci<sub>4</sub>alkyl substituted with one substituent selected from the group consisting of C<sub>3-6</sub>cycloalkyl, R<sup>13</sup> and R<sup>14</sup>:

R<sup>13</sup> represents a 4- to 7-membered monocyclic aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(=0) and N; or a 6- to 11-membered bicyclic fused aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(=0) and N;
said 4- to 7-membered monocyclic aromatic ring or 6- to 11-membered bicyclic fused aromatic ring is optionally substituted with one or two substituents selected from the group consisting of Ci<sub>4</sub>alkyl;
p represents 1 or 2;

R<sup>14</sup> represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;
Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3):

R<sup>3a</sup>, R<sup>3b</sup> and R<sup>3c</sup> each independently represent hydrogen, halo, -NR<sup>7a</sup>R<sup>7b</sup>, Ci<sub>4</sub>alkyl, or -0-Ci<sub>4</sub>alkyl;
R<sup>7a</sup> represents hydrogen;
R<sup>7b</sup> represents hydrogen or Ci<sub>4</sub>alkyl;
R₄ᵃ, R₄ᵇ and R₄ᶜ each independently represent hydrogen, halo, -NR₈ᴿ₄ᵇ, or Ci₄alkyl; R₅ᵃ and R₅ᵇ each independently represent hydrogen or Ci₄alkyl;
Q¹ represents N or CR₆ᵃ;
Q² represents N or CR₆ᵇ;
Q³ represents N or CR₆ᶜ;
Q⁴ represents N or CR₆ᵈ;
provided that maximum one of Q³ and Q⁴ represents N;
R₆ᵃ, R₆ᵇ, R₆ᶜ, R₆ᵈ, R₆ᵉ and R₆ᶠ each independently represent hydrogen, halogen, Ci₄alkyl, -NR₉ᴿ₉ᵇ, or Ci₄alkyl substituted with one, two or three halo atoms;
R₉ᵃ and R₉ᵇ each independently represent hydrogen or Ci₄alkyl;
and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
R¹ represents hydrogen or -C(=0)-Ci₄alkyl;
R² represents hydrogen or -C(=0)-Ci₄alkyl;
Y represents -O-, -CH₂- or -CF₂-;
Z represents -CH₂-, -X-CR₅ᴿ₅ᵇ-, -CR₅بوك₅-R₆ᵈ-, -CR₅بوك₅-R₅ᶜR₅ᵇ-, or -C≡C-;
and when Y represents -CH₂- or -CF₂- then Z can also represent -O- or -CR₅بوك₅-X-;
R₅ᵃ, R₅ᵇ, R₅ᶜ, R₅ᵈ, R₅ᵉ, R₅ᶠ, R₅ᵍ, and R₅ʰ each independently represent hydrogen or Ci₄alkyl;
X represents -O-, -S-, or -NR¹⁻⁻⁻⁻;
R¹⁻⁻⁻⁻ represents hydrogen, Ci₄alkyl, or Ci₄alkyl substituted with one substituent selected from the group consisting of -OH, -O-Ci₄alkyl, R¹⁻⁻⁻⁻, -NH₂, -NH-Ci₄alkyl, and
-N(Ci₄alkyl)₂;
R¹⁻⁻⁻⁻ represents a 4-, 5-, 6- or 7-membered heterocyclic ring containing one nitrogen atom and optionally one oxygen atom; said 4-, 5-, 6- or 7-membered heterocyclic ring being attached to the remainder of the molecule via a ring nitrogen atom;
Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, -OH, -NH₂, -NH-Ci₄alkyl, -N(Ci₄alkyl)₂, cyano, -CF₃, -C(=0)-NH-Ci₄alkyl, -C(=0)-Ci₄alkyl, Ci₄alkyloxy, and Ci₄alkyl optionally substituted with one -NR¹₀ᴿ¹₀ᵇ;
R¹₀ᵃ and R¹₀ᵇ each independently represent hydrogen or Ci₄alkyl;
Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3):

\[ R^{3a}, R^{3b} \text{ and } R^{3c} \text{ each independently represent hydrogen, halo, } -NR^{7a}R^{7b}, \text{ or } -0-Ci_{-4}alkyl; \]
\[ R^{7a} \text{ represents hydrogen; } \]
\[ R^{7b} \text{ represents hydrogen or } Ci_{-4}alkyl; \]
\[ R^{8a}, R^{8b} \text{ and } R^{8c} \text{ each independently represent hydrogen, halo, } -NR^{8a}R^{8b}, \text{ or } Ci_{-4}alkyl; \]
\[ R^{8a} \text{ and } R^{8b} \text{ each independently represent hydrogen or } Ci_{-4}alkyl; \]
\[ Q^{1} \text{ represents } N \text{ or } CR^{6a}; \]
\[ Q^{2} \text{ represents } N \text{ or } CR^{6b}; \]
\[ Q^{3} \text{ represents } N \text{ or } CR^{6c}; \]
\[ Q^{4} \text{ represents } N \text{ or } CR^{6d}; \]

provided that maximum one of \( Q^{3} \) and \( Q^{4} \) represents \( N \);

\[ R^{6a}, R^{6b}, R^{6c}, R^{6d}, R^{6e} \text{ and } R^{6f} \text{ each independently represent hydrogen, halogen, } Ci_{-4}alkyl, -NR^{9a}R^{9b}, \text{ or } Ci_{-4}alkyl \text{ substituted with one, two or three halo atoms; } \]
\[ R^{9a} \text{ and } R^{9b} \text{ each independently represent hydrogen or } Ci_{-4}alkyl; \]
\[ \text{and pharmaceutically acceptable addition salts, and solvates thereof.} \]

In an embodiment, the present invention concerns novel compounds of Formula (I), wherein

\[ R^{1} \text{ represents hydrogen or } -C(=0)-Ci_{-4}alkyl; \]
\[ R^{2} \text{ represents hydrogen or } -C(=0)-Ci_{-4}alkyl; \]
\[ Y \text{ represents } -0-, -CH}_{2}- \text{ or } -CF}_{2}^{-}; \]
\[ Z \text{ represents } -CH}_{2}^{-}, -X-CR^{5a}R^{5b}, -CR^{5c}CR^{5d}, -CR^{5e}R^{5f}CR^{5g}R^{5h}, \text{ or } -C=C^{-}; \]

and when \( Y \) represents \(-CH}_{2}- \text{ or } -CF}_{2}^{-}, \text{ then } Z \text{ can also represent } -0-, \text{ or } -CR^{5a}R^{5b}X^{-}; \]
\[ R^{5a}, R^{5b}, R^{5c}, R^{5d}, R^{5e}, R^{5f}, R^{5g}, \text{ and } R^{5h} \text{ each independently represent hydrogen or } Ci_{-4}alkyl; \]
\[ X \text{ represents } -0-, -S-, \text{ or } -NR^{11}^{-}; \]
R$^{11}$ represents hydrogen, Ci$_4$alkyl, or Ci$_4$alkyl substituted with one substituent selected from the group consisting of -OH, -0-Ci$_4$alkyl, R$^{12}$, -NH$_2$, -NH-Ci$_4$alkyl, and -N(C$_1$$_4$alkyl)$_2$;

R$^{12}$ represents a 4-, 5-, 6- or 7-membered heterocyclic ring containing one nitrogen atom and optionally one oxygen atom; said 4-, 5-, 6- or 7-membered heterocyclic ring being attached to the remainder of the molecule via a ring nitrogen atom;

Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings,

![Diagram of a bicyclic aromatic ring system]

10 wherein at least one ring carbon atom of ring B is replaced by a nitrogen atom;

wherein optionally 1 additional ring carbon atom of ring A or ring B is replaced by a nitrogen atom; provided that when a nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;

Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, -OH, -NH$_2$, -NH-Ci$_4$alkyl, -N(C$_1$$_4$alkyl)$_2$, -NHR$^{10}$, -NR$^{10}$R$^{10}$, cyano, -CF$_3$, -C(=0)-NH$_2$, -C(=0)-NH-Ci$_4$alkyl, -C(=0)-Ci$_4$alkyl, Ci$_4$alkyloxy, -C(=0)-0-Ci$_4$alkyl, C$_3$$_6$cyloalkyl, -0-C$_3$$_6$cyloalkyl, -NH-C$_3$$_6$cyloalkyl, -N(C$_3$$_6$cyloalkyl)$_2$, C$_2$$_6$alkenyl, Ci$_4$alkyl substituted with one Ci$_4$alkyloxy, and Ci$_4$alkyl optionally substituted with one -NR$^{10}$R$^{10}$b;

R$^{10}$a and R$^{10}$b each independently represent hydrogen or Ci$_4$alkyl;

R$^{10}$a and R$^{10}$b each independently represent C$_3$$_6$cyloalkyl; R$^{13}$; R$^{14}$; C$_3$$_6$Cyloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH and -0-Ci$_4$alkyl; Ci$_4$alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH and -0-Ci$_4$alkyl; or Ci$_4$alkyl substituted with one substituent selected from the group consisting of C$_3$$_6$Cyloalkyl, R$^{13}$ and R$^{14}$;

R$^{13}$ represents a 4- to 7-membered monocyclic aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(=0)$_p$ and N; or a 6- to 11-membered bicyclic fused aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(=0)$_p$ and N;

said 4- to 7-membered monocyclic aromatic ring or 6- to 11-membered bicyclic fused aromatic ring is optionally substituted with one or two substituents selected from the group consisting of Ci$_4$alkyl;

p represents 1 or 2;
R\textsuperscript{14} represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;

Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2), (a-3), (a-4) and (a-5):

\begin{align*}
\text{(a-1)} & \quad \text{(a-2)} & \quad \text{(a-3)} & \quad \text{(a-4)} & \quad \text{(a-5)} \\
\end{align*}

\[ R^3_a, R^3_b, R^3_c, R^3_d \text{ and } R^3_e \text{ each independently represent hydrogen, halo, } -NR^6_a, -R^7_b, \]  
\[ C_{i-4} \text{alkyl, } C_{2-4} \text{alkenyl, } c\text{ycloalkyl, } -\text{OH, or } -0-C_{i-4} \text{alkyl; } \\
R^3_b \text{ represents hydrogen; } \\
R^7_b \text{ represents hydrogen, } c\text{ycloalkyl, or } C_{i-4} \text{alkyl; } \\
\]

\[ R^8_a, R^8_b, R^8_c, R^8_d, R^8_e, R^8_f \text{ and } R^8_g \text{ each independently represent hydrogen, halo, } \\
-NR^6_a, -R^7_b, \text{ or } C_{i-4} \text{alkyl; } \\
R^8_b \text{ and } R^8_g \text{ each independently represent hydrogen or } C_{i-4} \text{alkyl; } \\
Q^1 \text{ represents } N \text{ or } CR^6_a; \\
Q^2 \text{ represents } N \text{ or } CR^6_b; \\
Q^3 \text{ represents } N \text{ or } CR^6_c; \\
Q^4 \text{ represents } N \text{ or } CR^6_d; \\
\]  
provided that maximum one of Q\textsuperscript{3} and Q\textsuperscript{4} represents N;

\[ Q^8 \text{ represents } N \text{ or } CR^6_g; \\
Q^9 \text{ represents } N \text{ or } CR^6_h; \\
Q^{10} \text{ represents } N \text{ or } CR^6_i; \\
Q^{11} \text{ represents } N \text{ or } CR^6_j; \\
Q^5 \text{ represents } CR^3_d; Q^6 \text{ represents } N; \text{ and } Q^7 \text{ represents } CR^4_f; \text{ or } \\
Q^5 \text{ represents } CR^3_d; Q^6 \text{ represents } CR^4_e; \text{ and } Q^7 \text{ represents } N; \text{ or } \\
Q^5 \text{ represents } N; Q^6 \text{ represents } CR^4_e; \text{ and } Q^7 \text{ represents } CR^4_f; \text{ or } \\
Q^5 \text{ represents } N; Q^6 \text{ represents } CR^4_f; \text{ and } Q^7 \text{ represents } N; \text{ or } \\
Q^5 \text{ represents } N; Q^6 \text{ represents } N; \text{ and } Q^7 \text{ represents } CR^4_f; \text{ or } \\
Q^5 \text{ represents } N; Q^6 \text{ represents } N; \text{ and } Q^7 \text{ represents } N;
R^6a, R^6b, R^6c, R^6d, R^6e, R^6f, R^6g, R^6h, and R^6i each independently represent hydrogen, halogen, Ci_4alkyl, -NR^5aR^5b, or Ci_4alkyl substituted with one, two or three halo atoms;
R^3a and R^3b each independently represent hydrogen or Ci_4alkyl;
and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I). wherein
R^1 represents hydrogen;

R^2 represents hydrogen;
Y represents -0-, -CH_2- or -CF_2-;
Z represents -CH_2-, -X-CR^5bR^6b, -CR^5ac=CR^5ad, -CR^5acR^5sc- CR^5adR^5sd, or -C≡C-;
and when Y represents -CH_2- or -CF_2-, then Z can also represent -O- or -CR^5acR^5bX-;
R^5a, R^5b, R^5c, R^5d, R^5e, R^5f, and R^5g each independently represent hydrogen or Ci_4alkyl;
X represents -0-, -S-, or -NR^{11}a-;
R^{11} represents hydrogen, Ci_4alkyl, or Ci_4alkyl substituted with one substituent selected from the group consisting of -OH, -0-Ci_4alkyl, R^{12}, -NH_2, -NH-Ci_4alkyl, and -N(Ci_4alkyl)_2;

R^{12} represents a 4-, 5-, 6- or 7-membered heterocyclic ring containing one nitrogen atom and optionally one oxygen atom; said 4-, 5-, 6- or 7-membered heterocyclic ring being attached to the remainder of the molecule via a ring nitrogen atom;

Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;

Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, -OH, -NH_2, -NH-Ci_4alkyl, -N(Ci_4alkyl)_2, -NHR^{10}, -NR^{10}aR^{10}b, cyan, -CF_3, -C(=0)-NH_2, -C(=0)-NH-Ci_4alkyl;

-C(=0)-Ci_4alkyl, Ci_4alkoxy, -C(=0)-0-Ci_4alkyl, C_3a cycloalkyl, -0-C_3a cycloalkyl, -NH-C_3a cycloalkyl, -N(C_3a cycloalkyl)_2, C_2a alkenyl, Ci_4alkyl substituted with one Ci_4alkoxy, and Ci_4alkyl optionally substituted with one -NR^{10}aR^{10}b;
R^{10a} and R^{10b} each independently represent hydrogen or Ci_4alkyl;
R^{10c} and R^{10d} each independently represent C_3a cycloalkyl; R^{13}; R^{14}; C_3a cycloalkyl

substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH and -0-Ci_4alkyl; Ci_4alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH
and -0-Ci_4 alkyl; or Ci_4 alkyl substituted with one substituent selected from the group consisting of C_3-6 cycloalkyl, R_1^4 and R_1^4;

R_1^4 represents a 4- to 7-membered monocyclic aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(=O), p and N; or a 6- to 11-membered bicyclic fused aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(=O), p and N;
said 4- to 7-membered monocyclic aromatic ring or 6- to 11-membered bicyclic fused aromatic ring is optionally substituted with one or two substituents selected from the group consisting of Ci_4 alkyl;
p represents 1 or 2;

R_1^4 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;

Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2), (a-3), (a-4) and (a-5):

\[
\begin{align*}
\text{(a-1)} & & \text{(a-2)} & & \text{(a-3)} & & \text{(a-4)} & & \text{(a-5)} \\
R_1^a, R_1^b, R_1^c, R_1^d, R_1^e & & R_1^a, R_1^b, R_1^c, R_1^d, R_1^e & & R_1^a, R_1^b, R_1^c, R_1^d, R_1^e & & R_1^a, R_1^b, R_1^c, R_1^d, R_1^e & & R_1^a, R_1^b, R_1^c, R_1^d, R_1^e
\end{align*}
\]

R_1^a, R_1^b, R_1^c, R_1^d and R_1^e each independently represent hydrogen, halo, -NR_5^a R_7^b, Ci_4 alkyl, C_2-4 alkenyl, C_3-6 cycloalkyl, -OH, or -0-Ci_4 alkyl;
R_1^a represents hydrogen;
R_1^b represents hydrogen, C_3-6 cycloalkyl, or Ci_4 alkyl;
R_1^a, R_1^b, R_1^c, R_1^d, R_1^e and R_1^f each independently represent hydrogen, halo, -NR_5^a R_8^b, or Ci_4 alkyl;
R_1^a and R_1^b each independently represent hydrogen or Ci_4 alkyl;
Q_1^1 represents N or CR_6^a;
Q_1^2 represents N or CR_6^b;
Q_3^3 represents N or CR_6^c;
Q_4^4 represents N or CR_6^d;
provided that maximum one of Q_3^3 and Q_4^4 represents N;
Q⁸ represents N or CR⁶⁺;  
Q⁹ represents N or CR⁶⁺;  
Q¹⁰ represents N or CR⁶⁺;  
Q¹¹ represents N or CR⁶⁺;  
Q⁵ represents CR³⁻; Q⁶ represents N; and Q⁷ represents CR⁴⁻; or  
Q⁵ represents CR³⁻; Q⁶ represents CR⁴⁻; and Q⁷ represents N; or  
Q⁵ represents N; Q⁶ represents CR⁴⁻; and Q⁷ represents CR⁴⁻; or  
Q⁵ represents N; Q⁶ represents CR⁴⁻; and Q⁷ represents N; or  
Q⁵ represents N; Q⁶ represents N; and Q⁷ represents CR⁴⁻; or  
R⁶a, R⁶b, R⁶c, R⁶d, R⁶e, R⁶f, R⁶g, R⁶h, R⁶i and R⁶j each independently represent hydrogen, halogen, Ci₄alkyl, -NR⁵bR⁹b, or Ci₄alkyl substituted with one, two or three halo atoms;  
R⁵a and R⁹b each independently represent hydrogen or Ci₄alkyl;  
and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I), wherein  
R¹ represents hydrogen;  
R² represents hydrogen;  
Y represents -O⁻, -CH₂⁻ or -CF₂⁻;  
Z represents -CH₂⁻, -X-CR⁵aR⁹b⁻, -CR⁵c⁻CR⁵d⁻, -CR⁵e⁻R⁵f⁻CR⁵g⁻R⁵h⁻, or -C≡C⁻;  
and when Y represents -CH₂⁻ or -CF₂⁻, then Z can also represent -O⁻ or -CR⁵aR⁹b-X⁻;  
R⁵a, R⁵b, R⁵c, R⁵d, R⁵e, R⁵f, R⁵g and R⁵h each independently represent hydrogen or Ci₄alkyl;  
X represents -O⁻, -S⁻, or -NR⁻¹⁻;  
R¹¹ represents hydrogen, Ci₄alkyl, or Ci₄alkyl substituted with one substituent selected from the group consisting of -OH, -O-Ci₄alkyl, R¹⁻⁻⁻, -NH₂⁻, -NH-Ci₄alkyl, and -N(C₄alkyl)₂⁻⁻;  
R¹² represents a 4-, 5-, 6- or 7-membered heterocyclic ring containing one nitrogen atom and optionally one oxygen atom; said 4-, 5-, 6- or 7-membered heterocyclic ring being attached to the remainder of the molecule via a ring nitrogen atom;  
Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, -OH, -NH_2, -NH-Ci_alkyl, -N(C_alkyl)_2, cyano, -CF_3, -C(=0)-NH-Ci_alkyl, -C(=0)-Ci_alkyl, Ci_alkyloxy, and Ci_alkyl optionally substituted with one -NR_{10a}R_{10b};

R_{10a} and R_{10b} each independently represent hydrogen or Ci_alkyl;

Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3);

R^{3a}, R^{3b} and R^{3c} each independently represent hydrogen, halo, -NR^{7a}R^{7b}, or -0-Ci_alkyl;

R^{3a} represents hydrogen;

R^{7b} represents hydrogen or Ci_alkyl;

R^{4a}, R^{4b} and R^{4e} each independently represent hydrogen, halo, -NR^{8a}R^{8b}, or Ci_alkyl;

R^{8a} and R^{8b} each independently represent hydrogen or Ci_alkyl;

Q^{1} represents N or CR^{6a};

Q^{2} represents N or CR^{6b};

Q^{3} represents N or CR^{6c};

Q^{4} represents N or CR^{6d};

provided that maximum one of Q^{3} and Q^{4} represents N;

R^{4a}, R^{4b}, R^{6c}, R^{6d}, R^{6e} and R^{6f} each independently represent hydrogen, halogen, Ci_alkyl, -NR^{9a}R^{9b}, or Ci_alkyl substituted with one, two or three halo atoms;

R^{9a} and R^{9b} each independently represent hydrogen or Ci_alkyl; and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I).

wherein

R^{1} represents hydrogen or -C(=0)-Ci_alkyl;

R^{2} represents hydrogen or -C(=0)-Ci_alkyl;

Y represents -0-, -CH_2- or -CF_2-;

Z represents -CH_2-, -X-CR^{5a}R^{5b}-, -CR^{5c}=CR^{5d}-, -CR^{5e}R^{5f}-, -CR^{5g}R^{5h}-, or -C≡C-;

and when Y represents -CH_2- or -CF_2-, then Z can also represent -O- or -CR^{5a}R^{5b}-X-;

R^{5a}, R^{5b}, R^{5c}, R^{5d}, R^{5e}, R^{5f}, R^{5g}, and R^{5h} each independently represent hydrogen or Ci_alkyl;

X represents -0-, -S-, or -NR^{11}-;

R^{11} represents hydrogen, Ci_alkyl, or Ci_alkyl substituted with one substituent

selected from the group consisting of -OH, -0-Ci_alkyl, R^{12}, -NH_2, -NH-Ci_alkyl, and -N(C_alkyl)_2;
R\textsuperscript{12} represents a 4-, 5-, 6- or 7-membered heterocyclic ring containing one nitrogen atom and optionally one oxygen atom; said 4-, 5-, 6- or 7-membered heterocyclic ring being attached to the remainder of the molecule via a ring nitrogen atom;

Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;

Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, -OH, -NH\textsubscript{2}, -NH-C\textsubscript{1a}-alkyl, -N(C\textsubscript{3a}alkyl)\textsubscript{2}, -NHR\textsubscript{10d}, -NR\textsubscript{10d}R\textsubscript{10d}, cyano, -CF\textsubscript{3}, -C(=0)-NH, -C(=0)-NH-C\textsubscript{1a}alkyl, -C(=0)-C\textsubscript{1a}alkyl, C\textsubscript{1a}alkyl, C\textsubscript{1a}alkyl, C\textsubscript{2a}alkenyl, C\textsubscript{3a}alkyl substituted with one C\textsubscript{4}alkyloxy, and C\textsubscript{4}alkyl optionally substituted with one -NR\textsubscript{10d}R\textsubscript{10b}, R\textsubscript{10a} and R\textsubscript{10b} each independently represent hydrogen or C\textsubscript{4}alkyl;

R\textsubscript{10a} and R\textsubscript{10b} each independently represent C\textsubscript{3a}cycloalkyl; R\textsubscript{13}; R\textsubscript{14}; C\textsubscript{3a}Cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH and -0-C\textsubscript{3a}alkyl; C\textsubscript{3a}alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH and -0-C\textsubscript{3a}alkyl; or C\textsubscript{3a}alkyl substituted with one substituent selected from the group consisting of C\textsubscript{3a}Cycloalkyl, R\textsubscript{13} and R\textsubscript{14};

R\textsubscript{13} represents a 4- to 7-membered monocyclic aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(=0)\textsubscript{p} and N; or a 6- to 11-membered bicyclic fused aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(=0)\textsubscript{p} and N;

said 4- to 7-membered monocyclic aromatic ring or 6- to 11-membered bicyclic fused aromatic ring is optionally substituted with one or two substituents selected from the group consisting of C\textsubscript{4}alkyl;

p represents 1 or 2;

R\textsubscript{14} represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;

Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);

R\textsuperscript{3a} represents hydrogen, halo, -NR\textsuperscript{7a}R\textsuperscript{7b}, C\textsubscript{3a}alkyl, C\textsubscript{2a}alkenyl, C\textsubscript{3a}cycloalkyl, -OH, or -0-C\textsubscript{3a}alkyl;

R\textsuperscript{7a} represents hydrogen;

R\textsuperscript{7b} represents hydrogen, C\textsubscript{3a}cycloalkyl, or C\textsubscript{4}alkyl.
R^{4a} represents hydrogen, halo, -NR^{8a}R^{8b}, or Ci_{4}alkyl;
R^{8a} and R^{8b} each independently represent hydrogen or Ci_{4}alkyl;
Q^1 represents N or CR^{6a};
Q^2 represents N or CR^{6b};
in particular Q^1 and Q^2 represent CH;
R^{8a} and R^{8b}, each independently represent hydrogen, halogen, Ci_{4}alkyl, -NR^{9a}R^{9b}, or
Ci_{4}alkyl substituted with one, two or three halo atoms;
R^{8a} and R^{8b} each independently represent hydrogen or Ci_{4}alkyl;
and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I),
wherein
R^1 represents hydrogen or -C(=0)-Ci_{4}alkyl;
R^2 represents hydrogen or -C(=0)-Ci_{4}alkyl;
Y represents -O-, -CH_{2}- or -CF_{2}-;
Z represents -CH_{2}-, -X-CR^{8a}R^{8b}, -CR^{8c}==CR^{8d}, -CR^{8e}R^{8f}CR^{8g}R^{8h}, or -C≡C-;
and when Y represents -CH_{2}- or -CF_{2}-, then Z can also represent -O- or -CR^{8a}R^{8b}X-;
R^{8a}, R^{8b}, R^{8c}, R^{8d}, R^{8e}, R^{8f}, R^{8g}, and R^{8h} each independently represent hydrogen or Ci_{4}alkyl;
X represents -O-, -S-, or -NR^{11}-(5);
R^{11} represents hydrogen, Ci_{alkyl}, or Ci_{alkyl} substituted with one substituent
selected from the group consisting of -OH, -O-Ci_{alkyl}, R^{12}, -NH_{2}, -NH-Ci_{alkyl}, and
-N(Ci_{alkyl})_{2};
R^{12} represents a 4-, 5-, 6- or 7-membered heterocyclic ring containing one nitrogen
atom and optionally one oxygen atom; said 4-, 5-, 6- or 7-membered heterocyclic ring
being attached to the remainder of the molecule via a ring nitrogen atom;
Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused
6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a
nitrogen atom; provided that when the nitrogen atom replaces one of the two fused
carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
Ar is optionally substituted with one, two, three or four substituents each independently
selected from the group consisting of halo, -OH, -NH_{2}, -NH-Ci_{alkyl}, -N(Ci_{alkyl})_{2},
cyano, -CF_{3}, -(=0)-NH-Ci_{alkyl}, -(=0)-Ci_{alkyl}, Ci_{alkyloxy}, and Ci_{alkyl}
optionally substituted with one -NR^{10a}R^{10b};
R^{10a} and R^{10b} each independently represent hydrogen or Ci_{alkyl};
Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
R^2a represents hydrogen, halo, -NR^2aR^7b, or -0-Ci_4alkyl;
R^2a represents hydrogen;
5 R^7b represents hydrogen or Ci_4alkyl;
R^8a represents hydrogen, halo, -NR^8aR^8b, or Ci_4alkyl;
R^8a and R^8b each independently represent hydrogen or Ci_4alkyl;
Q^1 represents N or CR^6a;
Q^2 represents N or CR^6b;
10 in particular Q^1 and Q^2 represent CH;
R^6a and R^6b each independently represent hydrogen, halo, Ci_4alkyl, -NR^9bR^9b, or
Ci_4alkyl substituted with one, two or three halo atoms;
R^9a and R^9b each independently represent hydrogen or Ci_4alkyl;
and pharmaceutically acceptable addition salts, and solvates thereof.
15 In an embodiment, the present invention concerns novel compounds of Formula (I),
wherein
R^1 represents hydrogen or -C(=0)-Ci_4alkyl;
R^2 represents hydrogen or -C(=0)-Ci_4alkyl;
Y represents -O- or -CH=CH-;
20 Z represents -CH=CH-, -X-CR^5aR^5b, -CR^5c=CR^5d, -CR^5eR^5f, -CR^5gR^5h, or -C≡C-;
and when Y represents -CH=CH-, then Z can also represent -CR^5aR^5b-X-;
R^5a, R^5b, R^5c, R^5d, R^5e, R^5f, R^5g, and R^5h each independently represent hydrogen or Ci_4alkyl;
X represents -O-, -S-, or -NR-;
25 R^11 represents hydrogen or Ci_4alkyl;
Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused
6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a
nitrogen atom; provided that when the nitrogen atom replaces one of the two fused
carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
30 Ar is optionally substituted with one, two, three or four substituents each independently
selected from the group consisting of halo, -OH, -NH_2, -NH-Ci_4alkyl, -N(Ci_4alkyl)_2,
-NHR, cyano, -CF_3, -C(=0)-NH_2, -C(=0)-NH-Ci_4alkyl, Ci_4alkyloxy, -C(=0)-0-Ci_4alkyl,
C_3-C_4cycloalkyl, C_2-C_3alkenyl, Ci_4alkyl substituted with one Ci_4alkyloxy, and Ci_4alkyl
optionally substituted with one -NR-;
35 R^10a and R^10b represent Ci_4alkyl;
R^{10d} represents C_{3-6}cycloalkyl; R^{14}; Ci_{4}alkyl substituted with one, two or three halo substituents; or Ci_{4}alkyl substituted with one substituent selected from the group consisting of C_{3-6}cycloalkyl, and R^{14};

R^{14} represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;

Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-4);

R^{3a}, R^{3b}, R^{3c} and R^{3d} each independently represent hydrogen, halo, -NR^{4a}R^{7b}, C_{2-4}alkenyl, C_{3-6}cycloalkyl, -OH, or -0-CN_{4}alkyl;

R^{7a} represents hydrogen;

R^{7b} represents hydrogen, C_{3-6}cycloalkyl, or Ci_{4}alkyl;

R^{4a}, R^{4b}, R^{4c}, R^{4d}, R^{4e} and R^{4f} each independently represent hydrogen, halo, -NR^{5a}R^{5b}, or Ci_{4}alkyl;

R^{5a} and R^{5b} each independently represent hydrogen;

Q^{1} represents CR^{6a};

Q^{2} represents CR^{6b};

Q^{6} represents CR^{6g};

Q^{5} represents CR^{3d}; Q^{6} represents N; and Q^{7} represents CR^{4f}; or

Q^{5} represents CR^{3d}; Q^{6} represents CR^{4e}; and Q^{7} represents N; or

Q^{5} represents N; Q^{6} represents CR^{4e}; and Q^{7} represents CR^{4f}; or

Q^{5} represents N; Q^{6} represents CR^{4e}; and Q^{7} represents N;

R^{6a}, R^{6b}, R^{6c}, R^{6d}, R^{6e}, R^{6f}, R^{6g} and R^{6h} each independently represent hydrogen, halogen, or Ci_{4}alkyl;

and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I), wherein

R^{1} represents hydrogen or -C(=0)-Ci_{4}alkyl;

R^{2} represents hydrogen or -C(=0)-Ci_{4}alkyl;

Y represents -0-, or -CH_{2}--;

Z represents -CH_{2}--; -X-CR^{5a}R^{5b}--; -CR^{5c}=CR^{5d}--; -CR^{5e}R^{5f}; -CR^{5g}R^{5h}--; or -C≡C--; and when Y represents -CH_{2}--; then Z can also represent -O--; or -CR^{5a}R^{5b}-X--; R^{5a}, R^{5b}, R^{5c}, R^{5d}, R^{5e}, R^{5f}, R^{5g}, and R^{5h} each independently represent hydrogen or Ci_{4}alkyl;

X represents -0-, -S-, or -NR^{11}--;

R^{11} represents hydrogen or Ci_{4}alkyl;
Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;

Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, -OH, -NH₂, -NH-Cᵣ₋₄alkyl, -N(C₁₋₄alkyl)₂, cyano, -CF₃, -C(=0)-NH-Cᵣ₋₄alkyl, -C(=0)-Ci₋₄alkyl, Ci₋₄alkyloxy, and Ci₋₄alkyl optionally substituted with one -NR₁₀⁻R₁₀⁺;

R₁₀⁻ and R₁₀⁺ each independently represent hydrogen or Ci₋₄alkyl;

Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3):

R₁ᵃ, R₂ᵇ and R₃ᶜ each independently represent hydrogen, halo, -NR₇⁻R₇⁺, or -0-Ci₋₄alkyl;

R₇ᵃ represents hydrogen;

R₇ᵇ represents hydrogen or Ci₋₄alkyl;

R₄ᵃ, R₅ᵇ and R₆ᶜ each independently represent hydrogen, halo, -NR₈⁻R₈ᵇ, or Ci₋₄alkyl;

R₈ᵃ and R₈ᵇ each independently represent hydrogen or Ci₋₄alkyl;

Q₁ represents CR₆ᵃ;

Q² represents CR₆ᵇ;

Q³ represents CR₆ᶜ;

Q⁴ represents CR₆ᵈ;

R₆ᵃ, R₆ᵇ, R₆ᶜ, R₆ᵈ, R₆ᵉ and R₆ᶠ each independently represent hydrogen, halogen, Ci₋₄alkyl, -NR₉ᵃR₉ᵇ, or Ci₋₄alkyl substituted with one, two or three halo atoms;

R₉ᵃ and R₉ᵇ each independently represent hydrogen or Ci₋₄alkyl;

and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I), wherein

R¹ represents hydrogen or -C(=0)-Ci₋₄alkyl;

R² represents hydrogen or -C(=0)-Ci₋₄alkyl;

Y represents -O⁻, or -CH₂⁻;

Z represents -CH₂⁻, -X-CR₅ᵉR₅ᵇ⁻, -CR₅ᵉ=CR₅ᵈ⁻, -CR₅ᵉ⁻CR₅ᵇ⁻CR₅ᵇ⁻, or -C≡C⁻;

and when Y represents -CH₂⁻, then Z can also represent -O⁻ or -CR₅ᵉ⁻R₅ᵇ⁻X⁻;

R₅ᵃ, R₅ᵇ, R₅ᶜ, R₅ᵈ, R₅ᵉ, R₅ᶠ, R₅ᵍ, and R₅ʰ each independently represent hydrogen or Ci₋₄alkyl;

X represents -O⁻, -S⁻, or -NR₁¹⁻;

R¹¹ represents hydrogen or Ci₋₄alkyl;
Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;

Ar is optionally substituted with one substituent selected from the group consisting of halo, -OH, -NH₂, -NH-Cᵣalkyl, -N(C₁₋₄alkyl)₂, cyano, -CF₃, -C(=0)-NH-C₁₋₄alkyl, -C(=O)-C₁₋₄alkyl, Ci₄alkyloxy, and Ci₄alkyl optionally substituted with one -

R₁₀a and R₁₀b each independently represent hydrogen or Ci₄alkyl;

Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3);

R³ᵃ, R³ᵇ and R³ᶜ each independently represent -NR²ᵇR⁷ᵇ;

R⁷ᵇ represents hydrogen;

R⁴ᵃ, R⁴ᵇ and R⁴ᶜ each independently represent hydrogen, halo, -NR⁸ᵇR⁸ᵇ or Ci₄alkyl;

R⁸ᵃ and R⁸ᵇ each independently represent hydrogen or Ci₄alkyl;

Q¹ represents CR⁶ᵃ;

Q² represents CR⁶ᵇ;

Q³ represents CR⁶ᶜ;

Q⁴ represents CR⁶ᵈ;

R⁶ᵃ, R⁶ᵇ, R⁶ᶜ, R⁶ᵈ, R⁶ᵉ and R⁶ᶠ each independently represent hydrogen, halogen, Ci₄alkyl, -NR⁹ᵇR⁹ᵇ or Ci₄alkyl substituted with one, two or three halo atoms;

R⁹ᵃ and R⁹ᵇ each independently represent hydrogen or Ci₄alkyl;

and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I), wherein

R¹ represents hydrogen or -C(=0)-Ci₄alkyl;

R² represents hydrogen or -C(=0)-Ci₄alkyl; in particular R¹ and R² represent hydrogen;

Y represents -O- or -CH₂⁻;

Z represents -CH₂⁻, -X-CR⁵ᵃR⁷ᵇ, -CR⁵ᶜ≡CR⁵ᵈ, -CR⁵ᵉR⁵ᵇ-CR⁵ᵇR⁷ᵇ, or -C≡C⁻; and when Y represents -CH₂⁻, then Z can also represent -CR⁵ᵇR⁷ᵇ-X⁻;

R⁵ᵃ, R⁵ᵇ, R⁵ᶜ, R⁵ᵈ, R⁵ᵉ, R⁵ᶠ, R⁵ᵍ, and R⁵ʰ each independently represent hydrogen or Ci₄alkyl;

X represents -O-, -S-, or -NR¹¹⁻;

R¹¹ represents hydrogen or Ci₄alkyl;
Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;

Ar is optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH, -NH₂, -NH-CN, -N(C₅H₄alkyl)₂, cyano, -CF₃, -C(=O)-NH-CN, CN, alkyl, alkylthio, aryloxy, and alkylthio; nitrogen

Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1) and (a-2);

R¹a and R¹c each independently represent halo, -NR²bR³b, or -O-CN₄alkyl; R³a represents hydrogen; R³b represents hydrogen; R⁴a, and R⁴c each independently represent hydrogen, halo, or CN₄alkyl; Q¹ represents CR⁶a; Q² represents CR⁶b; R⁶a, R⁶b, R⁶c and R⁶f each independently represent hydrogen, halogen, or CN₄alkyl; and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I).

wherein

R¹ represents hydrogen or -C(=O)-CN₄alkyl; R² represents hydrogen or -C(=O)-CN₄alkyl; in particular R¹ and R² represent hydrogen; Y represents -O- or -CH₂-.

Z represents -CH₂-, -X-CR⁵bR⁶b-, -CR⁵c=CR⁵d-, -CR⁵eR⁵fCR⁵gR⁵h-, or -C≡C-; and when Y represents -CH₂-, then Z can also represent -CR⁵bR⁵hX-.

R⁵a, R⁵b, R⁵c, R⁵d, R⁵e, R⁵f, R⁵g, and R⁵h each independently represent hydrogen or CN₄alkyl; X represents -O-, -S-, or -NR¹¹-.

R¹¹ represents hydrogen or CN₄alkyl; Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;
Ar is optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH, -NH₂, -NH-C₄₅alkyl, -N(C₁₄₂alkyl), -NHR, -CF₃, -C(=0)-NH-C₁₄₂alkyl, C₁₄₂alkyloxy, and C₄₂alkyl; R³d represents C₁₄₂alkyl substituted with one, two or three halo substituents; or C₄₂alkyl substituted with one C₃₂cycloalkyl; Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1) and (a-2); R³a and R³c each independently represent hydrogen, halo, -NR⁷aR⁷b, or -0-C₁₄₂alkyl; R⁷a represents hydrogen; R⁷b represents hydrogen or C₁₄₂alkyl; R⁸a, and R⁴e each independently represent hydrogen, halo, or C₁₄₂alkyl; Q¹ represents CR⁶a; Q² represents CR⁶b; R⁶a, R⁶b, R⁶e and R⁶f each independently represent hydrogen, halogen, or C₁₄₂alkyl; and pharmaceutically acceptable addition salts, and solvates thereof.

Another embodiment of the present invention relates to those compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more of the following restrictions apply:

(i) R¹ and R² represent hydrogen;
(ii) Y represents -O- or -CH₂⁻; in particular Y represents -O-;
(iii) Z represents -CH₂⁻, -X-CR⁵aR⁵b, -CR⁵cCR⁵d, -CR⁵aR⁵bCR⁵fR⁵b, or -C≡C⁻; and when Y represents -CH₂⁻, then Z can also represent -CR⁵aR⁵b-X⁻;
(iv) R⁵a, R⁵b, R⁵c, R⁵d, R⁵e, R⁵f, R⁵g, and R⁵h represent hydrogen;
(v) X represents -O⁻;
(vi) R¹¹ represents hydrogen or C₁₄₂alkyl;
(vii) Ar is optionally substituted with one, two or three substituents, in particular one substituent, each independently selected from the group consisting of halo, -OH, -NH₂, -NH-C₁₄₂alkyl, -N(C₁₄₂alkyl), cyano, -CF₃, -C(=0)-NH-C₁₄₂alkyl, C₁₄₂alkyloxy, and C₁₄₂alkyl;
(viii) Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1) and (a-2);
(ix) R³a and R³c each independently represent halo, -NR⁷aR⁷b, or -0-C₁₄₂alkyl;
(x) R⁷a and R⁷b represent hydrogen;
(xi) R⁴a, and R⁴e each independently represent hydrogen, halo, or C₁₄₂alkyl;
(xii) Q¹ represents CR⁶ᵃ;
(xiii) Q² represents CR⁶ᵇ;
(xiv) R⁶ᵃ, R⁶ᵇ, R⁶ᶜ and R⁶ᶠ each independently represent hydrogen, halogen, or Ci₄alkyl.

In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
R¹ represents hydrogen;
R² represents hydrogen;
Y represents -O- or -CH₂-;
Z represents -X-CR⁵ᵃR⁵ᵇ- or -CR⁵ᵃR⁵ᵇ-CR⁵ᶜR⁵ᵈ-; and when Y represents -CH₂-, then Z can also represent -CR⁵ᵃR⁵ᵇ-X-;
R⁵ᵃ, R⁵ᵇ, R⁵ᶜ, R⁵ᵈ, R⁵ᵉ and R⁵ᶠ represent hydrogen;
X represents -0-;

Ar represents

wherein Ar is optionally substituted in the position indicated by a with a substituent selected from the group consisting of -NH₂, -NH-Ci₄alkyl, and -NHR¹⁰ᵈ; and wherein Ar is optionally substituted in the position indicated by β with a substituent selected from the group consisting of halo and CF₃;

provided however that Ar is substituted in at least one of the positions indicated by a or β;
R¹⁰ᵈ represents C₃-cycloalkyl; Ci₄alkyl substituted with one, two or three halo substituents; or Ci₄alkyl substituted with one C₃-cycloalkyl substituent;
Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1) and (a-4);
R⁴ᵃ and R⁴ᵈ each independently represent hydrogen, halo, -NR⁷ᵃR⁷ᵇ, Ci₄alkyl, or -0-Ci₄alkyl;
R⁷ᵃ represents hydrogen;
R⁷ᵇ represents hydrogen or Ci₄alkyl;
R⁴ᵃ, R⁴ᵈ and R⁴ᶠ each independently represent hydrogen or halo;
Q¹ represents CR⁶ᵃ;
Q² represents CR⁶ᵇ;
Q⁸ represents CR⁶⁸; and
Q⁹ represents CR⁶ᵇ;
Q^5 represents CR^3d; Q^6 represents N; and Q^7 represents CR^4f;  
R^6a, R^6b, R^6f, and R^6h represent hydrogen;  
and pharmaceutically acceptable addition salts, and solvates thereof.

Another embodiment of the present invention relates to those compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more of the following restrictions apply:
(i) R^1 and R^2 represent hydrogen;
(ii) Y represents -O- or -CH=CH-;
(iii) Z represents -X-CR^5aR^5b- or -CR^5aR^5fCR^5fR^5h-;  
and when Y represents -CH=CH-, then Z can also represent -CR^5aR^5b-X-;
(iv) R^5a, R^5b, R^5c, R^5f, R^5g, and R^5h represent hydrogen;
(v) X represents -O-;
(vi) Ar represents

\[
\begin{array}{c}
\text{N} \\
\text{C} \\
\text{C} \\
\text{C} \\
\end{array}
\]

\(\alpha\)

\(\beta\)

wherein Ar is optionally substituted in the position indicated by a with a substituent selected from the group consisting of -NH_2, -NH-C_4alkyl, and -NHR^{10d}; and wherein Ar is optionally substituted in the position indicated by \(\beta\) with a substituent selected from the group consisting of halo and C_F;

provided however that Ar is substituted in at least one of the positions indicated by a or \(\beta\);
(vii) R^{10d} represents C_3cycloalkyl; C_{4alkyl substituted with one, two or three halo substituents; or C_{4alkyl substituted with one C_3cycloalkyl substituent;}
(viii) Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1) and (a-4);
(ix) R^3a and R^3d each independently represent hydrogen, halo, -NR^7aR^7b, C_{4alkyl}, or -O-C_{4alkyl};
(x) R^7a represents hydrogen;
(xi) R^7b represents hydrogen or C_{4alkyl};
(xii) R^4a, R^4d and R^4f each independently represent hydrogen or halo;
(xiii) Q^1 represents CR^6a;
(xiv) Q^2 represents CR^6b;
(xv) Q^8 represents CR^6g;
(xvi) Q^9 represents CR^6h;
(xvii) \( Q^5 \) represents CR\(^3d \); \( Q^6 \) represents N; and \( Q^7 \) represents CR\(^4f \);
(xviii) \( R^6a \), \( R^6b \), \( R^6g \), and \( R^6h \) represent hydrogen.

In an embodiment, the present invention concerns novel compounds of Formula (I),
wherein
\[ R^1 \] represents hydrogen;
\[ R^2 \] represents hydrogen;
\[ Y \] represents -O- or -CH\(_2\)-;
\[ Z \] represents -X-CR\(^5a\)R\(^5b\) or -CR\(^5g\)R\(^5g\)-CR\(^5f\)R\(^5h\); and when \( Y \) represents -CH\(_2\)-, then \( Z \) can also represent -CR\(^5a\)R\(^5b\)-X-;
\[ R^5a, R^5b, R^5g, R^5g, R^5f, R^5h \] represent hydrogen;
\[ X \] represents -O-;
\[ Ar \] represents

![Diagram](attachment:image.png)

wherein \( Ar \) is optionally substituted in the position indicated by a with a substituent selected from the group consisting of -NH\(_2\), -NH-C\(_4\)alkyl, and -NHR\(^{10d}\); and wherein \( Ar \) is optionally substituted in the position indicated by \( \beta \) with a substituent selected from the group consisting of halo and CF\(_3\); provided however that \( Ar \) is substituted in at least one of the positions indicated by a or \( \beta \);
\[ R^{10d} \] represents C\(_{4-6}\)cycloalkyl; C\(_{4-4}\)alkyl substituted with one, two or three halo substituents; or C\(_{4-4}\)alkyl substituted with one C\(_{3-4}\)cycloalkyl substituent;
\( Het \) represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
\[ R^{3a} \] represents hydrogen, halo, -NR\(^7a\)R\(^7b\), C\(_{4-4}\)alkyl, or -0-C\(_{4-4}\)alkyl;
\[ R^{7a} \] represents hydrogen;
\[ R^{7b} \] represents hydrogen or C\(_{4-4}\)alkyl;
\[ R^{4a} \] represents hydrogen or halo;
\[ Q^1 \] represents CR\(^6a\);
\[ Q^2 \] represents CR\(^6b\);
\[ R^6a \] and \( R^6b \) represent hydrogen;

and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I),
wherein
R¹ represents hydrogen;  
R² represents hydrogen;  
Y represents -O- or -CH₂⁻;  
Z represents -X-CR⁵αR⁵b or -CR⁵αR⁵f-CR⁵fR⁵b⁻;  
R⁵α, R⁵b, R⁵f, R⁵f, and R⁵f represent hydrogen;  
X represents -0⁻;  
Ar represents

wherein Ar is optionally substituted in the position indicated by a with a substituent selected from the group consisting of -NH₂, -NH-C₄alkyl, and -NHR₁₀d; and wherein Ar is optionally substituted in the position indicated by β with a substituent selected from the group consisting of halo and CF₃; provided however that Ar is substituted in at least one of the positions indicated by a or β;  
R₁₀d represents C₃₆cycloalkyl; Cᵣ₄alkyl substituted with one, two or three halo substituents; or Cᵣ₄alkyl substituted with one C₃₆cycloalkyl substituent;  
Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);  
R³α represents hydrogen, halo, -NR⁷αR⁷b, Cᵣ₄alkyl, or -0-Cᵣ₄alkyl;  
R⁷α represents hydrogen;  
R⁷b represents hydrogen or Cᵣ₄alkyl;  
R⁴α represents hydrogen or halo;  
Q¹ represents CR⁶α;  
Q² represents CR⁶b;  
R⁶α and R⁶b represent hydrogen;  
and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I), wherein  
R¹ represents hydrogen;  
R² represents hydrogen;  
Y represents -O- or -CH₂⁻;  
Z represents -X-CR⁵αR⁵b or -CR⁵αR⁵f-CR⁵fR⁵b⁻;  
and when Y represents -CH₂⁻, then Z can also represent -CR⁵αR⁵b-X⁻;  
R⁵α, R⁵b, R⁵f, R⁵f, and R⁵f represent hydrogen;
X represents -0-;

Ar represents

\[\begin{array}{c}
\text{N} \\
\swarrow \\
\alpha
\end{array}\]

wherein Ar is substituted in the position indicated by a with a substituent selected from the group consisting of -NH\_2, -NH-Ci\_4alkyl, and -NHR\_10d;

R\_10d represents C\_5\_6cycloalkyl; or C\_4alkyl substituted with one substituent selected from the group consisting of C\_3\_6Cycloalkyl, and R\_14;

R\_14 represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;

Het represents the bicyclic aromatic heterocyclic ring system (a-1);

R\_3a represents hydrogen, halo, -NR\_7aR\_7b, or Ci\_4alkyl;

R\_7a represents hydrogen;

R\_7b represents hydrogen or Ci\_4alkyl;

R\_8a represents hydrogen;

Q\_1 represents CR\_6a;

Q\_2 represents CR\_6b;

R\_6a and R\_6b represent hydrogen;

and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I), wherein

R\_1 represents hydrogen;

R\_2 represents hydrogen;

Y represents -O- or -CH\_2-;

Z represents -X-CR\_5aR\_5b or -CR\_5aR\_5c-CR\_5fR\_5h-;

and when Y represents -CH\_2-, then Z can also represent -CR\_5aR\_5b-X-;

R\_5a, R\_5b, R\_5c, R\_5f, R\_5g, and R\_5h represent hydrogen;

X represents -0-;

Ar represents

\[\begin{array}{c}
\text{N} \\
\swarrow \\
\beta
\end{array}\]

wherein Ar is optionally substituted in the position indicated by a with -NH\_2; and

wherein Ar is substituted in the position indicated by β with a substituent selected from the group consisting of halo and CF\_3;
Het represents the bicyclic aromatic heterocyclic ring system (a-1);
R^3a represents hydrogen, halo, -NR^7aR^7b, or Ci₄alkyl;
R^7a represents hydrogen;
R^7b represents hydrogen or Ci₄alkyl;
R^4a represents hydrogen;
Q^1 represents CR^6a;
Q^2 represents CR^6b;
R^6a and R^6b represent hydrogen;
and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I),
wherein
R^1 represents hydrogen;
R^2 represents hydrogen;
Y represents -O- or -CH₂-;
Z represents -X-CR^5aR^6b- or -CR^5aR^5e-CR^5fR^5h-;
and when Y represents -CH₂-, then Z can also represent -CR^5aR^5b.X-;
R^5a, R^5b, R^5e, R^5f, and R^5h represent hydrogen;
X represents -O-;
Ar represents
\[
\begin{array}{c}
\alpha \\
\beta \\
\end{array}
\]
wherein Ar is substituted in the position indicated by α with -NH₂; and
wherein Ar is substituted in the position indicated by β with a substituent selected from
the group consisting of halo and CF₃;
Het represents the bicyclic aromatic heterocyclic ring system (a-1);
R^3a represents hydrogen, halo, -NR^7aR^7b, or Ci₄alkyl;
R^7a represents hydrogen;
R^7b represents hydrogen or Ci₄alkyl;
R^4a represents hydrogen;
Q^1 represents CR^6a;
Q^2 represents CR^6b;
R^6a and R^6b represent hydrogen;
and pharmaceutically acceptable addition salts, and solvates thereof.
In an embodiment, the present invention concerns novel compounds of Formula (I),
wherein

R^1 represents hydrogen;
R^2 represents hydrogen;

Y represents -O- or -CH\_2-;
Z represents -X-CR^aR^b- or -CR^aR^b-CR^aR^b-;
and when Y represents -CH\_2-, then Z can also represent -CR^aR^b-X-;

R^a, R^b, R^s, R^s, R^s, and R^s represent hydrogen;

X represents -O-;

Ar represents

Het represents the bicyclic aromatic heterocyclic ring system (a-1);
R^3 represents hydrogen, halo, -NR^aR^b, or C\_i\_alkyl;
R^3 represents hydrogen;

R^3 represents hydrogen or C\_i\_alkyl;
R^a represents hydrogen;
Q^1 represents CR^6a;
Q^2 represents CR^6b;
R^6a and R^6b represent hydrogen;

and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I),
wherein

R^1 represents hydrogen or -C(=O)-C\_i\_alkyl;
R^2 represents hydrogen or -C(=O)-C\_i\_alkyl;
in particular R^1 and R^2 represent hydrogen;

Y represents -CH\_2- or -O-;
Z represents -X-CR^aR^b- or -CH\_2CH\_2-;
R^a and R^b each independently represent hydrogen or C\_i\_alkyl;

X represents -O-, -S-, or -NR^11-;
R^11 represents hydrogen;

Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused
6-membered rings, wherein 1 or 2 ring carbon atoms are replaced by a nitrogen atom;
provided that when the nitrogen atom replaces one of the two fused carbon atoms, a
carbonyl group is present in said bicyclic aromatic ring system;
Ar is optionally substituted with one or two substituents each independently selected from the group consisting of halo, -OH, -NH$_2$, -NH-C$_i$$_4$alkyl, -N(C$_i$$_4$alkyl)$_2$, cyano, -CF$_3$, -C(=0)-NH-C$_i$$_4$alkyl, -C(=0)-Ci$_4$alkyl, Ci$_4$alkyloxy, and Ci$_4$alkyl optionally substituted with one -NR$^{10a}$R$^{10b}$;

R$^{10a}$ and R$^{10b}$ each independently represent hydrogen or Ci$_4$alkyl;

Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);

R$_{3a}$ represents hydrogen, halo, -NR$^{7a}$R$^{7b}$, or -0-Ci$_4$alkyl;

R$^{7a}$ represents hydrogen;

R$^{7b}$ represents hydrogen;

R$_{4a}$ represents hydrogen, halo, -NR$^{8a}$R$^{8b}$, or Ci$_4$alkyl;

R$^{8a}$ and R$^{8b}$ each independently represent hydrogen or Ci$_4$alkyl;

Q$^1$ represents CR$_6$;

Q$^2$ represents CR$_6$;

R$_{6a}$ and R$^{6b}$ each independently represent hydrogen, halogen, Ci$_4$alkyl, -NR$^{9a}$R$^{9b}$, or Ci$_4$alkyl substituted with one, two or three halo atoms;

R$^{9a}$ and R$^{9b}$ each independently represent hydrogen or Ci$_4$alkyl;

and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I).

wherein

R$^1$ represents hydrogen;

R$^2$ represents hydrogen;

Y represents -CH$_2$;

Z represents -CR$^{5a}$R$^{5b}$-CR$^{5a}$R$^{5b}$;

R$^{5a}$, R$^{5b}$, and R$^{5b}$ represent hydrogen;

Ar represents any one of the following 10-membered bicyclic aromatic ring systems:

Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, -NH$_2$, -NH-Ci$_4$alkyl, -N(Ci$_4$alkyl)$_2$, -NHR$^{10a}$, -NR$^{10a}$R$^{10d}$;

R$^{10c}$ and R$^{10d}$ each independently represent C$_3$-$cycloalkyl$; C$_3$-$cycloalkyl$ substituted with one, two or three substituents each independently selected from the group
consisting of halo, -OH and -0-Ci₄alkyl; Ci₄alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH and -0-Ci₄alkyl; or Ci₄alkyl substituted with one C₃₋₆cycloalkyl substituent;

Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);

5 \( R^{3a} \) represents hydrogen, -NR\(^7a\)R\(^7b\), or -0-Ci₄alkyl;
\( R^{7a} \) represents hydrogen;
\( R^{7b} \) represents hydrogen or Ci₄alkyl;
\( R^{6a} \) represents hydrogen;

10 \( Q^1 \) represents CR\(^6a\);
\( Q^2 \) represents CR\(^6b\);
\( R^{6a} \) and \( R^{6b} \) represent hydrogen;
and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I), wherein

15 \( R^1 \) represents hydrogen;
\( R^2 \) represents hydrogen;
\( Y \) represents -CH\(_2\);

\( Z \) represents -CR\(^5e\)R\(^5f\)-CR\(^5f\)R\(^5b\);
\( R^{5e}, R^{5f}, R^{5g}, \) and \( R^{5b} \) represent hydrogen;

Ar represents

\[ \text{Ar} \]

Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, -NH₂, -NH-Ci₄alkyl, -N(Ci₄alkyl)₂,

\( R^{10d} \) represents CI₄alkyl substituted with one, two or three halo substituents; or
CI₄alkyl substituted with one C₃₋₆cycloalkyl substituent;

Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);

\( R^{3a} \) represents hydrogen, -NR\(^7a\)R\(^7b\), or -0-Ci₄alkyl;
\( R^{7a} \) represents hydrogen;
\( R^{7b} \) represents hydrogen or Ci₄alkyl;
\( R^{6a} \) represents hydrogen;

35 \( Q^1 \) represents CR\(^6a\);
Another embodiment of the present invention relates to those compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more of the following restrictions apply:

(i) $R^1$ represents hydrogen;

(ii) $R^2$ represents hydrogen;

(iii) $Y$ represents $-\text{CH}_2-$;

(iv) $Z$ represents $-\text{CR}^5\text{R}^5\text{R}^5\text{CR}^5$;

(v) $R^6$, $R^5$, $R^8$, and $R^5$ represent hydrogen;

(vi) $R^10d$ represents $\text{Ci}_4\text{alkyl}$ substituted with one, two or three halo substituents; or $\text{Ci}_4\text{alkyl}$ substituted with one $\text{C}_3$-$\text{C}_6$ cycloalkyl substituent;

(vii) Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);

(viii) $R^3$ represents hydrogen, $-\text{NR}^7\text{R}^7b$, or $-\text{0-Cl}_4\text{alkyl}$;

(ix) $R^7$ represents hydrogen;

(x) $R^4a$ represents hydrogen;

(xi) $Q^1$ represents $\text{CR}^{6a}$;

$xii) Q^2$ represents $\text{CR}^{6b}$;

(xii) $R^6a$ and $R^6b$ represent hydrogen.
(i) \( R^1 \) represents hydrogen or \(-\text{C}(=\text{O})\text{-C}1\text{a}_{\text{alkyl}}\);
\( R^2 \) represents hydrogen or \(-\text{C}(=\text{O})\text{-C}1\text{a}_{\text{alkyl}}\);
in particular \( R^1 \) and \( R^2 \) represent hydrogen;
(ii) \( Y \) represents \(-\text{CH}_2\text{- or -0-};\)
(iii) \( Z \) represents \(-\text{X}-\text{CR}^5\text{a}\text{R}^5\text{b} \) or \(-\text{CH}_2\text{CH}_2\text{-};\)
(iv) \( R^8\text{a} \) and \( R^8\text{b} \) each independently represent hydrogen or \( \text{Ci}_{\text{a}}\text{alkyl} \);
(v) \( X \) represents \(-\text{O-}, -\text{S-}, \) or \(-\text{NR}^1\text{a} \); 
(vi) \( R^1\text{a} \) represents hydrogen;
(vii) \( \text{Ar} \) is optionally substituted with one or two substituents each independently 
selected from the group consisting of \( \text{halo}, -\text{OH}, -\text{NH}_2, -\text{NH-Ci}_{\text{a}}\text{alkyl}, -\text{N(C}1\text{a}_{\text{alkyl}})_2,\)
\text{cyano, -CF}_3, -\text{C}(=\text{O})-\text{NH-C}1\text{a}_{\text{alkyl}}, -\text{C}1\text{a}_{\text{alkyl}}\text{, Ci}_{\text{a}}\text{alkyloxy, and Ci}_{\text{a}}\text{alkyl} \)
optionally substituted with one \(-\text{NR}^1\text{a}\text{R}^1\text{b} \);
(viii) \( R^{10}\text{a} \) and \( R^{10}\text{b} \) each independently represent hydrogen or \( \text{Ci}_{\text{a}}\text{alkyl} \);
(ix) \( \text{Het} \) represents a bicyclic aromatic heterocyclic ring system selected from the group
consisting of (a-1);
(x) \( R^{\text{8a}} \) represents hydrogen, \( \text{halo}, -\text{NR}^{7\text{a}}\text{R}^{7\text{b}}, \) or \( -\text{0-Ci}_{\text{a}}\text{alkyl} \);
(xi) \( R^{\text{7b}} \) represents hydrogen;
\( R^{\text{7a}} \) represents hydrogen;
\( R^{\text{4a}} \) represents hydrogen, \( \text{halo, -NR}^8\text{a}\text{R}^8\text{b}, \) or \( \text{Ci}_{\text{a}}\text{alkyl} \);
(xiii) \( R^{\text{8a}} \) and \( R^{\text{8b}} \) each independently represent hydrogen or \( \text{Ci}_{\text{a}}\text{alkyl} \);
(xiv) \( Q^1 \) represents \( \text{CR}^6\text{a} \);
(xv) \( Q^2 \) represents \( \text{CR}^6\text{b} \);
(xvi) \( R^{\text{8a}} \) and \( R^{\text{8b}} \) each independently represent hydrogen, \( \text{halogen, Ci}_{\text{a}}\text{alkyl, -NR}^9\text{a}\text{R}^9\text{b}, \)
or \( \text{Ci}_{\text{a}}\text{alkyl substituted with one, two or three halo atoms};\)
(xvii) \( R^{\text{9a}} \) and \( R^{\text{9b}} \) each independently represent hydrogen or \( \text{Ci}_{\text{a}}\text{alkyl} \).

In an embodiment, the present invention concerns novel compounds of Formula (I),
wherein
\( R^1 \) represents hydrogen or \(-\text{C}(=\text{O})\text{-Ci}_{\text{a}}\text{alkyl} \);
\( R^2 \) represents hydrogen or \(-\text{C}(=\text{O})\text{-Ci}_{\text{a}}\text{alkyl} \);
in particular \( R^1 \) and \( R^2 \) represent hydrogen;
\( Y \) represents \(-\text{0-};\)
\( Z \) represents \(-\text{X}-\text{CR}^5\text{a}\text{R}^5\text{b} \);
\( R^8\text{a} \) and \( R^8\text{b} \) each independently represent hydrogen or \( \text{Ci}_{\text{a}}\text{alkyl} \);
\( X \) represents \(-\text{O-}, -\text{S-}, \) or \(-\text{NR}^{11\text{a}} \);
\( R^{11} \) represents hydrogen;
Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;

Ar is optionally substituted with one or two substituents each independently selected from the group consisting of halo, -OH, -NH₂, -NH-C₄alkyl, -N(C₄alkyl)₂, cyano, -CF₃, -C(=0)-NH-C₄alkyl, -C(=0)-C₄alkyl, C₄alkyloxy, and C₄alkyl optionally substituted with one -NR₁⁰R₁⁰b; R₁⁰a and R₁⁰b each independently represent hydrogen or C₄alkyl;

Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-I);

R³a represents hydrogen, halo, -NR³aR³b, or 0-C₄alkyl; R³b represents hydrogen; R³b represents hydrogen;

R⁴a represents hydrogen, halo, -NR⁴aR⁴b, or C₄alkyl; R⁴a and R⁴b each independently represent hydrogen or C₄alkyl;

Q¹ represents CR⁶a; Q² represents CR⁶b;

R⁶a and R⁶b each independently represent hydrogen, halogen, C₄alkyl, -NR³aR⁹b, or C₄alkyl substituted with one, two or three halo atoms; R⁹a and R⁹b each independently represent hydrogen or C₄alkyl; and pharmaceutically acceptable addition salts, and solvates thereof.

Another embodiment of the present invention relates to those compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more of the following restrictions apply:

(i) R¹ represents hydrogen or -C(=0)-C₄alkyl;

R² represents hydrogen or -C(=0)-C₄alkyl; in particular R¹ and R² represent hydrogen;

(ii) Y represents -0-;

(iii) Z represents -X-CR⁵aR⁵b-;

(iv) R⁵a and R⁵b each independently represent hydrogen or C₄alkyl;

(v) X represents -0-, -S-, or -NR¹¹-;

(vi) R¹¹ represents hydrogen;

(vii) Ar is optionally substituted with one or two substituents each independently selected from the group consisting of halo, -OH, -NH₂, -NH-C₄alkyl, -N(C₄alkyl)₂,
cyano, -CF<sub>3</sub>, -C(=0)-NH-C<sub>4</sub>alkyl, -C(=0)-C<sub>4</sub>alkyl, C<sub>4</sub>alkyloxy, and C<sub>4</sub>alkyl optionally substituted with one -NR<sup>10a</sup>R<sup>10b</sup>;

(viii) R<sup>10a</sup> and R<sup>10b</sup> each independently represent hydrogen or C<sub>4</sub>alkyl;

(ix) Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);

(x) R<sup>3a</sup> represents hydrogen, halo, -NR<sup>7a</sup>R<sup>7b</sup>, or -0-C<sub>4</sub>alkyl;

(xi) R<sup>7a</sup> represents hydrogen;

R<sup>7b</sup> represents hydrogen;

(xii) R<sup>4a</sup> represents hydrogen, halo, -NR<sup>5a</sup>R<sup>5b</sup>, or C<sub>4</sub>alkyl;

(xiii) R<sup>5a</sup> and R<sup>5b</sup> each independently represent hydrogen or C<sub>4</sub>alkyl;

(xiv) Q<sup>1</sup> represents CR<sup>6a</sup>;

(xv) Q<sup>2</sup> represents CR<sup>6b</sup>;

(xvi) R<sup>6a</sup> and R<sup>6b</sup> each independently represent hydrogen, halogen, C<sub>4</sub>alkyl, -NR<sup>9a</sup>R<sup>9b</sup>, or C<sub>4</sub>alkyl substituted with one, two or three halo atoms;

(xvii) R<sup>9a</sup> and R<sup>9b</sup> each independently represent hydrogen or C<sub>4</sub>alkyl.

In an embodiment, the present invention concerns novel compounds of Formula (I), wherein

R<sup>1</sup> represents hydrogen or -C(=0)-C<sub>4</sub>alkyl;

R<sup>2</sup> represents hydrogen or -C(=0)-C<sub>4</sub>alkyl;

in particular R<sup>1</sup> and R<sup>2</sup> represent hydrogen;

Y represents -CH<sub>2</sub>- or -0-;

Z represents -X-CR<sup>5a</sup>R<sup>5b</sup>- or -CH<sub>2</sub>CH<sub>2</sub>-;

R<sup>5a</sup> and R<sup>5b</sup> each independently represent hydrogen or C<sub>4</sub>alkyl;

X represents -0-, -S-, or -NR<sup>11a</sup>;

R<sup>11</sup> represents hydrogen;

Ar represents ; in particular Ar represents ;

Ar is optionally substituted with one or two substituents each independently selected from the group consisting of halo, -OH, -NH<sub>2</sub>, -NH-C<sub>4</sub>alkyl, -N(C<sub>4</sub>alkyl)<sub>2</sub>, cyano, -CF<sub>3</sub>, -C(=0)-NH-C<sub>4</sub>alkyl, -C(=0)-C<sub>4</sub>alkyl, C<sub>4</sub>alkyloxy, and C<sub>4</sub>alkyl optionally substituted with one -NR<sup>10a</sup>R<sup>10b</sup>;

R<sup>10a</sup> and R<sup>10b</sup> each independently represent hydrogen or C<sub>4</sub>alkyl;

Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
R\textsuperscript{3a} represents hydrogen, halo, -NR\textsuperscript{7a}R\textsuperscript{7b}, or -0-C\textsubscript{i}_4 alkyl; 
R\textsuperscript{7a} represents hydrogen; 
R\textsuperscript{7b} represents hydrogen; 
R\textsuperscript{8a} represents hydrogen, halo, -NR\textsuperscript{8a}R\textsuperscript{8b}, or Ci\textsubscript{4}alkyl; 
5 R\textsuperscript{8a} and R\textsuperscript{8b} each independently represent hydrogen or Ci\textsubscript{4}alkyl; 
Q\textsuperscript{1} represents CR\textsuperscript{6a}; 
Q\textsuperscript{2} represents CR\textsuperscript{6b}; 
R\textsuperscript{6a} and R\textsuperscript{6b} each independently represent hydrogen, halogen, Ci\textsubscript{4}alkyl, -NR\textsuperscript{9a}R\textsuperscript{9b}, or Ci\textsubscript{4}alkyl substituted with one, two or three halo atoms; 
and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
15 R\textsuperscript{1} represents hydrogen or -C(=0)-Ci\textsubscript{4}alkyl; 
R\textsuperscript{2} represents hydrogen or -C(=0)-Ci\textsubscript{4}alkyl; 
in particular R\textsuperscript{1} and R\textsuperscript{2} represent hydrogen; 
Y represents -0-; 
Z represents -X-CR\textsuperscript{5a}R\textsuperscript{5b}-; 
20 R\textsuperscript{5a} and R\textsuperscript{5b} each independently represent hydrogen or Ci\textsubscript{4}alkyl; 
X represents -0-, -S-, or -NR\textsuperscript{11}-; 
R\textsuperscript{11} represents hydrogen; 

\begin{center}
\includegraphics{structure.png}
\end{center}

Ar represents ; in particular Ar represents ; 
Ar is optionally substituted with one or two substituents each independently selected from the group consisting of halo, -OH, -NH\textsubscript{2}, -NH-Ci\textsubscript{4}alkyl, -N(Ci\textsubscript{4}alkyl)\textsubscript{2}, cyano, -CF\textsubscript{3}, -C(=0)-NH-Ci\textsubscript{4}alkyl, -C(=0)-Ci\textsubscript{4}alkyl, Ci\textsubscript{4}alkyloxy, and Ci\textsubscript{4}alkyl optionally substituted with one -NR\textsuperscript{10a}R\textsuperscript{10b}; 
R\textsuperscript{10a} and R\textsuperscript{10b} each independently represent hydrogen or Ci\textsubscript{4}alkyl; 
Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1); 
30 R\textsuperscript{3a} represents hydrogen, halo, -NR\textsuperscript{7a}R\textsuperscript{7b}, or -0-Ci\textsubscript{4}alkyl; 
R\textsuperscript{7a} represents hydrogen; 
R\textsuperscript{7b} represents hydrogen; 
R\textsuperscript{8a} represents hydrogen, halo, -NR\textsuperscript{8a}R\textsuperscript{8b}, or Ci\textsubscript{4}alkyl;
R^{8a} and R^{8b} each independently represent hydrogen or Ci_{4}alkyl;
Q^{1} represents CR^{6a};
Q^{2} represents CR^{6b};
R^{8a} and R^{6b} each independently represent hydrogen, halogen, Ci_{4}alkyl, -NR^{9a}R^{9b}, or Ci_{4}alkyl substituted with one, two or three halo atoms;
R^{8a} and R^{6b} each independently represent hydrogen or Ci_{4}alkyl;
and pharmaceutically acceptable addition salts, and solvates thereof.

Another embodiment of the present invention relates to those compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more of the following restrictions apply:
(i) R^{1} represents hydrogen or -C(=0)-Ci_{4}alkyl;
R^{2} represents hydrogen or -C(=0)-Ci_{4}alkyl;
in particular R^{1} and R^{2} represent hydrogen;
(ii) Y represents -O-;
(iii) Z represents -X-CR^{5a}R^{5b} ;
(iv) R^{5a} and R^{5b} each independently represent hydrogen or Ci_{4}alkyl;
(v) X represents -O-, -S-, or -NR^{11-};
(vi) R^{11} represents hydrogen;
(vii) Ar represents ; in particular Ar represents ;
(viii) Ar is optionally substituted with one or two substituents each independently selected from the group consisting of halo, -OH, -NH_{2}, -NH-Ci_{4}alkyl, -N(C_{1-4}alkyl)_{2}, cyano, -CF_{3}, -C(=0)-NH-Ci_{4}alkyl, -C(=0)-Ci_{4}alkyl, Ci_{4}alkyloxy, and Ci_{4}alkyl optionally substituted with one -NR^{10a}R^{10b};
(ix) R^{10a} and R^{10b} each independently represent hydrogen or Ci_{4}alkyl;
(x) Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
(xi) R^{3a} represents hydrogen, halo, -NR^{7a}R^{7b}, or-0-Ci_{4}alkyl;
(xii) R^{7a} represents hydrogen;
R^{7b} represents hydrogen;
(xiii) R^{4a} represents hydrogen, halo, -NR^{8a}R^{8b}, or Ci_{4}alkyl;
(xiv) R^{8a} and R^{8b} each independently represent hydrogen or Ci_{4}alkyl;
(xv) Q^{1} represents CR^{6a};
(xvi) Q^{2} represents CR^{6b};
(xvii) \( R^{5a} \) and \( R^{5b} \) each independently represent hydrogen, halogen, \( \text{Ci}_4 \) alkyl, -NR\(^2\)R\(^b\), or \( \text{Ci}_4 \) alkyl substituted with one, two or three halo atoms;
(xviii) \( R^{5b} \) and \( R^{5b} \) each independently represent hydrogen or \( \text{Ci}_4 \) alkyl.

In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
\[
\begin{align*}
R^1 & \text{ represents hydrogen or } -\text{C}(=0)\text{-Ci}_4\text{ alkyl;}
R^2 & \text{ represents hydrogen or } -\text{C}(=0)\text{-Ci}_4\text{ alkyl;}
in \text{ particular } R^1 \text{ and } R^2 \text{ represent hydrogen;}
Y & \text{ represents } -\text{O-} \text{ or } -\text{CH}_2-;
Z & \text{ represents } -\text{X-CR}^5\text{a-R}^5\text{b-} \text{ or } -\text{CH}_2\text{CH}_2-;
R^5\text{a} \text{ and } R^5\text{b} \text{ represent hydrogen; } X \text{ represents } -\text{O-};
R^{11} & \text{ represents hydrogen;}
\end{align*}
\]
\[\text{Ar represents } \]
\[\text{Ar is optionally substituted with one or two substituents each independently selected from the group consisting of halo, } -\text{OH}, -\text{NH}_2, -\text{NH-Ci}_4\text{ alkyl, } -\text{N(Ci}_4\text{ alkyl)}_2, \text{ cyano, and } -\text{CF}_3; \]
Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
\[
\begin{align*}
R^3\text{a} & \text{ represents } -\text{NR}^2\text{b-R}^7\text{b};
R^7\text{a} & \text{ represents hydrogen;}
R^7\text{b} & \text{ represents hydrogen;}
Q^1 & \text{ represents } CR^6\text{a};
Q^2 & \text{ represents } CR^6\text{b};
R^6\text{a} \text{ and } R^6\text{b} \text{ represent hydrogen;}
\text{ and pharmaceutically acceptable addition salts, and solvates thereof.}
\end{align*}
\]

In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
\[
\begin{align*}
R^1 & \text{ represents hydrogen or } -\text{C}(=0)\text{-Ci}_4\text{ alkyl;}
R^2 & \text{ represents hydrogen or } -\text{C}(=0)\text{-Ci}_4\text{ alkyl;}
in \text{ particular } R^1 \text{ and } R^2 \text{ represent hydrogen;}
Y & \text{ represents } -\text{O-} \text{ or } -\text{CH}_2-;
Z & \text{ represents } -\text{X-CR}^5\text{a-R}^5\text{b-} \text{ or } -\text{CH}_2\text{CH}_2-;
R^5\text{a} \text{ and } R^5\text{b} \text{ represent hydrogen; } X \text{ represents } -\text{O-};
R^{11} & \text{ represents hydrogen;}
\end{align*}
\]
Ar represents; Ar is optionally substituted with one substituent selected from the group consisting of halo, -OH, -NH₂, -NH-Cᵣalkyl, -N(Cᵣalkyl)₂, cyano, and -CF₃; Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1):

R³ᵃ represents -NR⁷ᵃR⁷ᵇ;
R⁷ᵃ represents hydrogen;
R⁷ᵇ represents hydrogen;
R⁴ᵃ represents hydrogen;
Q¹ represents CR⁶ᵃ; Q² represents CR⁶ᵇ; R⁶ᵃ and R⁶ᵇ represent hydrogen; and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I), wherein

R¹ represents hydrogen or -C(=0)-Cᵣalkyl;
R² represents hydrogen or -C(=0)-Cᵣalkyl;
in particular R¹ and R² represent hydrogen;
Y represents -0-; Z represents -X-CR⁵ᵃR⁵ᵇ-;
R⁵ᵃ and R⁵ᵇ represent hydrogen; X represents -0-;
R¹¹ represents hydrogen;

Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1):

R³ᵃ represents -NR⁷ᵃR⁷ᵇ;
R⁷ᵃ represents hydrogen;
R⁷ᵇ represents hydrogen;
R⁴ᵃ represents hydrogen;
Q¹ represents CR⁶ᵃ; Q² represents CR⁶ᵇ; R⁶ᵃ and R⁶ᵇ represent hydrogen; and pharmaceutically acceptable addition salts, and solvates thereof.
In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
R\(^1\) represents hydrogen or -C(=0)-C\(_4\)alkyl;
R\(^2\) represents hydrogen or -C(=0)-C\(_4\)alkyl;
in particular R\(^1\) and R\(^2\) represent hydrogen;
Y represents -O-; Z represents -X-CR\(^5\)aR\(^5\)b-;
R\(^3\)a and R\(^5\)b represent hydrogen; X represents -O-;
R\(^1\) represents hydrogen;

\[
\begin{array}{c}
\text{Ar}
\end{array}
\]

Ar is optionally substituted with one substituent selected from the group consisting of halo, -OH, -NH\(_2\), -NH-C\(_4\)alkyl, -N(C\(_4\)alkyl), cyano, and -CF\(_3\);
Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
R\(^3\)a represents -NR\(^3\)aR\(^7\)b;
R\(^7\)b represents hydrogen;
R\(^4\)a represents hydrogen;
Q\(^1\) represents CR\(^6\)a; Q\(^2\) represents CR\(^6\)b; R\(^6\)a and R\(^6\)b represent hydrogen;
and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
R\(^1\) represents hydrogen or -C(=0)-C\(_4\)alkyl;
R\(^2\) represents hydrogen or -C(=0)-C\(_4\)alkyl;
in particular R\(^1\) and R\(^2\) represent hydrogen;
Y represents -O- or -CH\(_2\)-; Z represents -X-CR\(^5\)aR\(^5\)b- or -CH\(_2\)CH\(_2\)-;
R\(^3\)a and R\(^5\)b represent hydrogen; X represents -O-;
R\(^1\) represents hydrogen;

\[
\begin{array}{c}
\text{Ar}
\end{array}
\]

Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
R\(^3\)a represents -NR\(^3\)aR\(^7\)b;
R\(^7\)a represents hydrogen;
R\textsuperscript{7b} represents hydrogen;
R\textsuperscript{4a} represents hydrogen;
Q\textsuperscript{1} represents CR\textsuperscript{6a}; Q\textsuperscript{2} represents CR\textsuperscript{6b}; R\textsuperscript{6a} and R\textsuperscript{6b} represent hydrogen;
and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I), wherein
R\textsuperscript{1} represents hydrogen or \(-\text{C} (=\text{O})\)-C\textsubscript{14}alkyl;
R\textsuperscript{2} represents hydrogen or \(-\text{C} (=\text{O})\)-C\textsubscript{14}alkyl;
in particular R\textsuperscript{1} and R\textsuperscript{2} represent hydrogen;
Y represents \(-\text{O}\); Z represents \(-\text{X-CR\textsubscript{5a}R\textsuperscript{5b}}\);
R\textsuperscript{5a} and R\textsuperscript{5b} represent hydrogen; X represents \(-\text{O}\);
R\textsuperscript{11} represents hydrogen;
\(\text{Ar}\) represents ;
Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
R\textsuperscript{3a} represents \(-\text{NR\textsuperscript{3}R\textsuperscript{7b}}\);
R\textsuperscript{7a} represents hydrogen;
R\textsuperscript{7b} represents hydrogen;
R\textsuperscript{4a} represents hydrogen;
Q\textsuperscript{1} represents CR\textsuperscript{6a}; Q\textsuperscript{2} represents CR\textsuperscript{6b}; R\textsuperscript{6a} and R\textsuperscript{6b} represent hydrogen;
and pharmaceutically acceptable addition salts, and solvates thereof.

Another embodiment of the present invention relates to those compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein one or more of the following restrictions apply:
(i) R\textsuperscript{1} represents hydrogen or \(-\text{C} (=\text{O})\)-C\textsubscript{14}alkyl;
R\textsuperscript{2} represents hydrogen or \(-\text{C} (=\text{O})\)-C\textsubscript{14}alkyl;
in particular R\textsuperscript{1} and R\textsuperscript{2} represent hydrogen;
(ii) Y represents \(-\text{O}\);
(iii) Z represents \(-\text{X-CR\textsuperscript{5a}R\textsuperscript{5b}}\);
(iv) R\textsuperscript{5a} and R\textsuperscript{5b} represent hydrogen;
(v) X represents -0-;
(vi) \( R^{11} \) represents hydrogen;

\[
\begin{array}{c}
\text{Ar represents } \quad \text{;}
\end{array}
\]

Ar is optionally substituted with one or two substituents each independently selected from the group consisting of halo, -OH, -NH\(_2\), -NH-C\(_i\)-alkyl, -N(C\(_{1-4}\)-alkyl)\(_2\), cyano, and -CF\(_3\); in particular Ar is optionally substituted with one substituent selected from the group consisting of halo, -OH, -NH\(_2\), -NH-C\(_i\)-alkyl, -N(C\(_{1-4}\)-alkyl)\(_2\), cyano, and -CF\(_3\);

more in particular Ar represents

\[
\begin{array}{c}
\text{Br- } \quad \text{even more in particular Ar}
\end{array}
\]

(x) Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);

(xii) \( R^{1a} \) represents -NR\(^{7a}\)R\(^{7b}\);

(xii) \( R^{7a} \) represents hydrogen;

(xiii) \( Q^1 \) represents CR\(^{6a}\);

(xiv) \( Q^2 \) represents CR\(^{6b}\);

(xv) \( R^{6a} \) and \( R^{6b} \) represent hydrogen.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein \( R^1 \) and \( R^2 \) represent hydrogen.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein \( R^1 \) represents-C(=0)-C\(_i\)-alkyl; \( R^2 \) represents-C(=0)-C\(_i\)-alkyl.
In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R<sup>1</sup> and R<sup>2</sup> represent hydrogen;

Het represents (a-1);

Q<sup>1</sup> represents CH; Q<sup>2</sup> represents CH; and

Ar represents

optionally substituted according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R<sup>1</sup> and R<sup>2</sup> represent hydrogen;

Het represents (a-1);

Q<sup>1</sup> represents CH; Q<sup>2</sup> represents CH; and

Ar represents

wherein Ar is substituted with one, two, three or four substituents each independently selected from the group consisting of halo, -NH<sub>2</sub>, -NH-C<sub>i-4</sub>alkyl, -N(C<sub>i-4</sub>alkyl)<sub>2</sub>,

-NHR<sup>10d</sup>, -NR<sup>10d</sup>R<sub>10d</sub>;

R<sup>10e</sup> and R<sup>10d</sup> each independently represent C<sub>i-4</sub>alkyl substituted with one, two or three halo substituents; or C<sub>i-4</sub>alkyl substituted with one C<sub>3-6</sub>cycloalkyl substituent.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Y represents -O-.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Y represents -CH<sub>2</sub>- or -CF<sub>2</sub>-; in particular wherein Y represents -CH<sub>2</sub>-.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup
thereof as mentioned in any of the other embodiments, wherein maximum one of $Q^1$ and $Q^2$ represents N.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein $Q^1$ represents CR$_6^a$; and $Q^2$ represents CR$_6^b$; in particular wherein $Q^1$ represents CH; and $Q^2$ represents CH.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represents (a-1); $Q^1$ represents CR$_6^a$; and $Q^2$ represents CR$_6^b$; in particular wherein $Q^1$ represents CH; and $Q^2$ represents CH.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein $Q^5$ represents CR$_3^d$; $Q^6$ represents N; and $Q^7$ represents CR$_4^f$; or $Q^5$ represents CR$_3^d$; $Q^6$ represents CR$_4^e$; and $Q^7$ represents N; or $Q^5$ represents N; $Q^6$ represents CR$_4^f$; and $Q^7$ represents CR$_4^f$; or $Q^5$ represents N; $Q^6$ represents CR$_4^e$; and $Q^7$ represents N.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-4).

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein $R^1$ and $R^2$ represent hydrogen; and $Y$ represents -0-. 

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3).
In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1) and (a-2).

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1) and (a-4).

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represents a bicyclic aromatic heterocyclic ring system of Formula (a-1).

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein \( R^1 \) and \( R^2 \) represent hydrogen; \( Y \) represents -OH; and Het represents a bicyclic aromatic heterocyclic ring system of Formula (a-1).

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein \( A_r \) represents an optionally substituted 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that the nitrogen atom does not replace one of the two fused carbon atoms.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein \( A_r \) is optionally substituted with one or two substituents according to any of the other embodiments.
In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is optionally substituted with one substituent according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

\[ R^3_a, R^3_c, R^3_b \] represent hydrogen; and

\[ R^4_a, R^4_e, R^4_b \] represent hydrogen, halo, or \( \text{Ci}_{4}\text{alkyl} \); in particular \( R^4_a, R^4_e, R^4_b \) represent halo, or \( \text{Ci}_{4}\text{alkyl} \).

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

\[ R^3_a, R^3_\gamma, R^3_b, R^3_d \text{ and } R^3_e \] represent hydrogen; and

\[ R^4_a, R^4_c, R^4_b, R^4_d, R^4_e, R^4_f \text{ and } R^4_g \] represent hydrogen, halo, or \( \text{C}_{1,4}\text{alkyl} \); in particular \( R^4_a, R^4_c, R^4_b, R^4_d, R^4_e, R^4_f \text{ and } R^4_g \) represent halo, or \( \text{C}_{1,4}\text{alkyl} \).

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

\[ R^3_a, R^3_\gamma, R^3_b \] represent hydrogen, halo, \(-\text{NR}_7^a\text{R}_7^b\text{ or } -0\text{-Ci}_{4}\text{alkyl}\); in particular \( R^3_a, R^3_\gamma, R^3_b \) represent halo, \(-\text{NR}_7^a\text{R}_7^b\text{ or } -0\text{-C}_{1,4}\text{alkyl}\); and

\[ R^4_a, R^4_c, R^4_b \] represent hydrogen.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

\[ R^3_a, R^3_\gamma, R^3_b, R^3_d \text{ and } R^3_e \] represent hydrogen, halo, \(-\text{NR}_7^a\text{R}_7^b\text{ or } -0\text{-Ci}_{4}\text{alkyl}\); in particular \( R^3_a, R^3_\gamma, R^3_b, R^3_d \text{ and } R^3_e \) represent halo, \(-\text{NR}_7^a\text{R}_7^b\text{ or } -0\text{-C}_{1,4}\text{alkyl}\); and

\[ R^4_a, R^4_c, R^4_b, R^4_d, R^4_e, R^4_f \text{ and } R^4_g \] represent hydrogen.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein \( R^3_a, R^3_\gamma, R^3_b \) represent hydrogen, when \( R^4_a, R^4_e, R^4_b \) are different from hydrogen.
In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

$$R^{3a}, R^{3c}, R^{3b}, R^{3d}, R^{3e}$$ represent hydrogen, when $$R^{4a}, R^{4c}, R^{4b}, R^{4d}, R^{4e}, R^{4f}, R^{4g}$$ are different from hydrogen.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

$$R^{4a}, R^{4c}, R^{4b}$$ represent hydrogen, when $$R^{3a}, R^{3c}, R^{3b}$$ are different from hydrogen.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

$$R^{4a}, R^{4c}, R^{4b}, R^{4d}, R^{4e}, R^{4f}, R^{4g}$$ represent hydrogen, when $$R^{3a}, R^{3c}, R^{3b}, R^{3d}, R^{3e}$$ are different from hydrogen.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

$$R^{4a}, R^{4c}, R^{4b}, R^{4d}, R^{4e}, R^{4f}$$ represent hydrogen, when $$R^{3a}, R^{3c}, R^{3b}, R^{3d}, R^{3e}$$ are different from hydrogen.

$$R^{3a}, R^{3c}, R^{3b}, R^{3d}, R^{3e}$$ represent a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings,

wherein at least 1 ring carbon atom of ring B is replaced by a nitrogen atom; wherein optionally 1 additional ring carbon atom of ring A or ring B is replaced by a nitrogen atom; provided that when a nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system; $$Ar$$ is optionally substituted according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

$$Ar$$ represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings,
wherein at least 1 ring carbon atom of ring B is replaced by a nitrogen atom; wherein optionally 1 additional ring carbon atom of ring A or ring B is replaced by a nitrogen atom; provided that when a nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system; Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, -OH, -NH₂, -NH-C₄alkyl, -N(C₁₋₄alkyl)₂, -NHR₁₀, -NR₁₀R₁₀, cyano, -CF₃, -C(=0)-NH₂, -C(=0)-NH-C₁₋₄alkyl, -C(=0)-C₁₋₄alkyl, C₁₋₄alkyloxy, -C(=O)-O-C₁₋₄alkyl, C₃₋₆cycloalkyl, C₂₋₆alkenyl, C₁₋₄alkyl substituted with one C₁₋₄alkyloxy, and C₁₋₄alkyl optionally substituted with one -N₁₀R₁₀; in particular Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, -OH, -NH₂, -NH-C₄alkyl, -N(C₁₋₄alkyl)₂, cyano, -CF₃, -C(=0)-NH-C₁₋₄alkyl, -C(=0)-C₁₋₄alkyl, C₁₋₄alkyloxy, and C₁₋₄alkyl optionally substituted with one -NR₁₀R₁₀.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings with the following structure,

wherein optionally 1 additional ring carbon atom of ring A or ring B is replaced by a nitrogen atom; provided that when a nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system; Ar is optionally substituted according to any of the other embodiments.

It will be clear that covers any one of the following ring systems:
In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:

wherein each Ar is optionally substituted according to any of the other embodiments.
wherein each Ar is optionally substituted according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:

wherein each Ar is optionally substituted according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup
thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:

![Chemical structures](image)

wherein each Ar is optionally substituted according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is

![Chemical structure](image)

wherein Ar is optionally substituted according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is other than

![Chemical structure](image)

wherein Ar is optionally substituted according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents

![Chemical structure](image)

wherein Ar is substituted with one, two, three or four substituents each independently
selected from the group consisting of halo, \(-\text{NH}_2\), \(-\text{NH}-\text{C}_4\text{alkyl}\), \(-\text{N}(\text{C}_1-4\text{alkyl})_2\), \(-\text{NHR}^{10d}\), \(-\text{NR}^{\text{R}^{10d}}\).

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein \(\text{Ar}\) represents

\[
\begin{array}{c}
\text{N} \\
\text{H}
\end{array}
\]

wherein \(\text{Ar}\) is substituted with one substituent selected from the group consisting of \(-\text{NH}_2\), \(-\text{NH}-\text{C}_4\text{alkyl}\), \(-\text{N}(\text{C}_1-4\text{alkyl})_2\), \(-\text{NHR}^{10d}\), \(-\text{NR}^{\text{R}^{10d}}\); and optionally substituted with a halo substituent;

\(\text{R}^{10e}\) and \(\text{R}^{10d}\) each independently represent \(\text{Ci}_4\text{alkyl}\) substituted with one, two or three halo substituents; or \(\text{Ci}_4\text{alkyl}\) substituted with one \(\text{C}_3-6\text{cycloalkyl}\) substituent.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein \(\text{Ar}\) represents

\[
\begin{array}{c}
\text{N} \\
\text{H} \\
\alpha
\end{array}
\]

wherein \(\text{Ar}\) is substituted in the position indicated by \(\alpha\) with a substituent selected from the group consisting of \(-\text{NH}_2\), \(-\text{NH}-\text{C}_4\text{alkyl}\), \(-\text{N}(\text{C}_1-4\text{alkyl})_2\), \(-\text{NHR}^{10d}\), \(-\text{NR}^{\text{R}^{10d}}\); and wherein \(\text{Ar}\) is optionally substituted in the position indicated by \(\beta\) with a halo substituent.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein \(\text{Ar}\) represents

\[
\begin{array}{c}
\text{N} \\
\text{H} \\
\beta
\end{array}
\]

wherein \(\text{Ar}\) is substituted in the position indicated by \(\beta\) with a substituent selected from the group consisting of \(-\text{NH}_2\), \(-\text{NH}-\text{C}_4\text{alkyl}\), \(-\text{N}(\text{C}_1-4\text{alkyl})_2\), \(-\text{NHR}^{10d}\), \(-\text{NR}^{\text{R}^{10d}}\); and wherein \(\text{Ar}\) is optionally substituted in the position indicated by \(\beta\) with a halo substituent;

\(\text{R}^{10e}\) and \(\text{R}^{10d}\) each independently represent \(\text{Ci}_4\text{alkyl}\) substituted with one, two or three halo substituents; or \(\text{Ci}_4\text{alkyl}\) substituted with one \(\text{C}_3-6\text{cycloalkyl}\) substituent.
In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents

\[
\begin{array}{c}
\text{Ar}
\end{array}
\]

wherein Ar is substituted in the position indicated by \( \beta \) with a halo substituent; in particular chloro or bromo; more in particular bromo.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represents (a-1); \( Q^1 \) represents CR\(^6\); \( Q^2 \) represents CR\(^6\); and Ar represents

\[
\begin{array}{c}
\text{Ar}
\end{array}
\]

wherein Ar is substituted in the position indicated by \( \beta \) with a halo substituent; in particular chloro or bromo; more in particular bromo.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is substituted with one substituent selected from the group consisting of \(-\text{NH}_2\), \(-\text{NH-Ci}_\text{4-alkyl}\), \(-\text{N(Ci}_\text{4-alkyl})_2\), \(-\text{NHR}^{10d}\), \(-\text{NR}^{10d}\), \(-\text{R}^{10d}\); and wherein Ar is optionally substituted with another substituent selected from the list of substituents on Ar in any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents

\[
\begin{array}{c}
\text{Ar}
\end{array}
\]

optionally substituted according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents
optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH, -NH₂, -NH-C₄alkyl, -N(C₁₋₄alkyl)₂, cyano, -CF₃, -C(=0)-NH-C₄alkyl, C₄alkyloxy, and C₁₋₄alkyl;

in particular optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, -NH₂, -NH-C₄alkyl, cyano, -CF₃, C₄alkyloxy, and C₁₋₄alkyl;

more in particular optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, or -CF₃;

more in particular optionally substituted with one or two halo substituents;

more in particular substituted with one or two halo substituents;

even more in particular substituted with one halo substituent;

most in particular substituted with one chloro substituent.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents

optionally substituted according to any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents

optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH, -NH₂, -NH-C₄alkyl, -N(C₁₋₄alkyl)₂, cyano, -CF₃, -C(=0)-NH-C₄alkyl, C₄alkyloxy, and C₁₋₄alkyl;

in particular optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, -NH₂, -NH-C₄alkyl, cyano, -CF₃, C₄alkyloxy, and C₁₋₄alkyl;

more in particular optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, -NH₂, -NH-C₄alkyl, cyano, -CF₃, C₄alkyloxy, and C₁₋₄alkyl;

more in particular optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, -NH₂, -NH-C₄alkyl, cyano, -CF₃, C₄alkyloxy, and C₁₋₄alkyl;
independently selected from the group consisting of halo, or -CF₃;
more in particular optionally substituted with one or two halo substituents;
more in particular substituted with one or two halo substituents;
even more in particular substituted with one halo substituent;
most in particular substituted with one chloro substituent.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

Het represents (a-1); and

\[
\begin{array}{c}
\text{Het} \quad \text{Ar}
\end{array}
\]

optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH, -NH₂, -NH-C₄alkyl, -N(C₁₋₄alkyl)₂, cyano, -CF₃, -C(=O)-NH-C₄alkyl, C₄alkyloxy, and C₄alkyl;
in particular optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, -NH₂, -NH-C₄alkyl, cyano, -CF₃, C₄alkyloxy, and C₄alkyl;
more in particular optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, or -CF₃;
more in particular optionally substituted with one or two halo substituents;
more in particular substituted with one or two halo substituents;
even more in particular substituted with one or two halo substituents;
most in particular substituted with one chloro substituent.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
Het represents (a-1); and
A represents particular A represents more in particular A represents n a n embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R⁵, R⁵b and R⁵b represent hydrogen.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Q¹ represents CR⁶a; and Q² represents CR⁶b.
In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein X represents -0-; Q\(^1\) represents CR\(^6a\); and Q\(^2\) represents CR\(^6b\).

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein X represents -0-; Q\(^1\) represents CR\(^6a\); and Q\(^2\) represents CR\(^H\).

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R\(^5b\), R\(^5g\) and R\(^5h\) represent hydrogen; Y represents -CH\(_2\)- or -CF\(_2\)-; in particular Y represents -CH\(_2\)-; and Het represents (a-1); Q\(^1\) represents CR\(^6a\); and Q\(^2\) represents CR\(^6b\); in particular wherein Q\(^1\) represents CH; and Q\(^2\) represents CH.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R\(^5b\), R\(^5g\) and R\(^5h\) represent hydrogen; Y represents -0-; and Het represents (a-1); Q\(^1\) represents CR\(^6a\); and Q\(^2\) represents CR\(^6b\); in particular wherein Q\(^1\) represents CH; and Q\(^2\) represents CH.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Q\(^2\) represents CR\(^6b\).

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Z represents -X-CR\(^5a\)R\(^5b\).
In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Z represents -O-CH$_2$-.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Z represents -X-CR$_{5a}$R$_{5b}$; X represents -O-; and R$_{5a}$ and R$_{5b}$ represent hydrogen.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein X represents -O- or -NR$_{11}$; in particular X represents -O-.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein R$_{7a}$ and R$_{7b}$ represent hydrogen.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Het represents (a-1); R$_{3a}$ represents -NR$_{7a}$R$_{7b}$; and R$_{7a}$ and R$_{7b}$ represent hydrogen.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system; Ar is optionally substituted with one substituent selected from the group consisting of halo, -OH, -NH$_2$, -NH-C$_i$-alkyl, -N(C$_{1,4}$-alkyl)$_2$, cyano, -CF$_3$, -C(=0)-NH-Ci$_{4,7}$alkyl, -C(=O)-C$_{1,4}$alkyl, Cl$_{4,7}$alkyloxy, and Cl$_{4,7}$alkyl optionally substituted with one -

R$_{5a}$, R$_{5b}$ and R$_{3c}$ represent -NR$_{7a}$R$_{7b}$; and R$_{7a}$ and R$_{7b}$ represent hydrogen.
In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein 

\[ \text{Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;} \]

Ar is optionally substituted with one substituent selected from the group consisting of halo, -OH, -NH₂, -NH-Ci₄alkyl, -N(C₁₄alkyl)₂, cyano, -CF₃, -C(=O)-NH-Ci₄alkyl, -C(=O)-C₁₄alkyl, Ci₄alkyloxy, and Ci₄alkyl optionally substituted with one -

\[ R^{3a}, R^{3c}, R^{3b}, R^{3d} \text{ and } R^{3e} \text{ represent } -NR^7aR^7b; \text{ and } R^7a \text{ and } R^7b \text{ represent hydrogen.} \]

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein \( R^{3a}, R^{3b} \text{ and } R^{3c} \) represent other than halo.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein \( R^{3a}, R^{3c}, R^{3b}, R^{3d} \text{ and } R^{3e} \) represent other than halo.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

\[ R^{3a}, R^{3b} \text{ and } R^{3c} \text{ represent } -NR^7aR^7b; \]
\[ R^7a \text{ represents hydrogen;} \]
\[ R^7b \text{ represents hydrogen.} \]

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein \( R^{3a}, R^{3b} \text{ and } R^{3c} \) represent \(-N\)
In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;

Ar is optionally substituted with one substituent selected from the group consisting of halo, -OH, -NH₂, -NH-Cᵢ₋₄alkyl, -N(C₁₋₄alkyl)₂, cyano, -CF₃, -C(=O)-NH-C₁₋₄alkyl, -C(=O)-C₁₋₄alkyl, Cl₋₄alkyloxy, and Cl₋₄alkyl optionally substituted with one -NR₁₀ᵃR₁₀ᵇ;

Het represents (a-1); R₃ᵃ represents -NR₇ᵃR₇ᵇ; and R₇ᵃ and R₇ᵇ represent hydrogen.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;

Ar is substituted with one substituent selected from the group consisting of halo, -OH, -NH₂, -NH-Cᵢ₋₄alkyl, -N(Cᵢ₋₄alkyl)₂, cyano, -CF₃, -C(=O)-NH-Cᵢ₋₄alkyl, -C(=O)-Cᵢ₋₄alkyl, Cl₋₄alkyloxy, and Cl₋₄alkyl optionally substituted with one -NR₁₀ᵃR₁₀ᵇ;

Het represents (a-1); R₃ᵃ represents -NR₇ᵃR₇ᵇ; and R₇ᵃ and R₇ᵇ represent hydrogen.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents

 optionally substituted with one substituent selected from the group consisting of halo, -OH, -NH₂, -NH-Cᵢ₋₄alkyl, -N(C₁₋₄alkyl)₂, cyano, -CF₃, -C(=O)-NH-Cᵢ₋₄alkyl, Cl₋₄alkyloxy, and Cl₋₄alkyl;

in particular optionally substituted with one substituent selected from the group consisting of halo, -NH₂, -NH-Cᵢ₋₄alkyl, cyano, -CF₃, Cl₋₄alkyloxy, and Cl₋₄alkyl;

more in particular optionally substituted with one substituent selected from the group
consisting of halo, and -CF₃;
more in particular optionally substituted with one halo substituent;
more in particular substituted with one halo substituent;
even more in particular substituted with one chloro substituent.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:

wherein each Ar is optionally substituted according to any of the other embodiments; in particular wherein Ar is optionally substituted with one substituent as defined in any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:

wherein each Ar is optionally substituted according to any of the other embodiments; in particular wherein Ar is optionally substituted with one substituent as defined in any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup
therof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:

![Chemical Structures](image)

wherein each Ar is optionally substituted according to any of the other embodiments; in particular wherein Ar is optionally substituted with one substituent as defined in any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:

![Chemical Structures](image)

wherein each Ar is optionally substituted in position a with a substituent selected from the group consisting of -NH₂, -NH-C₃₋₄alkyl, -N(C₁₋₄alkyl)₂, -NHR, and -NR-C₆H₄R; R and R each independently represent C₃₋₆cycloalkyl; C₃₋₆cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH and -0-C₃₋₄alkyl; C₃₋₆cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH and -0-C₃₋₄alkyl; or C₃₋₆cycloalkyl substituted with one substituent selected from the group consisting of C₃₋₆cycloalkyl, R³ and R⁴;

R³ represents a 4- to 7-membered monocyclic aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(=0) and N; or a 6- to 11-membered bicyclic fused aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(=0) and N;

R⁴ represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup
thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:

\[
\begin{align*}
\alpha & \quad \alpha \\
\alpha & \quad \alpha \\
\end{align*}
\]

wherein each Ar is optionally substituted in position a with a substituent selected from the group consisting of -NH₂, -NH-Cᵢ₄alkyl, -N(Cᵢ₄alkyl)₂, -NHR¹⁰d, and -NR¹⁰cR¹⁰d; and wherein Ar is optionally substituted in another position with a halo substituent.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is selected from the group consisting of:

\[
\begin{align*}
\alpha & \quad \alpha \\
\alpha & \quad \alpha \\
\end{align*}
\]

wherein each Ar is substituted in position a with a substituent selected from the group consisting of -NH₂, -NH-Cᵢ₄alkyl, -N(Cᵢ₄alkyl)₂, -NHR¹⁰d, and -NR¹⁰cR¹⁰d; and wherein Ar is optionally substituted in another position with a halo substituent.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;

wherein each Ar is optionally substituted according to any of the other embodiments; in particular wherein Ar is optionally substituted with one substituent as defined in any of the other embodiments.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is optionally substituted with one substituent as defined in any of the other embodiments.
In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, -OH, -NH₂, -NH-C₄alkyl, -N(C₄alkyl)₂, -NHR, -NR₁₀d, -CF₃, -C(=O)-NH₂, -C(=O)-NH-C₁₄alkyl, -C(=O)-C₄alkyl, Ci₄alkyloxy, -C(=O)-0-C₄alkyl, C₂₋₆alkenyl, Ci₄alkyl substituted with one Ci₄alkyloxy, and Ci₄alkyl optionally substituted with one -NR₁₀aR₁₀d.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

\[ \text{Ar represents} \]

Ar is optionally substituted with one substituent selected from the group consisting of halo, -OH, -NH₂, -NH-C₄alkyl, -N(C₄alkyl)₂, cyano, and -CF₃;

more in particular Ar represents ; even more in particular Ar represents

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

\[ \text{Ar represents} \]

Ar is substituted with one substituent selected from the group consisting of halo, -OH, -NH₂, -NH-C₄alkyl, -N(C₄alkyl)₂, cyano, and -CF₃;
In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein the compounds of Formula (I) are restricted to compounds of Formula (I-al):

\[
\text{Ar} \rightarrow Z \quad \text{Y} \quad \text{N} \quad \text{R}^{3a} \quad \text{R}^{4a}
\]

\[
\text{R}^{1} \quad \text{OR}^{2} \quad \text{OR}^{2} \quad \text{R}^{4a}
\]

wherein \( R^{3a} \) represents -NH; and \( R^{4a} \) represents hydrogen.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup
thereof as mentioned in any of the other embodiments, wherein the compounds of Formula (I) are restricted to compounds of Formula (l-al):

\[
\text{Ar} \text{-} Z \text{Y} \text{N} \text{R}^3a \text{R}^{4a}
\]

\[\text{(I-al)}\]

wherein \(R^{3a}\) represents \(-\text{NH}_2\); \(R^{4a}\) represents hydrogen; and

5 \(\text{Ar}\) represents ; more in particular \(\text{Ar}\) represents

\[
\text{Br} \text{-} \text{N} \text{-} \text{N}
\]

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein the compounds of Formula (I) are restricted to compounds of Formula (l-al):

\[
\text{Ar} \text{-} Z \text{Y} \text{N} \text{R}^3a \text{R}^{4a}
\]

\[\text{(I-al)}\]

wherein

\(R^1\) and \(R^2\) represent hydrogen;

15 \(R^{3a}\) represents hydrogen, \(-\text{NR}^a\text{R}^b\), or \(-\text{OCi}_4\text{alkyl}\);

\(R^{4a}\) represents hydrogen; and

\(\text{Ar}\) represents

\[
\text{N} \text{-} \text{N} \text{-} \text{N}
\]

wherein \(\text{Ar}\) is substituted in the position indicated by a with a substituent selected from the group consisting of \(-\text{NH}_2\), \(-\text{NH-Ci}_4\text{alkyl}\), \(-\text{N(C}_1\text{alkyl)}_2\), \(-\text{NHR}^{10d}\), \(-\text{NR}^{10c}\text{R}^{10d}\); and
wherein Ar is optionally substituted in the position indicated by $\beta$ with a halo substituent;

$R^{10c}$ and $R^{10d}$ each independently represent $\text{Ci}_{1-4}$alkyl substituted with one, two or three halo substituents; or $\text{Ci}_{1-4}$alkyl substituted with one $\text{C}_{3-6}$cycloalkyl substituent.

In an embodiment, the present invention concerns novel compounds of Formula (I-al)  

\[
\begin{align*}
\text{Ar} & \xrightarrow{-Z} \text{Y} \\
& \xrightarrow{R^{10d}} \\
& \xrightarrow{R^{3a}} \\
& \xrightarrow{R^{4a}} \\
\end{align*}
\]

wherein

$R^1$ and $R^2$ represent hydrogen;

$R^{3a}$ represents hydrogen, $-\text{NR}^{7a}\text{R}^{7b}$, or $-\text{OCi}_{1-4}$alkyl;

$R^{7a}$ represents hydrogen;

$R^{7b}$ represents hydrogen or $\text{Ci}_{1-4}$alkyl;

$Z$ represents $-\text{CH}_2\text{CH}_2-$;

$Y$ represents $-\text{O}$, $-\text{CH}_2-$ or $-\text{CF}_2-$; in particular $-\text{CH}_2-$;

$R^{4a}$ represents hydrogen; and

$\text{Ar}$ represents

\[
\begin{align*}
\text{Ar} & \xrightarrow{\alpha} \text{N} \\
& \xrightarrow{\beta} \text{N} \\
\end{align*}
\]

wherein Ar is substituted in the position indicated by $\alpha$ with a substituent selected from the group consisting of $-\text{NH}_2$, $-\text{NH-}$ $\text{Ci}_{1-4}$alkyl, $-\text{N(C}_{1-4}$alkyl)$)_2$, $-\text{NHR}^{10d}$, $-\text{NR}^{10c}\text{R}^{10d}$; and

wherein Ar is optionally substituted in the position indicated by $\beta$ with a halo substituent;

$R^{10c}$ and $R^{10d}$ each independently represent $\text{Ci}_{1-4}$alkyl substituted with one, two or three halo substituents; or $\text{Ci}_{1-4}$alkyl substituted with one $\text{C}_{3-6}$cycloalkyl substituent; and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I-al)
wherein

\[ \text{R}^1 \text{ and } \text{R}^2 \text{ represent hydrogen; } \]

\[ \text{R}^{3a} \text{ represents hydrogen, -NR}^7 \text{R}^{7b}, \text{ or -OC}^4 \text{alkyl; } \]

\[ \text{R}^{7a} \text{ represents hydrogen; } \]

\[ \text{R}^{7b} \text{ represents hydrogen or } \text{Ci}_4 \text{alkyl; } \]

\[ \text{Z represents -X-CR}^5 \text{R}^{5b} \text{ or -CH}_2 \text{CH}_2^-; } \]

\[ \text{R}^{5a} \text{ and } \text{R}^{5b} \text{ represent hydrogen; } X \text{ represents -O-; } \]

\[ \text{Y represents -O-, -CH}_2^- \text{ or -CF}_2^-; \text{ in particular -CH}_2^-; } \]

\[ \text{R}^{4a} \text{ represents hydrogen; and } \]

\[ \text{Ar represents } \]

\[ \begin{array}{c}
\text{B} \\
\text{A}
\end{array} \]

wherein \( \text{Ar} \) is optionally substituted in the position indicated by a with a substituent selected from the group consisting of -NH\textsubscript{2}, -NH-C\textsubscript{i}-alkyl, -N(C\textsubscript{i}-alkyl)\textsubscript{2}, -NHR\textsubscript{10d}, -NR\textsubscript{10b}R\textsubscript{10d}; and

\[ \text{R}^{10a} \text{ and } \text{R}^{10d} \text{ each independently represent } \text{Ci}_4 \text{alkyl substituted with one, two or three halo substituents; or } \text{Ci}_4 \text{alkyl substituted with one c}_3\text{c}_6 \text{cycloalkyl substituent; } \]

and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention concerns novel compounds of Formula (I-a1)

\[ \begin{array}{c}
\text{Ar} \\
\text{Z}
\end{array} \]

wherein
R_1 and R_2 represent hydrogen;
R^{3a} represents -NR^{7a}R^{7b};
Z represents -XX-CCR^{5a}R^{b}; a or -CCH_2CH_2-;
R^{5a} a and R^{5b} represent hydrogen;
X represents -0-.

wherein Ar is optionally substituted in the position indicated by a with -NH_2; and
wherein Ar is substituted in the position indicated by β with a halo substituent, in particular Br;
and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment, the present invention relates to those compounds of Formula (I) and
pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
Z represents -X-CR^{5a}R^{b} or -CH_2CH_2-. 

In an embodiment, the present invention relates to those compounds of Formula (I) and
pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
Z represents -X-CR^{5a}R^{b} or -CH_2CH_2-;
R^{5a} and R^{5b} represent hydrogen;
X represents -0-.

In an embodiment, the present invention relates to those compounds of Formula (I) and
pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein
Z represents -X-CR^{5a}R^{b} or -CH_2CH_2-;
R^{5a} and R^{5b} represent hydrogen;
X represents -0-;
Met represents (a-1).
In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

\[ Z \text{ represents } -X-CR^aR^b \text{ or } -\text{CH}_2\text{CH}_2; \]

\[ R^a \text{ and } R^b \text{ represent hydrogen; } \]
\[ X \text{ represents } -0-; \]
\[ \text{Met represents } (a-1); \]
\[ R^3a \text{ represents } \text{NR}^7aR^7b; \]
\[ R^7a \text{ represents hydrogen; } \]
\[ R^7b \text{ represents hydrogen. } \]

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein \( X \) represents \(-0-\).

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

\[ Z \text{ represents } -X-CR^aR^b \text{ or } -\text{CH}_2\text{CH}_2; \]

\[ R^a \text{ and } R^b \text{ represent hydrogen; } \]
\[ X \text{ represents } -0-; \]
\[ Ar \text{ represents } \]
\[ \beta \]
\[ \alpha \]

wherein \( Ar \) is optionally substituted in the position indicated by \( a \) with a substituent selected from the group consisting of \(-\text{NH}_2, -\text{NH-Ci}_4\text{alkyl, and } -\text{NHR}^{10d}; \) and wherein \( Ar \) is optionally substituted in the position indicated by \( \beta \) with a substituent selected from the group consisting of halo and \( \text{CF}_3; \) provided however that \( Ar \) is substituted in at least one of the positions indicated by \( a \) or \( \beta; \)

\[ Het \text{ represents } (a-1); \]
\[ R^3a \text{ represents } \text{NR}^7aR^7b; \]
\[ R^7a \text{ represents hydrogen; } \]
\[ R^7b \text{ represents hydrogen. } \]
In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

Het represents (a-1);

R^{3a} represents NR \_7^a R^{7b};

R^{7a} represents hydrogen;  

R^{7b} represents hydrogen.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

R^{3a}, R^{3b}, R^{3c}, R^{3d} and R^{3e} represent -NR\_7^a R^{7b};

R^{7a} represents hydrogen;  

R^{7b} represents hydrogen, C\_3\_6 cycloalkyl, or C\_i\_4 alkyl.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

R^{3a}, R^{3b}, R^{3c}, R^{3d} and R^{3e} represent -NR\_7^a R^{7b};

R^{7a} represents hydrogen;  

R^{7b} represents hydrogen.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup thereof as mentioned in any of the other embodiments, wherein

R^{11} represents hydrogen, C\_i\_4 alkyl, or C\_i\_4 alkyl substituted with one substituent selected from the group consisting of -OH, -0-Ci\_4 alkyl, -NH\_2, -NH-Ci\_4 alkyl, and -N(Ci\_4 alkyl)\_2; and

R^{10e} and R^{10i} each independently represent C\_3\_6 cycloalkyl; R^{14}; C\_3\_4 cycloalkyl

substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH and -0-Ci\_4 alkyl; C\_i\_4 alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH and -0-Ci\_4 alkyl; or Ci\_4 alkyl substituted with one substituent selected from the group consisting of C\_3\_4 cycloalkyl, and R^{14}.

In an embodiment, the present invention relates to those compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup
thereof as mentioned in any of the other embodiments, wherein \( Y \) represents \(-\text{CH}_2-\); and \( Z \) represents \(-\text{CH}_2\text{CH}_2-\).

In an embodiment, the present invention relates to a subgroup of Formula (I) as defined in the general reaction schemes.

In an embodiment the compound of Formula (I) is selected from the group consisting of compounds 2 and 58.

In an embodiment the compound of Formula (I) is selected from the group consisting of compounds 2 and 80.

In an embodiment the compound of Formula (I) is selected from the group consisting of compounds 74, 75, 76, 77, 78, 79, 80 and 81.

In an embodiment the compound of Formula (I) is selected from the group consisting of compounds 2, 58, 74, 75, 76, 77, 78, 79, 80, 81, 154, 159, 235, 240 and 247.

In an embodiment the compound of Formula (I) is selected from the group consisting of compounds 2 and 58, and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment the compound of Formula (I) is selected from the group consisting of compounds 2 and 80, and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment the compound of Formula (I) is selected from the group consisting of compounds 74, 75, 76, 77, 78, 79, 80 and 81, and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment the compound of Formula (I) is selected from the group consisting of compounds 2, 58, 74, 75, 76, 77, 78, 79, 80, 81, 154, 159, 235, 240 and 247 and pharmaceutically acceptable addition salts, and solvates thereof.

In an embodiment the compound of Formula (I) is selected from the group consisting of any of the exemplified compounds, and the free bases, the pharmaceutically acceptable addition salts, and the solvates thereof.

All possible combinations of the above-indicated embodiments are considered to be embraced within the scope of this invention.
Methods for the Preparation

In this section, as in all other sections unless the context indicates otherwise, references to Formula (I) also include all other sub-groups and examples thereof as defined herein.

The general preparation of some typical examples of the compounds of Formula (I) is described hereunder and in the specific examples, and are generally prepared from starting materials which are either commercially available or prepared by standard synthetic processes commonly used by those skilled in the art. The following schemes are only meant to represent examples of the invention and are in no way meant to be a limit of the invention.

Alternatively, compounds of the present invention may also be prepared by analogous reaction protocols as described in the general schemes below, combined with standard synthetic processes commonly used by those skilled in the art of organic chemistry. The skilled person will realize that in the reactions described in the Schemes, it may be necessary to protect reactive functional groups, for example hydroxy, amino, or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups can be used in accordance with standard practice. This is illustrated in the specific examples.

The skilled person will realize that in the reactions described in the Schemes, it may be advisable or necessary to perform the reaction under an inert atmosphere, such as for example under N₂ gas atmosphere, for example when NaH is used in the reaction. It will be apparent for the skilled person that it may be necessary to cool the reaction mixture before reaction work-up (refers to the series of manipulations required to isolate and purify the product(s) of a chemical reaction such as for example quenching, column chromatography, extraction).

The skilled person will realize that heating the reaction mixture under stirring may enhance the reaction outcome. In some reactions microwave heating may be used instead of conventional heating to shorten the overall reaction time.

The skilled person will realize that another sequence of the chemical reactions shown in the Schemes below, may also result in the desired compound of Formula (I).

The skilled person will realize that intermediates and compounds shown in the schemes below may be further functionalized according to methods well-known by the person skilled in the art.

The skilled person will realize that more Compounds of Formula (I) can be prepared by using similar synthetic protocols as described in the Schemes below.
In case one of the starting materials is available as a salt form, the skilled person will realize that it may be necessary to first treat the salt with a base, such as for example N,N-diisopropylethylamine (DIPEA).

All variables are defined as mentioned hereabove unless otherwise is indicated or is clear from the context.

The skilled person will understand that analogous chemistry as described in Schemes 1 to 9, may also be applied to make compounds of Formula (I) wherein Het represents a bicyclic aromatic heterocyclic rings system (a-4) or (a-5). Some typical examples are illustrated in the specific examples. In addition, this information may be combined with standard synthetic processes commonly used by those skilled in the art of organic chemistry to obtain more compounds of Formula (I) wherein Het represents (a-4) or (a-5).

In general, compounds of Formula (I) can be prepared according to Scheme 1:
In scheme 1, 'LG	extsubscript{i}' is defined as a suitable leaving group such as for example halogen; 'LG	extsubscript{2}' is defined as a suitable leaving group such as for example halogen or -SCH	extsubscript{3}. 'LG	extsubscript{3}' is defined as a leaving group such as halogen and -SCH	extsubscript{3}. All other variables in Scheme 1 are defined according to the scope of the present invention.

In scheme 1, the following reaction conditions typically apply:

1. Different sets of reaction conditions dependent on the definition of R	extsuperscript{3a}, R	extsuperscript{3b} or R	extsuperscript{3c}:
   
   **ia:** When R	extsuperscript{3a}, R	extsuperscript{3b} or R	extsuperscript{3c} is halogen, step 1 can be skipped.

   **ib:** When R	extsuperscript{3a}, R	extsuperscript{3b} or R	extsuperscript{3c} is NR	extsuperscript{7a}R	extsuperscript{7b}, in the presence of a suitable amine of formula HNRR	extsuperscript{7a}R	extsuperscript{7b}, with a suitable solvent such as for example, H	extsubscript{2}O, MeOH, or EtOH, at a suitable temperature such as for example between 100-130 °C typical under microwave conditions or using an autoclave vessel for heating.

   **ic:** When R	extsuperscript{3a}, R	extsuperscript{3b} or R	extsuperscript{3c} is -0-Ci- 4alkyl, in the presence of a suitable HO-Ci-4alkyl, with a suitable base such as for example NaH, potassium tert-butoxide (tBuOK) in a suitable solvent such as for example tetrahydrofuran (THF) at a suitable temperature. Alternatively in the presence of the suitable HO-Ci-4alkyl as solvent with a suitable acid such as for example HCl.
**Id:** When R\(^3_a\), R\(^3_b\) or R\(^3_c\) is hydrogen, under hydrogenation conditions: H\(_2\)-gas atmosphere in the presence of a catalyst such as for example Raney Ni, Pd/C (for example 5 wt % or 10 wt %) or Pt/C (for example 5 wt %) in a suitable solvent such as for example methanol (MeOH), ethanol (EtOH) or THF;

**le:** When R\(^3_a\), R\(^3_b\) or R\(^3_c\) is -NH\(_2\) or -NHR; suitable according to the skilled person will realize a suitable protection group is needed when R\(^3_a\), R\(^3_b\) or R\(^3_c\) is -NH\(_2\) or -NHR;

2: in the presence of a suitable acid, such as for example 4M HCl in dioxane or 4M HCl in MeOH, with a suitable solvent such as for example MeOH at a suitable temperature such as for example room temperature; or alternatively in the presence of a suitable acid such as for example trifluoroacetic acid (TFA) in dichloromethane (DCM) at a suitable temperature, or acetic acid in THF and water at a suitable temperature such as for example room temperature.

3: in the presence of suitable acid anhydride of formula (Ci\(_4\)alkylC=0)\(_2\)O with a suitable solvent such as pyridine at a suitable temperature. When R\(^3_a\), R\(^3_b\) or R\(^3_c\) is NH\(_2\), (Ci\(_4\)alkylC=0)\(_2\)O can react with the NH\(_2\) to obtain the N(Ci\(_4\)alkylC=0)\(_2\) intermediate. Such an intermediate can be converted to the targeted product in a suitable solvent such as for example MeOH at a suitable temperature such as for example 100-130 °C under microwave conditions or using an autoclave vessel for heating. The reaction may benefit from the presence of an acid, such as HCl or C\(_{1-4}\)alkylC0\(_2\)H.

The starting materials in scheme 1 are commercially available or can be prepared by standard means obvious to those skilled in the art or as described in following general schemes.

**General scheme 2a**

In general, intermediates of Formula III, V and VII wherein Z represents -O-CHR\(^5_a\)- can all be prepared according to Scheme 2a. All other variables in Scheme 2a are defined according to the scope of the present invention. The skilled person will realize a suitable protection group is needed when R\(^3_a\), R\(^3_b\) or R\(^3_c\) is -NH\(_2\) or -NHR.
In scheme 2a, the following reaction conditions apply:

1: The Mitsunobu reaction:

la: In the presence of PPh$_3$-Polymer supported, diisopropyl azodicarboxylate (DIAD) or diethyl azodicarboxylate (DEAD) or Bis(1,1-dimethylethyl)-azodicarboxylate (DBAD) in a suitable solvent such as for example anhydrous THF at a suitable temperature such as for example room temperature.

lb: In the presence of triphenylphosphine (PPh$_3$), DIAD or DEAD in a suitable solvent such as for example anhydrous THF at a suitable temperature such as for example room temperature.

lc: In the presence of cyanomethylenetributylphosphorane (CMBP) or cyanomethylenetrimethylphosphorane (CMMP), in a suitable solvent such as for example anhydrous toluene at a suitable temperature such as for example 80°C.

The starting materials in scheme 2a are commercially available or can be prepared by standard means obvious to those skilled in the art or as described in following general schemes. The skilled person will realize that when R$_5^a$ is 

\[ \text{Ci}_4 \text{alkyl}, \] the different
isomers can be separated from each other by using Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) or Supercritical Fluid Chromatography (SFC).

**General scheme 2b**

Intermediates of Formula II, IV and VI wherein Z represents -X<sup>a</sup>-CHR<sup>5α</sup>- can be prepared according to Scheme 2b. In scheme 2b, 'X<sup>a</sup>' is defined as O or S; 'LG' is defined as a leaving group such as for example halogen, mesylate (MsO) and tosylate (TosO), preferably TosO. ‘LG<sub>1</sub>’ is defined as a leaving group such as for example halogen; ‘LG<sub>2</sub>’ is defined as a leaving group such as for example halogen or -SCH<sub>3</sub>. ’LG<sub>3</sub>’ is defined as a leaving group such as for example halogen or --SCH<sub>3</sub>. All other variables in Scheme 2b are defined according to the scope of the present invention.

In scheme 2b, the following reaction conditions apply:

1: in the presence of a base such as for example K<sub>2</sub>CO<sub>3</sub>, triethylamine (Et<sub>3</sub>N) or DIPEA, in a suitable solvent such as CH<sub>3</sub>CN, DCM or N,N-dimethylacetamide (DMA).

The starting materials in scheme 2b are commercially available or can be prepared by standard means obvious to those skilled in the art or as described in following general schemes. The skilled person will realize that when R<sup>5α</sup> is C<sub>1-4</sub>alkyl, the different
isomers can be separated from each other by using Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) or Supercritical Fluid Chromatography (SFC).

**General scheme 2c**
Intermediates III, V and VII wherein Z represents -Xa-CHR5a- can be prepared according to Scheme 2c. In scheme 2c, 'Xa' is defined as O or S. 'LG' is defined as a leaving group such as for example halogen, MsO or TosO, preferably TosO. All other variables in Scheme 2c are defined according to the scope of the present invention. The skilled person will realize that a suitable protection group is needed when R1, R2 or R3 is -NH2 or -NHR.

In scheme 2c, the following reaction conditions apply:
1: in the presence of a base such as for example K2CO3, Et3N or DIPEA, in a suitable solvent such as CH3CN, DCM or N,N-dimethylacetamide (DMA).

The starting materials in scheme 2c are commercially available or can be prepared by standard means obvious to those skilled in the art or as described in following general
The skilled person will realize that when \( R^5_a \) is \( \text{Ci}_4 \text{alkyl} \), the different isomers can be separated from each other by using Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) or Supercritical Fluid Chromatography (SFC).

5 General scheme 3

In general, intermediates wherein \( Z \) represents \(-X-\text{CHR}^5_{a-}\); and wherein \( X \) represents \(-\text{NH}^-\) or \(-\text{NR}^7\) can be prepared according to Scheme 3. In scheme 3, ‘LG’ is defined as a leaving group such as for example halogen; ‘LG\_2’ is defined as a leaving group such as for example halogen or \(-\text{SCH}_3\). ‘LG\_3’ is defined as a leaving group such as for example halogen or \(-\text{SCH}_3\). All other variables in Scheme 3 are defined according to the scope of the present invention.

In scheme 3, the following reaction conditions apply:

1: in the presence of a suitable reduction reagent such as for example sodium triacetoxyborohydride (\( \text{NaBH}((\text{AcO})_3) \)) together with a suitable solvent such as for example DCM at a suitable temperature such as for example room temperature; or alternatively \( \text{NaBH}_3\text{CN} \) together with a suitable solvent such as for example MeOH at a suitable temperature such as for example between room temperature and 50°C.

2: in the presence of a suitable base such as for example NaH together with a suitable solvent such as for example anhydrous \( \text{THF, } N,N\text{-dimethylformamide (DMF, DMA} \) at a suitable temperature such as for example between room temperature and 50°C.
The starting materials in scheme 3 are commercially available or can be prepared by standard means obvious to those skilled in the art or as described in the specific experimental part. The skilled person will realize that when \( R^{5a} \) is \( C_{1-4} \)alkyl, the different isomers can be separated from each other by using Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) or Supercritical Fluid Chromatography (SFC).

**General scheme 4**

In general, intermediates wherein \( Z \) represents \(-C=CH_{2}-\), \(-CH=CH_{2}-\), or \(-CH_{2}-CH_{2}-\) can be prepared according to Scheme 4. In scheme 4, 'LGi' is defined as a leaving group such as for example halogen; 'LG_2' is defined as a leaving group such as for example halogen or \(-SCH_{3}\). 'LG_3' is defined as leaving group such as for example halogen or \(-SCH_{3}\). All other variables in Scheme 4 are defined according to the scope of the present invention.

In scheme 4, the following reaction conditions apply:

1. In the presence of suitable amine, such as \( HNR'R'' \) or \( NaOR' \), with a suitable solvent such as for example \( H_{2}O \), \( MeOH \), or \( EtOH \) at a suitable temperature such as for
example between 100-130 °C under microwave condition or using an autoclave vessel for heating.

2: In the presence of suitable catalyst, such as bis(triphenylphosphine)palladium(II) dichloride and copper(I) iodide in a suitable solvent, such as 2-methyltetrahydrofuran with a suitable base, such as for example triethylamine at a suitable temperature, such as for example 80 °C.

3: in the presence of a suitable salt, such as for example tetrachloroammonium chloride (Et₄NCl), in a suitable solvent, such as for example DMF, with a suitable base such as for example DIPEA and a palladium catalyst, such as for example Pd(OAc)₂ (palladium(II) acetate) at suitable temperature such as for example 100 °C.

4: in the presence of a H₂-gas atmosphere and a catalyst such as for example Pd/C (for example 5 wt % or 10 wt %) in a suitable solvent such as for example MeOH.

The starting materials in scheme 4 are commercially available or can be prepared by standard means obvious to those skilled in the art or as described in the specific experimental part.

**General scheme 5**

In general, intermediates wherein Y represents CH₂ or CF₂, hereby named Yᵃ, and wherein Z represents -CH₂₀ - can be prepared according to Scheme 5.

In scheme 5, 'LG' is defined as a leaving group such as for example halogen; 'LG₂' is defined as a leaving group such as for example halogen or -SCH₃. 'LG₃' is defined as leaving group such as halogen or -SCH₃. All other variables in Scheme 5 are defined according to the scope of the present invention.
In scheme 5, the following reaction conditions apply:

1: in the presence of a base such as for example K₂CO₃, Et₃N or DIPEA, in a suitable solvent such as CH₃CN, DCM or N,N-dimethylacetamide (DMA).

**General scheme 6**

In general, intermediates wherein Z represents -CH₂- can be prepared according to Scheme 6. In scheme 6, 'LG₁' is defined as a leaving group such as for example halogen; 'LG₂' is defined as a leaving group such for example halogen or -SCH₃.

'LG₃' is defined as a leaving group such as for example halogen or -SCH₃. All other variables in Scheme 6 are defined according to the scope of the present invention.
In scheme 6, the following reaction conditions apply:

1: In the presence of tosylhydrazide, with a suitable solvent such as for example, MeOH, EtOH, or DCM at a suitable temperature such as room temperature.

2: In the presence of Boronic acids, with suitable base such as K$_2$CO$_3$, Na$_2$CO$_3$, Cs$_2$CO$_3$, with a suitable solvent such as for example, 1,4-dioxane at a suitable temperature such 90 °C.

The starting materials in scheme 6 are commercially available or can be prepared by standard means obvious to those skilled in the art or as described in the specific experimental part.

**General scheme 7**

In general, intermediates wherein Z represents -CH$_2$-CH$_2$- can be prepared according to Scheme 7. In scheme 7, 'LG$_1$' is defined as a leaving group such as for example halogen; 'LG$_2$' is defined as a leaving group such as for example halogen or -SCH$_3$. 'LG$_3$' is defined as leaving group such as for example halogen or -SCH$_3$. All other variables in Scheme 7 are defined according to the scope of the present invention.
In scheme 7, the following reaction conditions typically apply:

1: In a first step in the presence of an alkene precursor and a 9-Borabicyclo(3.3.1)nonane (9-BBN) solution 0.5 M in THF under nitrogen atmosphere at a temperature between room temperature and reflux and a reaction time between 1 to 3 hours. In a second step in the presence of, for example, a suitable Ar-bromide or Ar-iodide and a suitable catalyst as for example 1,1'-bis(diphenylphosphino)ferrocene dichloropalladium(II) in the presence of a suitable base as for example potassium phosphate tribasic in a suitable solvent mixture as for example THF and water at a suitable temperature between 50°C and reflux and a suitable reaction time between 1 and 3 hours.

2: Different sets of reaction conditions dependent on the definition of R³ᵃ, R³ᵇ or R³ᶜ:

2a: When R³ᵃ, R³ᵇ or R³ᶜ is halogen, step 1 can be skipped.

2b: When R³ᵃ, R³ᵇ or R³ᶜ is NRᵃRᵇ, in the presence of a suitable amine of formula HNRᵃRᵇ, with a suitable solvent such as for example, H₂O, MeOH, or EtOH, at a suitable temperature such as for example between 100-130 °C typically under microwave conditions or using an autoclave vessel for heating.

2c: When R³ᵃ, R³ᵇ or R³ᶜ is -0-Ci₀alkyl, in the presence of a suitable HO-Ci₀alkyl, with a suitable base such as for example NaH, potassium tert-butoxide (tBuOK) in a suitable solvent such as for example tetrahydrofuran (THF) at a suitable temperature. Alternatively in the presence of the suitable HO-Ci₀alkyl as solvent with a suitable acid such as for example HCl.
2d: When $R^a$, $R^b$ or $R^c$ is hydrogen, under hydrogenation conditions: $H_2$-gas atmosphere in the presence of a catalyst such as for example Raney Ni, Pd/C (for example 5 wt % or 10 wt %) or Pt/C (for example 5 wt %) in a suitable solvent such as for example methanol (MeOH), ethanol (EtOH) or THF;

2e: When $R^a$, $R^b$ or $R^c$ is $C_1$-alkyl, in the presence of a suitable boronic acid or ester such as for example methylboronic acid with a suitable catalyst such as for example $1,1'$-bis(diphenylphosphino)ferrocene and with a suitable base such as for example $K_3PO_4$ in a suitable solvent mixture such as for example dioxane/ $H_2O$ ratio 5 to 1 at a suitable temperature such as for example 100°C.

The starting materials in scheme 7 are commercially available or can be prepared by standard means obvious to those skilled in the art or as described in the specific experimental part.

**General scheme 8**

In general, intermediates wherein $Z$ represents -CH$_2$-CH$_2$- can be prepared according to Scheme 8. In scheme 8, ‘LG’ is defined as a leaving group such as for example halogen; ‘LG$_2$’ is defined as a leaving group such as for example halogen or -SCH$_3$. ‘LG$_3$’ is defined as leaving group such as for example halogen or -SCH$_3$. All other variables in Scheme 8 are defined according to the scope of the present invention.

In scheme 8, the following reaction conditions typically apply:
1: Different sets of reaction conditions dependent on the definition of \( R^3a, R^3b \) or \( R^3c \):

**la:** When \( R^3a, R^3b \) or \( R^3c \) is halogen, step 1 can be skipped.

**lb:** When \( R^3a, R^3b \) or \( R^3c \) is \( NR^7aR^7b \), in the presence of a suitable amine of formula \( HNR^7aR^7b \), with a suitable solvent such as for example, \( H_2O, MeOH \), or \( EtOH \), at a suitable temperature such as for example between 100-130 °C typically under microwave conditions or using an autoclave vessel for heating.

**lc:** When \( R^3a, R^3b \) or \( R^3c \) is -CH\(_2\)-CH\(_2\)-, can be prepared according to Scheme 9. In Scheme 9, ‘LGi’ is defined as a leaving group.

**Id:** When \( R^3a, R^3b \) or \( R^3c \) is hydrogen, under hydrogenation conditions: \( H_2\)-gas atmosphere in the presence of a catalyst such as for example Raney Ni, Pd/C (for example 5 wt % or 10 wt %) or Pt/C (for example 5 wt %) in a suitable solvent such as for example methanol (MeOH), ethanol (EtOH) or THF;

**le:** When \( R^3a, R^3b \) or \( R^3c \) is \( C_1\)-alkyl, in the presence of a suitable boronic acid or ester such as for example methylboronic acid with a suitable catalyst such as for example 1,1’-bis(diphenylphosphino)ferrocene and with a suitable base such as for example \( K_3PO_4 \) in a suitable solvent mixture such as for example dioxane/\( H_2O \) ratio 5 to 1 at a suitable temperature such as for example 100°C;

2: In a first step in the presence of an alkene precursor and a 9-BBN solution 0.5 M in THF under nitrogen atmosphere at a temperature between room temperature and reflux and a reaction time between 1 to 3 hours. In a second step in the presence of suitable (het)arylboronic acid or (het)aryl iodide and a suitable catalyst as for example 1,1’-bis(diphenylphosphino)ferrocene)dichloropalladium(II) and in the presence of a suitable base as for example potassium phosphate tribasic in a suitable solvent mixture as for example THF and water at a suitable temperature between 50°C and reflux and a suitable reaction time between 1 and 3 hours.

The starting materials in scheme 8 are commercially available or can be prepared by standard means obvious to those skilled in the art or as described in the specific experimental part.

**General scheme 9**

In general, intermediates as shown in Scheme 9 wherein \( Z \) represents -CH\(_2\)-CH\(_2\)- can be prepared according to Scheme 9. In scheme 9, 'LGi' is defined as a leaving group.
such as for example halogen. All other variables in Scheme 9 are defined according to the scope of the present invention.

1: In a first step in the presence of an alkene precursor and a 9-BBN solution 0.5 M in THF under nitrogen atmosphere at a temperature between room temperature and reflux and a reaction time between 1 to 3 hours. In a second step in the presence of, for example, a suitable Ar-bromide or Ar-iodide (X being Br or I respectively) and a suitable catalyst as for example 1,1′-bis(diphenylphosphino)ferrocene)dichloropalladium(II) and in the presence of a suitable base as for example potassium phosphate tribasic in a suitable solvent mixture as for example THF and water at a suitable temperature between 50°C and reflux and a suitable reaction time between 1 and 3 hours.

2: In the presence of triflic anhydride and a suitable base as for example pyridine in a suitable solvent as for example DCM at a suitable temperature as for example 0°C under an inert atmosphere of N₂ gas.

3: In the presence of a suitable base as for example C₅H₅N in a suitable solvent as for example DMF at a suitable temperature as for example room temperature under an inert atmosphere of N₂ gas.

The starting materials in scheme 9 are commercially available or can be prepared by standard means obvious to those skilled in the art or as described in the specific experimental part.

In all these preparations, the reaction products may be isolated from the reaction medium and, if necessary, further purified according to methodologies generally known in the art such as, for example, extraction, crystallization, trituration and chromatography.
The chirally pure forms of the compounds of Formula (I) form a preferred group of compounds. It is therefore that the chirally pure forms of the intermediates and their salt forms are particularly useful in the preparation of chirally pure compounds of Formula (I). Also enantiomeric mixtures of the intermediates are useful in the preparation of compounds of Formula (I) with the corresponding configuration.

**Pharmacology**

It has been found that the compounds of the present invention inhibit PRMT5 activity. In particular compounds of the present invention bind to the PRMT5 enzyme, and competitively with natural substrate SAM (S-adenosyl-L-methionine), to inhibit such enzyme.

It is therefore anticipated that the compounds according to the present invention or pharmaceutical compositions thereof may be useful for treating or preventing, in particular treating, of diseases such as a blood disorder, metabolic disorders, autoimmune disorders, cancer, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection, lung injuries and the like.

In particular the compounds according to the present invention or pharmaceutical compositions thereof may be useful for treating or preventing, in particular treating, of diseases such as allergy, asthma, hematopoietic cancer, lung cancer, prostate cancer, melanoma, metabolic disorder, diabetes, obesity, blood disorder, sickle cell anemia, and the like.

The compounds according to the present invention or pharmaceutical compositions thereof may be useful for treating or preventing, in particular treating, of diseases such as a proliferative disorder, such as an autoimmune disease, cancer, a benign neoplasm, or an inflammatory disease.

The compounds according to the present invention or pharmaceutical compositions thereof may be useful for treating or preventing, in particular treating, of diseases such as a metabolic disorder comprising diabetes, obesity; a proliferative disorder comprising cancer, hematopoietic cancer, lung cancer, prostate cancer, melanoma, or pancreatic cancer; blood disorder; hemoglobinopathy; sickle cell anemia; β-thalassemia, an inflammatory disease, and autoimmune disease e.g. rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, diarrhea, gastroesophageal reflux disease, and the like.
In some embodiments, the inhibition of PRMT5 by a provided compound may be useful in treating or preventing, in particular treating, the following non-limiting list of cancers: breast cancer, lung cancer, esophageal cancer, bladder cancer, hematopoietic cancer, lymphoma, medulloblastoma, rectum adenocarcinoma, colon adenocarcinoma, gastric cancer, pancreatic cancer, liver cancer, adenoid cystic carcinoma, lung adenocarcinoma, head and neck squamous cell carcinoma, brain tumors, hepatocellular carcinoma, renal cell carcinoma, melanoma, oligodendroglioma, ovarian clear cell carcinoma, and ovarian serous cystadenoma.

Examples of metabolic disorders which may be treated or prevented, in particular treated, include, but are not limited to, diabetes or obesity.

Examples of blood disorders which may be treated or prevented, in particular treated, include, but are not limited to, hemoglobinopathy, such as sickle cell disease or β-thalassemia.

Examples of cancers which may be treated or prevented, in particular treated, include, but are not limited to, acoustic neuroma, adenocarcinoma, adrenal gland cancer, anal cancer, angiosarcoma (e.g., lymphangio sarcoma, lymphangioendothelial sarcoma, hemangio sarcoma), appendix cancer, benign monoclonal gammopathy, biliary cancer (e.g., cholangiocarcinoma), bladder cancer, breast cancer (e.g., adenocarcinoma of the breast), papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast, brain cancer (e.g., meningioma; glioma, e.g., astrocytoma, oligodendroglioma: medulloblastoma), bronchus cancer, carcinoid tumor, cervical cancer (e.g., cervical adenocarcinoma), chordoma, choriocarcinoma, craniopharyngioma, colorectal cancer (e.g., colon cancer, rectal cancer, colorectal adenocarcinoma), epithelial carcinoma, ependymoma, endothelial sarcoma (e.g., Kaposi's sarcoma, multiple idiopathic hemorrhagic sarcoma), endometrial cancer (e.g., uterine cancer, uterine sarcoma), esophageal cancer (e.g., adenocarcinoma of the esophagus, Barrett's adenocarcinoma), Ewing sarcoma, eye cancer (e.g., intraocular melanoma, retinoblastoma), familiar hypereosinophilia, gall bladder cancer, gastric cancer (e.g., stomach adenocarcinoma), gastrointestinal stromal tumor (GIST), head and neck cancer (e.g., head and neck squamous cell carcinoma, oral cancer (e.g., oral squamous cell carcinoma (OSCC)), throat cancer (e.g., pharyngeal cancer, laryngeal cancer, nasopharyngeal cancer, oropharyngeal cancer), hematopoietic cancers (e.g., leukemia such as acute lymphocytic leukemia (ALL) (e.g., B-cell ALL, T-cell ALL), acute myelocytic leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myelocytic leukemia (CML) (e.g., B-cell CML, T-cell CML), and chronic lymphocytic leukemia (CLL) (e.g., B-cell
CLL, T-cell CLL); lymphoma such as Hodgkin lymphoma (HL) (e.g., B-cell HL, T-cell HL) and non-Hodgkin lymphoma (NHL) (e.g., B-cell NHL such as diffuse large cell lymphoma (DLCL) (e.g., diffuse large B-cell lymphoma (DLBCL)), follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphomas (e.g., mucosa-associated lymphoid tissue (MALT) lymphomas, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma (i.e., "Waldenstrom's macro globulinemia"), immunoblastic large cell lymphoma, hairy cell leukemia (HCL), precursor B-cell lymphoblastic lymphoma and primary central nervous system (CNS) lymphoma; and T-cell NHL such as precursor T-lymphoblastic lymphoma/leukemia, peripheral T-cell lymphoma (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (e.g., mycosis fungoides, Sezary syndrome), angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathy type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, anaplastic large cell lymphoma); a mixture of one or more leukemia/lymphoma as described above; and multiple myeloma (MM), heavy chain disease (e.g., alpha chain disease, gamma chain disease, mu chain disease), hemangioblastoma, inflammatory myofibroblastic tumors, immunocytic amyloidosis, kidney cancer (e.g., nephroblastoma a.k.a. Wilms' tumor, renal cell carcinoma), liver cancer (e.g., hepatocellular cancer (HCC), malignant hepatoma), lung cancer (e.g., bronchogenic carcinoma, non-small cell lung cancer (NSCLC), squamous lung cancer (SLC), adenocarcinoma of the lung. Lewis lung carcinoma, lung neuroendocrine tumors: typical carcinoid, atypical carcinoid, small cell lung cancer (SCLC), and large cell neuroendocrine carcinoma), leiomyosarcoma (LMS), mastocytosis (e.g., systemic mastocytosis), myelodysplasia syndromes (MDS), mesothelioma, myeloproliferative disorder (MPD) (e.g., polycythemia Vera (PV), essential thrombocytosis (ET), agnogenic myeloid metaplasia (AMM) a.k.a. myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myelocytic leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES)), neuroblastoma, neurofibroma (e.g., neurofibromatosis (NF) type 1 or type 2, schwannomatosis), neuroendocrine cancer (e.g., gastroenteropancreatic neuroendocrine tumor (GEP-NET), carcinoid tumor), osteosarcoma, ovarian cancer (e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma), papillary adenocarcinoma, pancreatic cancer (e.g., pancreatic adenocarcinoma), intraductal papillary mucinous neoplasm (IPMN), Islet cell tumors), penile cancer (e.g., Paget's disease of the penis and scrotum), pinealoma, primitive neuroectodermal tumor (PNT), prostate cancer (e.g., prostate adenocarcinoma), rectal cancer.
rhabdo myosarcoma, salivary gland cancer, skin cancer (e.g., squamous cell carcinoma (SCC), keratoacanthoma (KA), melanoma, basal cell carcinoma (BCC)), small bowel cancer (e.g., appendix cancer), soft tissue sarcoma (e.g., malignant fibrous histiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor (MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma), sebaceous gland carcinoma, sweat gland carcinoma, synovioma, testicular cancer (e.g., seminoma, testicular embryonal carcinoma), thyroid cancer (e.g., papillary carcinoma of the thyroid, papillary thyroid carcinoma (PTC), medullary thyroid cancer), urethral cancer, vaginal cancer, and vulvar cancer (e.g., Paget's disease of the vulva).

Examples of neurodegenerative diseases which may be treated or prevented, in particular treated, include, but are not limited to, motor neurone disease, progressive supranuclear palsy, corticobasal degeneration, Pick's disease, Alzheimer's disease, AIDS-related dementia, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, spinal muscular atrophy, and cerebellar degeneration.

Examples of cardiovascular diseases which may be treated or prevented, in particular treated, include, but are not limited to, cardiac hypertrophy, restenosis, atherosclerosis, and glomerulonephritis.

Examples of inflammatory diseases which may be treated or prevented, in particular treated, include, but are not limited to, inflammation associated with acne, anemia (e.g., aplastic anemia, haemolytic autoimmune anaemia), rhinitis, asthma, arthritis (e.g., polyarthritis, temporal arthritis, periarteritis nodosa, Takayasus's arteritis), arthritis (e.g., crystalline arthritis, osteoarthritis, psoriatic arthritis, gouty arthritis, reactive arthritis, rheumatoid arthritis and Reiter's arthritis), upper respiratory tract disease, ankylosing spondylitis, amylosis, amyotrophic lateral sclerosis, autoimmune diseases, allergies or allergic reactions, atherosclerosis, bronchitis, bursitis, chronic prostatitis, conjunctivitis. Chagas disease, chronic obstructive pulmonary disease, diverticulitis, cermatomyositis, diabetes (e.g., type I diabetes mellitus, type 2 diabetes mellitus), a skin condition (e.g., psoriasis, eczema, eczema hypersensitivity reactions, burns, dermatitis, pruritus (itch)), endometriosis, Guillain-Barre syndrome, infection, ischaemic heart disease, Kawasaki disease, glomerulonephritis, gingivitis, hypersensitivity, headaches (e.g., migraine headaches, tension headaches), ileus (e.g., postoperative ileus and ileus during sepsis), idiopathic thrombocytopenic purpura, interstitial cystitis (painful bladder syndrome), gastrointestinal disorder (e.g., selected from peptic ulcers, regional enteritis, diverticulitis, gastrointestinal bleeding, eosinophilic gastrointestinal disorders (e.g., eosinophilic esophagitis, eosinophilic gastritis, eosinophilic gastroenteritis, eosinophilic...
colitis), gastritis, diarrhea, gastroesophageal reflux disease (GORD, or its synonym GERD), inflammatory bowel disease (IBD) (e.g., Crohn's disease, ulcerative colitis, collagenous colitis, lymphocytic colitis, ischaemic colitis, diversion colitis, Behcet's syndrome, indeterminate colitis) and inflammatory bowel syndrome (IBS)), lupus, morphea, myasthenia gravis, myocardial ischemia, multiple sclerosis, nephrotic syndrome, pemphigus vulgaris, pernicious anaemia, peptic ulcers, polymyositis, primary biliary cirrhosis, neuroinflammation associated with brain disorders (e.g., Parkinson's disease, Huntington's disease, and Alzheimer's disease), prostatitis, chronic inflammation associated with cranial radiation injury, pelvic inflammatory disease, reperfusion injury, regional enteritis, rheumatic fever, systemic lupus erythematosus, scleroderma, scierodoma, sarcoidosis, spondyloarthopathies, Sjogren's syndrome, thyroiditis, transplantation rejection, tendonitis, trauma or injury (e.g., frostbite, chemical irritants, toxins, scarring, burns, physical injury), vasculitis, vitiligo and Wegener's granulomatosis.

In particular the inflammatory disease is an acute inflammatory disease (e.g., for example, inflammation resulting from infection). In particular the inflammatory disease is a chronic inflammatory disease (e.g., conditions resulting from asthma, arthritis and inflammatory bowel disease). The compounds may also be useful in treating inflammation associated with trauma and non-inflammatory myalgia. The compounds may also be useful in treating inflammation associated with cancer.

Examples of autoimmune diseases which may be treated or prevented, in particular treated, include, but are not limited to, arthritis (including rheumatoid arthritis, spondyloarthopathies, gouty arthritis, degenerative joint diseases such as osteoarthritis, systemic lupus erythematosus, Sjogren's syndrome, ankylosing spondylitis, undifferentiated spondylitis, Behcet's disease, haemolytic autoimmune anaemias, amyotrophic lateral sclerosis, amylosis, multiple sclerosis, acute painful shoulder, psoriatic, and juvenile arthritis), asthma, atherosclerosis, osteoporosis, bronchitis, tendonitis, bursitis, skin condition (e.g., psoriasis, eczema, eczema hypersensitivity reactions, burns, dermatitis, pruritus (itch)), enuresis, eosinophilic disease, gastrointestinal disorder (e.g., selected from peptic ulcers, regional enteritis, diverticulitis, gastrointestinal bleeding, eosinophilic gastrointestinal disorders (e.g., eosinophilic esophagitis, eosinophilic gastritis, eosinophilic gastroenteritis, eosinophilic colitis), gastritis, diarrhea, gastroesophageal reflux disease (GORD, or its synonym GERD), inflammatory bowel disease (IBD) (e.g., Crohn's disease, ulcerative colitis, collagenous colitis, lymphocytic colitis, ischaemic colitis, diversion colitis, Behcet's syndrome, indeterminate colitis) and inflammatory bowel syndrome (IBS)), and
disorders ameliorated by a gastroprokinetic agent (e.g., ileus, postoperative ileus and ileus during sepsis; gastroesophageal reflux disease (GORD, or its synonym GERD); eosinophilic esophagitis, gastroparesis such as diabetic gastroparesis; food intolerances and food allergies and other functional bowel disorders, such as non-ulcerative dyspepsia (NUD) and non-cardiac chest pain (NCCP, including costo-chondritis)).

In a particular embodiment, a provided compound may be useful in somatic cell reprogramming, such as reprogramming somatic cells into stem cells. In a particular embodiment, a provided compound may be useful in germ cell development, and are thus envisioned useful in the areas of reproductive technology and regenerative medicine.

Other diseases which may be treated or prevented, in particular treated, include, but are not limited to, ischemic injury associated myocardial infarctions, immunological diseases, stroke, arrhythmia, toxin-induced or alcohol related liver diseases, aspirin-sensitive rhinosinusitis, cystic fibrosis, cancer pain, and haematological diseases, for example chronic anemia and aplastic anemia.

The compounds of the present invention may also have therapeutic applications in sensitising tumour cells for radiotherapy and chemotherapy.

Hence the compounds of the present invention may be used as "radiosensitizer" and/or "chemosensitizer" or can be given in combination with another "radiosensitizer" and/or "chemosensitizer".

The term "radiosensitizer", as used herein, is defined as a molecule, preferably a low molecular weight molecule, administered to animals in therapeutically effective amounts to increase the sensitivity of the cells to ionizing radiation and/or to promote the treatment of diseases which are treatable with ionizing radiation.

The term "chemosensitizer", as used herein, is defined as a molecule, preferably a low molecular weight molecule, administered to animals in therapeutically effective amounts to increase the sensitivity of cells to chemotherapy and/or promote the treatment of diseases which are treatable with chemotherapeutics.

Several mechanisms for the mode of action of radiosensitizers have been suggested in the literature including: hypoxic cell radiosensitizers (e.g., 2-nitroimidazole compounds, and benzotriazine dioxide compounds) mimicking oxygen or alternatively behave like bioreductive agents under hypoxia; non-hypoxic cell radiosensitizers (e.g., halogenated pyrimidines) can be analogues of DNA bases and preferentially incorporate into the DNA of cancer cells and thereby promote the radiation-induced
breaking of DNA molecules and/or prevent the normal DNA repair mechanisms; and
various other potential mechanisms of action have been hypothesized for
radiosensitizers in the treatment of disease.
Many cancer treatment protocols currently employ radiosensitizers in conjunction with
radiation of x-rays. Examples of x-ray activated radiosensitizers include, but are not
limited to, the following: metronidazole, misonidazole, desmethylmisonidazole,
pimonidazole, etanidazole, nimorazole, mitomycin C, RSU 1069, SR 4233, E09,
RB 6145, nicotinamide, 5-bromodeoxyuridine (BUdR), 5-iododeoxyuridine (lUdR),
bromodeoxyctydine, fluorodeoxyuridine (FudR), hydroxyurea, cisplatin, and
therapeutically effective analogs and derivatives of the same.
Photodynamic therapy (PDT) of cancers employs visible light as the radiation activator
of the sensitizing agent. Examples of photodynamic radiosensitizers include the
following, but are not limited to: hematoporphyrin derivatives, Photofrin,
benzoporphyrin derivatives, tin etioporphyrin, bacteriochlorophylic-a,
naphthalocyanines, phthalocyanines, zinc phthalocyanine, and therapeutically effective
analgos and derivatives of the same.
Radiosensitizers may be administered in conjunction with a therapeutically effective
amount of one or more other compounds, including but not limited to: compounds
which promote the incorporation of radiosensitizers to the target cells; compounds
which control the flow of therapeutics, nutrients, and/or oxygen to the target cells;
chemotherapeutic agents which act on the tumour with or without additional radiation;
or other therapeutically effective compounds for treating cancer or other diseases.
Chemosensitizers may be administered in conjunction with a therapeutically effective
amount of one or more other compounds, including but not limited to: compounds
which promote the incorporation of chemosensitizers to the target cells; compounds
which control the flow of therapeutics, nutrients, and/or oxygen to the target cells;
chemotherapeutic agents which act on the tumour or other therapeutically effective
compounds for treating cancer or other disease. Calcium antagonists, for example
verapamil, are found useful in combination with antineoplastic agents to establish
chemosensitivity in tumor cells resistant to accepted chemotherapeutic agents and to
potentiate the efficacy of such compounds in drug-sensitive malignancies.
The compounds of the present invention might also reduce the risk of cancer
recurrence.
The invention relates to compounds of Formula (1) and pharmaceutically acceptable
addition salts, and solvates thereof, for use as a medicament.
The invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for use in the inhibition of PRMT5 activity.

The compounds of the present invention can be "anti-cancer agents", which term also encompasses "anti-tumor cell growth agents" and "anti-neoplastic agents".

The invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for use in the treatment of diseases mentioned above.

The invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for the treatment or prevention, in particular for the treatment, of said diseases.

The invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for the treatment or prevention, in particular in the treatment, of PRMT5 mediated diseases or conditions.

The invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for the manufacture of a medicament.

The invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for the manufacture of a medicament for the inhibition of PRMT5.

The invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for the manufacture of a medicament for the treatment or prevention, in particular for the treatment, of any one of the disease conditions mentioned hereinbefore.

The invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, for the manufacture of a medicament for the treatment of any one of the disease conditions mentioned hereinbefore.

The invention relates to compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, can be administered to mammals, preferably humans, for the treatment or prevention of any one of the diseases mentioned hereinbefore.

In view of the utility of the compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, there is provided a method of treating warm-blooded animals, including humans, suffering from or a method of preventing warm-blooded animals, including humans, to suffer from any one of the diseases mentioned hereinbefore.
Said methods comprise the administration, i.e. the systemic or topical administration, preferably oral administration, of an effective amount of a compound of Formula (I) or a pharmaceutically acceptable addition salt, or a solvate thereof, to warm-blooded animals, including humans.

Those of skill in the treatment of such diseases could determine the effective therapeutic daily amount from the test results presented hereinafter. An effective therapeutic daily amount would be from about 0.005 mg/kg to 50 mg/kg, in particular 0.01 mg/kg to 50 mg/kg body weight, more in particular from 0.01 mg/kg to 25 mg/kg body weight, preferably from about 0.01 mg/kg to about 15 mg/kg, more preferably from about 0.01 mg/kg to about 10 mg/kg, even more preferably from about 0.01 mg/kg to about 1 mg/kg, most preferably from about 0.05 mg/kg to about 1 mg/kg body weight. A particular effective therapeutic daily amount might be from about 0.01 to 1.00 g twice a day (BID), more in particular 0.30 to 0.85 g BID; even more in particular 0.40 g BID. The amount of a compound according to the present invention, also referred to here as the active ingredient, which is required to achieve a therapeutically effective will of course, vary on case-by-case basis, for example with the particular compound, the route of administration, the age and condition of the recipient, and the particular disorder or disease being treated.

A method of treatment may also include administering the active ingredient in a regimen of between one and four intakes per day. In these methods of treatment the compounds according to the invention are preferably formulated prior to administration. As described herein below, suitable pharmaceutical formulations are prepared by known procedures using well known and readily available ingredients.

The compounds of the present invention, that can be suitable to treat or prevent cancer or cancer-related conditions, may be administered alone or in combination with one or more additional therapeutic agents. Combination therapy includes administration of a single pharmaceutical dosage formulation which contains a compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof, and one or more additional therapeutic agents, as well as administration of the compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof, and each additional therapeutic agents in its own separate pharmaceutical dosage formulation. For example, a compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof, and a therapeutic agent may be administered to the patient together in a single oral dosage composition such as a tablet or capsule, or each agent may be administered in separate oral dosage formulations.
While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical composition.

Accordingly, the present invention further provides a pharmaceutical composition and, as active ingredient, a therapeutically effective amount of a compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof.

Accordingly, the present invention further provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof.

The carrier or diluent must be “acceptable” in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.

For ease of administration, the subject compounds may be formulated into various pharmaceutical forms for administration purposes. The compounds according to the invention, in particular the compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, or any subgroup or combination thereof may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs.

To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirable in unitary dosage form suitable, in particular, for administration orally, rectally, percutaneously, by parenteral injection or by inhalation. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable solutions containing a
compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof, may be formulated in an oil for prolonged action. Appropriate oils for this purpose are, for example, peanut oil, sesame oil, cottonseed oil, corn oil, soybean oil, synthetic glycerol esters of long chain fatty acids and mixtures of these and other oils. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. Acid or base addition salts of compounds of Formula (I) due to their increased water solubility over the corresponding base or acid form, are more suitable in the preparation of aqueous compositions.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage.

Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof.

In order to enhance the solubility and/or the stability of the compounds of Formula (I) and pharmaceutically acceptable addition salts, and solvates thereof, in pharmaceutical compositions, it can be advantageous to employ α-, β- or γ-cyclodextrins or their derivatives, in particular hydroxyalkyl substituted cyclodextrins, e.g. 2-hydroxypropyl-β-cyclodextrin or sulfobutyl-β-cyclodextrin. Also co-solvents such as alcohols may improve the solubility and/or the stability of the compounds according to the invention in pharmaceutical compositions.

Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99% by weight, more preferably from 0.1 to 70% by weight, even more preferably from 0.1 to 50% by weight of the compound of Formula (I), a pharmaceutically acceptable addition salt, or a solvate thereof, and from 1 to
99.95 % by weight, more preferably from 30 to 99.9 % by weight, even more preferably from 50 to 99.9 % by weight of a pharmaceutically acceptable carrier, all percentages being based on the total weight of the composition.

As another aspect of the present invention, a combination of a compound of the present invention with another anticancer agent is envisaged, especially for use as a medicine, more specifically for use in the treatment of cancer or related diseases.

For the treatment of the above conditions, the compounds of the invention may be advantageously employed in combination with antibody based immune cell redirection, for example T-cell/neutrophil redirection. This can be achieved for example by the use of bispecific monoclonal antibodies or artificial T-cell receptors.

For the treatment of the above conditions, the compounds of the invention may be advantageously employed in combination with one or more other medicinal agents, more particularly, with other anti-cancer agents or adjuvants in cancer therapy. Examples of anti-cancer agents or adjuvants (supporting agents in the therapy) include but are not limited to:

- platinum coordination compounds for example cisplatin optionally combined with amifostine, carboplatin or oxaliplatin;
- taxane compounds for example paclitaxel, paclitaxel protein bound particles (Abraxane™) or docetaxel;
- topoisomerase I inhibitors such as camptothecin compounds for example irinotecan, SN-38, topotecan, topotecan hcl;
- topoisomerase II inhibitors such as anti-tumour epipodophyllotoxins or podophyllotoxin derivatives for example etoposide, etoposide phosphate or teniposide:
- anti-tumour vinca alkaloids for example vinblastine, vincristine or vinorelbine;
- anti-tumour nucleoside derivatives for example 5-fluorouracil, leucovorin, gemcitabine, gemcitabine hcl, capecitabine, cladribine, fludarabine, nelarabine;
- alkylating agents such as nitrogen mustard or nitrosourea for example cyclophosphamide, chlorambucil, carmustine, thiopeta, mephalan (melphalan), lomustine, altretamine, busulfan, dacarbazine, estramustine, ifosfamide optionally in combination with mesna, pipobroman, procarbazine, streptozocin, temozolomide, uracil;
- anti-tumour anthracene derivatives for example daunorubicin, doxorubicin optionally in combination with dexrazoxane, doxil, idarubicin, mitoxantrone, epirubicin, epirubicin hcl, valrubicin;
- molecules that target the IGF-1 receptor for example picropodophilin;
- tetracarcin derivatives for example tctrocarcin A;
- glucocorticoids for example prednisone;
- antibodies for example trastuzumab (HER2 antibody), rituximab (CD20 antibody), gemtuzumab, gemtuzumab ozogamicin, cetuximab. pertuzumab, bevacizumab, alemtuzumab, ecuizumab, ibrutumomab tiuxetan, nofetimomab, panitumumab, tositumomab, CNTO 328;
- estrogen receptor antagonists or selective estrogen receptor modulators or inhibitors of estrogen synthesis for example tamoxifen, fulvestrant, toremifene, droloxifene, faslodex, raloxifene or letrozole;
- aromatase inhibitors such as exemestane, anastrozole, letrozole, testolactone and vorozole;
- differentiating agents such as retinoids, vitamin D or retinoic acid and retinoic acid metabolism blocking agents (RAMBA) for example accutane;
- DNA methyl transferase inhibitors for example azacytidine or decitabine;
- antifolates for example premetrexed disodium;
- antibiotics for example antinomycin D, bleomycin, mitomycin C, daictinomycin, carminomycin, daunomycin, levamisole, plicamycin, mithramycin;
- antimetabolites for example clofarabine, aminopterin. cytosine arabinoside or methotrexate, azacitidine, cytarabine, flouxuridine, pentostatin, thioguanine;
- apoptosis inducing agents and antiangiogenic agents such as Bcl-2 inhibitors for example YC 137, BH 3.12, ABT 737, gossypol, HA 14-1, TW 37 or decanoic acid;
- tubuline-binding agents for example combrestatin, colchicines or nocodazole;
- kinase inhibitors (e.g. EGFR (epithelial growth factor receptor) inhibitors, MTKI (mu si target kinase inhibitors), mTOR inhibitors) for example flavoperidoi, imatinib mesylate, erlotinib, gefitinib, dasatinib, lapatinib, lapatinib ditosylate, sorafenib, sunitinib, sunitinib maleate, temsirolimus;
- farnesyltransferase inhibitors for example tipifarnib;
- histone deacetylase (HDAC) inhibitors for example sodium butyrate, suberoylanilide hydroxamic acid (SAHA), depsipeptide (FR 901228), NVP-LAQ824, R30645, INJ-24681585, trichostatin A, vorinostat;
- Inhibitors of the ubiquitin-proteasome pathway for example PS-34 1, MLN 41 or bortezomib;
- Yondelis;
- Telomerase inhibitors for example telomestatin;
- Matrix metalloproteinase inhibitors for example batimastat, marimastat, prinostat or metastat.
- Recombinant interleukins for example aldesleukin, denilukin diftitox, interferon alfa 2a, interferon alfa 2b, peginterferon alfa 2b
- MAPK inhibitors
- Retinoids for example alitretinoin, bexarotene, tretinoin
- Asparaginase
- Steroids for example dromostanolone propionate, megestrol acetate, nandrolone (decanoate, phenpropionate), dexamethasone
- Gonadotropin releasing hormone agonists or antagonists for example abarelix, goserelin acetate, histrelin acetate, leuprolide acetate
- Thalidomide, lenalidomide
- Mercaptopurine, mitotane, pamidronate, pegademase, pegasparagase, rasburicase
- BH3 mimetics for example ABT-737
- MEK inhibitors for example PD98059, AZD6244, CI-1040
- colony-stimulating factor analogs for example filgrastim, pegfilgrastim, sargramostim; erythropoietin or analogues thereof (e.g. darbepoetin alfa); interleukin 11; orelvekin; zoledronate, zoledronic acid; fentanyl; bisphosphonate; palitriemin
- a steroidal cytochrome P450 17alpha-hydroxylase-17,20-lyase inhibitor
- colony-stimulating factor analogs for example filgrastim, pegfilgrastim, sargramostim; erythropoietin or analogues thereof (e.g. darbepoetin alfa); interleukin 11; orelvekin; zoledronate, zoledronic acid; fentanyl; bisphosphonate; palitriemin
- a steroidal cytochrome P450 17alpha-hydroxylase-17,20-lyase inhibitor
- Glycolysis inhibitors, such as 2-deoxyglucose
- mTOR inhibitors such as rapamycins and rapalogs, and mTOR kinase inhibitors
- PI3K inhibitors and dual mTOR/PI3K inhibitors
- autophagy inhibitors, such as chloroquine and hydroxy-choroquine
- antibodies that re-activate the immune response to tumors, for example nivolumab (anti-PD-1), lambrolizumab (anti-PD-1), ipilimumab (anti-CTLA4), and MPDL3280A (anti-PD-L1).

The present invention further relates to a product containing as first active ingredient a compound according to the invention and as further active ingredient one or more anticancer agents, as a combined preparation for simultaneous, separate or sequential use in the treatment of patients suffering from cancer.

The one or more other medicinal agents and the compound according to the present invention may be administered simultaneously (e.g. in separate or unitary compositions) or sequentially in either order. In the latter case, the two or more compounds will be administered within a period and in an amount and manner that is
sufficient to ensure that an advantageous or synergistic effect is achieved. It will be appreciated that the preferred method and order of administration and the respective dosage amounts and regimes for each component of the combination will depend on the particular other medicinal agent and compound of the present invention being administered, their route of administration, the particular tumour being treated and the particular host being treated. The optimum method and order of administration and the dosage amounts and regime can be readily determined by those skilled in the art using conventional methods and in view of the information set out herein.

The weight ratio of the compound according to the present invention and the one or more other anticancer agent(s) when given as a combination may be determined by the person skilled in the art. Said ratio and the exact dosage and frequency of administration depends on the particular compound according to the invention and the other anticancer agent(s) used, the particular condition being treated, the severity of the condition being treated, the age, weight, gender, diet, time of administration and general physical condition of the particular patient, the mode of administration as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that the effective daily amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. A particular weight ratio for the present compound of Formula (I) and another anticancer agent may range from 1/10 to 10/1, more in particular from 1/5 to 5/1, even more in particular from 1/3 to 3/1.

The platinum coordination compound is advantageously administered in a dosage of 1 to 500 mg per square meter (mg/m²) of body surface area, for example 50 to 400 mg/m², particularly for cisplatin in a dosage of about 75 mg/m² and for carboplatin in about 300 mg/m² per course of treatment.

The taxane compound is advantageously administered in a dosage of 50 to 400 mg per square meter (mg/m²) of body surface area, for example 75 to 250 mg/m², particularly for paclitaxel in a dosage of about 175 to 250 mg/m² and for docetaxel in about 75 to 150 mg/m² per course of treatment.

The camptothecin compound is advantageously administered in a dosage of 0.1 to 400 mg per square meter (mg/m²) of body surface area, for example 1 to 300 mg/m², particularly for irinotecan in a dosage of about 100 to 350 mg/m² and for topotecan in about 1 to 2 mg/m² per course of treatment.
The anti-tumour podophyllotoxin derivative is advantageously administered in a dosage of 30 to 300 mg per square meter (mg/m²) of body surface area, for example 50 to 250 mg/m², particularly for etoposide in a dosage of about 35 to 100 mg/m² and for teniposide in about 50 to 250 mg/m² per course of treatment.

The anti-tumour vinca alkaloid is advantageously administered in a dosage of 2 to 30 mg per square meter (mg/m²) of body surface area, particularly for vinblastine in a dosage of about 3 to 12 mg/m², for vincristine in a dosage of about 1 to 2 mg/m², and for vinorelbine in dosage of about 10 to 30 mg/m² per course of treatment.

The anti-tumour nucleoside derivative is advantageously administered in a dosage of 200 to 2500 mg per square meter (mg/m²) of body surface area, for example 700 to 1500 mg/m², particularly for 5-FU in a dosage of 200 to 500 mg/m², for gemcitabine in a dosage of about 800 to 1200 mg/m² and for capecitabine in about 1000 to 2500 mg/m² per course of treatment.

The alkylating agents such as nitrogen mustard or nitrosourea is advantageously administered in a dosage of 100 to 500 mg per square meter (mg/m²) of body surface area, for example 120 to 200 mg/m², particularly for cyclophosphamide in a dosage of about 100 to 500 mg/m², for chlorambucil in a dosage of about 0.1 to 0.2 mg/kg, for carmustine in a dosage of about 150 to 200 mg/m², and for lomustine in a dosage of about 100 to 150 mg/m² per course of treatment.

The anti-tumour anthracycline derivative is advantageously administered in a dosage of 10 to 75 mg per square meter (mg/m²) of body surface area, for example 15 to 60 mg/m², particularly for doxorubicin in a dosage of about 40 to 75 mg/m², for daunorubicin in a dosage of about 25 to 45 mg/m², and for idarubicin in a dosage of about 10 to 15 mg/m² per course of treatment.

The antiestrogen agent is advantageously administered in a dosage of about 1 to 100 mg daily depending on the particular agent and the condition being treated. Tamoxifen is advantageously administered orally in a dosage of 5 to 50 mg, preferably 10 to 20 mg twice a day, continuing the therapy for sufficient time to achieve and maintain a therapeutic effect. Toremifene is advantageously administered orally in a dosage of about 60 mg once a day, continuing the therapy for sufficient time to achieve and maintain a therapeutic effect. Anastrozole is advantageously administered orally in a
dosage of about 1 mg once a day. Droloxifene is advantageously administered orally in a dosage of about 20-100 mg once a day. Raloxifene is advantageously administered orally in a dosage of about 60 mg once a day. Exemestane is advantageously administered orally in a dosage of about 25 mg once a day.

Antibodies are advantageously administered in a dosage of about 1 to 5 mg per square meter (mg/m²) of body surface area, or as known in the art, if different. Trastuzumab is advantageously administered in a dosage of 1 to 5 mg per square meter (mg/m²) of body surface area, particularly 2 to 4 mg/m² per course of treatment.

These dosages may be administered for example once, twice or more per course of treatment, which may be repeated for example every 7, 14, 21 or 28 days.

The following examples illustrate the present invention. In case no specific stereochemistry is indicated for a stereocenter of a compound, this means that a mixture of the R and the S enantiomers was obtained. In case more than 1 stereocenter is present in a structure, each stereocenter for which no specific stereochemistry is indicated was obtained as a mixture of R and S.

The skilled person will realize that typically after a column purification, the desired fractions were collected and the solvent was evaporated to obtain the desired compound or intermediate.

Examples
Hereinafter, the term "rt", "r.t." or "RT" means room temperature; "Me" means methyl; "MeOH" means methanol; "Et" means ethyl; "EtOH" means ethanol; "NaH" means sodium hydride; "DEAD" means diethyl azodicarboxylate; "DMF" means N,N-dimethyl formamide; "DBAD" means di-tert-butyl azodicarboxylate; "LAH" means lithium aluminum hydride; "NaBH(OAc)₃" or "NaBH(AcO)" means sodium triacetoxyborohydride; "EtOAc" means ethyl acetate; "TEA" or "Et₂N" means triethylamine; "DCM" means dichloromethane; "q.s." means quantum sufficit; "Int." Means intermediate; "MeCN" or "ACN" means acetonitrile; "DMF" means N,N-dimethyl formamide; "DMA" means N,N-dimethyl acetamide; "DMF-DMA" means N,N-Dimethylformamide dimethyl acetal; "Pd(dppf)G." means [1,1'-Bis(diphenylphosphino)ferrocene][dichloropalladium(II)]; "THF" means tetrahydrofuran; "C₅H₂N₂FeP₂C₂Pd" means [1,1'-bis(diphenylphosphino)ferrocene]
dichloropalladium(ii); "i-PrOH" or "iPrOH" means 2-propanol; "LC" means liquid chromatography; "LCMS" means Liquid Chromatography/Mass spectrometry; "HPLC" means high-performance liquid chromatography; "int." means intermediate; "prep-HPLC" means preparative high-performance liquid chromatography; "m-CPBA" means meta-Chloroperoxybenzoic acid; "TFA" means trifluoroacetic acid; "m.p." means melting point; "RP" means reversed phase; "min" means minute(s); "h" means hour(s); "PE" means petroleum ether; "v/v" means volume per volume; "Celite ®" means diatomaceous earth; "DMSO" means dimethyl sulfoxide; "SFC" means Supercritical Fluid Chromatography; "DIPE" means diisopropyl ether; "dppf ' or "DPPF" means 1,1'-Bis(diphenylphosphino)ferrocene; "DIPEA" or "DIEA" means N,N-diisopropylethylamine; "PPh₃" means triphenylphosphine; "Et₂O" means diethyl ether; "Pd/C" means palladium on carbon; "Pt/C" means platina on carbon; "Pd(OH)₂/C" means palladium hydroxide on carbon; "CPME" means cyclopentyl methyl ether; "Pd₂(dba)₃ means Tris(dibenzylideneacetone)dipalladium; "DIAD" means diisopropyl azodicarboxylate; "TMSCF₃" means trimethyl(trifluoromethyl)silane; "TBAF" means tetraethylammonium fluoride; "psi" means pound-force per square inch; "Et₄NG " means tetraethylammonium chloride; "eq." means equivalent(s); "Pd(OAc)₂" means palladium(II) acetate; "AcOH" means acetic acid; "DMAP" means 4-(dimethylamino)pyridine; "t-BuOK", "BuOK" or "KOtBu" means potassium tert-butoxide; "Dess-Martin periodinane" means 1,1,1-Triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one; "TBDMSC1" means tert-Butyldimethylsilyl chloride; "PPh₃-polymer" or "PPh₃-pol" means triphenylphosphine polymer bound; "Ph,PCH₃,Br" means methyltriphenylphosphonium bromide; "Bn" means benzyl; "Bz" means benzoyl; "p-TSA" means 4-methylbenzenesulfonic acid; "BF₃·Et₂O" means Boron Trifluoride-Ethyl Ether Complex; "9-BBN" means 9-Borabicyclo[3.3.1]nonane; "Pd-118" means Dichlorof 1,1'-bis(di-tert-butylphosphino)ferrocenylplatinum(II); and "TLC" means thin layer chromatography; "prep-TLC" means preparative TLC; "p-Me₃C₆H₄SO₃H.H₂O" means para toluenesulfonic acid hydrate; "PMB" means para methoxybenzyl; "KOAc" means potassium acetate; "PTSA" para toluenesulfonic acid; "MTBE" means methyl tert. butyl ether; Rh(acac)(eth)₂ means Acetylacetonatobis(ethylene)rhodium( II); "(S)-MonoPhos" means (S)-N,N-dimethylindinaphtho[2,1-D:1’2’-F][1,3,2]dioxaphosphepin-4-amine; "Tf₂O" means triflic anhydride; "Mel" means methyliodide; "Me₂NH" means dimethylamine; "Me₂NH.HCl" means dimethylamine hydrochloric acid; "Me₄NCl" means tetramethyl ammonium chloride; "MeONa" means sodium methoxide; "Ts" means tosyl; "MsCl" means mesylchloride; "DIBAH" means Diisobutylalumium hydride;
"TBDMS" means tertButyl dimethylsilyl; "Pd(dppf)Cl\(\text{2}.\text{CH}_2\text{Cl}_2\)" means [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane.; "PPA" means polyphosphoric acid; "NH\(_2\)Bn" means benzylamine; "Pd(PPh\(_3\))\(\text{2}.\text{Cl}_2\)" means Dichlorobis(triphenylphosphine)palladium(II).

Intermediates containing a double bond with substituents which may be in the E or the Z configuration are shown in one particular configuration in the experimental part below. However, unless explicitly indicated by (E) or (Z), it is unknown if these intermediates were obtained in the E or Z configuration or as a mixture of both configurations. For example intermediates 24-26, 29-31, 72-76, and intermediates 79-88 might be in the E or Z configuration or might be mixtures thereof. For example Intermediates 44, 97-100, 136-138, 150 and compounds 55, 57, 57a and 61 were obtained in the E configuration and are explicitly indicated as such (E) in the experimental part below.

For intermediates that were used in a next reaction step as a crude or as a partially purified intermediate, estimated mol amounts (in some cases indicated by ~) are indicated in the reaction protocols described below, or alternatively theoretical mol amounts are indicated.

20 A. Preparation of intermediates

Example A1

Preparation of intermediate 1

To a mixture of 6-chloro-7-deazapurine-beta-d-riboside (25.0 g, 87.5 mmol) in acetone (330 mL) was added 2,2-dimethoxypropane (18.2 g, 175 mmol) and 4-methylbenzenesulphonic acid (TosOH) (1.51 g, 8.75 mmol) in one portion at 25°C under N\(_2\). The mixture was stirred at 60°C for 2 hours. The mixture was cooled to 25°C. The reaction was quenched by adding saturated NaHCO\(_3\) (100 mL) slowly and then extracted with ethyl acetate (125 mL x 5). The combined organic phase was washed
with saturated brine (120 mL), dried with anhydrous MgSO₄, filtered and concentrated in vacuum. The residue was purified by silica gel chromatography (gradient elution: DCM/Ethyl acetate from 1:0 to 2:1) to afford crude intermediate 1 (38.0 g) as light yellow gum.

Example A2

Preparation of intermediate 3

To a solution of 5-0-tert-Butyldimethylsilyl-2,3-o-isopropylidene-D-ribofuranose (intermediate 2) (24.3 g, 79.8 mmol) in CCl₄ (12.8 mL, 133 mmol) and toluene (200 ml) was added dropwise HMPT at -50 °C over 30 minutes. After the mixture was stirred at -50°C for 2 hours, the reaction mixture was quickly washed with ice cold brine (30 mL), dried over anhydrous Na₂SO₄ and added immediately to a heavily stirred mixture of powdered KOH (6.5 g, 117 mmol), 2,4-dichloro-7h-pyrrolopyrimidine (10.0 g, 53 mmol), tris(3,6-dioxaheptyl)amine (8.27 mL, 26.6 mmol) and toluene (200 ml). The mixture was stirred at room temperature for 48 hours. Then the solvent was concentrated in vacuum. The residue was treated with 250 ml NH₄Cl solution and extracted with ethyl acetate (300 ml x 2). The organic layers were combined and dried with Na₂SO₄, filtered and the filtrate was concentrated in vacuum. The residue was purified by column chromatography over silica gel (gradient elution: petroleum ether/ethyl acetate from 25:1 to 15:1). The product fractions were collected and the solvent was evaporated to give the desired intermediate 3 (6.50 g, crude).

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 3 using the appropriate starting materials (Table 1).
Table 1:

<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td><img src="#" alt="Structure 1" /></td>
<td>Intermediate 2 and 4-chloro-2-methyl-7H-pyrrolo[2,3-d]pyrimidine</td>
</tr>
<tr>
<td>5</td>
<td><img src="#" alt="Structure 2" /></td>
<td>Intermediate 2 and 4-Chloro-5-fluoro-7H-pyrrolo[2,3-d]-pyrimidine</td>
</tr>
<tr>
<td>185</td>
<td><img src="#" alt="Structure 3" /></td>
<td>Intermediate 2 and 4-Chloro-5-methyl-7H-pyrrolo[2,3-d]-pyrimidine</td>
</tr>
<tr>
<td>189</td>
<td><img src="#" alt="Structure 4" /></td>
<td>Intermediate 2 and 4-Chloro-6-methyl-7H-pyrrolo[2,3-d]-pyrimidine</td>
</tr>
<tr>
<td>282</td>
<td><img src="#" alt="Structure 5" /></td>
<td>Intermediate 2 and 4-Chloro-6-Iodo-7H-pyrrolo[2,3-d]-pyrimidine</td>
</tr>
</tbody>
</table>
Example A3

Preparation of intermediate 6

Intermediate 3 (7.00 g, 14.8 mmol) was dissolved into the solvent mixture of acetic acid, water and THF with ratio as 13:7:3 (100 mL). The reaction mixture was stirred at room temperature for 12 hours. The solvent was removed under reduced pressure at 60 °C, afforded 6.8 g of crude intermediate 6 together with by-product. To the solution of the above crude product in acetone (50 mL) was added 2,2-dimethoxypropane (5 mL, 42 mmol) and 4-methyl benzene sulfonylic acid monohydrate (13 mg, 0.07 mmol) at room temperature under N₂. The mixture was stirred at 60°C for 2 hours. The solvent was removed under reduced pressure below 30 °C. The residue was purified by column chromatography (gradient elution: EtOAc/petroleum ether from 1/10 to 1/3) on silica gel to afford the desired intermediate 6 (3.02 g, 34% yield).

Example A4

Preparation of intermediate 7

To a solution of intermediate 4 (9.50 g, 20.9 mmol) in THF (82 mL) was added 1M TBAF solution in THF (41.8 mL, 41.8 mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 hours. The mixture was evaporated to dryness. The residue was taken up into water and extracted with DCM (150 mL x 2). The organic layers were dried (Na₂SO₄), filtered and the filtrate was concentrated in vacuum. The residue was purified by column chromatography over silica gel (gradient elution: petroleum ether/ethyl acetate from 10/1 to 4/1) to give the desired intermediate 7 (3.68 g, 88% yield).
Below intermediate was prepared by an analogous reaction protocol as was used for the preparation of *intermediate 7* using the appropriate starting materials (Table 2).

Table 2:

<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting material</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td><img src="image1" alt="Structure 8" /></td>
<td>Intermediate 5</td>
</tr>
<tr>
<td>186</td>
<td><img src="image2" alt="Structure 186" /></td>
<td>Intermediate 185</td>
</tr>
<tr>
<td>190</td>
<td><img src="image3" alt="Structure 190" /></td>
<td>Intermediate 189</td>
</tr>
</tbody>
</table>

Example A5

**Preparation of intermediate 10**

![Structure 10](image4)

*intermediate 10*
To a mixture of 4,6-dichloro-5-(2,2-diethoxyethyl)pyrimidine (14.0 g, 52.8 mmol) and (1R,2S,3R,5R)-3-amino-5-(hydroxymethyl)cyclopentane-1,2-diol hydrochloride (10.7 g, 58.1 mmol) in propan-2-ol/H₂O (208 mL, 7:1), was added Et₃N (13.4 g, 132 mmol) in one portion at 25 °C under N₂. The mixture was stirred at 90 °C for 23 hours. The mixture was cooled to 50 °C and 4M HCl (24 mL, 106 mmol) was added slowly. The residue was then stirred at 50 °C for 2 hours. The reaction mixture was cooled to 25 °C and NaHCO₃ (14 g, 100 mmol) was added slowly. Ethyl acetate (230 mL x 2) was added, followed by the addition of a half-saturated NaHCO₃ solution (q.s.). The organic phase was isolated and the aqueous phase was extracted with ethyl acetate (230 mL x 2). The combined organic phase was dried with anhydrous MgSO₄, filtered and concentrated in vacuum to afford intermediate 9 as yellow solid (17.4 g, quantitative yield in 2 steps). The crude product was directly used as such in the next reaction step without further purification.

Step b)

To a mixture of intermediate 9 (17.4 g, -52.7 mmol) in acetone (250 mL) was added 2,2-dimethoxypropane (11.0 g, 105 mmol) and TsOH·H₂O (908 mg, 5.27 mmol) in one portion at 25 °C under N₂. The mixture was stirred at 60 °C for 2 hours. The mixture was cooled to 25 °C and the solution was concentrated in vacuum, quenched by saturated NaHCO₃ (100 mL) slowly and then extracted with ethyl acetate (100 mL x 3). The combined organic phase was washed with saturated brine (100 mL), dried with anhydrous MgSO₄, filtered and concentrated in vacuum. The residue was purified by flash chromatography on silica gel (gradient elution: DCM/Ethyl acetate from 1/0 to 2/1) to afford intermediate 10 as light yellow gum (15.5 g, 89 % yield).
Example A6

Preparation of intermediate 14

An oven-dried flask was charged with 7-bromo-4-(methylthio)pyrrolo[2,1-
10 f][1,2,4]triazine (45.0 g, 184 mmol) and dry THF (1.20 L) under N\textsubscript{2}. The yellow solution was cooled to -78 °C, and a yellow suspension was formed. n-BuLi (2.5 M, 79.6 mL) was added dropwise to the reaction mixture over period of 25 minutes at -78 °C. The reaction mixture was stirred at -78 °C for 1 hour and a yellow-brown solution formed. A pre-cooled solution of intermediate 10 (84.0 g, 201 mmol) in dry THF (800 mL) in another flask (-78 °C) was added to the solution under N\textsubscript{2}. The resulting red-brown solution was stirred at -78 °C for 1.5 h. 2 batches were carried out in parallel. The reaction was quenched by addition of a saturated NH\textsubscript{4}Cl aqueous solution (300 mL) at -78 °C, and subsequently the mixture was warmed to 10 °C. The mixture was extracted with ethyl acetate (500 mL x 3). The combined organic layers were washed with brine, dried over MgSO\textsubscript{4}, filtered and concentrated under reduced pressure. The residue was load on silica gel then purified by column chromatography (SiO\textsubscript{2}, gradient elution: Petroleum ether/Ethyl acetate from 10/1 to 3:1) to afford intermediate 11 (149 g, 56 % yield) as an orange gum.
To a stirred solution of intermediate 11 (74.0 g, 127 mmol) and triethylsilane (59.9 g, 515 mmol) in DCM (1.80 L) was added BF$_3$·Et$_2$O (90.9 g, 640 mmol) dropwise at -30—20°C. 2 batches were carried out in parallel. The resulting orange solution was stirred between -30 and -20 °C for 4.5 hours. The reaction mixture was carefully poured into a saturated NaHCO$_3$ aqueous solution (2.5 L) with vigorous stirring (gas evolution). The mixture was stirred for 2 hours. The organic layer was separated and the aqueous phase was extracted with DCM (200 mL x 3). The combined organic layers were washed with brine (500 ml, x 2), dried over MgSO$_4$, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, gradient elution: petroleum ether:ethyl acetate: from 12:1 to 8:1), affording intermediate 12 as a light yellow gum (125.7 g, 83% yield.)

1M BCl$_3$ in CH$_2$Cl$_2$ (860 mL, 860 mmol) was added dropwise at -78 °C to a stirred solution of intermediate 12 (75.0 g, 132 mmol) in DCM (1.20 L) dropwise over period of 2.5 hour under N$_2$. The mixture was stirred at -78 °C for 1 hour. The reaction mixture was slowly warmed to -40 °C. The reaction mixture was poured into MeOH (2.5 L, 20 °C) with stirring. The resulting red solution was stirred for 3 hours. Water (250 mL) was added into the mixture and left at 20 °C for 16 h. The solution was portion wise poured onto solid NaHCO$_3$ (500 g) carefully with vigorous stirring (gas evolution, the color of mixture was turned from orange-red to yellow). The resulting suspension was filtered and the filtrate was concentrated under reduced pressure. The residue was
dispensed in iPrOH/CH₂Cl₂ (1:3, 1 L) then filtered (to remove some inorganic salt) and
the filtrate was concentrated under reduced pressure. The residue was triturated with
petroleum ether (500 mL x 3) to afford crude intermediate 13 (40.2 g, crude) as an
orange solid, which used in the next reaction step without further purification.

Step d) R and S mixture

![Diagram of intermediates 13 and 14]

To a suspension of intermediate 13 (40.2 g, crude) and 2,2-dimethoxypropane (34 mL,
277 mmol) in acetone (600 mL) was added TsOH·H₂O (5.92 g, 31.10 mmol, 0.23 eq) at
25 °C (pH = 2). The resulting mixture was heated at 60 °C for 2 hours. After being
cooled to 25 °C, the reaction mixture was concentrated under reduced pressure. The
residue was partitioned between ethyl acetate (500 mL) and saturated aqueous NaHCO₃
solution (500 mL). The layers were separated and the aqueous phase was extracted with
ethyl acetate (200 mL x 3). The combined organic layers were washed with brine (100
mL), dried over MgSO₄, filtered and concentrated under reduced pressure. The residue
was purified by column chromatography (silica gel, gradient elution: CH₂Cl₂/Ethyl
acetate from 10/1 to 6/1). The fractions containing desired intermediate 14 were
combined and concentrated under reduced pressure. The residue (28 g, about 80% purity)
was purified again by column chromatography (silica gel, gradient elution:
Petroleum ether/Ethyl acetate: from 20/1 to 4/1). The desired fractions were combined
and concentrated under reduced pressure. The residue was diluted with CH₂Cl₂ (15 mL)
then petroleum ether/ethyl acetate (4:1, 200 mL) was added. The mixture was
concentrated to about 150 mL and solids were precipitated. The slurry was diluted with
petroleum ether to about 400 mL and stirred for 16 hours at 20 °C. The mixture was
filtered and the solid was rinsed with petroleum ether/ethyl acetate (20/1, 100 mL). The
solids were collected and dried under high vacuum to afford pure intermediate 14 as
white solid (18.6 g, 42 % yield for 2 steps).

Example A7
Preparation of intermediate 15
The intermediate 1 (10.0 g, -28.6 mmol), TEA (12 mL, 85.7 mmol) and DMAP (0.70 g, 5.71 mmol) were dissolved in CH₂Cl₂ (100 mL). p-toluenesulfonyl chloride (10.9 g, 57.1 mmol) was added at 0°C. The mixture was stirred at room temperature overnight. Water (100 mL) was added to the above solution. The aqueous layer was extracted with DCM (100 mL x 3). The combined organic layer was dried over Na₂SO₄ and concentrated to dryness. The residue was purified by flash column (gradient edition: petroleum ether/EtOAc from 10 to 3/1). The product fractions were collected and the solvent was evaporated to give intermediate 15 as yellow oil (14.5 g, 97% yield).

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 15 using the appropriate starting materials (Table 3).

<table>
<thead>
<tr>
<th>Int.</th>
<th>structure</th>
<th>Starting material</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td><img src="image" alt="Intermediate 16" /></td>
<td>Intermediate 8</td>
</tr>
<tr>
<td>17</td>
<td><img src="image" alt="Intermediate 17" /></td>
<td>Intermediate 10</td>
</tr>
</tbody>
</table>

Example A8

Preparation of intermediate 18
Intermediate 1

Intermediate 1 (100.0 g, theoretically 307 mmol) was dissolved in 400 mL of 1,4-dioxane. Then 400 mL of Ammonia water (28-30% N3¾ basis) was added. The mixture was stirred in a sealed tube at 100°C for 20 hours. The mixture was cooled to room temperature. The reaction mixture was evaporated in vacuum to remove half of the solvent. Water (200 mL) was added and extracted with EtOAc (500 mL x 3). The combined organic layers were washed with brine (200 mL x 2), dried and concentrated to give Intermediate 18 as white solid (93 g, 93% yield).

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of Intermediate 18 using the appropriate starting materials (Table 4).

<table>
<thead>
<tr>
<th>Intermediates</th>
<th>structure</th>
<th>Starting material</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td><img src="19.png" alt="Image" /></td>
<td>Intermediate 6</td>
</tr>
<tr>
<td>20</td>
<td><img src="20.png" alt="Image" /></td>
<td>Intermediate 7</td>
</tr>
<tr>
<td>283</td>
<td><img src="283.png" alt="Image" /></td>
<td>Intermediate 282</td>
</tr>
<tr>
<td>502</td>
<td><img src="502.png" alt="Image" /></td>
<td>Intermediate 10</td>
</tr>
</tbody>
</table>
Example A9

Preparation of intermediate 23

\[
\text{intermediate 23}
\]

Step a:

To a solution of intermediate 21 (6.6 g, 9.75 mmol) in THF (130 mL) was added ammonia (28% in \( \text{H}_2\text{O} \), 65 mL) at room temperature. The reaction mixture was stirred at 100°C (using an autoclave) for 16 hours. The reaction mixture cooled to room temperature and evaporated to dryness under reduced pressure. The residue was taken up into water (100 mL) and DCM (100 mL) and stirred for 1 hour. The layers were separated and the water layer was washed again with DCM (100 mL) to remove impurities. The water layer was filtered and the filtrate was evaporated to dryness. The residue was purified on flash chromatography on silica (gradient elution: DCM/MeOH from 95:5 to 90:10). The desired fractions were collected and the solvent was evaporated, yielding intermediate 22 (3.4 g, crude). The crude product was directly used for the next reaction step without further purification.

Step b:

To a mixture of intermediate 22 (1.0 g, crude) in acetone (32 mL) was added 2,2-dimethoxy propane (1.78 mL g, 14.5 mmol) and 4-methylbenzenesulfonic acid (0.61 g, 3.19 mmol) in one portion at room temperature. The mixture was stirred at 60°C for 3
hours. The mixture was cooled to room temperature and quenched by adding saturated NaHCO$_3$ (10 mL) slowly and then extracted with ethyl acetate (50 mL x 5). The combined organic phase was washed with saturated brine (120 mL), dried with MgSO$_4$, filtered and concentrated in vacuum, offered intermediate 23 (0.80 g, crude). The crude product was directly used for the next reaction step without further purification.

Example A10

Preparation of intermediate 24

Intermediate 18 (10.0 g, 32.6 mmol) was dissolved in THF (200 mL). Then Dimethyl formamide Dimethylacetal (DMF-DMA) (5.84 g, 49.0 mmol) was added. The mixture was stirred at 60°C for 24 hours. The mixture was cooled to room temperature and the solvent was concentrated in vacuum. The residue was triturated with EtOAc (200 mL) and water (100 mL). The organic layer was separated, the aqueous was extracted with EtOAc (200 mL x 1), the combined organic layer was washed by brine (50 mL), dried over anhydrous Na$_2$SO$_4$, filtration and concentration to afford the desired intermediate 24 as a yellow solid (10.5 g, 85% yield)

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 24 using the appropriate starting materials (Table 5).

Table 5:

<table>
<thead>
<tr>
<th>Intermediates</th>
<th>structure</th>
<th>Starting material</th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td><img src="image" alt="Intermediate 19" /></td>
<td>Intermediate 19</td>
</tr>
</tbody>
</table>
Example A 11

<table>
<thead>
<tr>
<th>Intermediates</th>
<th>structure</th>
<th>Starting material</th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td><img src="image" alt="Structure 26" /></td>
<td>Intermediate 20</td>
</tr>
<tr>
<td>503</td>
<td><img src="image" alt="Structure 503" /></td>
<td>Intermediate 502</td>
</tr>
</tbody>
</table>

Step a:

To the mixture of intermediate 18 (88.0 g, 287 mmol) and imidazole (39.1 g, 575 mmol) in DMF (300.0 mL) was added TBDMSCl (52.0 g, 345 mmol) in one portion at 0 °C under N₂. The reaction mixture was stirred overnight at room temperature. Subsequently, water (500 mL) was added and the mixture was extracted with EtOAc (800 mL x 3). The organic layer was washed with brine (500mL). Then the organic phase was dried with anhydrous Na₂SO₄, filtered, and the organic phase was concentrated under vacuum to give the crude product. The crude product was purified by column chromatography over silica gel (gradiante edition: petroleum ether/ethyl acetate 1:1). The desired fraction was concentrated to give the intermediate 27 as oil (120 g, 96 % yield).
Step b:

To the solution of intermediate 27 (12.4 g, -24.4 mmol) and DMAP (0.30 g, 2.44 mmol) in THF (50 mL) was added (Boc)$_2$O (13.3 g, 61.0 mmol) dropwise at room temperature. The reaction mixture was stirred at room temperature for 3 hours. Then 1 M TBAF solution in THF (24.4 mL, 24.4 mL) was added dropwise. The reaction mixture was stirred at rt for 18 hours. The reaction mixture was poured into 250 mL of water and extracted with ethylacetate (250 mL x 2). The organ ice layer was washed (water) and brine, dried with Na$_2$SO$_4$, and concentrated to be dry. The residue was purified by flash chromatography (edition: ethylacetate / heptane = 50 / 50). The desired fraction was collected and the residue was stirred in heptane. The solid product is filtered off and dried at rt under reduced pressure, yielding intermediate 28 (10.2 g, 83% yield) as solid product.

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 28 using the appropriate starting materials (Table 23).

Table 23

<table>
<thead>
<tr>
<th>Intermediates</th>
<th>structure</th>
<th>Starting material</th>
</tr>
</thead>
<tbody>
<tr>
<td>284</td>
<td><img src="image" alt="Structure" /></td>
<td>Intermediate 283</td>
</tr>
</tbody>
</table>

Example A 12

Preparation of intermediate 29
To a reaction mixture of intermediate 24 (15.0 g, 41.7 mmol), Et₃N (11.6 mL, 83.3 mmol) and DMAP (509 mg, 4.17 mmol) in DCM (200 ml.) was added p-Toluenesulfonyl chloride (8.74 g, 45.9 mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 hours. Water (100 mL) was added into the reaction mixture, the organic layer was separated, and the aqueous layer was extracted with EtOAc (100 mL x 2). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na₂SO₄, filtered and concentrated to yield the crude intermediate 29 as a brown solid, which was used in the next reaction step without further purification.

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 29 using the appropriate starting materials (Table 6).

Table 6:

<table>
<thead>
<tr>
<th>Int.</th>
<th>structure</th>
<th>Starting material</th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td><img src="image1" alt="Structure" /></td>
<td>Intermediate 25</td>
</tr>
<tr>
<td>31</td>
<td><img src="image2" alt="Structure" /></td>
<td>Intermediate 26</td>
</tr>
</tbody>
</table>
Example A 12b

Preparation of intermediate 32

Intermediate 28 (4.5 g, 8.89 mmol), TEA (2.70 g, 26.6 mmol), DMAP (0.54 g, 4.4 mmol) and DCM (40 ml) were stirred on an ice bath. p-Toluenesulfonyl chloride (3.39 g, 17.8 mmol) was added dropwise. The mixture was stirred at room temperature for 5 hours. The reaction mixture was poured into water and was extracted with DCM. The organic layer was evaporated and purified with flash chromatography on silica (eluent: DCM 98% MeOH 2%) to give intermediate 32 (5.6 g, 95% yield).

Example A 13

Preparation of intermediate 33
To a mixture of intermediate 1 (2.00 g, theoretically 6.18 mmol) in DCM (40 mL) was added Dess-Martin periodinane (5.24 g, 12.36 mmol) in one portion at 0°C under N\textsubscript{2}. The mixture was stirred at 0°C for 3 hours. To the mixture was added Na\textsubscript{2}S\textsubscript{2}O\textsubscript{3} (4 g) in saturated NaHCO\textsubscript{3} (20 mL) and stirred for 10 min. The aqueous phase was extracted with DCM (20 mL x 3). The combined organic phase was washed with saturated brine (20 mL x 2), dried with anhydrous MgSO\textsubscript{4}, filtered and concentrated in vacuum to afford intermediate 33 (1.80 g, crude) as light yellow gum. The crude product was directly used for the next reaction step without further purification.

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 33 using the appropriate starting materials (Table 7).

Table 7:

<table>
<thead>
<tr>
<th>Int.</th>
<th>structure</th>
<th>Starting material</th>
</tr>
</thead>
<tbody>
<tr>
<td>34</td>
<td><img src="structure1.png" alt="Image" /></td>
<td>intermediate 7</td>
</tr>
<tr>
<td>35</td>
<td><img src="structure2.png" alt="Image" /></td>
<td>intermediate 10</td>
</tr>
<tr>
<td>36</td>
<td><img src="structure3.png" alt="Image" /></td>
<td>intermediate 14</td>
</tr>
</tbody>
</table>
Example A 14

Preparation of intermediate 37

To a solution of intermediate 33 (6.5 g, crude, -15.46 mmol) in THF (200 mL) was added dropwise MeMgBr (1M, 18.55 ml, 18.55 mmol) at -78°C under N₂. The mixture was stirred overnight at room temperature under N₂. The reaction mixture was concentrated under vacuum to give crude product as a yellow solid. The crude product was purified by column chromatography (gradient elution: petroleum ether/EtOAc from 40:1 to 10:1). The desired fractions were collected and the solvent was evaporated to give Intermediate 37 as light yellow oil (700 mg crude; and 3 g crude with more impurities).

Example A 15

Preparation of intermediate 38

Method 1
To a mixture of methyltriphenylphosphonium bromide (4.87 g, 13.62 mmol) in THF (500 mL) was added t-BuOK (11.4 ml, 1 M in THF, 1.27 g, 11.35 mmol) dropwise at 0°C under N₂. The suspension was turned to bright yellow and stirred at 0°C for 0.5 h and then warmed to 25°C for 0.5 h. The mixture was cooled to -40°C. The solution of Intermediate 35 (1.46 g, theoretically 4.54 mmol) in THF (130.0 ml) was added drop-wise and then stirred at -20°C for 1 h, after this, the mixture was warmed to 25°C for 2 h. To the mixture was added saturated NH₄Cl (300 ml) and stirred for 10 min. Layers were separated and the aqueous phase was extracted with DCM (300 mL x 2). The combined organic phase was washed with saturated brine (500 mL), dried with anhydrous MgSO₄, filtered and concentrated in vacuum. The residue was purified by silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Gradient eluention: From 0 to 15% of Ethyl acetate / Petroleum ether). The desired fractions were collected and the solvent was evaporated. Intermediate 38 was obtained as off-white solid (530 mg, 36% yield).

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 38 (Method 1) using the appropriate starting materials (Table 8).

**Table 8:**

<table>
<thead>
<tr>
<th>Int.</th>
<th>structure</th>
<th>Starting material</th>
</tr>
</thead>
<tbody>
<tr>
<td>39</td>
<td><img src="image1" alt="Structure" /></td>
<td>Intermediate 33</td>
</tr>
<tr>
<td>40</td>
<td><img src="image2" alt="Structure" /></td>
<td>Intermediate 36</td>
</tr>
<tr>
<td>513</td>
<td><img src="image3" alt="Structure" /></td>
<td>Intermediate 512</td>
</tr>
</tbody>
</table>
Method 2

A solution of Intermediate 35 (10.0 g, theoretically 31.1 mmol) in THF (100 mL) was added drop-wise under \( \text{N}_2 \) over a period of 30 minutes to a bis(iodozincio)methane solution in THF (180 mL, 0.31 M, 55.9 mmol, prepared according to the procedure described in *Tetrahedron* 2002, 58, 8255-8262), stirring was continued until complete conversion (approximately 2 hours). The reaction mixture was quenched by the slow addition of a saturated aqueous \( \text{NH}_4\text{Cl} \) solution, during which salt formation was observed. Prior to extraction (EtOAc, 2 x 200 mL), the salts were dissolved again by the addition of an aqueous ammonia solution (25%). The combined organic phases were washed with an aqueous sodium bisulfite solution and brine, dried with anhydrous MgSO\(_4\), filtered and concentrated in vacuum. The residue was purified by silica gel chromatography (eluent: dichloromethane/EtOAc 95/5) to provide Intermediate 38 as an off-white solid (6.9 g, 66%).

Method 3

Step 1

Preparation of Intermediate 408

Acetylacetonatobis(ethylene)rhodium(I) (0.837 g, 3.24 mmol) and (R)-N,N-dimethyldinaphtho[2, 1-B:1',2'-F][1,3,2]dioxaphosphepin-4-amine (2.91 g, 8.11 mmol) were dissolved in EtOH (625 mL) under nitrogen atmosphere. The mixture was stirred at room temperature and flushed through with nitrogen gas for 15 minutes. Then (-)-
(3AR,6AR)-3 A,6A-dihydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-one (25 g, 162.16 mmol) and potassium vinyltrifluoroborate (45.73 g, 324.33 mmol) were added and then the reaction mixture was stirred and refluxed for 4 hours. The reaction mixture (suspension) was cooled down to room temperature. The precipitate was filtered off over a pad of Celite and washed with ethanol. The solvents of the filtrate were evaporated. 1L heptane was added to the residue. The resulting suspension was filtered off over a pad of Celite and washed with heptanes resulting in a dark brown solid residue. The filtrate was washed three times with 300 mL NH₄OH, washed with brine, dried with MgSO₄, filtered and the solvents of the filtrate evaporated yielding **intermediate 408** (16.18 g, 51% yield).

**Step 2**

Preparation of **intermediate 409**

A solution of **intermediate 408** (16.18 g, 82.58 mmol) in THF (200 mL) was added dropwise to a stirred solution of lithium aluminum hydride 1M in THF (24.78 mL, 1 M, 24.78 mmol) in THF (400 mL) at -78°C under nitrogen atmosphere. The reaction mixture was stirred at -78°C under nitrogen atmosphere for 30 minutes. The reaction was quenched by the dropwise addition of acetone (6.1 mL) followed by 50 mL water at -78°C. After addition the reaction mixture was allowed to warm up to room temperature and then 400 mL EtOAc was added. The mixture was shaken vigorously. The organic layer was seprated, washed three times with water, washed with brine, dried with MgSO₄, filtered and the solvents of the filtrate evaporated. The residue was dissolved in ethylacetate and purified over a SiO₂ column, type Grace Reveleris SRC, 80 g. Si 40, on an Armen Spot 11Ultimate purification system using ethyl acetate and heptane as eluent in a gradient starting from 100% heptanes and ending with 50% heptane and 50% ethyl acetate. The fractions containing product were combined and the solvents were evaporated yielding **intermediate 409** (10.77 g, 71% yield).
Preparation of **intermediate 410**

A solution of Tf$_2$O (13.31 mL, 1.71 g/mL, 80.93 mmol) in DCM, anhydrous (60 mL) was added dropwise to a mixture of **intermediate 409** (9.94 g, 53.95 mmol) and pyridine, anhydrous (85 mL) in DCM, anhydrous (140 mL) at 0°C. The reaction mixture was stirred for 30 minutes and then 75 mL cold water was added. The layers were separated and the organic layer was washed three times with 75 mL water, dried with MgSO$_4$, filtered and the solvents evaporated and co-evaporated with 200 mL toluene. The residue was dissolved in heptane and ethyl acetate and purified over a SiO$_2$ column, type Grace Revealeris SRC, 40 g, 40, on an Armen Spot II Ultimate purification system using ethyl acetate and heptane as eluent in a gradient starting from 100% heptane and ending with 50% heptane and 50% ethyl acetate. The fractions containing product were combined and the solvents were evaporated yielding **intermediate 410** (13.0 g, 67% yield).

**Step 4**

Preparation of **intermediate 411**

A mixture of 4-chloro-7H-pyrrolo[2,3-D]pyrimidine (100 g, 651 mmol) and KOTBu (73.07 g, 651 mmol) in THF (1 L) was stirred at room temperature for 45 minutes until
a clear solution was obtained. The solvents were evaporated. The residue was triturated in DIPE. The white solids were filtered off and dried in vacuo at 30°C yielding intermediate 411 (112.6 g, 90% yield).

Step 5

Preparation of Intermediate 38

A solution of intermediate 410 (13 g, 41.1 mmol) in DMF (50 ml.) was added dropwise to a stirred solution of intermediate 411 (7.88 g, 41.1 mmol) in DMF (150 ml) at 0°C. After addition the reaction mixture was allowed to warm up to room temperature and was then stirred for 18 hours. Another amount of intermediate 411 (1.57 g, 8.22 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was poured out into a beaker with ice and water (-0.5L). The resulting suspension was stirred for 2 hours and then filtered off. The residue was washed three times with water and then dried in vacuo at 50°C yielding intermediate 38 as a white solid (8.75 g, 65% yield).

Example A 54

Preparation of intermediate 433
A solution of intermediate 38 (18.3 g, 57.22 mmol) in a mixture of aqueous ammonia (25%, 100 ml) and THF (100 ml) was heated in a sealed metal pressure vessel at 110 °C until complete conversion (~16 h). The reaction mixture was allowed to cool to room temperature, after which ethyl acetate and brine were added. Both layers were separated, the water layer was extracted once with ethyl acetate. The combined organic phases were washed with brine, dried with anhydrous MgSO₄, filtered and concentrated in vacuum to give intermediate 433 as a light yellow solid (17.2 g, 100%), which was used in the next reaction step without further purification.

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 433 using the appropriate starting materials (Table 24:

<table>
<thead>
<tr>
<th>Int.</th>
<th>structure</th>
<th>Starting materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>487</td>
<td><img src="image" alt="Intermediate 487" /></td>
<td><em>Intermediate 38</em> methylamine</td>
</tr>
<tr>
<td>490</td>
<td><img src="image" alt="Intermediate 490" /></td>
<td><em>Intermediate 39</em> methylamine</td>
</tr>
</tbody>
</table>

Example A 16
Preparation of intermediate 41

To a solution of potassium tert-butoxide (1.28 g; 11.4 mmol) in THF (30 mL) at -78°C was added a solution of dimethyl (1-diazo-2-oxopropyl)phosphonate (1.72 g; 11.4 mmol) in THF (5 mL). The solution was stirred for 5 min and then the solution of intermediate 33 (1.90 g; theoretically 5.87 mmol) in THF (20 mL) was added. The solution was allowed to warm to room temperature and stirred at room temperature for 15 minutes. Water and EtOAc were added, the organic layer was separated, dried over MgSO4, filtered and evaporated in vacuo. The residues were purified by preparative LC (Irregular SiOH 15-40 µµι, 80 g Grace, DCM loading, mobile phase gradient elution: heptane : 10% MeOH in EtOAc from 90:10, to 70:30). The desired fractions were collected and the solvent was evaporated to yield intermediate 41 as a colorless oil (1.08 g, 58% yield).

Example A17

Preparation of intermediate 43

To a solution of intermediate 42 (9.2 g, 34.114 mmol) in acetone (100 mL) was added 2,2-dimethoxypropane (7.1 g, 68.118 mmol) and p-TSA (1.8 g, 10.184 mmol). The reaction mixture was stirred overnight at room temperature. The reaction mixture was treated with aqueous NaHCO3 (PH to 7-8), then concentrated under reduced pressure. The resulting residue was diluted with water (100 mL) and extracted with ethyl acetate (100 mL x 3). The organic layer was dried and concentrated under reduced pressure.
The crude product was purified by silica gel chromatography (gradient elution: petroleum ether/ethyl acetate from 8/1 to 2/1). The desired fractions were collected and the solvent was evaporated to afford the intermediate 43 as a pale yellow solid (9.5 g, 90% yield).

Example A18

Preparation of intermediate 44

A solution of intermediate 1 (2.00 g, theoretically 6.18 mmol) in DCM (30.00 mL) was added dropwise to a suspension of Dess-Martin periodinane (3.14 g, 7.41 mmol) in DCM (30.00 mL) at 0°C under N₂. The reaction mixture was allowed to warm to room temperature and stirred until oxidation was finished (2 hours). Subsequently, MeOH (60 mL) and tosylhydrazide (1.50 g, 8.03 mmol) were added and stirring was continued for 3 hours. Water and ethyl acetate were added to the reaction mixture, the organic phase was separated and washed with saturated Na₂CO₃, dried with anhydrous MgSO₄, filtered and concentrated in vacuum. The crude product was purified by silica gel column chromatography (gradient elution: dichloromethane / methanol from 100:0 to 98.5:1.5). The desired fractions were collected and the solvent was evaporated to yield intermediate 44 as a white powder (2.60 g, 70% yield: (E)).

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 44 using the appropriate starting materials (Table 25).

Table 25

<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>


Example A 55

Preparation of intermediate 224

Step 1: Preparation of intermediate 222

DIAD (7.6 mL, 38.4 mmol, 2.5 eq) was added to a solution of intermediate 2 (5.0 g, 15.3 mmol, 1.0 eq), triphenylphosphine (10.0 g, 38.4 mmol, 2.5 eq) and acetone cyanohydrin (5.6 mL, 61.4 mmol, 4.0 eq) in anhydrous THF (75 mL) at r.t. The reaction mixture was stirred for 1 hour and then concentrated in vacuo. The crude product was purified by normal phase flash chromatography using heptane and DCM as eluent (SiO$_2$ column, gradient: 50% to 100% DCM, isocratic 100% DCM) and then...
followed by a preparative reversed phase flash chromatography using acetonitrile and water with 0.2% NH₄HCO₃ as eluent to afford intermediate 222 as white solid product (2.8 g, 8.5 mmol, yield 55%)

**Step 2:**
Preparation of intermediate 223 and intermediate 224

A solution of intermediate 222 (1.54 g, 4.6 mmol, 1 eq) in anhydrous DCM was dried overnight over molecular sieves and filtered. The filtrate was cooled to -78 °C and then 1M DIBAH in DCM (4.6 mL, 4.6 mmol, 1 eq) was added dropwise. The reaction mixture was stirred for 1 hour at -78°C, then extra 1M DIBAH in DCM (0.46 mL, 0.46 mmol, 0.1 eq) was added and stirred for another 1.5 hours, then quenched with sodium acetate (4.2 g, 51.2 mmol, 11.1 eq) and acetic acid (4.2 mL, 73.4 mL, 16.0 eq) in a mixture of water/THF (57 mL/12mL). After the quench, the cooling bath was removed and the mixture was stirred until all ice was melted. The layers were separated and then the aqueous phase was extracted twice with DCM (30 mL). The organic phases were combined, washed twice with brine, dried over MgSO₄ and filtered. To the obtained filtrate containing intermediate 223 was added MeOH (50 mL), 1- toluenesulfonyl hydrazide (1.1 g, 6.0 mmol, 3 eq) and then stirred at r.t. for 40 minutes The reaction mixture was washed three times with sat. NaHCO₃, twice with brine, dried over MgSO₄, filtered and concentrated in vacuo. The crude product was purified by normal phase flash chromatography using heptane and EtOAc as eluent (gradient: 40% to 60% EtOAc) to afford the crude product. The mixture was further purified by normal phase flash chromatography using EtOAc and heptane as eluent (SiO₂ column, gradient: 40% to 60% EtOAc) to afford intermediate 224 (0.5 g, 0.6 mmol, yield: 14%).

Example A 19
Preparation of intermediate 45

**Intermediate 1**

**Intermediate 45**
Intermediate 1 (300 mg, theoretically 0.921 mmol), 7-Quinolinol (160 mg, 1.11 mmol) and polymer-bound Triphenylphosphine (~3 mmol/g triphenylphosphine loading, 0.8 g, 2.4 mmol) were stirred in anhydrous THF (12 ml.) under N₂. Subsequently, DIAD (0.465 g, 2.30 mmol) was added dropwise at 0 °C. The mixture was stirred at room temperature for 12 hours under N₂. The reaction mixture was filtered over a pad of diatomaceous earth. The residue was washed with MeOH. The filtrate was concentrated in vacuum. The residue was purified by column chromatography over silica gel (eluent: petroleum ether/ethyl acetate from 10/1 to 3/1). The desired fractions were collected and the solvent was evaporated to give the crude intermediate 45 as oil (342 mg).

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 45 using the appropriate starting materials (Table 9).

<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 46   | ![Structure](image) | a) Intermediate 1   
        b) 7-isoquinolinol |
| 47   | ![Structure](image) | a) Intermediate 1   
        b) 6-hydroxyquinoline |
| 48   | ![Structure](image) | a) Intermediate 1   
        b) 3-hydroxyquinoline |
<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 49   | ![Structure](image1) | a) Intermediate 1  
b) 8-hydroxyisoquinoline |
| 50   | ![Structure](image2) | a) Intermediate 1  
b) 1,5-naphthyridin-3-ol |
| 51   | ![Structure](image3) | a) Intermediate 1  
b) 6-quinazolinol |
| 52   | ![Structure](image4) | a) Intermediate 1  
b) Quinazolin-7-ol |
| 53   | ![Structure](image5) | a) Intermediate 1  
b) 2-(trifluoromethyl)-quinolin-7-ol |
| 54   | ![Structure](image6) | a) Intermediate 1  
b) 4-chloro-7-hydroxyquinoline |
| 55   | ![Structure](image7) | a) Intermediate 1  
b) 3-chloroquinolin-7-ol |
<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 56   | ![Structure](image56) | a) Intermediate 1  
b) 4-chloro-7-hydroxy-quinoline-3-carbonitrile |
| 57   | ![Structure](image57) | a) Intermediate 1  
b) 4-chloro-7-hydroxy-6-methoxyquinoline-3-carbonitrile |
| 58   | ![Structure](image58) | a) Intermediate 1  
b) 4-chloro-6-methoxyquinolin-7-ol |
| 59   | ![Structure](image59) | a) Intermediate 1  
b) 3-bromoquinolin-7-ol |
| 60   | ![Structure](image60) | a) Intermediate 34  
b) 7-quinolinol |
| 187  | ![Structure](image187) | a) Intermediate 186  
b) 7-quinolinol |
| 191  | ![Structure](image191) | a) Intermediate 190  
b) 7-quinolinol |
<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 233  | ![Structure](image) | *a) Intermediate 190*  
* b) 3-bromoquinolin-7-ol* |

Example A19b

**Preparation of intermediate 59**

![Intermediate 59](image)

Diisopropyl azodicarboxylate (0.221 mL, 1.125 mmol) was added dropwise to a stirred suspension of *intermediate 1* (0.27 g, 0.80 mmol), 3-bromoquinolin-7-ol (0.18 g, 0.80 mmol) and triphenylphosphine resin (0.375 g, 3 mmol/g, 1.125 mmol) in THF (8 ml) at room temperature. After addition the reaction mixture was stirred for 18 hours. The reaction mixture was filtered over a pad of Dicalite®. The residue was washed with methanol. The solvents of the filtrate were evaporated. The residue was used as such in the next step.

Example A20

**Preparation of intermediate 61**

![Intermediate 61](image)

The mixture of *intermediate 1* (2.46 g, theoretically 7.54 mmol), 2-methylquinolin-7-ol (1.2 g, 7.54 mmol) and PPh₃ (5.93 g, 22.6 mmol) in dry THF (40 ml) was stirred at room temperature under N₂. DIAD (4.57 g, 22.6 mmol) was added dropwise. The
reaction mixture was stirred overnight at room temperature. Water (80 mL) was added to the mixture, extracted with EtOAc (100 mL x 3). The combined organic layers were washed by brine (100 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under vacuum. The residue was purified by column chromatography (gradient elution: EtOAc/Petroleum ether from 1:20 to 1:1). The desired fractions were collected and the solvent was evaporated to yield intermediate 61 (3.0 g, crude). The crude intermediate 61 was used for the next reaction step without further purification.

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 61 using the appropriate starting materials (Table 10).

Table 10:

<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 62   | ![Structure 62](image) | a) Intermediate 1  
                      b) 5-Quinolinol |
| 63   | ![Structure 63](image) | a) Intermediate 1  
                      b) 5-Isoquinolinol |
| 64   | ![Structure 64](image) | a) Intermediate 1  
                      b) 8-Quinolinol |
| 65   | ![Structure 65](image) | a) Intermediate 1  
                      b) 6-Isoquinolinol |
<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 66   | ![Structure](image1) | a) Intermediate 1  
b) 1,8-naphthyridin-2-ol |
| 67   | ![Structure](image2) | a) Intermediate 1  
b) 2-chloroquinolin-7-ol |
| 68   | ![Structure](image3) | a) Intermediate 1  
b) 3-(trifluoromethyl)quinolin-7-ol |
| 69   | ![Structure](image4) | a) Intermediate 10  
b) 7-Quinolinol |
| 70   | ![Structure](image5) | a) Intermediate 14  
b) 7-Quinolinol |
| 515  | ![Structure](image6) | a) Intermediate 1  
b) 2-Quinolinecarboxylic acid, 7-hydroxy-, methyl ester |

Example A21

*Preparation of intermediate 71*
To a solution of intermediate 1 (1.00 g, -2.92 mmol) and 2-naphthol (463 mg, 3.21 mmol) in toluene (30 mL) was added CMBP (1.15 mL, 4.38 mmol). The solution was heated at 80 °C for 18 hours and was then cooled down to room temperature. The reaction mixture was evaporated in vacuo. The residues were purified by preparative LC (Irregular SiOH 15-40 μm, 120 g Grace, DCM deposit, mobile phase gradient: heptane/EtOAc from 80/20 to 70/30) to give intermediate 71 as a colourless gum (1.00 g, 76% yield).

Example A22

Preparation of intermediate 72

A mixture of PPh₃ (9.07 g, 34.6 mmol) and DEAD (4.82g, 27.7 mmol) in THF (100 mL) was stirred at room temperature for 10 min. Then Intermediate 24 (5.0 g, theoretically 13.8 mmol) was added, followed by 2-chloroquinolin-7-ol (2.98g, 16.6 mmol). The resulting mixture was stirred at room temperature overnight. Subsequently, the mixture was diluted with EtOAc (100 mL), washed with water and brine. The organic phase was dried over Na₂SO₄, filtered and concentrated. The residue was purified by chromatography (elution: Petroleum ether/EtOAc = 5/95). The desired fractions were collected and concentrated to give Intermediate 72 as solid (6.0 g, 83 % yield).

Example A23

Preparation of intermediate 73
To a solution of *intermediate 24* (700 mg, theoretically 1.94 mmol) and 4-methylquinolin-7-ol (370 mg, 2.32 mmol) in THF (20 mL) were added triphenylphosine (624 mg, 2.71 mmol) and DBAD (711 mg, 2.71 mmol). The mixture was stirred overnight at room temperature and was then evaporated in vacuo. The crude was purified by preparative LC (irregular SiOH, 15-40 μm, 50 g, Merck, dry loading (Celite®) mobile phase gradient: from Heptane 80%, EtOAc 18%, MeOH 2% to Heptane 10%, EtOAc 81%, MeOH 9%) to give *intermediate 73* as an off-white foam (697 mg, 67% yield).

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of *intermediate 73* using the appropriate starting materials (Table 12).

<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 74   | ![Structure](image1) | a) *Intermediate 24*  
   b) 6-iodoquinolin-7-ol |
| 75   | ![Structure](image2) | a) *Intermediate 24*  
   b) 8-methylQuinolin-7-ol |
| 76   | ![Structure](image3) | a) *Intermediate 24*  
   b) 8-iodoquinolin-7-ol |
Example A24

5 Preparation of intermediate 77

Cesium Carbonate (2.18 g, 6.70 mmol) was added to a solution of intermediate 17 (1.15 g, 2.23 mmol) and 3-bromoquinolin-7-ol (0.5 g, 2.23 mmol) in DMF (25 mL).

The mixture was stirred overnight at room temperature. The reaction mixture was treated with H₂O (100 ml) and filtrated. The resulting residue was washed with H₂O (30 mL) and dried under reduced pressure to obtain desired crude intermediate 77 as a pale yellow solid (1.1 g).

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 77 using the appropriate starting materials (Table 13).

<table>
<thead>
<tr>
<th>Int. Structure</th>
<th>Starting materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>504</td>
<td>Intermediate 503, 3-chloroquinolin-7-ol</td>
</tr>
<tr>
<td>517</td>
<td>Intermediate 24, 2-Quinolinecarboxylic acid, 7-hydroxy-, methyl ester</td>
</tr>
<tr>
<td>Int.</td>
<td>Structure</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
</tr>
</tbody>
</table>
| 78   | ![Structure 78](image) | a) Intermediate 16  
b) 7-Quinolinol |
| 262  | ![Structure 262](image) | a) Intermediate 15  
b) 2-amino-7-hydroxy quinoline |
| 264  | ![Structure 264](image) | a) Intermediate 15  
b) Intermediate 263 |
| 270  | ![Structure 270](image) | a) Intermediate 15  
b) 2-Quinolinamine, 7-hydroxy-N-methyl- |
| 275  | ![Structure 275](image) | a) Intermediate 15  
b) Intermediate 274 |
| 461  | ![Structure 461](image) | a) Intermediate 17  
b) 7-Quinolinol, 2,3-dichloro- |
<table>
<thead>
<tr>
<th>Int. Structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| ![Structure](image1.png) | a) Intermediate 17  
b) Intermediate 274 |
| ![Structure](image2.png) | a) Intermediate 17  
b) 2-Quinolinamine, 7-hydroxy-N-methyl- |
| ![Structure](image3.png) | a) Intermediate 17  
b) Intermediate 468 |
| ![Structure](image4.png) | a) Intermediate 15  
b) Intermediate 477 |
| ![Structure](image5.png) | a) Intermediate 17  
b) Intermediate |

Example A25

5 Preparation of intermediate 79
intermediate 29
intermediate 79

To a solution of intermediate 29 (500 mg, crude, -0.67 mmol) in DMF (20 mL) were added 3-methoxyquinolin-7-ol (187 mg, 0.80 mmol) and CS₂O₃ (652 mg, 2.0 mmol). The reaction mixture was stirred at room temperature for 12 hours. The mixture was quenched with water (80 mL) and extracted with DCM (50 mL x 3). The organic layers were dried (Na₂SO₄), filtered and the solvent was concentrated in vacuum to give the crude intermediate 79 as a yellow oil (650 mg).

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 79 using the appropriate starting materials (Table 14).

<table>
<thead>
<tr>
<th>Int.</th>
<th>structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 80   | ![Structure 80](image) | a) Intermediate 29  
b) 3-fluoroquinolin-7-ol |
| 81   | ![Structure 81](image) | a) Intermediate 29  
b) 5-(trifluoromethyl)quinolin-7-ol |
| 82   | ![Structure 82](image) | a) Intermediate 29  
b) 6-(trifluoromethyl)quinolin-7-ol |
<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 83   | ![Structure](image) | a) Intermediate 29  
b) 8-chloroquinolin-7-ol |
| 84   | ![Structure](image) | a) Intermediate 29  
b) 3,4-dichloroquinolin-7-ol  
(which was Prepared from 3,4-dichloro-7-methoxyquinoline) |
| 85   | ![Structure](image) | a) Intermediate 29  
b) 7-cinnolinol |
| 86   | ![Structure](image) | a) Intermediate 30  
b) 3-chloroquinolin-7-ol |
| 87   | ![Structure](image) | a) Intermediate 30  
b) 3-bromoquinolin-7-ol |
| 88   | ![Structure](image) | a) Intermediate 31  
b) 3-bromoquinolin-7-ol |
Example A26

**Preparation of intermediate 89**

**Intermediate 32** (48.3 g, -67.99 mmol) was dissolved in 400 ml of DMF. 7-Br-quinolin-7-ol (16.03 g, -67.98 mmol) and Cs₂CO₃ (44.33 g, 135.97 mmol) were added into the reaction mixture and the mixture was stirred at room temperature 16 hours. The reaction mixture was poured into 1000 ml of cold water and extracted by EtOAc (2× 600 mL). The organic layer was washed with water (300 mL x 2), dried with anhydrous Na₂SO₄, filtered and the solvent was concentrated in vacuum to give the crude **intermediate 89** (52 g) as an oil which was used in the next step without further purification.

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of **intermediate 89** using the appropriate starting materials (Table 26

<table>
<thead>
<tr>
<th>Int.</th>
<th>structure</th>
<th>Starting materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>199</td>
<td>![Image]</td>
<td>a) Intermediate 29</td>
</tr>
<tr>
<td></td>
<td></td>
<td>b) 7-Quinolinol, 6-chloro</td>
</tr>
</tbody>
</table>

Table 26
<table>
<thead>
<tr>
<th>Int.</th>
<th>structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 206  | ![Structure 206](image) | a) Intermediate 32  
b) Intermediate 205 |
| 211  | ![Structure 211](image) | a) Intermediate 32  
b) Intermediate 210 |
| 213  | ![Structure 213](image) | a) Intermediate 32  
b) Intermediate 212 |
| 215  | ![Structure 215](image) | a) Intermediate 32  
b) 7-Quinolino!, 4-(trifluoromethyl)- |
| 217  | ![Structure 217](image) | a) Intermediate 32  
b) Intermediate 216 |
<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 219  | ![Structure 219](image1) | a) Intermediate 32  
b) Intermediate 218 |
| 221  | ![Structure 221](image2) | a) Intermediate 32  
b) Intermediate 220a |
| 227  | ![Structure 227](image3) | a) Intermediate 32  
b) 7-Quinolinol, 4-methoxy- |
| 228  | ![Structure 228](image4) | a) Intermediate 32  
b) 3-Quinolinecarboxylic acid, 7-hydroxy-, methyl ester |
| 230  | ![Structure 230](image5) | a) Intermediate 32  
b) Intermediate 229 |
<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 232  | ![Structure 232](image) | a) Intermediate 32 
b) Intermediate 231 |
| 236  | ![Structure 236](image) | a) Intermediate 32 
b) Intermediate 235 |
| 241  | ![Structure 241](image) | a) Intermediate 32 
b) Intermediate 240 |
| 247  | ![Structure 247](image) | a) Intermediate 32 
b) Intermediate 246 |
| 279  | ![Structure 279](image) | a) Intermediate 32 
b) Intermediate 274 |
Example A27

**Preparation of intermediate 90**

A mixture of intermediate 15 (893 mg, -1.68 mmol), 7-quinolinethiol (1.6 g, 3.374 mmol, crude) and $\text{CS}_2\text{CO}_3$ (1.21 g, 3.72 mmol) in DMF (20 mL) was stirred overnight at room temperature. The reaction was quenched with water (100 mL). The aqueous phase was extracted with ethyl acetate (200 mL x 2). The combined organic layer was washed with brine (100 mL), dried over $\text{Na}_2\text{SO}_4$ and concentrated under reduced pressure. The residue was purified by flash column (gradient elution: Petroleum ether/ethyl acetate from 100/0 to 1/1) to give desired compound intermediate 90 (170 mg, 20% yield) as off-white solid.

Example A28

**Preparation of intermediate 91**
7-aminoquinoline (Ar-NH₂ in scheme above) (700 mg, 4.85 mmol) was added to a solution of intermediate 33 (2.20 g, theoretically 6.80 mmol) in DCM (45 mL) and acetic acid (278 µL, 4.85 mmol). The solution was stirred for 10 min then sodium triacetoxyborohydride (2.98 g; 14.1 mmol) was added and the mixture was stirred at room temperature for 18 hours. A saturated aqueous solution of NaHCO₃ was added and the mixture was stirred for 30 minutes. The layers were separated and the aqueous layer was extracted with DCM. The combined organic layers were dried over MgSO₄, filtered off and evaporated in vacuo. The residues were purified by preparative LC (Irregular SiOH 15-40 µm, 80 g Grace, mobile phase gradient: from DCM 100% to DCM 95%, MeOH 5%) to give intermediate 91 as a yellow oil which crystallized on standing (1.22 g, 56% yield).

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 91 using the appropriate starting materials (Table 15).

<table>
<thead>
<tr>
<th>Int.</th>
<th>structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 92   | ![structure](image1.png) | a) Intermediate 33  
b) 3-chloroquinolin-7-amine |
| 93   | ![structure](image2.png) | a) Intermediate 33  
b) 3-bromoquinolin-7-amine |
To a stirred solution of intermediate 93 (1.0 g, 1.88 mmol) in DMF (20 mL) was added NaH (60% dispersion in mineral oil) (0.151 g, 3.77 mmol) at 0°C under nitrogen atmosphere. Subsequently, the reaction mixture was stirred at room temperature for 30 minutes. Then CH₃I (0.141 mL, 2.261 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was quenched by pouring it out into a beaker with ice and water under nitrogen atmosphere. The precipitate was filtered off yielding the precipitated int. 96. The remaining product was extracted from the water layer with ethylacetate. The separated organic layer was combined with the precipitated int. 96 and then dried with MgSO₄, filtered and the solvents of the filtrate evaporated. The residue was dissolved in ethylacetate and purified over a Si02 column, type Grace Reveileris SRC, 40 g, Si 40, on a Grace Reveileris X2 purification system using heptanes and ethylacetate as eluens in a gradient starting from 100% heptanes to 100% ethylacetate. The fractions containing product were combined and the solvents were evaporated yielding intermediate 96 (0.51 g, crude). This intermediate was used for next step reaction without further purification.
Below intermediates were also formed with the same reaction protocol as was used for the preparation of intermediate 96 (Table 27).

Table 27:

<table>
<thead>
<tr>
<th>Int.</th>
<th>structure</th>
<th>Starting materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>195</td>
<td><img src="image" alt="Structure 195" /></td>
<td>intermediate 93</td>
</tr>
<tr>
<td>196</td>
<td><img src="image" alt="Structure 196" /></td>
<td>intermediate 93</td>
</tr>
</tbody>
</table>

Example A30

**Preparation of intermediate 97**

A mixture of intermediate 38 (520 mg, 1.60 mmol), 7-bromoquinoline (390 mg, 1.87 mmol) and Et₄NCl (261 mg, 1.79 mmol) in DMF (15.00 mL) was degassed under vacuum and purged with N₂ for three times. DIEA (1.05 g, 8.15 mmol) and Pd(OAc)₂ (54.9 mg, 244 µmol) were added to the reaction mixture. The mixture was stirred at 100°C for 16 hours. The mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic phase was dried with anhydrous MgSO₄, filtered and concentrated in vacuum. The residue was purified by silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, gradient elution from 100% of DCM to 25% Ethyl acetate in DCM), yielded Intermediate 97 as off-white solid. (670 mg, 91% yield; (E)).
The intermediates in Table 16 (all in the E configuration) were prepared by an analogous reaction protocol as was used for the preparation of intermediate 97 using the appropriate starting materials (Table 16).

Table 16:

<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>98</td>
<td></td>
<td>a) Intermediate 38 b) 7-bromo-3-chloroquinoline</td>
</tr>
<tr>
<td>99</td>
<td></td>
<td>a) Intermediate 39 b) 7-bromo-3-chloroquinoline</td>
</tr>
<tr>
<td>100</td>
<td></td>
<td>a) Intermediate 40 b) 7-bromoquinoline</td>
</tr>
</tbody>
</table>

Example A31

Preparation of intermediate 101

In a sealed tube, bis(triphenylphosphine)palladium(II) dichloride (79.0 mg; 113 μmol) and copper(I) iodide (21.4 mg; 113 μmol) were added to a solution of 7-bromoquinoline (468 mg; 2.25 mmol) in 2-methyltetrahydrofuran (8 mL) previously degassed with N₂. The reaction mixture was degassed with N₂ and Et₃N (1.25 mL; 9.01
mmol) was added, followed by adding intermediate 41 (1.08 g; 3.38 mmol) in (4 mL). The reaction mixture was degassed with N₂ then refluxed (80°C) for 18h. After cooling down to room temperature, the crude was partitioned between EtOAc and H₂O. The aqueous layer was separated and extracted with EtOAc. The combined organic layers were dried over MgSO₄, filtered off and evaporated in vacuo. The residues were purified by preparative LC (Irregular SiOH 15-40 μm, 50 g Merck, DCM loading, mobile phase gradient: from heptane 80%, EtOAc 20% to heptane 50%, EtOAc 50%) to give intermediate 101 as a pale yellow oil (304 mg, yield: 27%).

Example A32

Preparation of intermediate 102

To a solution of intermediate 43 (100 mg, 0.323 mmol) and 7-(bromomethyl)quinoline (117 mg, 0.387 mmol) in DMF (3 mL) was added NaH (117 mg, 80% purity in mineral oil, 1.615 mmol). The mixture was stirred at room temperature for 5 h. The reaction mixture was quenched with saturated aqueous NH₄Cl (10 mL) and extracted with ethyl acetate (50 mL x 3). The organic phase was washed with H₂O (25 mL x 3), dried with anhydrous Na₂SO₄ and concentrated under reduced pressure to give the crude product. The crude product was purified with Preparative-TLC (petroleum ether/ethyl acetate = 3/2) to give intermediate 102 as a colourless oil (50 mg, 91% purity, 35% yield).

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 102 using the appropriate starting materials (Table 17).

Table 17:

<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 102a | ![Structure](image.png) | a) Intermediate 43  
b) 6-(Bromomethyl)quinoline |
Example A33

**Preparation of intermediate 103**

Potassium carbonate (507 mg, 3.67 mmol) was added in one portion to a solution of intermediate 44 (600 mg, 1.23 mmol) and quinolin-7-yl boronic acid (254 mg, 1.47 mmol) in dioxane (15 mL). The reaction mixture was stirred at 90 °C under N₂ for 2 hours, after which the mixture was allowed to cool to room temperature. Subsequently, ethyl acetate was added, the organic phase was washed with saturated Na₂CO₃ and brine, dried with anhydrous MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (gradient elution: heptane/ethyl acetate from 100/0 to 40/60) to give intermediate 103 (100 mg, 19 % yield).

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 103 using the appropriate starting materials (Table 28).

Table 28:
Example A34

5 Preparation of intermediate 104

*Intermediate 45* (350 mg, crude, -0.626 mmol) was dissolved in 5 mL of dioxane. Then 5 mL of NH₃·H₂O was added. The mixture was heated in a sealed tube (autoclave) at 90°C for 12 hours. The mixture was cooled to room temperature. The solvent was concentrated in vacuum to give the crude *intermediate 104* (300 mg, ) as a yellow oil.
Example A35

Preparation of intermediate 105

\[
\begin{align*}
\text{intermediate 59} & \rightarrow \text{intermediate 105} \\
\text{Br} & - \text{O} - \text{O} - \text{N} - \text{Cl} & \text{Br} & - \text{O} - \text{O} - \text{N} - \text{NH}_2 \\
\text{7N NH}_3 \text{ in MeOH} & \rightarrow 130^\circ \text{C}, 2\text{h} \\
\end{align*}
\]

The crude Intermediate 59 (q.s., theoretically 0.83 mmol) was dissolved in 7M NH\textsubscript{3} in MeOH (20 mL, 7 M, 140 mmol). The resulting solution was stirred and heated at 130°C using microwave irradiation for 2 hour. The solvents were evaporated. The residue was dissolved in dichloromethane and purified over a SiO\textsubscript{2} column, type Grace Reveleris SRC, 12 g, Si 40, on a Grace Reveleris X2 purification system using dichloromethane and methanol as eluens in a gradient starting from 100% DCM for 20 column volumes to 20% MeOH and 80% DCM over 20 column volumes. The fractions containing the product were combined and the solvents were evaporated yielding crude Intermediate 105 (175 mg) used as such in the next reaction step.

The intermediates in Table 18 were prepared by an analogous reaction protocol as described in A34 or A35 using the appropriate starting materials (Table 18). Intermediates 136, 137 and 138 were obtained in the E-configuration.

<table>
<thead>
<tr>
<th>Int.</th>
<th>structure</th>
<th>Ref</th>
<th>Starting material</th>
</tr>
</thead>
<tbody>
<tr>
<td>106</td>
<td>[Diagram of intermediate 106]</td>
<td>A34</td>
<td>Intermediate 62</td>
</tr>
<tr>
<td>Int.</td>
<td>structure</td>
<td>Ref</td>
<td>Starting material</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>------</td>
<td>-------------------</td>
</tr>
<tr>
<td>107</td>
<td><img src="image1" alt="Structure 107" /></td>
<td>A34</td>
<td>Intermediate 63</td>
</tr>
<tr>
<td>108</td>
<td><img src="image2" alt="Structure 108" /></td>
<td>A34</td>
<td>Intermediate 49</td>
</tr>
<tr>
<td>109</td>
<td><img src="image3" alt="Structure 109" /></td>
<td>A34</td>
<td>Intermediate 64</td>
</tr>
<tr>
<td>110</td>
<td><img src="image4" alt="Structure 110" /></td>
<td>A34</td>
<td>Intermediate 71</td>
</tr>
<tr>
<td>111</td>
<td><img src="image5" alt="Structure 111" /></td>
<td>A34</td>
<td>Intermediate 48</td>
</tr>
<tr>
<td>Int.</td>
<td>structure</td>
<td>Ref</td>
<td>Starting material</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>-----</td>
<td>-------------------</td>
</tr>
<tr>
<td>112</td>
<td><img src="image" alt="Structure 112" /></td>
<td>A34</td>
<td>Intermediate 47</td>
</tr>
<tr>
<td>113</td>
<td><img src="image" alt="Structure 113" /></td>
<td>A34</td>
<td>Intermediate 65</td>
</tr>
<tr>
<td>114</td>
<td><img src="image" alt="Structure 114" /></td>
<td>A34</td>
<td>Intermediate 46</td>
</tr>
<tr>
<td>115</td>
<td><img src="image" alt="Structure 115" /></td>
<td>A34</td>
<td>Intermediate 50</td>
</tr>
<tr>
<td>116</td>
<td><img src="image" alt="Structure 116" /></td>
<td>A34</td>
<td>Intermediate 51</td>
</tr>
<tr>
<td>117</td>
<td><img src="image" alt="Structure 117" /></td>
<td>A35</td>
<td>Intermediate 52</td>
</tr>
<tr>
<td>Int.</td>
<td>structure</td>
<td>Ref</td>
<td>Starting material</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>-----</td>
<td>-------------------</td>
</tr>
<tr>
<td>118</td>
<td><img src="image" alt="Structure 118" /></td>
<td>A34</td>
<td>Intermediate 66</td>
</tr>
<tr>
<td>119</td>
<td><img src="image" alt="Structure 119" /></td>
<td>A34</td>
<td>Intermediate 67</td>
</tr>
<tr>
<td>120</td>
<td><img src="image" alt="Structure 120" /></td>
<td>A34</td>
<td>Intermediate 61</td>
</tr>
<tr>
<td>121</td>
<td><img src="image" alt="Structure 121" /></td>
<td>A35</td>
<td>Intermediate 53</td>
</tr>
<tr>
<td>122</td>
<td><img src="image" alt="Structure 122" /></td>
<td>A35</td>
<td>Intermediate 55</td>
</tr>
<tr>
<td>123</td>
<td><img src="image" alt="Structure 123" /></td>
<td>A34</td>
<td>Intermediate 68</td>
</tr>
<tr>
<td>124</td>
<td><img src="image" alt="Structure 124" /></td>
<td>A35</td>
<td>Intermediate 54</td>
</tr>
<tr>
<td>Int.</td>
<td>structure</td>
<td>Ref</td>
<td>Starting material</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>-----</td>
<td>-------------------</td>
</tr>
<tr>
<td>125</td>
<td><img src="image1.png" alt="Structure 125" /></td>
<td>A35</td>
<td>Intermediate 58</td>
</tr>
<tr>
<td>126</td>
<td><img src="image2.png" alt="Structure 126" /></td>
<td>A34</td>
<td>Intermediate 78</td>
</tr>
<tr>
<td>127</td>
<td><img src="image3.png" alt="Structure 127" /></td>
<td>A34</td>
<td>Intermediate 69</td>
</tr>
<tr>
<td>128</td>
<td><img src="image4.png" alt="Structure 128" /></td>
<td>A34</td>
<td>Intermediate 77</td>
</tr>
<tr>
<td>129</td>
<td><img src="image5.png" alt="Structure 129" /></td>
<td>A34</td>
<td>Intermediate 90</td>
</tr>
<tr>
<td>130</td>
<td><img src="image6.png" alt="Structure 130" /></td>
<td>A34</td>
<td>Intermediate 91</td>
</tr>
<tr>
<td>Int.</td>
<td>Structure</td>
<td>Ref</td>
<td>Starting material</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>-----</td>
<td>-------------------</td>
</tr>
<tr>
<td>131</td>
<td><img src="image1" alt="Structure 131" /></td>
<td>A34</td>
<td>Intermediate 92</td>
</tr>
<tr>
<td>132</td>
<td><img src="image2" alt="Structure 132" /></td>
<td>A34</td>
<td>Intermediate 93</td>
</tr>
<tr>
<td>133</td>
<td><img src="image3" alt="Structure 133" /></td>
<td>A35</td>
<td>Intermediate 96</td>
</tr>
<tr>
<td>134</td>
<td><img src="image4" alt="Structure 134" /></td>
<td>A34</td>
<td>Intermediate 94</td>
</tr>
<tr>
<td>135</td>
<td><img src="image5" alt="Structure 135" /></td>
<td>A34</td>
<td>Intermediate 95</td>
</tr>
<tr>
<td>136</td>
<td><img src="image6" alt="Structure 136" /></td>
<td>A34</td>
<td>Intermediate 99</td>
</tr>
<tr>
<td>137</td>
<td><img src="image7" alt="Structure 137" /></td>
<td>A34</td>
<td>Intermediate 97</td>
</tr>
<tr>
<td>Int.</td>
<td>Structure</td>
<td>Ref</td>
<td>Starting material</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>-----</td>
<td>------------------</td>
</tr>
<tr>
<td>138</td>
<td><img src="image1.png" alt="Structure 138" /></td>
<td>A34</td>
<td>Intermediate 98</td>
</tr>
<tr>
<td>139</td>
<td><img src="image2.png" alt="Structure 139" /></td>
<td>A35</td>
<td>Intermediate 101</td>
</tr>
<tr>
<td>140</td>
<td><img src="image3.png" alt="Structure 140" /></td>
<td>A34</td>
<td>Intermediate 60</td>
</tr>
<tr>
<td>141</td>
<td><img src="image4.png" alt="Structure 141" /></td>
<td>A34</td>
<td>Intermediate 102</td>
</tr>
<tr>
<td>142</td>
<td><img src="image5.png" alt="Structure 142" /></td>
<td>A34</td>
<td>Intermediate 102a</td>
</tr>
<tr>
<td>143</td>
<td><img src="image6.png" alt="Structure 143" /></td>
<td>A35</td>
<td>Intermediate 103</td>
</tr>
<tr>
<td>Int.</td>
<td>structure</td>
<td>Ref</td>
<td>Starting material</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>-----</td>
<td>-------------------</td>
</tr>
<tr>
<td>188</td>
<td><img src="image" alt="Structure 188" /></td>
<td>A34</td>
<td>Intermediate 187</td>
</tr>
<tr>
<td>192</td>
<td><img src="image" alt="Structure 192" /></td>
<td>A34</td>
<td>Intermediate 191</td>
</tr>
<tr>
<td>194</td>
<td><img src="image" alt="Structure 194" /></td>
<td>A34</td>
<td>Intermediate 102b</td>
</tr>
<tr>
<td>198</td>
<td><img src="image" alt="Structure 198" /></td>
<td>A35</td>
<td>Intermediate 197</td>
</tr>
<tr>
<td>209</td>
<td><img src="image" alt="Structure 209" /></td>
<td>A34</td>
<td>Intermediate 208</td>
</tr>
<tr>
<td>226</td>
<td><img src="image" alt="Structure 226" /></td>
<td>A34</td>
<td>Intermediate 225</td>
</tr>
<tr>
<td>234</td>
<td><img src="image" alt="Structure 234" /></td>
<td>A35</td>
<td>Intermediate 233</td>
</tr>
<tr>
<td>Int.</td>
<td>structure</td>
<td>Ref</td>
<td>Starting material</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>-----</td>
<td>-------------------</td>
</tr>
<tr>
<td>265</td>
<td><img src="image1.png" alt="structure" /></td>
<td>A34</td>
<td>Intermediate 264</td>
</tr>
<tr>
<td>334</td>
<td><img src="image2.png" alt="structure" /></td>
<td>A34</td>
<td>Intermediate 333</td>
</tr>
<tr>
<td>462</td>
<td><img src="image3.png" alt="structure" /></td>
<td>A34</td>
<td>Intermediate 461</td>
</tr>
<tr>
<td>464</td>
<td><img src="image4.png" alt="structure" /></td>
<td>A34</td>
<td>Intermediate 463</td>
</tr>
<tr>
<td>485</td>
<td><img src="image5.png" alt="structure" /></td>
<td>A34</td>
<td>Intermediate 484</td>
</tr>
<tr>
<td>Int.</td>
<td>structure</td>
<td>Ref</td>
<td>Starting material</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>-----</td>
<td>-------------------</td>
</tr>
<tr>
<td>496</td>
<td><img src="image1.png" alt="Structure 496" /></td>
<td>A34</td>
<td>Intermediate 495</td>
</tr>
<tr>
<td>498</td>
<td><img src="image2.png" alt="Structure 498" /></td>
<td>A34</td>
<td>Intermediate 497</td>
</tr>
<tr>
<td>500</td>
<td><img src="image3.png" alt="Structure 500" /></td>
<td>A34</td>
<td>Intermediate 499</td>
</tr>
<tr>
<td>501</td>
<td><img src="image4.png" alt="Structure 501" /></td>
<td>A34</td>
<td>Intermediate 497</td>
</tr>
<tr>
<td>Int.</td>
<td>structure</td>
<td>Ref</td>
<td>Starting material</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>-----</td>
<td>-------------------</td>
</tr>
<tr>
<td>516</td>
<td><img src="image1" alt="Chemical Structure" /></td>
<td>A34</td>
<td>Intermediate 515</td>
</tr>
<tr>
<td>518</td>
<td><img src="image2" alt="Chemical Structure" /></td>
<td>A34</td>
<td>Intermediate 517</td>
</tr>
<tr>
<td>520</td>
<td><img src="image3" alt="Chemical Structure" /></td>
<td>A34</td>
<td>Intermediate 519</td>
</tr>
<tr>
<td>522</td>
<td><img src="image4" alt="Chemical Structure" /></td>
<td>A34</td>
<td>Intermediate 521</td>
</tr>
<tr>
<td>524</td>
<td><img src="image5" alt="Chemical Structure" /></td>
<td>A34</td>
<td>Intermediate 523</td>
</tr>
</tbody>
</table>
Example A36

Preparation of \textit{intermediate 144 and 144a}

A solution of \textit{Intermediate 56} (35.7 mg, -0.0662 mmol) in 7M NH₃ in MeOH (1 mL, 7 mmol) was stirred and heated at 130 °C using microwave irradiation for 1 hour. The solvents were evaporated. The residues were purified with Prep HPLC (Stationary phase: RP XBridge Prep C18 OBD-10 µm, 30 x 150 mm, Mobile phase: 0.25% NH₄HC0₃ solution in water, CH₃CN). The solvents of the purified fractions were evaporated and co-evaporated with MeOH yielding \textit{Intermediate 144} (12.9 mg, 37% yield) and \textit{Intermediate 144a} (26.5 mg, 73%).

Example A37

Preparation of \textit{intermediate 145 and 145a}
A solution of crude Intermediate 57 (theoretically 2.36 mmol) in 7 M \( \text{NH}_3 \) in MeOH (20 mL, 7 mmol) was stirred and heated at 130 °C using microwave irradiation for 2 hours. The solvents were evaporated. The residue was dissolved in DCM with MeOH and purified over a SiO\(_2\) column, type Grace Reveleris SRC, 40 g, Si 40, on a Armen Spot II Ultimate purification system (gradient elution: DCM:MeOH from 100:0 to 20:80). The fractions containing product were combined and the solvents were removed, yielding crude Intermediate 145 (0.64 g) and crude Intermediate 145a (0.13 g). Both crude intermediates were used for the next reaction step reaction without further purification.

Example A38

Preparation of Intermediate 146

To a mixture of Intermediate 137 (340 mg, theoretically 795 \( \mu\text{mol} \)) in MeOH (10.0 mL) was added Pd/C (100 mg, 10%) at 25 °C. The suspension was degassed under
vacuum and purged with H₂ (several times). The mixture was stirred under H₂ (15psi) at 25 °C for 5 hours. The mixture was filtered and the filtrate was concentrated. The residue was purified by preparative-HPLC (Column: Diamonsil 150*20μm, 5μm). Mobile phase: from 15% MeCN in water (0.225% formic acid) to 45% MeCN in water (0.225% formic acid).

Flow Rate (ml/min): 25 ml/min, The fractions containing the desired product were combined and lyophilized. The residues were further purified by Chiral SFC (Column: OD (250μm*30μm, 10μm), Mobile phase: Supercritical CO₂ / EtOH + NH₃·H₂O (0.1%) = 50/50 Flow rate: 80 ml/min). **Intermediate 146** (130 mg, 38 % yield) was obtained as a white solid.

Below intermediates were prepared by an analogous reaction protocol as described for preparing intermediate 146 using the appropriate starting materials (Table 19).

**Table 19:**

<table>
<thead>
<tr>
<th>Int.</th>
<th>structure</th>
<th>Starting material</th>
</tr>
</thead>
<tbody>
<tr>
<td>147</td>
<td><img src="image1" alt="structure" /></td>
<td>Intermediate 138</td>
</tr>
<tr>
<td>148</td>
<td><img src="image2" alt="structure" /></td>
<td>Intermediate 136</td>
</tr>
</tbody>
</table>

**Example A39**

**Preparation of intermediate 149**

![reaction](image3)

To a solution of **Intermediate 70** (360 mg, -542 μmol) in THF (3.00 mL) was added iPrOH (3.00 mL) and ammonia (28 % in water, 6.00 mL). The mixture was stirred at
85 °C for 72 hours in an autoclave. The solvent was removed and the residue was purified by flash column on silica gel (gradient elution: MeOH/DCM from 0/100 to 4/96), yielded **Intermediate 149** as a white solid. (230 mg, 65 % yield).

The intermediate in Table 20 was prepared by an analogous reaction protocol as was used for the preparation of **Intermediate 149** using the appropriate starting materials (Table 20). Intermediate 150 was obtained in the E-configuration.

Table 20:

<table>
<thead>
<tr>
<th>Int.</th>
<th>structure</th>
<th>Starting material</th>
</tr>
</thead>
<tbody>
<tr>
<td>150</td>
<td><img src="image" alt="Structure of Intermediate 150" /></td>
<td>Intermediate 100</td>
</tr>
</tbody>
</table>

Example A40

**Preparation of intermediate 151**

A suspension of **intermediate 150** (150 mg, 349 μmol) and Pd/C (80 mg, 10%) was stirred under an atmosphere of ¾ (15 Psi) for 7 hours at 15 °C. The reaction mixture was filtered through Celite. The filtrate was concentrated under reduced pressure to afford **intermediate 151** as a yellow solid (135 mg, 90 % yield).

Example A41

**Preparation of intermediate 152**
To the solution of Intermediate 119 (550 mg, theoretically 1.18 mmol) in DMA (20 mL) were added Zinc cyanide (410 mg, 3.49 mmol), Zinc (55 mg, 0.86 mmol), Tris(dibenzylideneacetone)dipalladium (46 mg, 0.051 mmol), Ι,Γ-Bis(diphenylphosphino)ferrocene (92 mg, 0.17 mmol). The mixture was stirred at 100 ºC for 12 hours under N₂. The catalyst was filtered and the solvent was evaporated. The residue was purified by flash column chromatography over silica gel (gradient eluent: EtOAc/Petroleum ether from 1/20 to 1/0). The solvent was evaporated to give the intermediate 152 as oil (450 mg, 70% yield).

Example A56

Preparation of intermediate 214

A mixture of intermediate 105 (512 mg, 1 mmol), CuCN (358.2 mg, 4 mmol), Pd!dba₂, (92 mg, 0.1 mmol) and DPPF (221.7 mg, 0.4 mmol) in dioxane (6 mL) were stirred at 100ºC for 16h. The reaction mixture was cooled, poured into water and extracted three times with ethylacetate. The organic layer was washed two times with water. The organic layer was dried and evaporated to dryness. The residue was purified by Prep HPLC (Stationary phase: RP XBridge Prep C18 OBD- lQtm, 50x 150 mm. Mobile phase: 0.25% NH₄HCO₃ solution in water, CH₃CN) yielding intermediate 214 (363 mg, 79% yield).

Example A42

Preparation of intermediate 153
The mixture of \textit{intermediate 23} (50 mg, theoretically 0.13 mmol), 7-hydroxyquinoline (22 mg, 0.156 mmol) and PPh$_3$ (53 mg, 0.26 mmol) in dry THF (20 ml) was stirred at room temperature under N$_2$. DIAD (6.47 g, 32.037 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrate to dryness, yielding crude \textit{intermediate 153}.

Example A43

Preparation of \textit{intermediate 154} and \textit{intermediate 154a}

To a solution of \textit{intermediate 72} (1.0 g, 1.91 mmol) in 1,4-dioxane (10 mL) was added 2M NaOH (10 mL, 20 mmol). The reaction mixture was stirred at 150 °C for 1 hour under microwave condition. The mixture was diluted with water (15 mL), extracted with EtOAc (10 mL x 3). The organic phase was washed with brine (15 mL), dried over Na$_2$SO$_4$, filtered and concentrated. The residue was purified by chromatography
column (elution: EtOAc/MeOH 85/15). The desired fractions were collected and concentrated to give *intermediate 154* (359 mg of a white solid, 41% yield) and *intermediate 154a* (300 mg, 32% yield).

Example A44

**Preparation of intermediate 155**

Sodium (440 mg, 19.1 mmol) was stirred in MeOH (25 mL) at room temperature until sodium was dissolved completely. Then *intermediate 72* (1.0 g, 1.91 mmol) was added into the reaction mixture and the reaction mixture was refluxed for 72 hours. The mixture was diluted with DCM (100 mL), washed with water (10 mL), brine (10 mL). The organic phase was dried over Na$_2$SO$_4$, filtered and concentrated to give crude *intermediate 155* which was used as such for the next reaction step without further purification.

Example A45

**Preparation of intermediate 157**

7-bromo-2-chloro-quinoline (10.0 g, 41.2 mmol) and cyclopropylmethylamine (18 mL) in EtOH (80 mL) was stirred in a sealed tube at 120°C overnight. The mixture was evaporated under vacuo to give *intermediate 157* (15 g; crude) as a brown solid which used as such in the next reaction step without further purification.

**Preparation of intermediate 159**
Intermediate 38 (3.8 g, 11.9 mmol) in 9-BBN (0.5 M in THF, 95.1 mL, 47.5 mmol) was refluxed for 1 h under N₂. The mixture was cooled to room temperature, then K₃PO₄ (7.56 g, 35.6 mmol) in H₂O (20 mL) was added, followed by THF (150 mL), intermediate 157 (4.4 g, ~13 mmol) and Pd-18 (155 mg, 0.24 mmol). The resulting mixture was refluxed overnight. The mixture was diluted with H₂O (100 mL), extracted with ethyl acetate (150 mL), the organic phase was dried by Na₂SO₄, then filtered and concentrated in vacuo to give the crude product. The crude product was purified by chromatography (ethyl acetate/petroleum ether 0/1 to 1/3) to give intermediate 159 (3.1 g, yield: 42.8%) as a yellow oil.

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 159 using the appropriate starting materials (Table 29).

Table 29:

<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 242  | ![Intermediate 242](image) | a) Intermediate 38  
b) 3-methyl-7-bromoquinoline |
| 245  | ![Intermediate 245](image) | a) Intermediate 38  
b) Intermediate 244 |
<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 248  | ![Structure](image) | a) Intermediate 38  
b) 7-bromo-N-methyl-2-quinolinamine |
| 249  | ![Structure](image) | a) Intermediate 39  
b) 7-bromo-3-ethyl-quinoline |
| 251  | ![Structure](image) | a) Intermediate 39  
b) 7-bromo-3-methyl-quinoline |
| 254  | ![Structure](image) | a) Intermediate 38  
b) Intermediate 253 |
| 256  | ![Structure](image) | a) Intermediate 38  
b) 7-bromo-3-ethyl-quinoline |
| 259  | ![Structure](image) | a) Intermediate 39  
b) 7-bromo-N-methyl-2-quinolinamine |
<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 266  | ![Structure](image-url) | a) Intermediate 39  
b) 7-bromo-2-Quinolinamine |
| 268  | ![Structure](image-url) | a) Intermediate 39  
b) Intermediate 253 |
| 272  | ![Structure](image-url) | a) Intermediate 39  
b) Intermediate 157 |
| 277  | ![Structure](image-url) | a) Intermediate 38  
b) Intermediate 276 |
| 281  | ![Structure](image-url) | a) Intermediate 38  
b) Intermediate 280 |
| 288  | ![Structure](image-url) | a) Intermediate 38  
b) Intermediate 287 |
<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 291  | ![Structure](image1.png) | a) Intermediate 38  
     |                        | b) Intermediate 290   |
| 294  | ![Structure](image2.png) | a) Intermediate 38  
     |                        | b) Intermediate 293   |
| 297  | ![Structure](image3.png) | a) Intermediate 38  
     |                        | b) Intermediate 296   |
| 300  | ![Structure](image4.png) | a) Intermediate 38  
     |                        | b) Intermediate 299   |
| 303  | ![Structure](image5.png) | a) Intermediate 38  
<pre><code> |                        | b) Intermediate 302   |
</code></pre>
<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 306  | ![Structure](image1) | a) Intermediate 38  
b) Intermediate 305 |
| 309  | ![Structure](image2) | a) Intermediate 38  
b) Intermediate 308 |
| 312  | ![Structure](image3) | a) Intermediate 38  
b) Intermediate 311 |
| 315  | ![Structure](image4) | a) Intermediate 38  
b) Intermediate 314 |
| 318  | ![Structure](image5) | a) Intermediate 38  
b) Intermediate 317 |
<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 321  | ![Structure 321](image1.png) | a) Intermediate 38  
b) Intermediate 320 |
| 324  | ![Structure 324](image2.png) | a) Intermediate 38  
b) Intermediate 323 |
| 327  | ![Structure 327](image3.png) | a) Intermediate 39  
b) Intermediate 326 |
| 330  | ![Structure 330](image4.png) | a) Intermediate 38  
b) Intermediate 329 |
| 336  | ![Structure 336](image5.png) | a) Intermediate 38  
b) Intermediate 335 |
Preparation of intermediate 160

Reaction performed in a sealed tube. Intermediate 159 (3.1 g, -5.1 mmol) was added to NH3·H2O (30 mL) and dioxane (30 mL) and was stirred at 120°C overnight. The mixture was concentrated in vacuo to give crude intermediate 160. This residue was purified by silica gel chromatography (ethylacetate 100% to ethyl acetate/MeOH 90/10) to give intermediate 160 (3.95 g, yield: 77%).

Example A46

Preparation of intermediate 161

7- Bromo-2- chloro-quinoline (1.5 g, 6.18 mmol) and 2,2-difluoroethylamine (0.552 g, 6.804 mmol) in EtOH (30 mL) were heated in a sealed tube at 120°C overnight. The mixture was evaporated under vacuo to give intermediate 161 (1.8 g, yield: 88.1%) as a brown solid which used for next step without further purification.
Preparation of intermediate 162

Intermediate 38 (500 mg, 1.56 mmol) in 9-BBN (0.5M in THF, 15.6 mL, 7.8 mmol) was refluxed for 1h under N₂. The mixture was cooled to room temperature, then K₃PO₄ (995.6 mg, 4.7 mmol) in H₂O (2 mL) was added, followed by THF (20 mL), intermediate 161 (538.7 mg, -1.88 mmol) and Pd-18 (20.4 mg, 0.031 mmol). The resulting mixture was refluxed overnight. The mixture was diluted with H₂O (60 mL), extracted with ethyl acetate (100 mL x 2), the combined organic phases were dried by Na₂SO₄, then filtered and concentrated in vacuo to give the crude product. The crude product was purified by chromatography (ethyl acetate : petroleum ether ratio 1:10 to 1:5) to give intermediate 162 (650 mg, yield: 68.1%) as yellow oil.

Preparation of intermediate 163

Reaction performed in a sealed tube. Intermediate 162 (650 mg, -1.06 mmol) was added to NH₃.H₂O (15 mL) and dioxane (10 mL) and was stirred at 120°C overnight. The mixture was concentrated in vacuo to give intermediate 163 (680 mg, yield: 97.9%).

Example A47

Preparation of intermediate 164

Preparation of intermediate 163

Reaction performed in a sealed tube. Intermediate 162 (650 mg, -1.06 mmol) was added to NH₃.H₂O (15 mL) and dioxane (10 mL) and was stirred at 120°C overnight. The mixture was concentrated in vacuo to give intermediate 163 (680 mg, yield: 97.9%).

Example A47

Preparation of intermediate 164
A mixture of 7-bromo-2-chloroquinoline (10 g, 41.24 mmol) and 4-methoxybenzylamine (11.3 g, 82.5 mmol) in ethanol (40 ml) was heated in a sealed tube at 120 °C for 72 h. The mixture was evaporated under reduced pressure and purified by chromatography column (gradient eluent: CH₂Cl₂/petroleum ether from 1/10 to 1/0) to afford the desired product **intermediate 164** (13 g, 82% yield) as a white solid.

**Preparation of intermediate 165**

A mixture of **intermediate 38** (2 g, 5.0 mmol) in 9-BBN (50.0 ml, 25.0 mmol, 0.5M in THF) was refluxed for 1 h under N₂. The mixture was cooled to room temperature, then K₃PO₄ (3.18 mg, 15.0 mmol) in H₂O (10 mL) was added, followed by THF (20 ml), **intermediate 164** (2.58 mg, -7.50 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (163.0 mg, 0.25 mmol). The resulting mixture was refluxed for 3h. The mixture was concentrated. The residue was dissolved in ethyl acetate (40 ml), washed with water (6 ml), brine (6 ml). The organic phase was dried over Na₂SO₄, filtered and concentrated to obtain the crude product. This was purified by chromatography column (gradient eluent: ethyl acetate/petroleum ether from 1/10 to 1/1). The desired fractions were collected and concentrated to give product **intermediate 165** as a solid (2 g, 52.4% yield).

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of **intermediate 165** using the appropriate starting materials (Table 30).

<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 237  | ![Structure](image) | a) **Intermediate 38**  
b) 2-amino-7-bromoquinoline |
<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 238  | ![Structure 238](image) | *a*) Intermediate 39  
  
  *b*) 3-bromo-7-iodoquinoline |
| 260  | ![Structure 260](image) | *a*) Intermediate 38  
  
  *b*) 3-bromo-7-iodoquinoline |
| 482  | ![Structure 482](image) | *a*) Intermediate 39  
  
  *b*) Intermediate 175 |
| 488  | ![Structure 488](image) | *a*) Intermediate 487  
  
  *b*) Intermediate 175 |
| 491  | ![Structure 491](image) | *a*) Intermediate 490  
  
  *b*) Intermediate 175 |
Preparation of intermediate 166

A mixture of intermediate 165 (500 mg, -0.655 mmol) and NH₃.H₂O(10 ml) in dioxane(10 ml) was heated in a sealed tube at 120°C for 14h. This reaction was evaporated under vacuo to obtain intermediate 166 (400 mg, 93.5% yield) as an oil.

Preparation of intermediate 167

The mixture of intermediate 166 (340 mg, -0.52 mmol) in CF₃COOH(5 ml) was stirred at 60°C for 1h. The mixture was evaporated under vacuo to obtain intermediate 167 as a crude product(300 mg, 85.9 % yield).

Example A48

Preparation of intermediate 168
Intermediate 165 (300 mg, -0.39 mmol) was dissolved in EtOH (20 ml) and ethyl acetate (4 ml) and hydrogenated under 1 atm of H₂ over Pd(OH)₂/C (30 mg) for 7 hours. The mixture was filtered and evaporated under vacuo to obtain intermediate 168 as a crude product (200 mg, 70.6 % yield).

Preparation of intermediate 169

The mixture of intermediate 168 (200 mg, -0.278 mmol) in CF₃COOH (5 ml) was stirred at 60°C for 1h. The mixture was evaporated under vacuo to obtain intermediate 169 as a crude product (120 mg, 89.0% yield).

Example A49

Preparation of intermediate 170

A mixture of intermediate 165 (310 mg, -0.406 mmol) and CH₃NH₂/H₂O (5 ml) in dioxane (5 ml) was stirred in a sealed tube at 120°C for 14h. This mixture was evaporated under vacuo to obtain intermediate 170 (200 mg, 80.1 % yield) as a crude product.

Preparation of intermediate 171
The mixture of intermediate 170 (200 mg, -0.325 mmol) in CF3COOH (5 ml) was stirred at 50°C for 1h. The mixture was evaporated under vacuo to obtain intermediate 777 (160 mg, 84.0 % yield) as a crude product.

Example A50

Preparation of intermediate 172

A mixture of intermediate 165 (300 mg, 0.393 mmol) and sodium methoxide (63.7 mg, 1.18 mmol) in methanol (10 ml) was refluxed at 60°C for 12h. The mixture was evaporated under vacuo to give a crude product. Water (10 ml) was added, the mixture was extracted with ethyl acetate(10 ml x 2), the organic layers were combined and evaporated under vacuo to obtain intermediate 172 (200 mg, 71.8 % yield) as a crude product.

Preparation of intermediate 173
The mixture of intermediate 172 (200 mg, -0.282 mmol) in TFA (5 ml) was stirred at 60°C for 1h. The mixture was evaporated under vacuo to obtain intermediate 173 (250 mg, 85.3 % yield,) as the crude product.

Example A51

Preparation of intermediate 174

3-Bromo-7-iodo-quinoline (5.99 g, 17.7 mmol) was dissolved in dichloromethane (60 mL), then m-CPBA (4.57 g, 26.5 mmol) was added in portions. The mixture was stirred at room temperature for 4 days. The mixture was quenched by a saturated Na₂S₂O₃ aqueous solution (40 mL) and a saturated NaHCO₃ aqueous solution (pH to 6-7), then extracted by dichloromethane (50 mL x3). The organic phase was washed with H₂O (50 mL), dried with anhydrous Na₂SO₄ and evaporated under reduced pressure. The residue was purified by silica gel column (eluent: petroleum ether/ethyl acetate = 10/1 to 1/1) to afford the desired product intermediate 174 (1.9 g, 14.1% yield) as a yellow solid.

Preparation of intermediate 175

To a solution of intermediate 174 (2.9 g, 8.29 mmol) in chloroform (60 mL) was added phosphoryl trichloride (8.3 g, 54.1 mmol). The mixture was stirred at 80°C for 12 h. The mixture was evaporated under reduced pressure to obtain crude product. The crude product was purified by chromatography column (eluent: petroleum ether/ethyl acetate = 10/1 to 1/1). The desired fractions were collected and concentrated to give product intermediate 175 (1.3 g, 41.5% yield) as a white solid.

Preparation of intermediate 176
4-methoxybenzylamine (1.34 g, 9.78 mmol) was added into the mixture of intermediate 175 (0.8 g, 1.95 mmol) in ethanol (10 ml). The mixture was heated in a sealed tube at 100°C for 12 h. The mixture was evaporated under vacuo to obtain the crude product. This was purified by chromatography column (gradient eluent: ethyl acetate/petroleum ether from 0/1 to 1/10). The desired fractions were collected and concentrated to give product intermediate 176 (600 mg, 51.6% yield) as an oil.

**Preparation of intermediate 177**

A mixture of intermediate 38 (44 mg, 0.138 mmol) in 9-BBN (1.3 ml, 0.69 mmol, 0.5 M in THF) was refluxed for 1 h under N₂. The mixture was cooled to room temperature, then K₃PO₄ (87 mg, 0.413 mmol) in H₂O (1 mL) was added, followed by THF (5 ml), intermediate 176 (122.727 mg, -0.206 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (4.48 mg, 0.007 mmol). The reaction mixture was refluxed for 3 hours. The mixture was concentrated. The residue was dissolved in ethyl acetate (40 ml), washed with water (6 ml), brine (6 ml). The organic phase was dried over Na₂SO₄, filtered and concentrated to give crude intermediate 177 fraction 1 (120 mg, 71.5% yield).

A mixture of intermediate 38 (233 mg, 0.73 mmol) in 9-BBN (7.31 ml, 3.65 mmol, 0.5 M in THF) was refluxed for 1 h under N₂. The mixture was cooled to room temperature, then K₃PO₄ (87 mg, 0.413 mmol) in H₂O (1 mL) was added, followed by THF (5 ml), intermediate 176 (478 mg, -0.80 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (23.8 mg, 0.037 mmol). The reaction mixture was refluxed for 3 hours. The mixture was concentrated. The residue was dissolved in ethyl acetate (40 ml), washed with water (6 ml), brine (6 ml). The organic phase was dried over Na₂SO₄, filtered and concentrated to with crude intermediate 177 fraction 2 (600 mg, 63.1% yield).

The two fractions were combined and purified by chromatography column (gradient
eluent: ethyl acetate/petroleum ether from 1/10 to 1/1). The desired fractions were collected and concentrated to give intermediate 177 (300 mg, 61.0 % yield) as a solid.

Preparation of intermediate 178

A mixture of intermediate 177 (300 mg, -0.446 mmol) and NH₃·H₂O (10 ml) in dioxane (10 ml) was stirred in a sealed tube at 120°C for 14h. This reaction was evaporated under vacuo to obtain intermediate 178 (250 mg, 87.1% yield) as an oil.

Preparation of intermediate 179

The mixture of intermediate 178 (250 mg, -0.388 mmol) in TFA (5 ml) was stirred at 50°C for 1h. The mixture was evaporated under vacuo to obtain intermediate 179 (350 mg, 63.4% yield) as an oil.

Example A52

Preparation of intermediate 180

3-Chloro-7-bromo-quinoline (10 g, 41.2 mmol) was dissolved in dichloromethane (150 mL). Then m-CPBA (7.83 g, 45.3 mmol) was added in portions. The mixture was stirred at 35°C for 16 hours. The mixture was poured into a saturated Na₂S₀₃ aqueous
solution. The mixture was extracted by CH₂Cl₂. Then the mixture was washed by a saturated Na₂S0₃ aqueous solution (50 mL x2) and a saturated NaHCO₃ aqueous solution (50 mL x2). The organic was dried over anhydrous Na₂SO₄ and concentrated.

The white solid was precipitated and filtered to give intermediate 180 (10 g, 78.8 % yield) as a yellow solid.

Preparation of intermediate 181

To a solution of intermediate 180 (6 g, 23.2 mmol) in chloroform (30 mL) was added phosphoryl trichloride (18.8 g, 122.5 mmol). The mixture was stirred at 80°C for 1 h. The mixture was poured into water slowly. Then a saturated NaHCO₃ aqueous solution was added into the mixture to change the PH to approximately 7.

The mixture was extracted by CH₂Cl₂ (50 mL x2) and dried over anhydrous Na₂SO₄. The organic phase was concentrated. The crude product was purified by chromatography column (eluent: petroleum ether/ethyl acetate = 1/0 to 4/1). The desired fractions were collected and concentrated to give intermediate 181 (5 g, 72.3 % yield).

Preparation of intermediate 182

To NH₃ in H₂O (10 ml) and dioxane (15 ml) was added intermediate 181 (1 g, 3.6 mmol). The mixture was heated in a sealed tube at 120°C for 16h. The mixture was extracted by EtOAc. The organic layer was dried by anhydrous Na₂SO₄ and concentrated. The residue was purified by chromatography column (gradient eluent: ethyl acetate/petrol ether from 0/1 to 1/3). The desired fractions were collected and concentrated to give product intermediate 182 (650 mg, 69.2 % yield) as a pink solid.

Preparation of intermediate 183
A mixture of intermediate 38 (100 mg, 0.313 mmol) in 9-BBN (2.19 ml, 1.09 mmol, 0.5M in THF) was refluxed for 1.5h under N₂. The mixture was cooled to room temperature, then K₃PO₄ (199 mg, 0.938 mmol) in H₂O (2 mL) was added, followed by THF (8 ml), intermediate 182 (88.6 mg, 0.344 mmol) and Pd-18 (26.48 mg, 0.407 mmol). The mixture was refluxed for 3 hours. The mixture was concentrated. The residue was dissolved in water, extracted with in ethyl acetate (20 x 2ml) and washed with brine (10 x2ml). The organic phase was dried over Na₂SO₄, filtered and concentrated. The residue was purified by chromatography column (gradient eluent: ethyl acetate/petroleum ether from 0/1 to 1/3). The desired fractions were collected and concentrated to give intermediate 183 (100 mg, 55.4 % yield).

Preparation of intermediate 184

A mixture of intermediate 183 (800 mg, -1.605 mmol) and NH₃.H₂O (10 ml) in dioxane (10 ml) was heated in a sealed tube at 120°C for 48h. The mixture was extracted by EtOAc (30mL x 3). The organic phase was concentrated to obtain intermediate 184 (800 mg, 90% yield).

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 184 using the appropriate starting materials (Table 31).

<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Int.</td>
<td>Structure</td>
<td>Starting materials</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>--------------------</td>
</tr>
<tr>
<td>239</td>
<td><img src="image" alt="Structure" /></td>
<td>Intermediate 238</td>
</tr>
<tr>
<td>243</td>
<td><img src="image" alt="Structure" /></td>
<td>Intermediate 242</td>
</tr>
<tr>
<td>250</td>
<td><img src="image" alt="Structure" /></td>
<td>Intermediate 249</td>
</tr>
<tr>
<td>252</td>
<td><img src="image" alt="Structure" /></td>
<td>Intermediate 251</td>
</tr>
<tr>
<td>255</td>
<td><img src="image" alt="Structure" /></td>
<td>Intermediate 254</td>
</tr>
<tr>
<td>257</td>
<td><img src="image" alt="Structure" /></td>
<td>Intermediate 256</td>
</tr>
<tr>
<td>258</td>
<td><img src="image" alt="Structure" /></td>
<td>Intermediate 248</td>
</tr>
<tr>
<td>Int.</td>
<td>Structure</td>
<td>Starting materials</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>--------------------</td>
</tr>
<tr>
<td>261</td>
<td><img src="image" alt="Structure 261" /></td>
<td>Intermediate 260</td>
</tr>
<tr>
<td>267</td>
<td><img src="image" alt="Structure 267" /></td>
<td>Intermediate 266</td>
</tr>
<tr>
<td>269</td>
<td><img src="image" alt="Structure 269" /></td>
<td>Intermediate 268</td>
</tr>
<tr>
<td>271</td>
<td><img src="image" alt="Structure 271" /></td>
<td>Intermediate 259</td>
</tr>
<tr>
<td>273</td>
<td><img src="image" alt="Structure 273" /></td>
<td>Intermediate 272</td>
</tr>
<tr>
<td>278</td>
<td><img src="image" alt="Structure 278" /></td>
<td>Intermediate 277</td>
</tr>
<tr>
<td>Int.</td>
<td>Structure</td>
<td>Starting materials</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>--------------------</td>
</tr>
<tr>
<td>289</td>
<td><img src="image1" alt="Structure" /></td>
<td>Intermediate 288</td>
</tr>
<tr>
<td>292</td>
<td><img src="image2" alt="Structure" /></td>
<td>Intermediate 291</td>
</tr>
<tr>
<td>295</td>
<td><img src="image3" alt="Structure" /></td>
<td>Intermediate 294</td>
</tr>
<tr>
<td>298</td>
<td><img src="image4" alt="Structure" /></td>
<td>Intermediate 297</td>
</tr>
<tr>
<td>301</td>
<td><img src="image5" alt="Structure" /></td>
<td>Intermediate 300</td>
</tr>
<tr>
<td>304</td>
<td><img src="image6" alt="Structure" /></td>
<td>Intermediate 303</td>
</tr>
<tr>
<td>Int.</td>
<td>Structure</td>
<td>Starting materials</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>-------------------</td>
</tr>
<tr>
<td>307</td>
<td><img src="image1" alt="Structure 307" /></td>
<td>Intermediate 306</td>
</tr>
<tr>
<td>310</td>
<td><img src="image2" alt="Structure 310" /></td>
<td>Intermediate 309</td>
</tr>
<tr>
<td>313</td>
<td><img src="image3" alt="Structure 313" /></td>
<td>Intermediate 312</td>
</tr>
<tr>
<td>316</td>
<td><img src="image4" alt="Structure 316" /></td>
<td>Intermediate 315</td>
</tr>
<tr>
<td>319</td>
<td><img src="image5" alt="Structure 319" /></td>
<td>Intermediate 318</td>
</tr>
<tr>
<td>Int.</td>
<td>Structure</td>
<td>Starting materials</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>--------------------</td>
</tr>
<tr>
<td>322</td>
<td><img src="image1.png" alt="Structure 322" /></td>
<td>Intermediate 321</td>
</tr>
<tr>
<td>325</td>
<td><img src="image2.png" alt="Structure 325" /></td>
<td>Intermediate 324</td>
</tr>
<tr>
<td>328</td>
<td><img src="image3.png" alt="Structure 328" /></td>
<td>Intermediate 327</td>
</tr>
<tr>
<td>331</td>
<td><img src="image4.png" alt="Structure 331" /></td>
<td>Intermediate 330</td>
</tr>
<tr>
<td>337</td>
<td><img src="image5.png" alt="Structure 337" /></td>
<td>Intermediate 336</td>
</tr>
</tbody>
</table>
Example A57

5 Preparation of *intermediate 316*

\[ \text{intermediate 314} \quad \rightarrow \quad \text{intermediate 433} \quad \rightarrow \quad \text{intermediate 316} \]

*Intermediate 433* (10.8 g, 35.96 mmol) was dissolved in 60 mL of THF and 9-BBN 0.5 M in THF (226.5 mL, 113.2 mmol) was added and the reaction mixture was stirred for 2 hours. K$_3$PO$_4$ (38.1 g, 179.78 mmol) in 65 mL of water was added and the reaction mixture was vigorously stirred for 30 min. *Intermediate 314* (10.46 g, 35.96 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(ii) were added, and the reaction mixture was degassed. The resulting mixture was stirred for 2 hours at 60 °C and allowed to cool to room temperature overnight. EtOAc was added to the
reaction mixture, the organic layer was washed with water and brine, dried on MgSO\textsubscript{4} and concentrated under reduced pressure to give crude product. The residue was purified by normal phase HPLC (Stationary phase: silicagel type: 60A 25-40μm (Merck), Mobile phase: Gradient from 95% Dichloromethane, 5% methanol to 90% Dichloromethane, 10% methanol). The desired fractions were collected and evaporated. The residue was re-purified by normal phase HPLC (Stationary phase: silicagel type 60A 25-40μm (Merck), Mobile phase: isocratic 95% Ethyl acetate and 5% ethanol yielding intermediate 316 (7.9 g, 43% yield).

Example A 99

Preparation of intermediate 528

\[
\begin{align*}
\text{Br} & \quad \text{NH}_3\cdot\text{H}_2\text{O} \\
\text{Cl} & \quad \text{dioxane} \\
\text{I} & \quad \text{Br} \\
\text{H}_2\text{N} & \quad \text{I}
\end{align*}
\]

intermediate 175 \quad \text{intermediate 528}

Intermediate 175 (630 mg, 1.71 mmol) was dissolved in dioxane (10 ml). Then NH\textsubscript{3},H\textsubscript{2}O (10 ml) was added. The reaction mixture was stirred at 120°C for 24 hours in a sealed tube. The reaction mixture was extracted with EtOAc (50 ml x 3). The organic layers were combined, dried with Na\textsubscript{2}SO\textsubscript{4}, and the solvent was evaporated to give intermediate 528 (380 mg, 62% yield) as a solid.

Preparation of intermediate 529

\[
\begin{align*}
\text{intermediate 433} & \quad \text{1} \text{) 9-BBN/THF, reflux} \\
& \quad \text{2) intermediate 528} \\
& \quad \text{Pd(dppf)Cl}_2, \text{K}_3\text{PO}_4, \text{50°C, THF}
\end{align*}
\]

intermediate 433 \quad intermediate 529

A mixture of intermediate 433 (22 g, 72.7 mmol) in 9-BBN/THF (0.5M THF solution, 585 mL, 292.3 mmol) was stirred at 50°C for 1 hour under N\textsubscript{2}. The mixture was cooled to room temperature, and K\textsubscript{3}PO\textsubscript{4} (77.6 g, 365.6 mmol) and H\textsubscript{2}O (80 mL) were added.
The mixture stirred at room temperature for 0.5 hour, then THF (95 mL), intermediate 528 (22.9 g, 65.8 mmol) and Pd(dppf)Cl₂ (4.77 g, 7.30 mmol) were added under N₂. The resulting mixture was stirred at 50°C for 3 hours. The mixture was concentrated. The residue was dissolved in ethyl acetate (120 ml). The organic layer was washed with water (10 mL) and brine (10 mL). The organic phase was dried over Na₂S₀₄, filtered and concentrated. The residue was purified by column chromatography over silica gel (petroleum ether/ethyl acetate ratio 1/1 to petroleum ether/ethyl acetate ratio 0/1). The pure fractions were collected and the solvent was evaporated under vacuum to give 23.5 g of intermediate 529.

Example A53

Preparation of intermediate 193

To a solution of intermediate 105 (256 mg, 0.5 mmol) and cyclopropyboronic acid (107.5 mg, 1.25 mmol) in dioxane (3 ml) at r.t. was added Pd(dppf)Cl₂·CH₂Cl₂ (4.1 mg, 0.05 mmol). Nitrogen was purged through reaction mixture for one minute followed by addition of K₂CO₃ (174 mg, 1.25 mmol) and water (0.2 ml) and again nitrogen was purged through reaction mixture for one minute. The reaction mixture was heated in a closed vessel up to 100 °C for 16h. The reaction mixture was filtered over decalite and evaporated to dryness. The residue was purified via Prep HPLC (Stationary phase: RP XBridge Prep C18 OBD-I) with water, CH₃CN yielding intermediate 193 (110 mg, 46.5%).

Example A58

Step 1

Preparation of intermediate 434
4-chloro-3-methoxyaniline  intermediate 434

2-bromomalonaldehyde (2.1 g, 13.96 mmol) was added in portions to a solution of 4-chloro-3-methoxyaniline (2.0 g, 12.69 mmol) in EtOH (100 mL) at 0°C under N₂ atmosphere. After stirring at room temperature for 2 h, the mixture was concentrated to give intermediate 434 (4.0 g, 69.5% yield) which used in the next step without further purification.

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 434 using the appropriate starting materials (Table 32).

Table 32:

<table>
<thead>
<tr>
<th>Intermediates</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>435</td>
<td><img src="435.png" alt="Structure" /></td>
<td>a) 2-chloro-3-methoxyaniline</td>
</tr>
<tr>
<td></td>
<td></td>
<td>b) 2-bromomalonaldehyde</td>
</tr>
<tr>
<td>436</td>
<td><img src="436.png" alt="Structure" /></td>
<td>a) 4-fluoro-3-methoxyaniline</td>
</tr>
<tr>
<td></td>
<td></td>
<td>b) 2-bromomalonaldehyde</td>
</tr>
</tbody>
</table>

Step 2

Preparation of intermediate 437

The reaction was executed twice.

A mixture of intermediate 434 (1.0 g, 3.44 mmol) and PPA (1.0 g) in EtOH (20 mL) was heated at 95°C in a Microwave Tube for 1 h. The two reaction mixtures were combined and concentrated. The residue was diluted with water and extracted with
CH₂Cl₂ (50mL x 5). The organic phase was washed with aq.NaHCO₃, brine, dried over Na₂SO₄, filtered and concentrated. The residue was purified by chromatography column (eluens: Petroleum ether/EtOAc 85/15). The desired fractions were collected and concentrated to give intermediate 437 (0.77 g, 41% yield) as a yellow solid.

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 437 using the appropriate starting materials (Table 33).

Table 33:

<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>438</td>
<td><img src="image" alt="Structure" /></td>
<td>intermediate 435</td>
</tr>
<tr>
<td>439</td>
<td><img src="image" alt="Structure" /></td>
<td>intermediate 436</td>
</tr>
</tbody>
</table>

Step 3

Preparation of intermediate 200

**intermediate 437**

BBBr₃ (1.6mL, 16.60 mmol) was added to a solution of intermediate 437 (1.28g, 4.70 mmol) in CHCl₃ (25 mL) at 0°C. The reaction mixture was refuxed for 48 hours. The reaction mixture was adjusted to pH 7 with a sat. sodium hydrogen carbonate solution. The mixture was concentrated until CHCl₃ was removed. The resulting mixture was filtered to give intermediate 200 (1.1 g, 91% yield) as a solid.

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 200 using the appropriate starting materials (Table 34).
Example A59

Step 1

Preparation of intermediate 440

A mixture of intermediate 437 (720 mg, 2.64 mmol), Tetramethylammonium Chloride (2.90 g, 26.42 mmol), Copper(I) Oxide (378.0 mg, 2.64 mmol) and L-Proline (608.3 mg, 5.28 mmol) in EtOH (15mL) was stirred at 110°C in a microwave tube for 60 min. The mixture was filtered, and the filtrate was concentrated. The residue was purified by chromatography (eluens: Petroleum ether/EtOAc 3/1). The desired fractions were collected and concentrated to give intermediate 440 (290 mg, 48-% yield) as solid.

Step 2

Preparation of intermediate 216

<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>205</td>
<td><img src="image" alt="Structure 205" /></td>
<td>intermediate 438</td>
</tr>
<tr>
<td>229</td>
<td><img src="image" alt="Structure 229" /></td>
<td>intermediate 439</td>
</tr>
</tbody>
</table>

Table 34:
BBr₃ (2.34 mL, 24.5 mmol) was added to a solution of intermediate 440 (280 mg, 1.23 mmol) in CICH₂CH₂CI (15 mL) at 0°C. The reaction mixture was refluxed overnight. The reaction mixture was adjusted to pH 7 with a sat. sodium hydrogen carbonate solution. The mixture was concentrated until CICH₂CH₂CI was removed. The resulting solid was filtered to give intermediate 216 (250 mg, 87.5% yield).

Example A60

Step 1

Preparation of intermediate 441

![Diagram of intermediate 441]

The quinoline-2, 7-diol (20 g, 124.1 mmol, 1.0 eq) was taken up into DMF (40 mL), POCl₃ (107.7 g, 702.5 mmol, 5.7 eq) was added at room temperature. The reaction mixture was stirred at 70 °C for 1 h. The solvent was removed under reduced pressure, the residue was poured slowly into water (300 mL) at 0°C. To the solution was added a saturation Na₂CO₃ aq. until pH = 8. The mixture was extracted with ethyl acetate 1000 mL x 2. The organic layer was washed with brine 1000 mL and concentrated under vacuum to afford the product intermediate 441 (20 g, 88% yield) as a solid.

Step 2

Preparation of intermediate 442

![Diagram of intermediate 442]

Intermediate 441 (2.5 g, 13.9 mmol, 1.0 eq) was dissolved in DMF (25 mL), K₂CO₃ (5.76 g, 41.76 mmol, 3 eq) and CH₃I (5.2 g, 36.6 mmol, 2.63 eq) were added. The reaction mixture was stirred at 25°C for 12 hr. The reaction mixture was poured into water (100 mL) and was extracted with EtOAc (150 mL). The organic layer was washed by water (80 mL x 2), brine (800 mL) and dried over anhydrous Na₂SO₄. The
solvent was removed under reduced pressure to give intermediate 442 (2.6 g, 96% yield) as a white solid.

Step 3

Preparation of intermediate 443

\[
\text{CHCl}_{2}N\text{H}_{2} \xrightarrow{\text{NH}_{2}\text{Bn, Pd}_{2}(\text{dba})_{3}, \text{Cs}_{2}\text{CO}_{3}, \text{BINAP, DMF, 100°C, 12 h}} \text{CHCl}_{2}\text{NHNH}_{2}
\]

To a solution of intermediate 442 (900 mg, 4.5 mmol, 1.0 eq.), NH\textsubscript{2}Bn (0.578 g, 5.4 mmol, 1.2 eq) and Cs\textsubscript{2}CO\textsubscript{3} (2.93 g, 9 mmol, 2.0 eq) in DMF (5 mL) were added Pd\textsubscript{2}(dba)\textsubscript{3} (412 mg, 0.45 mmol, 0.1 eq) and BINAP (280 mg, 0.45 mmol, 0.1 eq). The resulted mixture was stirred at 100°C under N\textsubscript{2} for 12 hr. The solvent was removed under reduced pressure, the residue was triturated with EtOAc (100 mL) and water (100 mL). The aqueous layer was extracted with EtOAc (100 mL). The combined organic layers were washed with brine (60 mL) and dried over anhydrous Na\textsubscript{2}SO\textsubscript{4}. The solvent was removed under reduced pressure, the residue was purified by column chromatography (eluent: EtOAc/ petroleum ether ratio 0/1 to 1/5) to afford intermediate 443 (450 mg, 37% yield) as a yellow solid.

Step 4

Preparation of intermediate 231

\[
\text{CHCl}_{2}N\text{H} \xrightarrow{\text{HCl, 180°C, 2 h}} \text{CHCl}_{2}\text{OCH}_{2}N\text{H}
\]

Intermediate 443 (500 mg, 1.78 mmol, 1.0 eq.) and pyridine hydrochloride (3.2 g, 28 mmol, 16 eq) were placed in a tube. The reaction mixture was stirred at 180°C for 2 hr. The reaction mixture was cooled to room temperature. The reaction mixture was dissolved in 25 mL of DCM and 25 mL of H\textsubscript{2}O, and the pH was adjusted to around 8-9
by progressively adding solid \( \text{K}_2\text{CO}_3 \), and the layers were separated. The aqueous layer was extracted with DCM (20 mL x 3). The combined organic layers were dried (\( \text{Na}_2\text{SO}_4 \)), filtered and the solvent was concentrated in vacuum to give intermediate 231 (440 mg, 96% yield) as an oil which was used in the next step without further purification.

Example A61

Step 1

Preparation of intermediate 444

A mixture of CuI (6.80 g, 35.84 mmol), CsF (14.15 g, 93.18 mmol) 1-iodo-2-methoxy-4-nitrobenzene (10 g, 35.84 mmol) and sulfolane (20 ml), was stirred rapidly at 45 °C. To this mixture was added trimethyl(trifluoromethyl)silane (13.25 g, 93.18 mmol) dropwise over 4 hours using a syringe pump, and the resulting mixture was stirred at 45°C for 18 hours. The mixture was diluted with ethyl acetate (500 mL) and stirred with Celite for 5 min. The reaction mixture was filtered through a pad of Celite, diluted with ethyl acetate (500 mL). The organic layer was washed with 10% \( \text{NH}_4\text{OH} \), 1.0 N HCl, brine, dried over \( \text{Na}_2\text{SO}_4 \), filtered, and concentrated to give the crude product. The crude product was purified by chromatography (ethyl acetate/petroleum ether 0/1 to 1/4) to give intermediate 444 (8 g, 91% yield) as a white solid.

Step 2

Preparation of intermediate 445

A mixture of intermediate 444 was hydrogenated (H2, Pd/C) to give intermediate 445.
Intermediate 444 (7.1 g, 28.9 mmol) was taken up into methanol (100 mL) and then 5% Pd/C (0.7 g.) was added. The mixture was hydrogenated at room temperature for 48 hours under \( \frac{3}{4} \) (50 Psi) atmosphere. The mixture was filtered and the filtrate was evaporated under vacuum to obtain intermediate 445 (7 g) as a white solid.

Step 3

Preparation of intermediate 446

\[
\begin{align*}
\text{Intermediate 445} & \quad \text{Intermediate 446} \\
\text{H}_2\text{N} & \quad \text{O} \\
\text{CF}_3 & \quad \text{Br} \\
\text{i-PrOH, rt} & \quad \text{Br}
\end{align*}
\]

A mixture of intermediate 445 (6.2 g, 32.4 mmol), 2-bromomalondehyde (5.38 g, 35.7 mmol) and i-PrOH (120 mL) was stirred at room temperature for 5 min. The mixture was filtered and the filtered cake was washed with i-PrOH (10 mL). The filtered cake was dried under vacuum to obtain intermediate 446 (6 g, 51% yield) as a yellow solid.

Step 4

Preparation of intermediate 447

\[
\begin{align*}
\text{Intermediate 446} & \quad \text{PPA} \\
\text{EtOH, 80°C} & \quad \text{Intermediate 447}
\end{align*}
\]

A mixture of intermediate 446 (6 g, 18.5 mmol) and PPA (10 mL) in ethanol (150 mL) was stirred at 80°C overnight. The mixture was evaporated under vacuum. Water (100 mL) was added to the mixture and the mixture was extracted with ethyl acetate (100 mL x 3). The organic layers were combined and evaporated under vacuum to give the crude product. The crude product was purified by chromatography (ethyl acetate/petroleum ether 0/1 to 1/10) to give intermediate 447 (3.3 g, 54% yield) as a white solid.
Step 5

Preparation of intermediate 210

A mixture of intermediate 447 (1 g, 3.27 mmol) and pyridine hydrochloride (6 g, 51.9 mmol) was stirred at 210°C for 2 hours. The reaction mixture was cooled to room temperature. Water (20 mL) was added into the mixture. The mixture was extracted with ethyl acetate (20 mL, x 3). The organic layers were combined and evaporated under vacuo to give the crude product. The crude product was purified by chromatography (ethyl acetate /petroleum ether 0/1 to 1/10) to obtain intermediate 210 (500 mg, 49% yield) as a white solid.

Example A62

Step 1

Preparation of intermediate 448

3-bromo-7-hydroxyquinoline (5 g, 22.3 mmol) was dissolved in a mixture of DMF (50 mL) and CH3OH (50 mL). [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium(ii) (0.816 g, 1.12 mmol) and N(C(T1,3))3 (6.76 g, 66.9 mmol) were added. The mixture was stirred at 140°C overnight under a CO atmosphere (3MPa). The mixture was evaporated under vacuum. The residue was purified by column chromatography (eluent: petroleum ether/ethyl acetate: ratio 10/1 to 0/1). The product fractions were collected and the solvent was evaporated to afford intermediate 448 (2.5 g, yield: 45.1%) as a yellow solid.

Step 2

Preparation of intermediate 449
intermediate 448

CS₂CO₃ (15.76 g, 48.37 mmol) was added to the mixture of intermediate 448 (4 g, 16.1 mmol) and benzyl bromide (2.76 g, 16.1 mmol) in DMF (50 mL) under ice cooling. The mixture was stirred at room temperature for 12 h. The reaction mixture was filtered. The filtrate was concentrated under vacuo to give the crude product as a brown solid.

Step 3

Preparation of intermediate 450

LiAlH₄ (1.1 g, 28.3 mmol) was added to the mixture of intermediate 449 (3 g, 9.45 mmol) in THF (60 mL) under N₂ with ice cooling. The mixture was stirred at room temperature for 2 h. H₂O (0.5 mL) and aq. NaOH (10%, 0.3 mL) were added to the mixture. The mixture was filtered. The filtrate was treated with H₂O (20 mL) and extracted with EtOAc (40 mL, x 2). The organic layer was concentrated under vacuo to give crude product as solid. The product was purified by chromatography column (eluent: petroleum ether/EtOAc 1/2) to give the intermediate 450 (822 mg, yield: 32%) as a solid.

Step 4

Preparation of intermediate 451
NaH 60% (178mg, 4.46 mmol,) was added to the mixture of \textit{intermediate 450} (600 mg, 2.23 mmol) in THF (30 mL) under \textit{N}_2 with ice cooling. \textit{CH}_3\text{I} (316mg, 2.23 mmol) was added and the reaction was stirred at room temperature overnight. \textit{EtOAc} (40 mL) and water (20 mL) were added to the mixture. The organic phase was separated and dried over \textit{Na}_2\text{SO}_4, filtered and concentrated to give crude product as a yellow oil. The crude product was purified by chromatography column (eluent: Petroleum ether/EtOAc 1/2) to give \textit{intermediate 451} (620 mg, yield: 98%) as an oil.

\textbf{Step 5}

\textbf{Preparation of \textit{intermediate 246}}

\textit{intermediate 451} \hspace{1cm} \textit{Br}_2\text{Br}_2 \hspace{1cm} \textit{Br} \hspace{1cm} \textit{DCM/-70°C} \hspace{1cm} \textit{intermediate 246}

\textit{BBr}_3 (1g, 4.29 mmol) was added to solution of \textit{intermediate 451} (600 mg, 2.15 mmol) in \textit{CH}_2\text{Cl}_2 (60 mL) at -70°C and the reaction was stirred for 30 min. \textit{MeOH} (40 mL) was added to the reaction mixture at -70°C. The reaction mixture was stirred for 10 min. The mixture was concentrated under vacuum to give \textit{intermediate 246} (400 mg, yield: 95%) as yellow oil.

\textbf{Example A63}

\textbf{Preparation of \textit{intermediate 263}}

\textit{intermediate 441} \hspace{1cm} \textit{Cl-\text{\textit{Ar}}} \hspace{1cm} \textit{NH}_2 \hspace{1cm} \textit{Cl-\text{\textit{Ar}}} \hspace{1cm} \textit{NH} \hspace{1cm} \textit{Cl-\text{\textit{Ar}}} \hspace{1cm} \textit{OH} \hspace{1cm} \textit{intermediate 263}

\textit{Intermediate 441} (1.2 g, 6.68 mmol), 4-chlorobenzylamine (2.84 g, 20.0 mmol) and \textit{DIEA} (1.73 g, 13.36 mmol) were dissolved in \textit{CH}_3\text{CN} (25 mL). The mixture was heated at 120 °C for 1.5 hours by microwave. The mixture was concentrated under reduced pressure to give the crude product as a brown oil. The crude product was
purified by chromatography on silica gel (petroleum ether/ethyl acetate: ratio from 20/1 to 3/1) to give intermediate 263 (1.2 g, 35% yield) as a yellow solid.

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 263 using the appropriate starting materials (Table 35).

Table 35:

<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 274  | ![Structure](image) | a) Intermediate 441  
b) cyclopropylnmethanamine |

Example A66

**Step 1**

Preparation of intermediate 452

To the solution of intermediate 441 (5 g, 27.84 mmol) and imidazole (2.27 g, 33.5 mmol) in \( CH_2C_1_2 \) (100 mL) was added TBDMSI (5.04 g, 33.4 mmol) at 0°C. The reaction was stirred at room temperature for 4 hours. Water (100 mL) was added and the mixture was extracted with \( CH_2C_1_2 \) (80 mL, x 3). The organic phase was washed with brine (50 mL), dried over anhydrous Na\(_2\)SO\(_4\), filtered and concentrated to give the crude product. The crude product was purified by column chromatography over silica gel (petroleum ether/ethyl acetate: ratio 10/1). The desired fractions were concentrated to give intermediate 452 (8.0 g, 98% yield) as an oil.

**Step 2**

Preparation of intermediate 453
A solution of intermediate 452 (5 g, 17.0 mmol), Pd(PPh₃)₂Cl₂ (1.19 g, 1.70 mmol) and Et₃N (3.44 g, 34.0 mmol) in DMF (10 mL) and MeOH (60 mL) was stirred in an autoclave at room temperature under CO (50 psi) atmosphere. The solution was heated to 80 °C overnight. The reaction mixture was then filtered. The filtrate was concentrated to give the crude product. The crude product was purified by column chromatography on silica gel (petroleum ether/ethyl acetate, from 20/1 to 1/1) to afford intermediate 453 (3.4 g, 98% yield) as a light yellow solid.

Step 3
Preparation of intermediate 454

To the solution of intermediate 453 (1.5 g, 7.38 mmol) and imidazole (0.60 g, 8.86 mmol) in CH₂Cl₂ (80 mL) was added TBDMSCl (1.34 g, 8.86 mmol) at 0°C. The reaction was stirred at room temperature for 2 hours. The reaction was poured into water and extracted with ethyl acetate (150 mL x 3) and the organic phase was washed with brine (80 mL). The organic phase was dried over anhydrous Na₂SO₄, filtered and concentrated to give the crude product. The crude product was purified by column chromatography over silica gel (petroleum ether/ethyl acetate; ratio 5:1). The desired fractions were concentrated to give intermediate 454 (2.4 g, 97.5% yield) as a white oil.

Step 4
Preparation of intermediate 455
To a solution of NaBH₄ (2.264 g, 59.85 mmol) in EtOH (20 mL) cooled to 0 °C was added dropwise a solution of intermediate 454 (1.9 g, 5.98 mmol) in THF (20 mL) over 5 min under N₂. The solution was allowed to warm to room temperature and was stirred for 2 hours. A saturated aqueous NaHCO₃ solution (20 mL) and water (50 mL) were added to the reaction. The mixture was extracted with EtOAc (80 mL x 3). The combined organic layers were washed with brine (50 mL), dried with Na₂SO₄, filtered and concentrated to give the crude product intermediate 455 (1.2 g, 66.5 % yield).

Step 5

Preparation of intermediate 456

To a solution of intermediate 455 (1.2 g, 4.15 mmol) and Et₃N (1.26 g, 12.44 mmol) cooled in THF (20 mL) was added MsCl (569.9 mg, 4.98 mmol) dropwise under N₂. The reaction mixture was stirred at 0°C under N₂ for 30 minutes. Dimethylamine hydrochloride (1.69 g, 20.73 mmol, 5 eq) and Et₃N (4.195 g, 10 eq) were added. The reaction mixture was stirred at room temperature for 2 days. Water (40 mL) was added and the mixture was extracted with ethyl acetate (50 mL x 3). The organic layers were combined, dried over Na₂SO₄, filtered and concentrated to give the crude product as an oil. The crude product was purified by column chromatography over silica gel (petroleum ether/ethyl acetate: ratio 1/1). The desired fractions were concentrated to give intermediate 456 (550 mg) as an oil.

Step 6

Preparation of intermediate 212
To a solution of intermediate 456 (500 mg, 1.58 mmol) in THF (20 mL) was added TBAF (1 M solution in THF, 1.58 mL, 1.58 mmol) dropwise at room temperature under N₂. The reaction mixture was stirred at room temperature for 30 minutes. The reaction mixture was poured into water (40 ml) and was extracted with EtOAc (50 ml x 3). The organic layers were combined, dried over Na₂SO₄, filtered and evaporated to give the crude product. The crude product was purified by TLC (CH₂Cl₂/MeOH: ratio 5/1) to give intermediate 212 (80 mg, 22.5 % yield) as a light yellow oil.

Example A67

Step 1

Preparation of intermediate 457 and intermediate 458

3-chloro-5-bromoaniline (1 g, 4.84 mmol) was dissolved in 75% H₂SO₄ (10 mL). Then glycerol (1.11 g, 12.1 mmol) and nitrobenzene (0.59 g, 4.84 mmol) were added. The reaction mixture was stirred at 150°C for 3 hours under N₂. EtOAc (50 ml) was added and the mixture was adjusted to pH to 6-7 with a 30% solution of NaOH in water. The solid was filtered off over celite and the organic layer was separated and evaporated. The residue was purified by flash column chromatograph over silica gel (gradient eluent: petroleum ether/EtOAc from 20/1 to 5/1). The desired fractions were collected and the solvent was evaporated to give a mixture of intermediate 457 and intermediate 458 (750 mg) as a white solid.

Step 2

Preparation of intermediate 459 and intermediate 460
A mixture of intermediate 457 and intermediate 458 (750 mg), bis(pinacolato)diboron (942.5 mg, 3.7 mmol), Pd(dppf)Cl₂ (113.1 mg, 0.155 mmol) and KOAc (910.6 mg, 9.28 mmol) in THF (20 mL) was stirred at 60°C for 2 hours under N₂. Water (30 ml) was added and extracted with EtOAc (30 mL x 3). The organic layers were combined, dried over Na₂SO₄, filtered and concentrated to give a mixture of intermediate 459 and intermediate 460 (1.0 g) as a yellow oil.

Step 3

Preparation of intermediate 220a and intermediate 220b

To a mixture of intermediate 459 and intermediate 460 (1 g) in acetone (10 mL) was added a solution of oxone (1.25 g 2.03 mmol) in H₂O (10 mL) dropwise under N₂ at 0°C. The reaction mixture was stirred at 0°C for 1 hour. Water (20 ml) was added and the mixture was extracted with EtOAc (3 x 30 ml). The organic layer was combined, dried over Na₂SO₄, filtered and concentrated. The residue was triturated under EtOAc/petroleum ether (1/10). The precipitate was filtered off and dried to give a mixture of intermediate 220a and intermediate 220b (150 mg) as a yellow solid.

Example A68

Preparation of intermediate 218
A mixture of intermediate 205 (400 mg, 1.55 mmol), Me$_4$NCl (1.36 g, 12.4 mmol), Cu$_2$O (88.5 mg, 0.62 mmol) and L-Proline (142.5 mg, 1.24 mmol) in EtOH (10 mL) was stirred at 110°C for 120 min using a single mode microwave. The reaction mixture was concentrated and purified by column chromatography (eluent: petroleum ether/ethyl acetate: ratio 1/0 to 1/1). The product fractions were collected and the solvent was evaporated to afford intermediate 218 (350 mg, 97%) as a yellow solid.

Example A69

Preparation of intermediate 235

To a solution of 3-bromo-7-hydroxyquinoline (500 mg, 2.23 mmol) in THF (10 mL) was added cyclopentylzinc(II) bromide (0.5 M solution, 7.14 mL, 3.57 mmol), bis(tri-tert-butylphosphine)palladium(O) (114.0 mg, 0.223 mmol) and t-BuOK (250.4 mg, 2.23 mmol) under a N$_2$ atmosphere. The reaction mixture was heated to 100°C for 45 min in a microwave. The reaction mixture was cooled to room temperature, filtered and concentrated under reduced pressure to give the crude product as a yellow oil. The two crude products were combined and purified on silica gel column (petroleum ether/ethyl acetate ratio: 5/1 to 1/1) to obtain intermediate 235 (300 mg) as a yellow solid.

Preparation of intermediate 240

The reaction was performed twice.
To a solution of 3 bromo-7-hydroxyquinoline (700 mg 3.12 mmol) in THF (10 mL) was added isobutylzinc(II) bromide (0.5 M solution, 9.37 mL, 4.69 mmol), bis(tri-tert-butylphosphine)platinum(0) (3.193 mg 0.625 mmol) and t-BuOK (350.58 mg 3.12 mmol) under a N₂ atmosphere. The reaction mixture was heated at 100 °C for 45 min in a microwave. The reaction mixture was cooled to room temperature, filtered and concentrated under reduced pressure to give the crude product. The two crude products were combined and purified on silica gel column (petroleum ether/ethyl acetate: ratio 3/1 to 1/1) to obtain intermediate 240 (410 mg) as a yellow solid.

Example A98

Step 1:

Preparation of intermediate 505

3-bromo 7-methoxyquinoline (5 g, 21 mmol) was dissolved in dichloromethane (50 mL). Then 3-chloroperoxybenzoic acid (5.116 g, 25.2 mmol) was added into the mixture in fractions at 0°C. The resulting mixture was stirred at room temperature overnight. The mixture was poured into a sat.Na₂SO₃ aqueous solution (30 mL). The mixture was extracted by dichloromethane (50 mL x 2). Then the organic phase was washed with a sat.NaHCO₃ aqueous solution (50 mL) and brine (50 mL). The organic layer was dried over anhydrous Na₂SO₄. A white solid precipitated which was filtered to obtain intermediate 505 (6.4 g, 87% yield).

Step 2:

Preparation of intermediate 506

intermediate 505
Intermediate 505 (6.4 g, 18.25 mmol) was dissolved in chloroform (100 mL). Then phosphorus oxychloride (20 ml) was added and the reaction mixture was refluxed at 80°C for 3 hours. The solvent was removed under reduced pressure to obtain intermediate 506 (5.8 g, 97% yield) as a white solid, which was used in the next step without further purification.

Step 3:

Preparation of intermediate 507

A mixture of intermediate 506 (3 g, 11 mmol) and NH₃·H₂O (20 ml) in dioxane (20 ml) was heated in a sealed tube at 120°C for 72h. The mixture was extracted with CH₂Cl₂ (50 mL x 3). The organic phase was concentrated under vacuum to give the crude product. The crude product was purified by chromatography (ethyl acetate/petroleum ether 0/20 to 1/20) to obtain intermediate 507 (0.9 g, 32% yield) as a white solid.

Step 4:

Preparation of intermediate 477

Intermediate 507 (1.2 g, 4.74 mmol) was dissolved in CH₂Cl₂ (12 ml). Then the yellow clear reaction was cooled to 0°C and BBr₃ (23.75 g, 94.82 mmol) was added. The reaction mixture was stirred at room temperature for 16 hours. The reaction was quenched with MeOH slowly at 0°C and stirred at 15°C for 15 min. The red suspension was concentrated. The residue was adjusted to pH 8 with aqueous NaHCO₃. The precipitate was filtered and washed with i¾0 (10 mL). The filter cake was dried in
vacuum to obtain \textit{intermediate 477} (1.1 g, 97% yield) as off-white solid.

Example A99

Step 1:

Preparation of \textit{intermediate 508}

\begin{equation*}
\begin{array}{c}
\text{Br} \hspace{1cm} \text{CuCl} \hspace{1cm} \text{NaCl} \hspace{1cm} \text{Cl}
\end{array}
\end{equation*}

\textit{intermediate 508}

A mixture of 3- \textit{bromo 7-methoxyquinoline} (10 g, 42 mmol), CuCl (20 g, 204 mmol), NaCl (20 g, 345 mmol) and N-methylpyrrolidin-2-one (200 ml) was heated at 120°C for 2 hours. Then the reaction mixture was stirred at 170°C for 2 hours. The reaction was diluted with a saturated aqueous ammonium chloride solution, ethyl acetate was added and the mixture was stirred to dissolve the product. The mixture was filtered to remove the insoluble material and the organic phase was separated. The aqueous phase was extracted with ethyl acetate (200 mL x 3) and the insoluble material was washed with warm ethyl acetate (200 mL x 3). The ethyl acetate fractions were combined, washed with water, dried over Na$_2$SO$_4$ and evaporated under reduced pressure. The residue was purified by flash chromatography (gradient eluent: EtOAc/petrol ether from 1/20 to 1/5) to obtain \textit{intermediate 508} (2 g, 22% yield) as white solid.

Step 2:

Preparation of \textit{intermediate 509}

\begin{equation*}
\begin{array}{c}
\text{Cl} \hspace{1cm} \text{m-CPBA} \hspace{1cm} \text{Cl}
\end{array}
\end{equation*}

\textit{intermediate 509}

\textit{Intermediate 508} (2 g, 10.3mmol) was dissolved in dichloromethane (40 mL). Then 3-chloroperoxybenzoic acid (3.565 g, 20.65 mmol) was added into the mixture in fractions at 0°C. The resulting mixture was stirred at room temperature overnight. The
mixture was poured into a sat. Na$_2$SO$_3$ aqueous solution (30 ml). The mixture was extracted by dichloromethane (50 mL x 2). Then the organic phase was washed with a sat. NaHCO$_3$ aqueous solution (50 ml) and brine (50 mL). The organic layer was dried over anhydrous Na$_2$SO$_4$. A white solid precipitated and was filtered to obtain intermediate **509** (2 g, 83% yield).

**Step 3:**

**Preparation of intermediate 510**

\[
\begin{align*}
\text{Intermediate } 509 & \xrightarrow{\text{POCl}_3, \text{CHCl}_3} \text{Intermediate } 510 \\
\end{align*}
\]

**Intermediate 509** (2.4 g, 18.25 mmol) was dissolved in chloroform (50 mL). Then **phosphorus oxychloride** (10.5 g, 68.69 mmol) was added and the reaction mixture was refluxed at 80°C for 2 hours. The reaction mixture was slowly poured into water. Then a sat. NaHCO$_3$ aqueous solution was added into the mixture to change the pH to ~7. The reaction mixture was extracted with dichloromethane (200mL x 2 ) and the organic layer was dried over anhydrous Na$_2$SO$_4$. The organic phase was concentrated to obtain **intermediate 510** (2.5 g, 93% yield) as a white solid.

**Step 4:**

**Preparation of intermediate 511**

\[
\begin{align*}
\text{Intermediate } 510 & \xrightarrow{\text{Pd(OAc)}_2, \text{BINAP}, \text{Cs}_2\text{CO}_3} \text{Intermediate } 511 \\
\end{align*}
\]

A mixture of **intermediate 510** (2.2 g, 9.64 mmol), benzophenone imine (1.78 g, 9.83mmol), Pd(OAc)$_2$ (0.2 1 g ,0.96 mmol), BINAP (0.6 g, 0.96 mmol) Cs$_2$C0$_3$ (6.28 g, 19.29 mmol) and toluene (50 mL) was heated at 110°C for 48 hours under N$_2$. The catalyst was filtered and the solvent was evaporated. The residue was purified by flash column chromatography over silica gel (gradient eluent: EtOAc/petrol ether from 1/15 to 1/1). The product fractions were collected and the solvent was evaporated to obtain
intermediate 511 (2 g, 54% yield) as an oil.

Step 5:

Preparation of intermediate 468

Intermediate 511 (2 g, 54% yield) was dissolved in CH₂Cl₂ (100 ml). Then the yellow clear reaction was cooled to 0°C and BBr₃ (20 g, 79.84 mmol) was added. The reaction mixture was stirred at room temperature for 14 hours. The reaction mixture was adjusted to pH 7 with sat. sodium hydrogen carbonate solution and extracted with EtOAc (3 × 300 mL). The combined organic layers were separated, dried with Na₂SO₄, and the solvent was evaporated to obtain intermediate 468 (2 g, 69.5% yield) as white solid.

Example A70

Preparation of intermediate 305

A mixture of 7-Bromo-2-Chloroquinoline (2.45 g, 10.1 mmol) and 2,2,2-Trifluoroethyamine (5.0 g, 50.5 mol) in EtOH (60 mL) was stirred in a sealed tube at 120°C overnight. The reaction mixture was treated with aq. NaCl (80mL) and extracted with EtOAc (80mL x 2). The organic layers were combined and concentrated under vacuo to give crude product. The crude product was purified by silica gel chromatography (ethyl acetate/petroleum ether 0/1 to 3/7) to give intermediate 305 (2.5 g, 62.5% yield) as white solid.
Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of **intermediate 305** using the appropriate starting materials (Table 36).

Table 36:

<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>244</td>
<td><img src="image" alt="Structure" /></td>
<td>7-bromo-2-chloroquinoline (4-chlorophenyl)methanamine</td>
</tr>
<tr>
<td>263</td>
<td><img src="image" alt="Structure" /></td>
<td>2-chloro-7-hydroxyquinoline (4-chlorophenyl)methanamine</td>
</tr>
<tr>
<td>274</td>
<td><img src="image" alt="Structure" /></td>
<td>2-chloro-7-hydroxyquinoline cyclopropylmethylamine</td>
</tr>
<tr>
<td>299</td>
<td><img src="image" alt="Structure" /></td>
<td>propan-2-amine 7-bromo-2-chloroquinoline</td>
</tr>
<tr>
<td>308</td>
<td><img src="image" alt="Structure" /></td>
<td>7-bromo-2-chloroquinoline Cyclopropylamine</td>
</tr>
<tr>
<td>320</td>
<td><img src="image" alt="Structure" /></td>
<td>7-bromo-2-chloroquinoline Cyclobutylamine</td>
</tr>
<tr>
<td>302</td>
<td><img src="image" alt="Structure" /></td>
<td>7-bromo-2-chloroquinoline Tert.-butylamine</td>
</tr>
<tr>
<td>290</td>
<td><img src="image" alt="Structure" /></td>
<td>7-bromo-2-chloroquinoline Cyclopentylamine</td>
</tr>
<tr>
<td>293</td>
<td><img src="image" alt="Structure" /></td>
<td><strong>intermediate181</strong> cyclopropylmethylamine</td>
</tr>
<tr>
<td>296</td>
<td><img src="image" alt="Structure" /></td>
<td><strong>intermediate175</strong> cyclopropylmethylamine</td>
</tr>
</tbody>
</table>
Example A71

Preparation of intermediate 338

A mixture of intermediate 306 (520 mg, 0.95 mmol) and $\text{CH}_3\text{NH}_2\text{EtOH}$ (15 mL) in EtOH (15 mL) was stirred at 120°C overnight in a sealed tube. The reaction was concentrated to give intermediate 338 (590 mg) which was used for next step without further purification.

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 338 using the appropriate starting materials (Table 37).
<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>339</td>
<td><img src="image1" alt="Structure Image" /></td>
<td>Intermediate 248 methylamine</td>
</tr>
<tr>
<td>340</td>
<td><img src="image2" alt="Structure Image" /></td>
<td>Intermediate 309 methylamine</td>
</tr>
<tr>
<td>341</td>
<td><img src="image3" alt="Structure Image" /></td>
<td>Intermediate 321 methylamine</td>
</tr>
<tr>
<td>342</td>
<td><img src="image4" alt="Structure Image" /></td>
<td>Intermediate 162 methylamine</td>
</tr>
<tr>
<td>343</td>
<td><img src="image5" alt="Structure Image" /></td>
<td>Intermediate 262 methylamine</td>
</tr>
<tr>
<td>344</td>
<td><img src="image6" alt="Structure Image" /></td>
<td>Intermediate 183 methylamine</td>
</tr>
<tr>
<td>345</td>
<td><img src="image7" alt="Structure Image" /></td>
<td>Intermediate 183 isopropylamine</td>
</tr>
<tr>
<td>Int.</td>
<td>Structure</td>
<td>Starting materials</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>-------------------</td>
</tr>
<tr>
<td>346</td>
<td><img src="image" alt="Structure 346" /></td>
<td>Intermediate 183</td>
</tr>
<tr>
<td></td>
<td></td>
<td>cyclopropylamine</td>
</tr>
<tr>
<td>347</td>
<td><img src="image" alt="Structure 347" /></td>
<td>Intermediate 327</td>
</tr>
<tr>
<td></td>
<td></td>
<td>methylamine</td>
</tr>
<tr>
<td>348</td>
<td><img src="image" alt="Structure 348" /></td>
<td>Intermediate 315</td>
</tr>
<tr>
<td></td>
<td></td>
<td>methylamine</td>
</tr>
<tr>
<td>349</td>
<td><img src="image" alt="Structure 349" /></td>
<td>Intermediate 330</td>
</tr>
<tr>
<td></td>
<td></td>
<td>methylamine</td>
</tr>
<tr>
<td>350</td>
<td><img src="image" alt="Structure 350" /></td>
<td>Intermediate 324</td>
</tr>
<tr>
<td></td>
<td></td>
<td>methylamine</td>
</tr>
<tr>
<td>351</td>
<td><img src="image" alt="Structure 351" /></td>
<td>Intermediate 300</td>
</tr>
<tr>
<td></td>
<td></td>
<td>methylamine</td>
</tr>
<tr>
<td>352</td>
<td><img src="image" alt="Structure 352" /></td>
<td>Intermediate 262</td>
</tr>
<tr>
<td></td>
<td></td>
<td>dimethylamine</td>
</tr>
<tr>
<td>Int.</td>
<td>Structure</td>
<td>Starting materials</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>--------------------</td>
</tr>
<tr>
<td>405</td>
<td><img src="image1" alt="Structure Image" /></td>
<td>Intermediate 159 methylamine</td>
</tr>
<tr>
<td>465</td>
<td><img src="image2" alt="Structure Image" /></td>
<td>Intermediate 463 methylamine</td>
</tr>
<tr>
<td>467</td>
<td><img src="image3" alt="Structure Image" /></td>
<td>Intermediate 466 methylamine</td>
</tr>
<tr>
<td>470</td>
<td><img src="image4" alt="Structure Image" /></td>
<td>Intermediate 469 methylamine</td>
</tr>
<tr>
<td>474</td>
<td><img src="image5" alt="Structure Image" /></td>
<td>Intermediate 473 methylamine</td>
</tr>
<tr>
<td>476</td>
<td><img src="image6" alt="Structure Image" /></td>
<td>Intermediate 473 NH$_4$OH</td>
</tr>
<tr>
<td>479</td>
<td><img src="image7" alt="Structure Image" /></td>
<td>Intermediate 478 methylamine</td>
</tr>
<tr>
<td>Int.</td>
<td>Structure</td>
<td>Starting materials</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>--------------------</td>
</tr>
</tbody>
</table>
| 480  | ![Structure 480](image) | Intermediate 478  
NH₄OH |
| 481  | ![Structure 481](image) | Intermediate 478  
NH₄OH |
| 486  | ![Structure 486](image) | Intermediate 484  
methylamine |
| 489  | ![Structure 489](image) | Intermediate 488  
NH₄OH |
| 492  | ![Structure 492](image) | Intermediate 491  
methylamine |

Example A72

5 Preparation of *intermediate 353*
A mixture of intermediate 262 (310 mg, 0.61 mmol) in MeOH (5 mL) was hydrogenated at room temperature (H₂, atmospheric pressure) with Pd(OH)₂ (20 mg) as catalyst over weekend. After uptake of H₂ (1 equiv), the mixture was filtered and the filtrate was evaporated to give intermediate 353 (260 mg, 81.3% yield) which was used in the next step without further purification.

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 353 using the appropriate starting materials (Table 38).

Table 38:

<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>354</td>
<td><img src="image1.png" alt="Image" /></td>
<td>Intermediate 248</td>
</tr>
<tr>
<td>355</td>
<td><img src="image2.png" alt="Image" /></td>
<td>Intermediate 268</td>
</tr>
<tr>
<td>356</td>
<td><img src="image3.png" alt="Image" /></td>
<td>Intermediate 159</td>
</tr>
<tr>
<td>357</td>
<td><img src="image4.png" alt="Image" /></td>
<td>Intermediate 266</td>
</tr>
<tr>
<td>Int.</td>
<td>Structure</td>
<td>Starting materials</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>--------------------</td>
</tr>
<tr>
<td>358</td>
<td><img src="image1" alt="Structure" /></td>
<td>Intermediate 272</td>
</tr>
<tr>
<td>359</td>
<td><img src="image2" alt="Structure" /></td>
<td>Intermediate 259</td>
</tr>
<tr>
<td>360</td>
<td><img src="image3" alt="Structure" /></td>
<td>Intermediate 275</td>
</tr>
<tr>
<td>361</td>
<td><img src="image4" alt="Structure" /></td>
<td>Intermediate 254</td>
</tr>
<tr>
<td>362</td>
<td><img src="image5" alt="Structure" /></td>
<td>Intermediate 254</td>
</tr>
<tr>
<td>401</td>
<td><img src="image6" alt="Structure" /></td>
<td>Intermediate 264</td>
</tr>
<tr>
<td>402</td>
<td><img src="image7" alt="Structure" /></td>
<td>Intermediate 270</td>
</tr>
</tbody>
</table>
Example A73

Preparation of intermediate 403

A mixture of intermediate 119 (600 mg, 0.82 mmol) and CH$_2$NH$_2$/EtOH (25 mL) in EtOH (25 mL) were stirred at 120°C overnight in a sealed tube. The reaction mixture was concentrated to give intermediate 403 (600 mg) which used in the next step without further purification.

Example A74

Preparation of intermediate 404

Intermediate 228 (350 mg, 0.5 mmol) and methylamine (15 mL, 2 M) in EtOH were stirred at 120°C for 1.5 hours in a microwave. The mixture was concentrated in vacuo to give intermediate 404 as yellow solid. The crude product was used in the next step directly without purification.

Example A75

Step 1

Preparation of intermediate 363
A mixture of intermediate 1 (250 mg, 0.77 mmol) and MeONa (331.5 mg, 6.14 mmol) in MeOH was stirred at room temperature for 1 h. The mixture was diluted with water (20 mL), and was extracted with CH2Cl2 (50 mL x 3). The organic phase was washed with brine (10 mL), dried over Na2SO4, filtered and concentrated to give intermediate 363 (250 mg, 96% yield) which was used for the next reaction step without further purification.

**Step 2**

Preparation of intermediate 364

TosCl (0.415 g, 2.18 mmol) was added dropwise into the mixture of intermediate 363 (0.35 g, 1.1 mmol), triethylamine (0.455 mL, 3.27 mmol) and 4-dimethylaminopyridine (67 mg, 0.545 mmol) in dichloromethane (5 mL) under ice cooling. The mixture was stirred at room temperature for 3 h. The mixture was quenched with water (10 mL) and extracted with CH2Cl2 (30 mL x 3). The organic phase was washed with brine (10 mL), dried over Na2SO4, filtered and concentrated. Then residue was purified by column chromatography (eluent: Petroleum ether/ethyl acetate ratio 1/0 to 3/1). The product fractions were collected and the solvent was evaporated to afford intermediate 364 (446 mg, 86% yield) as an oil.

**Step 3**

Preparation of intermediate 365
A mixture of intermediate 364 (446 mg, 0.94 mmol), 2-amino-7-hydroxyquinoline (167 mg, 1.04 mmol) and $\text{Cs}_2\text{CO}_3$ (1.02 g, 3.13 mmol) in DMF (5 mL) was stirred at room temperature overnight. The mixture was filtered, and the solvent was evaporated. The residue was purified by column chromatography (eluent: ethyl acetate). The product fractions were collected and the solvent was evaporated to afford intermediate 365 (257.3 mg, 53.3% yield) as solid.

Example A76

Preparation of intermediate 366

A mixture of intermediate 306 (400 mg, 0.73 mmol) and MeONa (158.2 mg, 2.93 mmol) in MeOH (10 mL) was stirred at 60°C for 10 h. The mixture was diluted with water (20 mL), extracted with $\text{CH}_2\text{Cl}_2$ (50 mL x 3). The organic phase was washed with brine (10 mL), dried over $\text{Na}_2\text{SO}_4$, filtered and concentrated to give intermediate 366 which used in the next step without further purification.

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 366 using the appropriate starting materials (Table 39).
<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>367</td>
<td><img src="image1" alt="Structure" /></td>
<td>Intermediate 248</td>
</tr>
<tr>
<td>368</td>
<td><img src="image2" alt="Structure" /></td>
<td>Intermediate 309</td>
</tr>
<tr>
<td>369</td>
<td><img src="image3" alt="Structure" /></td>
<td>Intermediate 162</td>
</tr>
<tr>
<td>366</td>
<td><img src="image4" alt="Structure" /></td>
<td>Intermediate 306</td>
</tr>
<tr>
<td>371</td>
<td><img src="image5" alt="Structure" /></td>
<td>Intermediate 183</td>
</tr>
<tr>
<td>372</td>
<td><img src="image6" alt="Structure" /></td>
<td>Intermediate 327</td>
</tr>
<tr>
<td>373</td>
<td><img src="image7" alt="Structure" /></td>
<td>Intermediate 315</td>
</tr>
</tbody>
</table>
### Example A76

**Preparation of intermediate 472**

**Intermediate 471** (900 mg, 1.36 mmol) was dissolved in TFA (3 ml).

The reaction mixture was stirred at 50°C for 7 hours.

The solvent was evaporated to give desired **intermediate 472** as an oil.
Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 472 using the appropriate starting materials (Table 49).

Table 49:

<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>527</td>
<td><img src="image" alt="Structure" /></td>
<td>Intermediate 526</td>
</tr>
<tr>
<td>535</td>
<td><img src="image" alt="Structure" /></td>
<td>Intermediate 534</td>
</tr>
</tbody>
</table>

Example A77

Preparation of intermediate 376

To intermediate 264 (330 mg, 0.44 mmol) and C$_3$H$_9$B$_3$O$_3$ (164 mg, 1.3 mmol) in dioxane/H$_2$O (6 ml, dioxane/H$_2$O ratio 5/1) was added K$_3$PO$_4$ (277 mg, 1.3 mmol) and 1,1’-bis (di-tert-butylphosphino) ferrocene palladium dichloride (28.3 mg, 0.04 mmol). The mixture was stirred at 80°C overnight. The mixture was treated with water (30 mL) and extracted with ethyl acetate (40 mL x 3), dried (Na$_2$SO$_4$), filtered and concentrated by vacuum to give the crude product as a brown oil. The crude product was purified by flash column chromatography (gradient eluent: petroleum ether: ethyl acetate from 20/1 to 3/1) to give intermediate 376 (170 mg, 69% yield) as a yellow oil.

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 376 using the appropriate starting materials (Table 40).
Table 40:

<table>
<thead>
<tr>
<th>Int.</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>377</td>
<td><img src="image" alt="Structure 377" /></td>
<td>Intermediate 248</td>
</tr>
<tr>
<td>378</td>
<td><img src="image" alt="Structure 378" /></td>
<td>Intermediate 268</td>
</tr>
<tr>
<td>379</td>
<td><img src="image" alt="Structure 379" /></td>
<td>Intermediate 159</td>
</tr>
<tr>
<td>380</td>
<td><img src="image" alt="Structure 380" /></td>
<td>Intermediate 266</td>
</tr>
<tr>
<td>381</td>
<td><img src="image" alt="Structure 381" /></td>
<td>Intermediate 245</td>
</tr>
</tbody>
</table>

Example A78

5 Step 1

Preparation of intermediate 382

intermediate 159 → intermediate 382

Pd-118, K$_3$PO$_4$, potassium vinyltrifluoroborate reflux, dioxane, H$_2$O

intermediate 382
To a solution of intermediate 159 (0.85 g, 1.28 mmol) in dioxane (20 ml) and H₂O (5 ml) was added potassium vinyltrifluoroborate (223 mg, 1.67 mmol) and potassium phosphate tribasic (544 mg, 2.57 mmol) at room temperature. 1,1’-bis(di-tert-butylphosphino)ferrocene palladium dichloride (42 mg, 0.064 mmol) was added to the above solution under nitrogen atmosphere. The reaction mixture was stirred at 80°C under nitrogen atmosphere overnight. The mixture was extracted with ethyl acetate (20 ml x 2), the organic layers were combined and concentrated under vacuo. The residue was purified by chromatography column (gradient eluent: ethyl acetate/petrol ether from 1/10 to 1/1). The desired fractions were collected and concentrated to give product intermediate 382 (400 mg, yield: 60%) as an oil.

Preparation of intermediate 383

Trifluoroacetic acid (0.5 ml) was added to a solution of intermediate 382 (400 mg, 0.78 mmol) in CH₂Cl₂ (10 ml). The mixture was stirred at room temperature for 3 h. The mixture was evaporated under vacuo to give intermediate 383 (300 mg, yield: 48%).

Example A79

Preparation of intermediates 384 and 385

Me₂NH (20 mL) was added into the mixture of intermediate 262 (200 mg, 0.43 mmol) in dioxane (20 mL) and stirred in sealed tube at 110°C overnight. The reaction mixture
was concentrated to give a mixture of intermediate 384 and intermediate 385 (210 mg) as solid.

Example A80

Step 1

Preparation of intermediate 412

A mixture of 2-amino-4-bromo-benzaldehyde (13 g, 65 mmol) and urea (54.6 g, 910 mmol) was heated to 180°C in an oil bath for 2 hours. Then the reaction was cooled to room temperature and H₂O (500 mL) was added. The reaction mixture was stirred at room temperature for 1 hour. The solid was collected by filtration to obtain intermediate 412 (16 g, 93% yield) as white solid.

Step 2

Preparation of intermediate 413

A mixture of intermediate 412 (16 g, 71 mmol) and POCl₃ (280 g, 1.84 mol) was heated to 110°C in an oil bath under N₂ for 3 hours. Then the reaction was cooled to room temperature and poured into ice/water (4000 g). The reaction mixture was stirred at room temperature for 1 hour and was extracted with ethyl acetate (2000 mL x 2). The organic layer was washed with brine and dried over anhydrous Na₂SO₄. The solvent was evaporated under vacuum to give the crude product. The crude product was purified by chromatography (ethyl acetate/petroleum ether 0/1 to 1/5) to obtain intermediate 413 (10 g, 53% yield) as white solid.

Step 3
Preparation of intermediate 386

A mixture of intermediate 413 (4 g, 16.5 mmol), 4-methoxybenzylamine (3.4 g, 24.6 mmol) and cesium carbonate (15 g, 49.3 mmol) in THF (100 mL) was stirred at room temperature for 12 hours. The reaction mixture was filtered and the filtrate was evaporated under vacuum to give the crude product. The crude product was purified by chromatography (ethyl acetate/petroleum ether 0/1 to 1/10) to obtain intermediate 386 (2.3 g, 29%) yield as oil.

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 386 using the appropriate starting materials (Table 42).

Table 42:

<table>
<thead>
<tr>
<th>Intermediates</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
</table>
| 276           | ![Structure of intermediate 276](image)  | intermediate 413  
cyclopropylmethylamine |
| 287           | ![Structure of intermediate 287](image)  | intermediate 413  
cyclopropylamine |

Preparation of intermediate 387
Intermediate 38 (1.5 g, 4.69 mmol) in 9-BBN (0.5 M in THF, 56.3 mL, 28.1 mmol) was refluxed for 1h under N₂. The mixture was cooled to room temperature, then K₂PO₄ (2.98 g, 14.1 mmol) in H₂O (5 mL) was added, followed by THF (40 mL), intermediate 386 (2.1 g, 6.1 mmol) and Pd-1 18 (61.1 mg, 0.094 mmol). The resulting mixture was refluxed overnight. The mixture was diluted with H₂O (50 mL), extracted with ethyl acetate (150 mL), the organic phase was dried by Na₂S₀₄, then filtered and concentrated in vacuo to give the crude product. The crude product was purified by chromatography (ethyl acetate/petroleum ether 0/1 to 1/10) to give intermediate 387 (1.3 g, yield: 47%) as an oil.

Step 5

Preparation of intermediate 388

Intermediate 387 (500 mg, 0.85 mmol) was dissolved in TFA (10 mL) and stirred at 60°C for 1 hour. The mixture was concentrated to obtain crude intermediate 388 (1 g as a solid).

Example A81

Step 1

Preparation of intermediate 389

A mixture of intermediate 387 (450 mg, 0.77 mmol) and NH₂.FLO (10 mL) in dioxane
was heated to 80°C for 24 hours in a sealed tube. The reaction mixture was extracted with ethyl acetate (50 ml x 3). The organic layers were separated, dried with Na₂SO₄, and the solvent was evaporated to obtain intermediate 389 (290 mg, 66.6% yield) as oil.

**Step 2**

Preparation of intermediate 390

Intermediate 389 (290 mg, 0.51 mmol) was dissolved in TFA (10 mL) and stirred at 60°C for 1 hour. The mixture was concentrated to obtain crude intermediate 390 (300 mg) as an oil.

Example A82

Preparation of intermediate 347

A mixture of intermediate 327 (1100 mg, 2.20 mmol) in methylene chloride (30 mL, 40%) was heated in a sealed tube at 80°C for 24 h. The organic phase was concentrated to obtain intermediate 347 (1.2 g, 99% yield).

Example A83

Preparation of intermediate 372
A mixture of **intermediate 327** (550 mg, 1.1 mmol), sodium methoxide (356.3 mg, 6.60 mmol) in methanol (10 ml) was refluxed at 60 °C for 2 h. The reaction mixture was evaporated under vacuum. Water (10 ml) was added and the mixture was extracted with ethyl acetate (10 ml x 2), the organic layers were combined and evaporated under vacuum to obtain **intermediate 372** (510 mg, 75% yield) as an oil.

**Example A84**

### Step 1

**Preparation of intermediate 393**

![Chemical structure](image)

**7-bromo-3-(trifluoromethyl) quinoline** (1.0 g, 3.62 mmol) was dissolved in DCM (30 mL), m-CPBA (1.25 g, 7.25 mmol) was added into the mixture in portions. The resulting mixture was stirred at room temperature overnight. The reaction mixture was poured into a mixture of saturated Na$_2$S$_2$O$_3$ (50.0 mL) and 1N NaOH (50 mL) aqueous solution. The mixture was then extracted with DCM (200 ml, x 2), and the combined organic phases were washed with brine (100 mL), dried over anhydrous Na$_2$SO$_4$, filtered and concentrated to afford the product **intermediate 393** (1.0 g, 80% yield) as a brown solid, which was used in the next step without further purification.

### Step 2

**Preparation of intermediate 394**
Intermediate 393 (200 mg, 0.685 mmol) was taken up into CHCl₃ (10 mL). POCh (1.0 mL) was added at room temperature. The reaction mixture was stirred at 80 °C for 12 hours. The solvent was removed under reduced pressure, the residue was triturated with ethyl acetate (50 mL) and sat. Na₂CO₃ (50 mL), the organic layer was separated, the organic layer was washed with brine (50 mL) and dried over anhydrous Na₂SO₄. The solvent was removed under reduced pressure to give intermediate 394 (200 mg, 83%) as a brown oil.

Step 3

Preparation of intermediate 314

Intermediate 394 (2.2 g, 5.43 mmol) was dissolved in dioxane (30 mL) and NH₃H₂O (30 mL) was added. The reaction mixture was stirred at 120 °C in an autoclave overnight. The solvent was removed under reduced pressure, the residue was purified by column chromatography (EtOAc/petroleum ether ratio: 0/10 to 1/10) to afford intermediate 314 (1.4 g, 88.6% yield) as a white solid.

Example A85

Preparation of intermediate 348
**Intermediate 315** (420 mg, 0.79 mmol) was dissolved in an ethanol solution of MeNH₂ (30%, 30 mL) and EtOH (30 mL). The reaction mixture was stirred at 100 °C in an autoclave for 12 hours. The solvent was removed under reduced pressure to afford **intermediate 348** (450 mg, crude) as a brown solid, which was used in the next step without further purification.

Example A86

**Step 1**

Preparation of **intermediate 373**

**Intermediate 373** (300 mg, 0.56 mmol) was dissolved in MeOH (20 mL), MeONa (483 mg, 4.46 mmol) was added. The reaction mixture was stirred at 70 °C for 12 hours. The solvent was removed under reduced pressure to afford **intermediate 373** (340 mg, crude) as a brown solid, which was used in the next step without further purification.

Example A87

**Step 1**

Preparation of **intermediate 395**
$1H$-Isoindole-$1,3(2H)$-dione, potassium salt (1:1) (50 g, 221.9 mmol) and 2-bromo-1,1-diethoxy-ethane (54.7 g, 277.4 mmol) in DMF were stirred at 150 °C for 4 hours. The DMF was removed under reduced pressure. The residue was purified by column chromatography (elution: petroleum ether/ethyl acetate ratio 5/1) to afford intermediate 395 (40 g, yield: 64%) as a white solid.

Step 2
Preparation of intermediate 396

A mixture of intermediate 395 (22.1 g, 84.0 mmol), 4-bromo-2-amino-benzaidehyde (14 g, 70.0 mmol) and p-MeC$_6$H$_4$SO$_2$H.H:0 (13.3 g, 70.0 mmol) in PhMe (200 mL) was refluxed for 4 hours. The mixture was cooled and filtered. The solid was washed with toluene to give the crude PTSA-salt of the product as a brown solid. The solid was stirred in saturated aq. sodium bicarbonate and extracted with dichloromethane. The solvent was evaporated and the residual solid was slurried in ethanol and collected to obtain intermediate 396 (14.2 g, 56% yield).

Step 3
Preparation of intermediate 397
A suspension of intermediate 396 (14 g, 38.5 mmol) in ethanol (150 mL) was treated with NH₂NH₂H₂O (4.5 g, 76.9 mmol) and was refluxed for 1 hour. The mixture was allowed to cool and filtered. The filtrate was collected and evaporated to obtain intermediate 397 (8.6 g, 94% yield).

Step 4

Preparation of intermediate 398

Intermediate 397 (8 g, 35.86 mmol) was dissolved in PhCl (80 mL). Boron trifluoride diethyl etherate (4.45 mL) was added drop-wise over 10 mins. The mixture was heated to 60 °C. Tert-butyl nitrite (6.1 mL) was added drop-wise over 20 mins at this temperature. The reaction solution was heated to 100 °C and stirred for 1 hour. The mixture was cooled and poured into an ice/aqueous sodium bicarbonate solution. The mixture was extracted with CH₂Cl₂ (500 mL x 2). The combined organic layers were washed with brine, dried (Na₂SO₄) and concentrated by vacuum to give the crude product. The crude product was purified by column chromatography (gradient eluent: petroleum ether/ethyl acetate from 1/0 to 20/1) to obtain intermediate 398 (1.57 g, 19% yield).

Step 5

Preparation of intermediate 399
A mixture of intermediate 398 (1.57 g, 6.95 mmol) and m-CPBA (2.1 g, 10.4 mmol) in CHCl₃ (30 mL) was stirred at 50 °C overnight. The reaction solution was quenched with a solution of Na₂SO₃ (50 mL) and basified with a solution of NaHCO₃ (50 mL). The mixture was extracted with CH₂Cl₂ (300 mL x 3). The combined organic layers were washed with brine, dried (Na₂SO₄), filtered and concentrated by vacuum to obtain intermediate 399 (2 g, 97.2 % yield) as a brown solid.

Step 6

Preparation of intermediate 400

\[
\text{intermediate 399} \xrightarrow{\text{POCl₃}} \text{intermediate 400}
\]

The mixture of intermediate 399 (2 g, 6.75 mmol) and POCl₃ (10.6 g, 69 mmol) in CHCl₃ (40 mL) was refluxed for 3 hours. The reaction solution was poured into water (100 mL), basified with a solution of NaHCO₃ (80 mL) to pH > 7 and stirred for 5 mins. The mixture was extracted with DCM (500 ml, x 3). The combined organic layers were washed with brine, dried (Na₂SO₄), filtered and concentrated in vacuum to give the crude product as yellow solid. The crude product was purified by column chromatography over silica gel (petroleum ether/ethyl acetate: ratio 1/0 to petroleum ether/ethyl acetate 10/1). The pure fractions were collected and the solvent was evaporated under vacuum to give intermediate 400 (1.4 g, 78% yield) as a white solid.

Step 7

Preparation of intermediate 329

\[
\text{intermediate 400} \xrightarrow{\text{NH₃·H₂O}} \text{intermediate 329}
\]

A mixture of intermediate 400 (600 mg, 2.3 mmol) and NH₃·LLO (15 mL) in CH₃CH₂OH (15 mL) was heated in a sealed tube at 120 °C overnight. The mixture was concentrated in vacuum. The residue was purified by column chromatography over
silica gel (petroleum ether/ethyl acetate from 20/1 to petroleum ether/ethyl acetate 1/1). The pure fractions were collected and the solvent was evaporated under vacuum to give intermediate 329 (390 mg, 67% yield) as white solid.

Example A88

Preparation of intermediate 330

Intermediate 329 (470 mg, 1.47 mmol) in 9-BBN (0.5 M in THF, 11.8 mL, 5.9 mmol) was refluxed for 1 h under N₂. The mixture was cooled to room temperature, then K₃PO₄ (936.6 mg, 4.41 mmol) in H₂O (2 mL) was added, followed by THF (20 mL), intermediate 329 (390 mg, 1.62 mmol) and Pd-118 (19.2 mg, 0.029 mmol). The resulting mixture was refluxed overnight. The mixture was diluted with H₂O (80 mL) and extracted with ethyl acetate (150 mL). The organic phase was dried by Na₂SO₄, then filtered and concentrated in vacuo to give the crude product. The crude product was purified by chromatography (ethyl acetate/petroleum ether from 0/1 to 1/3) to give intermediate 330 (460 mg, 55% yield) as a yellow oil.

Step 2

Preparation of intermediate 374

A mixture of intermediate 330 (400 mg, 0.70 mmol) and CH₃ONa (380.17 mg, 7.04 mmol) in CH₃OH (15 mL) was refluxed overnight. The mixture was concentrated by
vacuum. The residue was treated with water (60 mL) and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine, dried (Na$_2$SO$_4$), filtered and concentrated under reduced pressure to give intermediate 374 (350 mg, 87% yield) as a brown oil.

Example A89

Step 1

Preparation of intermediate 323

A solution of intermediate 400 (400 mg, 1.54 mmol) in CH$_3$NH$_2$ (40% solution in 20 mL CH$_3$CH$_2$OH) was heated in sealed tube at 120 °C overnight. The mixture was concentrated in vacuum. The crude product was purified by column chromatography (gradient eluent: petroleum ether/ethyl acetate from 20/1 to 5/1) to give intermediate 323 (350 mg, 89% yield) as yellow solid.

Step 2

Preparation of intermediate 324

Intermediate 38 (365 mg, 1.14 mmol) in 9-BBN (0.5 mol/L in THF, 11.4 mL, 5.72 mmol) was refluxed for 1h under N$_2$. The mixture was cooled to room temperature, then K$_3$PO$_4$ (728 mg, 3.43 mmol) in H$_2$O (2 mL) was added, followed by THF (20 mL), intermediate 323 (350 mg, 1.37 mmol) and Pd-I 18 (14.90 mg, 0.023 mmol). The resulting mixture was refluxed overnight. The mixture was diluted with FLO (80 mL) and extracted with ethyl acetate (100 mL). The organic phase was dried with Na$_2$SO$_4$. 
filtered and concentrated in vacuo to give the crude product. The crude product was purified by chromatography (ethyl acetate / petroleum ether from 1/10 to 1/5) to give intermediate 324 (350 mg, 61% yield) as a yellow oil.

Step 3

Preparation of intermediate 350

A solution of intermediate 324 (350 mg, 0.71 mmol) in CH$_3$NH$_2$ (40% solution in 10 ml EtOH) was heated in sealed tube at 120 °C overnight. The mixture was concentrated by vacuum to give the intermediate 350 (350 mg, 97% yield).

Example A90

Preparation of intermediate 349

A solution of intermediate 330 (350 mg, 0.726 mmol) in CH$_3$NH$_2$ (40% solution in 15 ml CH$_3$CH$_2$OH) was heated in sealed tube at 120 °C for overnight. The mixture was concentrated by vacuum to give the intermediate 349 (350 mg, 99.9% yield).

Example A91

Step 1

Preparation of intermediate 414
To the solution of intermediate 1 (1.0 g, 4.9 mmol), 7-hydroxyquinoline-2-methylarboxylate (1.36 g, 4.18 mmol) and PPh₃ (2.58 g, 9.84 mmol) in THF (10 mL) was added DIAD (1.99 g, 9.84 mmol) at 0°C. The mixture was stirred at room temperature overnight under N₂. Water (25 mL) was added and the mixture was extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine (1000 mL). The organic phase was dried over anhydrous Na₂SO₄, filtered and concentrated to give the crude product as an oil. The crude product was purified by column chromatography over silica gel (eluent: petroleum ether/ethyl acetate ratio 1/1). The desired fractions were collected and concentrated to give the intermediate 414 (1.2 g, 31% yield) as a solid.

Step 2

Preparation of intermediate 415

To a solution of intermediate 414 (600 mg, 1.18 mmol) in EtOH (5 mL) was added NaBH₄ (0.132 g, 3.53 mmol) at room temperature under N₂. The reaction mixture was stirred at room temperature for 3 hours. Water (20 ml) was added and the mixture was extracted with CH₂Cl₂ (50 ml x 3). The organic layers were combined, dried (Na₂SO₄), filtered and concentrated to give the desired product as an oil. The crude product was purified by column chromatography over silica gel (eluens: ethyl acetate). The desired fractions were concentrated to give the intermediate 415 (0.27 g, 54.3% yield) as a solid.
Step 3

Preparation of intermediate 416

To a solution of intermediate 415 (0.27 g, 0.56 mmol) in anhydrous DMF (5 mL) was added NaH 60% (33.5 mg, 0.83 mmol). The reaction mixture was stirred at room temperature for 20 min under argon. Then Mel (158 mg, 1.12 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 1 h. The mixture was poured into ice-water (10 mL) and extracted with CH₂Cl₂ (40 mL x 3). The combined extracts were washed with brine, dried over Na₂SO₄, filtered and evaporated to give the product as an oil. The crude product was purified by column (eluens: petroleum ether/ethyl acetate 20/1 to 1/1) to give the intermediate 416 (120 mg, 43% yield) as a solid.

Step 4

Preparation of intermediate 417

A solution of intermediate 416 (120 mg, 0.24 mmol) in NH₃·H₂O (5 mL) and dioxane (5 mL) was stirred in a sealed tube. The mixture was stirred at 90°C overnight. The reaction was concentrated to give a crude product as an oil. The crude product was
purified by precp-TLC (DCM/MeOH: ratio 10/1) to give intermediate 417 (70 mg, 44% yield) as a solid.

Example A92

Step 1

Preparation of intermediate 418

To a solution of Adenosine (75 g, 281 mmol) in acetone (1200 mL) and DMF (400 mL) was added 2,2-dimethoxypropane (35.1 g, 336.8 mmol) and methanesulfonic acid (40.5 g, 421 mmol) under N₂. The reaction mixture was stirred at 60°C for 6 h. The reaction mixture was treated with aqueous NaHCO₃ (pH to 7-8) and then concentrated under reduced pressure. The residue was diluted with H₂O (1200 mL) and extracted with ethyl acetate (1500 mL x 3). The organic layers were combined, washed with brine (500 mL), dried and concentrated under reduced pressure to give intermediate 418 (85 g, 96.3% yield) as a white solid.

Step 2

Preparation of intermediate 419

TBDMS.
To a solution of intermediate 418 (87.8 g, 286 mmol) and imidazole (38.9 g, 571.4 mmol) in DMF (800 mL) was added TBDMSCI (51.67 g, 342.8 mmol) at room temperature under N₂. The reaction was stirred at room temperature for overnight. Water (1000 ml) was added at room temperature, then a white solid was formed and filtered off. The solid was collected and dissolved in ethyl acetate (1500 ml) and washed with brine (500 ml). The organic phase was dried over anhydrous Na₂S0₄, filtered and concentrated to give intermediate 419 (120 g, 99% yield) as a white solid.

**Step 3**

Preparation of intermediate 420

A mixture of intermediate 419 (116.3 g, 275.9 mmol), DMAP (3.37 g, 27.6 mmol) and THF (1500 mL) was stirred at room temperature. Boc₂O (150.5 g, 689.7 mmol) was added dropwise. The mixture was stirred at room temperature for 2 hours. The mixture was evaporated under vacuum. The residue was dissolved in ethyl acetate (1500 ml) and washed with brine (1000 ml). The organic phases were combined, dried over anhydrous Na₂S0₄, filtered and concentrated to give intermediate 420 (170 g, 83% yield) as a white solid.

**Step 4**

Preparation of intermediate 421
To a solution of intermediate 420 (176 g, 238.8 mmol) in THF (2000 mL) was added TBAF (1 v1 in THF, 238.8 mL, 238.8 mmol) dropwise at room temperature under N₂. The reaction mixture was stirred at room temperature for 1 hour. The mixture was poured into water (2000 ml) and extracted with ethyl acetate (2000 ml x 3). The combined organic layers were dried over Na₂SO₄, filtered and evaporated to give the crude product. This residue was purified by flash column chromatograph over silica gel (eluents: petroleum ether/ethyl acetate 10/1 to 1/1). The desired fractions were collected and the solvent was evaporated to give intermediate 421 (85 g, 72.5%) as a yellow oil.

Step 5

Preparation of intermediate 422

To a solution of intermediate 421 (1 g, 1.97 mmol), intermediate 200 (509 mg, 1.97 mmol) and DIAD (1.19 g, 5.91 mmol) in THF (20 mL) was added PPh₃ (1.55 g, 5.91 mmol) at room temperature under N₂. The mixture was stirred at room temperature for 4 hours. Water (40 mL) was added and the mixture was extracted with ethyl acetate (3 x 50 mL). The organic layers were combined, dried over Na₂SO₄, filtered and concentrated under reduced pressure to give the crude product. This residue was purified by flash column chromatograph over silica gel (eluent: petroleum/ethyl acetate from 10/1 to 2/1). The desired fractions were collected and the solvent was evaporated to give the product as a yellow oil. The oil was purified by HPLC column: Phenomenex Gemini C18 250 x 50mm x10 urn; Conditions: A: water (0.05% ammonia hydroxide
v/v), B : MeCN; at the beginning: A (48%) and B (52%), at the end: A (18%) and B (82%); Gradient Time (min) 30; 100% B Hold Time (min) 5; Flow Rate (ml/min) 90) to give intermediate 422 (650 mg, 41% yield) as a white solid.

Example A93

Preparation of intermediate 423

Step 1

A mixture of intermediate 421 (2 g, 3.94 mmol), Et$_3$N (0.797 g, 7.88 mmol) and DMAP (0.096 g, 0.788 mmol) was stirred in DCM (40 ml) at room temperature. TosCl (1.127 g, 5.91 mmol) was added. The reaction mixture was stirred overnight. Then 50 ml of saturated NaHCO$_3$ was added into the mixture and the layers were separated. The aqueous layer was extracted with DCM (50 mL x 2). The combined organic layers were dried with Na$_2$SO$_4$, filtered and concentrated under vacuum to give crude product as an oil. The crude product was purified by column (eluent: petroleum ether/EtOAc ratio 10 to 3/1) to give intermediate 423 (1.25 g, yield 45%) as a white solid.

Step 2

Preparation of intermediate 424
To a solution of intermediate 423 (1.1 g, 1.66 mmol), 3- bromo-7- hydroxy quinoline (0.372 g, 1.66 mmol) and DMF (40 mL) was added Cs₂CO₃ (1.63 g, 4.98 mmol) at room temperature under N₂. The mixture was stirred at 40°C for 6 hours. The reaction mixture was filtered and the filtrate was evaporated. The residue was purified by column over silica gel (eluents: petroleum ether/ethyl acetate: ratio 20/1 to 0/1) to give intermediate 424 (1.1 g, 87% yield) as a yellow oil.

Example A94

Step 1

Preparation of intermediate 425

A mixture of intermediate 165 (300 mg, 0.393 mmol,) and NaOH solution (19.2 ml, 38.5 mmol, 2M) in dioxane (5 ml) was refluxed at 60°C for 48h. The mixture was extracted with ethyl acetate (10ml x 3), the organic layers were combined and evaporated under vacuo to obtain intermediate 425 (300 mg, 42% yield) as a crude product.

Step 2

Preparation of intermediate 426

The solution of intermediate 425 (300 mg, 0.164 mmol) in trifluoroacetic acid (5 ml) was stirred at 50°C for 1h. The mixture was evaporated under vacuo to obtain intermediate 426 (150 mg, 75% yield) as a crude product.
Example A95

Step 1
Preparation of intermediate 427

To a solution of intermediate 157 (4 g, 14.4 mmol) in THF (100 mL) was added LiHMDS (28.8 mL, 1 M). The reaction mixture was stirred at 0 °C for 15 min, then Boc₂O (6.3 g, 28.8 mmol) was added. The reaction mixture was stirred at room temperature for another 30 min. The reaction mixture was quenched with saturated aq. NH₄Cl (50 mL) and extracted with ethyl acetate (50 mL x 2). The organic layers were combined and evaporated under vacuum to obtain intermediate 427 (5 g) as a crude product.

Step 2
Preparation of intermediate 428

To a solution of intermediate 427 (5.0 g, 13.25 mmol) in MeOH (25 mL) and DMF (25 mL) was added Pd(dppf)Cl₂ (0.970 g, 1.32 mmol) and Et₃N (4.02 g, 39.76 mmol). The reaction mixture was degassed under vacuum and purged with CO- gas three times. The reaction was stirred overnight under CO atmosphere at 120 °C. The reaction mixture was diluted with H₂O (100 mL) and was then extracted with ethyl acetate (100 mL x 3). The organic layer was washed with FLO (100 mL) and dried with anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by column chromatography over silica gel (petroleum ether/ethyl acetate: ratio 5/1 to
petroleum ether/ethyl acetate 2/1). The pure fractions were collected and the solvent was evaporated under vacuum to obtain intermediate 428 (4.0 g, 85% yield).

Step 3
Preparation of intermediate 429

To a solution of intermediate 428 (4.0 g, 11.2 mmol) in THF (20 ml) was added LiAlH₄ (0.426 mg, 11.2 mmol). The reaction mixture was stirred at room temperature for 3 hrs. The mixture was quenched with aq. 10% KOH (0.5 mL), filtered and the filtrate was concentrated under reduced pressure to give intermediate 429 (3.4 g, 90% yield) as an oil.

Step 4
Preparation of intermediate 332

To a solution of intermediate 429 (1.3 g, 3.96 mmol) in DCM (20 ml) was added mesyl chloride (0.907 g, 7.92 mmol), DMAP (96.7 mg, 0.792 mmol) and Et₃N (1.2 g, 11.88 mmol). The reaction mixture was stirred overnight at room temperature. The reaction mixture was diluted with DCM (100 ml) and the organic phase was then washed with aq. K₂CO₃ (50 mL x 3). The organic phase was dried with Na₂SO₄ and was then concentrated under reduced pressure to give intermediate 332 as a yellow oil which was used in the next step reaction without further purification.

Example A96
Step 1

Preparation of intermediate 430

\[
\text{intermediate 430}
\]

Br\(_2\) (0.89 mL) was added to the solution of 2-Hydroxyquinoxaline (1.5 g, 10.2 mmol) in HOAc (15 mL) and the reaction was stirred at room temperature for 6 hours. The solid was filtered and washed with ethyl acetate to give intermediate 430 (2.2 g, yield: 95%) as a white solid.

Step 2

Preparation of intermediate 431

\[
\text{intermediate 431}
\]

POCl\(_3\) (48.5 g, 316 mmol) was added to intermediate 430 (2.2 g, 9.7 mmol). The mixture was stirred at 70°C for 2 hours. The mixture was poured slowly into water, aq. NaHCO\(_3\) was added into the mixture until no more gas evolution occurred. The mixture was extracted with EtOAc. The organic phase was filtered and washed with brine. The organic phase was dried over Na\(_2\)SO\(_4\) and concentrated to give intermediate 431 (2 g, yield: 81%)

Step 3

Preparation of intermediate 432
A solution of intermediate 431 (100 mg, 0.41 mmol) in dioxane (4 mL) and N\textsubscript{3}H\textsubscript{2}O (10 mL, 25%) was stirred in a sealed tube at 110°C overnight. The mixture was concentrated to give the crude intermediate 432 (108 mg) as a yellow solid.

Example A97

Step 1

Preparation of intermediate 493

A mixture of intermediate 408 (10 g, 54.88 mmol) in a 9-BBN 0.5 M solution in THF (439 mL, 219.5 mmol) was stirred at 50°C for 1 h under N\textsubscript{2}. The mixture was cooled to room temperature, then K\textsubscript{3}PO\textsubscript{4} (34.9 g, 164.6 mmol) in H\textsubscript{2}O (20 mL) were added, followed by THF (110 mL), intermediate 181 (15.19 g, 54.88 mmol) and Pd-118 (1788 mg, 2.74 mmol). The resulting mixture was stirred at 50°C for 0.5 h. The mixture was concentrated. The residue was dissolved in ethyl acetate (400 mL), washed with water (400 mL) and brine (400 mL). The organic phase was dried over Na\textsubscript{2}SO\textsubscript{4}, filtered and concentrated. The crude product was purified by column chromatography over silica gel (petroleum ether/ethyl acetate 10/1 to petroleum ether/ethyl acetate 1/1). The pure fractions were collected and the solvent was evaporated under vacuum to give intermediate 393 (19 g, 82% yield) as a solid.

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 393 using the appropriate starting materials (Table 50).
Table 50:

<table>
<thead>
<tr>
<th>Intermediates</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>530</td>
<td><img src="image" alt="Structure" /></td>
<td>intermediate 408, intermediate 175</td>
</tr>
</tbody>
</table>

**Step 2**

**Preparation of intermediate 494**

*Intermediate 493* (4 g, 10.46 mmol) and pyridine (2.48 g, 31.39 mmol) were dissolved in DCM (50 ml) under N₂. Triflic anhydride (5.9 g, 20.93 mmol) was added at 0°C and the reaction mixture was stirred for 0.5 hour. Then the reaction mixture was stirred at 25°C for 1 hour. The solvent was removed in vacuo. The residue was purified by column chromatography over silica gel (petroleum ether/ethyl acetate ratio 10/0 to petroleum ether/ethyl acetate ratio 4/1). The pure fractions were collected and the solvent was evaporated under vacuum to give *intermediate 494* (3.5 g, 65% yield) as a white solid.

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of *intermediate 394* using the appropriate starting materials (Table 51).
Step 3

5 Preparation of intermediate 495

7/1-Pyrrolo[2,3-\textit{J}]pyrimidinc, 2,4-dichloro-(1.24 g, 6.61 mmol) and Cs$_2$CO$_3$(3.23 g, 9.91 mmol) were dissolved in DMF (20 ml) under N$_2$. Then intermediate 494 was added. The reaction mixture was stirred at 25°C for 12 hours. To the mixture was added ethyl acetate (50 mL) and water (50 ml). The organic layer was separated, washed with H$_2$O, and dried (Na$_2$SO$_4$). The solvent was removed under reduced pressure. The crude product was purified by column chromatography over silica gel (petroleum ether/ethyl acetate ratio 10/1 to petroleum ether/ethyl acetate ratio 4/1). The pure fractions were collected and the solvent was evaporated under vacuum to give intermediate 495 (900 mg, 37% yield) as a yellow solid.

Below intermediates were prepared by an analogous reaction protocol as was used for the preparation of intermediate 495 using the appropriate starting materials (Table 43).
Table 43:

<table>
<thead>
<tr>
<th>Intermediates</th>
<th>Structure</th>
<th>Starting Materials</th>
</tr>
</thead>
</table>
| 497           | ![Structure 497](image) | Intermediate 494  
7H-Pyrrolo[2,3-d]pyrimidine, 2-chloro |
| 499           | ![Structure 499](image) | Intermediate 494  
7H-Pyrrolo[2,3-J] pyrimidine |
| 519           | ![Structure 519](image) | Intermediate 494  
1H-Pyrrolo[3,2-c]pyridine |
| 521           | ![Structure 521](image) | Intermediate 494  
1H-Pyrrolo[3,2-b]pyridine |
| 523           | ![Structure 523](image) | Intermediate 494  
1/-Pyrrolo[2,3-h]pyridine |
<table>
<thead>
<tr>
<th>intermediates</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>525</td>
<td><img src="image1" alt="Structure 525" /></td>
<td>Intermediate 494 5/1-Pyrrolo[2,3-(\beta)]pyrazine</td>
</tr>
<tr>
<td>532</td>
<td><img src="image2" alt="Structure 532" /></td>
<td>Intermediate 531 2H-Pyrrolo[3,2-r]pyridine</td>
</tr>
<tr>
<td>533</td>
<td><img src="image3" alt="Structure 533" /></td>
<td>Intermediate 531 (1H)-Pyrrolo[3,2-c]pyridine, 4-chloro-</td>
</tr>
</tbody>
</table>

Example A100

A solution of **intermediate 533** (1.75 g, 3.1 mmol), 2,4-dimethoxybenzylamine hydrochloride (2.6 g, 15.6 mmol) and DIPEA(1.2 g, 9.3 mmol) in n-BuOH(5 mL) was stirred at 140°C for 3 days. The reaction mixture was diluted with CH\(_2\)C\(_2\)(30 mL) and washed with H\(_2\)O (20 mL x 2). The organic phase was separated and dried with Na\(_2\)SO\(_4\) and the solvent was removed under vacuo. The crude product was purified by column chromatography over silica gel (petroleum ether/ethyl acetate ratio 10/1 to petroleum ether/ethyl acetate ratio 1/2) to give **intermediate 534** (1.1 g, yield 81%) as a yellow solid.

Example A98
Preparation of **intermediate 526**

![Diagram of intermediate 526 preparation](image)

**Intermediate 525** (900 mg, 1.862 mmol), benzophenone imine (354.3 mg, 1.95 mmol), Pd(OAc)$_2$ (41.8 mg, 0.186 mmol), BINAP (115.9 mg, 0.186 mmol) and Cs$_2$CO$_3$ (1213 mg, 3.72 mmol) were dissolved in toluene (20 ml). The mixture was stirred at 110°C for 14 hours under N$_2$. The catalyst was filtered and the solvent was evaporated. The residue was purified by flash column chromatography over silica gel (gradient eluent: EtOAc/petrol ether from 1/15 to 1/1) The product fractions were collected and the solvent was evaporated to give **intermediate 526** (660 mg, 51% yield) as a yellow solid.

**B. Preparation of the compounds**

Example B1

Preparation of **Compound 1**

![Diagram of Compound 1 preparation](image)

**Intermediate 104** (300 mg, crude, ≈ 0.568 mmol) was dissolved in 5 ml of 4M HCl/MeOH. The mixture was stirred at room temperature for 3 hours. The solvent was concentrated in vacuum. The residue was dissolved in 4 ml of MeOH and the pH was
adjusted to around pH = 9 with a saturated Na₂CO₃ solution. The solvent was purified by preparative-HPLC (HPLC condition: Column: Gemini 150*25 μm*5μm; gradient elution: 0.05 % ammonia/CH₃CN, from 81/19 to 71/29) to give compound 1 (70 mg, 30 % yield) as a white solid.

Example B2

Preparation of Compound 2

![Chemical Structure of Intermediate 105]

Intermediate 105

4M HCl in dioxane (0.7 mL, 2.9 mmol) was added to a stirred solution of intermediate 105 (175.1 mg, crude, ≈ 0.29 mmol) in MeOH (10 mL) at room temperature. The reaction mixture was stirred at room temperature for 18 hours. The reaction was quenched by the addition of 1.5 mL of a 7 N solution of NH₃ in MeOH. The solvents were evaporated. The residue was dissolved in DCM. The precipitate was filtered off. The filtrate was purified over a SiO₂ column, type Grace Reve leris SRC, 12 g, Si 40, on an Armen Spot II Ultimate purification system using DCM and MeOH as eluens in a gradient starting from 100 % DCM and ending with 40 % MeOH and 60 % DCM. The fractions containing the product were combined and the solvents were evaporated yielding 24.5 mg of compound 2.

Example B3

Preparation of Compound 2
Intermediate 89 (12.2 g, -15.751 mmol) was dissolved in HCl/MeOH (220 ml, 4M). The mixture was stirred at room temperature for 3 days. The solid was precipitate out after 18 hours reaction. The reaction mixture was combined with another batch of reaction mixture (1 g of intermediate 89). The resulting solid was filtered through a funnel collected. The residue was triturated with water, and the pH was adjusted to around 8 by progressively adding solid K₂CO₃. The resulting solid was filtered through a buchner funnel rinsed with water (100 mL*5) and collected, which was lyophilized to give the compound 2 (5.95 g, 73 % yield) as a white solid.

Example B4

Preparation of Compound 3

To a solution of intermediate 74 (249 mg, 0.405 mmol) in DCM (3.5 mL) was added TFA (0.8 mL, 10.5 mmol) and the mixture was stirred at rt for 5 days. The mixture was evaporated in vacuo. The residue was solubilized in MeOH (6 mL) and HCl (3M in CPME) (1.5 mL, 4.5 mmol) was added and the mixture was stirred overnight at room temperature. The mixture was quenched with NH₃ in MeOH (7N) and evaporated in vacuo. The residue was taken-up in DCM/MeOH (1/1), filtered off and the filtrate was evaporated in vacuo. The residues were purified by preparative LC (irregular SiOH, 15-40 µιη, 10 g, Merck, dry loading (Celite®),
mobile phase gradient elution: from DCM:MeOH/aq. NH$_3$ (9:1) from 97.5:2.5 to 87.5:12.5) to give **compound 3** as a white solid (156 mg, 73% yield).

**Example B5**

**Preparation of Compound 4**

To a solution of **intermediate 86** (750 mg, -0.71 mmol) in MeOH (40 mL) was added 4M HCl in MeOH (20 mL) at rt. Subsequently the mixture was stirred at 50°C for 12 hours. The solvent was concentrated in vacuo. The residues were dissolved in 10 mL MeOH and the pH was adjusted to around 8 with NaHC0$_3$. The mixture was filtered and the solvent was purified by preparative-HPLC (gradient elution: 0.05% NH$_3$.H$_2$O in MeOH / 0.05% NH$_3$.H$_2$O in H$_2$O). The desired fractions were combined and the solvent was evaporated to give **compound 4** as a white solid (207 mg, 61%).

Below compounds were prepared by an analogous reaction protocol as example B1, B2, B3, B4, B5 or B20 (further in experimental part) using the appropriate starting materials (Table 21). Compounds 55, 57, 57a and 61 were obtained in the E-configuration.

**Table 21:**

<table>
<thead>
<tr>
<th>Compound</th>
<th>Structure</th>
<th>Reaction protocol</th>
<th>Starting material</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td><img src="image" alt="Structure" /></td>
<td><strong>B1</strong></td>
<td><strong>Intermediate 106</strong></td>
</tr>
<tr>
<td>6</td>
<td><img src="image" alt="Structure" /></td>
<td><strong>B1</strong></td>
<td><strong>Intermediate 107</strong></td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Reaction protocol</td>
<td>Starting material</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>7</td>
<td><img src="image1" alt="Compound 7 Structure" /></td>
<td>-bl</td>
<td>Intermediate 108</td>
</tr>
<tr>
<td>8</td>
<td><img src="image2" alt="Compound 8 Structure" /></td>
<td>-bl</td>
<td>Intermediate 109</td>
</tr>
<tr>
<td>9</td>
<td><img src="image3" alt="Compound 9 Structure" /></td>
<td>-b4</td>
<td>Intermediate 110</td>
</tr>
<tr>
<td>10</td>
<td><img src="image4" alt="Compound 10 Structure" /></td>
<td>-bl</td>
<td>Intermediate 111</td>
</tr>
<tr>
<td>11</td>
<td><img src="image5" alt="Compound 11 Structure" /></td>
<td>-bl</td>
<td>Intermediate 112</td>
</tr>
<tr>
<td>12</td>
<td><img src="image6" alt="Compound 12 Structure" /></td>
<td>-bl</td>
<td>Intermediate 113</td>
</tr>
<tr>
<td>13</td>
<td><img src="image7" alt="Compound 13 Structure" /></td>
<td>-bl</td>
<td>Intermediate 114</td>
</tr>
<tr>
<td>14</td>
<td><img src="image8" alt="Compound 14 Structure" /></td>
<td>-bl</td>
<td>Intermediate 115</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Reaction protocol</td>
<td>Starting material</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>15</td>
<td><img src="structure15.png" alt="Structure" /></td>
<td>Bl</td>
<td>Intermediate 116</td>
</tr>
<tr>
<td>16</td>
<td><img src="structure16.png" alt="Structure" /></td>
<td>B2</td>
<td>Intermediate 117</td>
</tr>
<tr>
<td>17</td>
<td><img src="structure17.png" alt="Structure" /></td>
<td>Bl</td>
<td>Intermediate 118</td>
</tr>
<tr>
<td>18</td>
<td><img src="structure18.png" alt="Structure" /></td>
<td>Bl</td>
<td>Intermediate 154</td>
</tr>
<tr>
<td>19</td>
<td><img src="structure19.png" alt="Structure" /></td>
<td>Bl</td>
<td>Intermediate 155</td>
</tr>
<tr>
<td>20</td>
<td><img src="structure20.png" alt="Structure" /></td>
<td>Bl</td>
<td>Intermediate 119</td>
</tr>
<tr>
<td>21</td>
<td><img src="structure21.png" alt="Structure" /></td>
<td>Bl</td>
<td>Intermediate 120</td>
</tr>
<tr>
<td>22</td>
<td><img src="structure22.png" alt="Structure" /></td>
<td>B2</td>
<td>Intermediate 121</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Reaction protocol</td>
<td>Starting material</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>23</td>
<td><img src="image1" alt="Structure" /></td>
<td>B2</td>
<td>Intermediate 154a</td>
</tr>
<tr>
<td>24</td>
<td><img src="image2" alt="Structure" /></td>
<td>B2</td>
<td>Intermediate 80</td>
</tr>
<tr>
<td>25</td>
<td><img src="image3" alt="Structure" /></td>
<td>B2</td>
<td>Intermediate 122</td>
</tr>
<tr>
<td>26</td>
<td><img src="image4" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 79</td>
</tr>
<tr>
<td>27</td>
<td><img src="image5" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 123</td>
</tr>
<tr>
<td>28</td>
<td><img src="image6" alt="Structure" /></td>
<td>B2</td>
<td>Intermediate 144</td>
</tr>
<tr>
<td>29</td>
<td><img src="image7" alt="Structure" /></td>
<td>B2</td>
<td>Intermediate 144a</td>
</tr>
<tr>
<td>30</td>
<td><img src="image8" alt="Structure" /></td>
<td>B2</td>
<td>Intermediate 145</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Reaction protocol</td>
<td>Starting material</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>31</td>
<td><img src="image1" alt="Structure 31" /></td>
<td>B2</td>
<td>Intermediate 145a</td>
</tr>
<tr>
<td>32</td>
<td><img src="image2" alt="Structure 32" /></td>
<td>B4</td>
<td>Intermediate 73</td>
</tr>
<tr>
<td>33</td>
<td><img src="image3" alt="Structure 33" /></td>
<td>B2</td>
<td>Intermediate 124</td>
</tr>
<tr>
<td>34</td>
<td><img src="image4" alt="Structure 34" /></td>
<td>B2</td>
<td>Intermediate 54</td>
</tr>
<tr>
<td>35</td>
<td><img src="image5" alt="Structure 35" /></td>
<td>B1</td>
<td>Intermediate 84</td>
</tr>
<tr>
<td>36</td>
<td><img src="image6" alt="Structure 36" /></td>
<td>B2</td>
<td>Intermediate 125</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Reaction protocol</td>
<td>Starting material</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>37</td>
<td><img src="image1" alt="Structure 37" /></td>
<td>B5</td>
<td>Intermediate 81</td>
</tr>
<tr>
<td>38</td>
<td><img src="image2" alt="Structure 38" /></td>
<td>B5</td>
<td>Intermediate 82</td>
</tr>
<tr>
<td>39</td>
<td><img src="image3" alt="Structure 39" /></td>
<td>B4</td>
<td>Intermediate 75</td>
</tr>
<tr>
<td>40</td>
<td><img src="image4" alt="Structure 40" /></td>
<td>B4</td>
<td>Intermediate 76</td>
</tr>
<tr>
<td>41</td>
<td><img src="image5" alt="Structure 41" /></td>
<td>B5</td>
<td>Intermediate 83</td>
</tr>
<tr>
<td>42</td>
<td><img src="image6" alt="Structure 42" /></td>
<td>B5</td>
<td>Intermediate 87</td>
</tr>
<tr>
<td>43</td>
<td><img src="image7" alt="Structure 43" /></td>
<td>B5</td>
<td>Intermediate 88</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Reaction protocol</td>
<td>Starting material</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>44</td>
<td><img src="image1.png" alt="Structure 44" /></td>
<td>B3</td>
<td>Intermediate 126</td>
</tr>
<tr>
<td>45</td>
<td><img src="image2.png" alt="Structure 45" /></td>
<td>B2</td>
<td>Intermediate 153</td>
</tr>
<tr>
<td>46</td>
<td><img src="image3.png" alt="Structure 46" /></td>
<td>B1</td>
<td>Intermediate 127</td>
</tr>
<tr>
<td>47</td>
<td><img src="image4.png" alt="Structure 47" /></td>
<td>B1</td>
<td>Intermediate 128</td>
</tr>
<tr>
<td>48</td>
<td><img src="image5.png" alt="Structure 48" /></td>
<td>B1</td>
<td>Intermediate 129</td>
</tr>
<tr>
<td>49</td>
<td><img src="image6.png" alt="Structure 49" /></td>
<td>B1</td>
<td>Intermediate 130</td>
</tr>
<tr>
<td>50</td>
<td><img src="image7.png" alt="Structure 50" /></td>
<td>B1</td>
<td>Intermediate 131</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Reaction protocol</td>
<td>Starting material</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>51</td>
<td><img src="image1.png" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 132</td>
</tr>
<tr>
<td>52</td>
<td><img src="image2.png" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 133</td>
</tr>
<tr>
<td>53</td>
<td><img src="image3.png" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 134</td>
</tr>
<tr>
<td>54</td>
<td><img src="image4.png" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 135</td>
</tr>
<tr>
<td>54a</td>
<td><img src="image5.png" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 135</td>
</tr>
<tr>
<td></td>
<td>.2HCl</td>
<td></td>
<td></td>
</tr>
<tr>
<td>55</td>
<td><img src="image6.png" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 137</td>
</tr>
<tr>
<td>56</td>
<td><img src="image7.png" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 146</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Reaction protocol</td>
<td>Starting material</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>57</td>
<td><img src="image1" alt="Structure 57" /></td>
<td>B1</td>
<td>Intermediate 138</td>
</tr>
<tr>
<td>57a</td>
<td><img src="image2" alt="Structure 57a" /></td>
<td>B1</td>
<td>Intermediate 136</td>
</tr>
<tr>
<td>58</td>
<td><img src="image3" alt="Structure 58" /></td>
<td>B1</td>
<td>Intermediate 147</td>
</tr>
<tr>
<td>59</td>
<td><img src="image4" alt="Structure 59" /></td>
<td>B1</td>
<td>Intermediate 148</td>
</tr>
<tr>
<td>60</td>
<td><img src="image5" alt="Structure 60" /></td>
<td>B1</td>
<td>Intermediate 149</td>
</tr>
<tr>
<td>61</td>
<td><img src="image6" alt="Structure 61" /></td>
<td>B1</td>
<td>Intermediate 150</td>
</tr>
<tr>
<td>62</td>
<td><img src="image7" alt="Structure 62" /></td>
<td>B1</td>
<td>Intermediate 150</td>
</tr>
<tr>
<td>63</td>
<td><img src="image8" alt="Structure 63" /></td>
<td>B2</td>
<td>Intermediate 139</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Reaction protocol</td>
<td>Starting material</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>64</td>
<td><img src="image1" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 141</td>
</tr>
<tr>
<td>65</td>
<td><img src="image2" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 142</td>
</tr>
<tr>
<td>66</td>
<td><img src="image3" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 143</td>
</tr>
<tr>
<td>82</td>
<td><img src="image4" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 188</td>
</tr>
<tr>
<td>83</td>
<td><img src="image5" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 192</td>
</tr>
<tr>
<td>84</td>
<td><img src="image6" alt="Structure" /></td>
<td>B20</td>
<td>Intermediate 193</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Reaction protocol</td>
<td>Starting material</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>85</td>
<td><img src="image" alt="Structure 85" /></td>
<td>B1</td>
<td>Intermediate 194</td>
</tr>
<tr>
<td>86</td>
<td><img src="image" alt="Structure 86" /></td>
<td>B2</td>
<td>Intermediate 96</td>
</tr>
<tr>
<td>87</td>
<td><img src="image" alt="Structure 87" /></td>
<td>B2</td>
<td>Intermediate 195</td>
</tr>
<tr>
<td>88</td>
<td><img src="image" alt="Structure 88" /></td>
<td>B2</td>
<td>Intermediate 196</td>
</tr>
<tr>
<td>90</td>
<td><img src="image" alt="Structure 90" /></td>
<td>B1</td>
<td>Intermediate 198</td>
</tr>
<tr>
<td>91</td>
<td><img src="image" alt="Structure 91" /></td>
<td>B5</td>
<td>Intermediate 199</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Reaction protocol</td>
<td>Starting material</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>92</td>
<td><img src="image1" alt="Structure 92" /></td>
<td>B3</td>
<td>Intermediate 201</td>
</tr>
<tr>
<td>94</td>
<td><img src="image2" alt="Structure 94" /></td>
<td>B3</td>
<td>Intermediate 206</td>
</tr>
<tr>
<td>95</td>
<td><img src="image3" alt="Structure 95" /></td>
<td>B1</td>
<td>Intermediate 209</td>
</tr>
<tr>
<td>96</td>
<td><img src="image4" alt="Structure 96" /></td>
<td>B3</td>
<td>Intermediate 211</td>
</tr>
<tr>
<td>97</td>
<td><img src="image5" alt="Structure 97" /></td>
<td>B3</td>
<td>Intermediate 213</td>
</tr>
<tr>
<td>98</td>
<td><img src="image6" alt="Structure 98" /></td>
<td>B2</td>
<td>Intermediate 214</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Reaction protocol</td>
<td>Starting material</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>99</td>
<td><img src="image" alt="Structure 99" /></td>
<td>B3</td>
<td>Intermediate 215</td>
</tr>
<tr>
<td>100</td>
<td><img src="image" alt="Structure 100" /></td>
<td>B3</td>
<td>Intermediate 217</td>
</tr>
<tr>
<td>101</td>
<td><img src="image" alt="Structure 101" /></td>
<td>B3</td>
<td>Intermediate 219</td>
</tr>
<tr>
<td>102</td>
<td><img src="image" alt="Structure 102" /></td>
<td>B3</td>
<td>Intermediate 221</td>
</tr>
<tr>
<td>103</td>
<td><img src="image" alt="Structure 103" /></td>
<td>B1</td>
<td>Intermediate 226</td>
</tr>
<tr>
<td>104</td>
<td><img src="image" alt="Structure 104" /></td>
<td>B3</td>
<td>Intermediate 227</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Reaction protocol</td>
<td>Starting material</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>105</td>
<td><img src="image" alt="Structure of 105" /></td>
<td>B3</td>
<td>Intermediate 228</td>
</tr>
<tr>
<td>106</td>
<td><img src="image" alt="Structure of 106" /></td>
<td>B3</td>
<td>Intermediate 230</td>
</tr>
<tr>
<td>107</td>
<td><img src="image" alt="Structure of 107" /></td>
<td>B3</td>
<td>Intermediate 232</td>
</tr>
<tr>
<td>108</td>
<td><img src="image" alt="Structure of 108" /></td>
<td>B20</td>
<td>Intermediate 234</td>
</tr>
<tr>
<td>109</td>
<td><img src="image" alt="Structure of 109" /></td>
<td>B3</td>
<td>Intermediate 236</td>
</tr>
<tr>
<td>110</td>
<td><img src="image" alt="Structure of 110" /></td>
<td>B1</td>
<td>Intermediate 237</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Reaction protocol</td>
<td>Starting material</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>111</td>
<td><img src="image1" alt="Structure" /></td>
<td>B20</td>
<td>Intermediate 239</td>
</tr>
<tr>
<td>112</td>
<td><img src="image2" alt="Structure" /></td>
<td>B3</td>
<td>Intermediate 241</td>
</tr>
<tr>
<td>113</td>
<td><img src="image3" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 243</td>
</tr>
<tr>
<td>114</td>
<td><img src="image4" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 245</td>
</tr>
<tr>
<td>115</td>
<td><img src="image5" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 159</td>
</tr>
<tr>
<td>120</td>
<td><img src="image6" alt="Structure" /></td>
<td>B3</td>
<td>Intermediate 247</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Reaction protocol</td>
<td>Starting material</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>121</td>
<td><img src="image" alt="Structure 121" /></td>
<td>B1</td>
<td>Intermediate 248</td>
</tr>
<tr>
<td>122</td>
<td><img src="image" alt="Structure 122" /></td>
<td>B1</td>
<td>Intermediate 250</td>
</tr>
<tr>
<td>123</td>
<td><img src="image" alt="Structure 123" /></td>
<td>B1</td>
<td>Intermediate 252</td>
</tr>
<tr>
<td>124</td>
<td><img src="image" alt="Structure 124" /></td>
<td>B1</td>
<td>Intermediate 255</td>
</tr>
<tr>
<td>125</td>
<td><img src="image" alt="Structure 125" /></td>
<td>B1</td>
<td>Intermediate 257</td>
</tr>
<tr>
<td>126</td>
<td><img src="image" alt="Structure 126" /></td>
<td>B1</td>
<td>Intermediate 258</td>
</tr>
<tr>
<td>127</td>
<td><img src="image" alt="Structure 127" /></td>
<td>B1</td>
<td>Intermediate 254</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Reaction protocol</td>
<td>Starting material</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>128</td>
<td><img src="image1.png" alt="Structure 128" /></td>
<td>B1</td>
<td>Intermediate 259</td>
</tr>
<tr>
<td>129</td>
<td><img src="image2.png" alt="Structure 129" /></td>
<td>B20</td>
<td>Intermediate 261</td>
</tr>
<tr>
<td>130</td>
<td><img src="image3.png" alt="Structure 130" /></td>
<td>B2</td>
<td>Intermediate 262</td>
</tr>
<tr>
<td>131</td>
<td><img src="image4.png" alt="Structure 131" /></td>
<td>B2</td>
<td>Intermediate 264</td>
</tr>
<tr>
<td>132</td>
<td><img src="image5.png" alt="Structure 132" /></td>
<td>B2</td>
<td>Intermediate 265</td>
</tr>
<tr>
<td>133</td>
<td><img src="image6.png" alt="Structure 133" /></td>
<td>B1</td>
<td>Intermediate 266</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Reaction protocol</td>
<td>Starting material</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>134</td>
<td><img src="image1.png" alt="Structure 134" /></td>
<td>B1</td>
<td>Intermediate 267</td>
</tr>
<tr>
<td>135</td>
<td><img src="image2.png" alt="Structure 135" /></td>
<td>B1</td>
<td>Intermediate 269</td>
</tr>
<tr>
<td>136</td>
<td><img src="image3.png" alt="Structure 136" /></td>
<td>B2</td>
<td>Intermediate 270</td>
</tr>
<tr>
<td>137</td>
<td><img src="image4.png" alt="Structure 137" /></td>
<td>B2</td>
<td>Intermediate 271</td>
</tr>
<tr>
<td>138</td>
<td><img src="image5.png" alt="Structure 138" /></td>
<td>B2</td>
<td>Intermediate 272</td>
</tr>
<tr>
<td>139</td>
<td><img src="image6.png" alt="Structure 139" /></td>
<td>B1</td>
<td>Intermediate 273</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Reaction protocol</td>
<td>Starting material</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>140</td>
<td><img src="image1.png" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 275</td>
</tr>
<tr>
<td>141</td>
<td><img src="image2.png" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 278</td>
</tr>
<tr>
<td>142</td>
<td><img src="image3.png" alt="Structure" /></td>
<td>B3</td>
<td>Intermediate 279</td>
</tr>
<tr>
<td>143</td>
<td><img src="image4.png" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 281</td>
</tr>
<tr>
<td>144</td>
<td><img src="image5.png" alt="Structure" /></td>
<td>B20</td>
<td>Intermediate 286</td>
</tr>
<tr>
<td>145</td>
<td><img src="image6.png" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 289</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Reaction protocol</td>
<td>Starting material</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>146</td>
<td><img src="image" alt="Structure 146" /></td>
<td>B1</td>
<td>Intermediate 292</td>
</tr>
<tr>
<td>147</td>
<td><img src="image" alt="Structure 147" /></td>
<td>B1</td>
<td>Intermediate 295</td>
</tr>
<tr>
<td>148</td>
<td><img src="image" alt="Structure 148" /></td>
<td>B1</td>
<td>Intermediate 298</td>
</tr>
<tr>
<td>149</td>
<td><img src="image" alt="Structure 149" /></td>
<td>B2</td>
<td>Intermediate 301</td>
</tr>
<tr>
<td>150</td>
<td><img src="image" alt="Structure 150" /></td>
<td>B2</td>
<td>Intermediate 304</td>
</tr>
<tr>
<td>151</td>
<td><img src="image" alt="Structure 151" /></td>
<td>B1</td>
<td>Intermediate 307</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Reaction protocol</td>
<td>Starting material</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>152</td>
<td><img src="image" alt="Structure 152" /></td>
<td>B1</td>
<td>Intermediate 310</td>
</tr>
<tr>
<td>153</td>
<td><img src="image" alt="Structure 153" /></td>
<td>B1</td>
<td>Intermediate 313</td>
</tr>
<tr>
<td>154</td>
<td><img src="image" alt="Structure 154" /></td>
<td>B1</td>
<td>Intermediate 316</td>
</tr>
<tr>
<td>155</td>
<td><img src="image" alt="Structure 155" /></td>
<td>B1</td>
<td>Intermediate 319</td>
</tr>
<tr>
<td>156</td>
<td><img src="image" alt="Structure 156" /></td>
<td>B1</td>
<td>Intermediate 322</td>
</tr>
<tr>
<td>157</td>
<td><img src="image" alt="Structure 157" /></td>
<td>B1</td>
<td>Intermediate 325</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Reaction protocol</td>
<td>Starting material</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>158</td>
<td><img src="image" alt="Structure 158" /></td>
<td>B1</td>
<td>Intermediate 328</td>
</tr>
<tr>
<td>159</td>
<td><img src="image" alt="Structure 159" /></td>
<td>B1</td>
<td>Intermediate 331</td>
</tr>
<tr>
<td>160</td>
<td><img src="image" alt="Structure 160" /></td>
<td>B1</td>
<td>Intermediate 334</td>
</tr>
<tr>
<td>161</td>
<td><img src="image" alt="Structure 161" /></td>
<td>B1</td>
<td>Intermediate 337</td>
</tr>
<tr>
<td>222</td>
<td><img src="image" alt="Structure 222" /></td>
<td>B1</td>
<td>Intermediate 504</td>
</tr>
<tr>
<td>223</td>
<td><img src="image" alt="Structure 223" /></td>
<td>B1</td>
<td>Intermediate 462</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Reaction protocol</td>
<td>Starting material</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>224</td>
<td><img src="image1" alt="Structure 224" /></td>
<td>B1</td>
<td>Intermediate 464</td>
</tr>
<tr>
<td>236</td>
<td><img src="image2" alt="Structure 236" /></td>
<td>B1</td>
<td>Intermediate 484</td>
</tr>
<tr>
<td>240</td>
<td><img src="image3" alt="Structure 240" /></td>
<td>B1</td>
<td>Intermediate 496</td>
</tr>
<tr>
<td>241</td>
<td><img src="image4" alt="Structure 241" /></td>
<td>B1</td>
<td>Intermediate 498</td>
</tr>
<tr>
<td>242</td>
<td><img src="image5" alt="Structure 242" /></td>
<td>B1</td>
<td>Intermediate 500</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Reaction protocol</td>
<td>Starting material</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>-------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>243</td>
<td><img src="image" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 501</td>
</tr>
<tr>
<td>244</td>
<td><img src="image" alt="Structure" /></td>
<td>B20</td>
<td>Intermediate 514</td>
</tr>
<tr>
<td>245</td>
<td><img src="image" alt="Structure" /></td>
<td>B2</td>
<td>Intermediate 516</td>
</tr>
<tr>
<td>246</td>
<td><img src="image" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 518</td>
</tr>
<tr>
<td>247</td>
<td><img src="image" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 520</td>
</tr>
<tr>
<td>248</td>
<td><img src="image" alt="Structure" /></td>
<td>B1</td>
<td>Intermediate 522</td>
</tr>
</tbody>
</table>
Example B6

Preparation of *Compound 67 and compound 68*

*Intermediate 140* (210 mg, crude, -0.399 mmol) was dissolved in 5 ml of HCl/MeOH. The mixture was stirred at room temperature for 7 hours. The reaction was quenched by addition of NH₃/MeOH to adjust the pH to around 8 at 0°C. The resulting solid was then removed by filtration and washed with CH₂Cl₂ (10 ml) and the combined organic filtrate was concentrated under reduced pressure to give the crude product. The residue was purified by preparative-HPLC (HPLC condition: Columns: Phenomenex Gemini...
150*25mm*10um; mobile phase gradient elution with 21% Water in ACN;) to yield compound 67 (40 mg) and compound 68 (52 mg) as a white solid.

Example B7

![Diagram of compound 67 and 68]

The reaction mixture of intermediate 85 (150 mg, -0.233 mmol) in 5 mL of mixed solvent AcOH, water and THF with ration as 13:7:3 was stirred overnight at 60°C. Then the mixture was stirred at 80°C for 1 days. The solvent was concentrated in vacuum. The residue was dissolved in 4 mL of MeOH and the pH was adjusted to around 9 with Na₂CO₃ solid. The solvent was purified by preparative-HPLC (HPLC condition: Columns: Gemini 150*25mm*5µM; gradient elution with water (0.05% ammonia hydroxide v/v):ACN from 97:3 to 67:33) to give compound 69 as a white solid. (13 mg, 14% yield).

Example B8

![Diagram of compound 152 and 70]

Intermediate 152 (425 mg, 0.927 mmol) was dissolved in the mixed solution of AcOH (22 mL), THF (5 mL) and H₂O (12 mL). The mixture was stirred at 50°C for 12 hours. The solvent was concentrated in vacuum. The crude product was purified by preparative-HPLC (gradient elution: 0.05% NH₃·H₂O in MeOH / 0.05% NH₃·H₂O in H₂O). The combined solvent was evaporated to give the desired compound 70 as a solid (69.3 mg, 18% yield).
Example B9

To a solution of intermediate 59 (187 mg, -0.18 mmol) in 1,4-dioxane (5 mL) was added 4M HCl in dioxane (0.46 mL, 1.8 mmol). The reaction mixture was stirred at room temperature for 18 hours. The reaction was quenched by the addition of 1.5 mL 7N solution of NH₃ in MeOH. The solvents were evaporated. The residue was dissolved in dichloromethane with methanol (q.s.) and then purified over a SiO₂ column, type Grace Reveferis SRC, 12 g, Si 40, on a Armen Spot II Ultimate purification system using dichloromethane and methanol as eluens in a gradient starting from 100% DCM for 5 column volumes and ending with 40% MeOH and 60% DCM over 25 column volumes. The fractions containing product were combined and the solvents were evaporated yielding 62 mg crude product mixture. The crude product mixture was purified by Prep HPLC (Stationary phase: RP XBridge Prep C18 OBD-IQµη, 30x150 mm, Mobile phase: 0.25% NH₄HCO₃ solution in water, CH₃CN), yielding compound 71 (5.5 mg, 6%> yield).

Example B10

Preparation of Compound 1a

To a solution of intermediate 100 (9.26 g, -17.5 mmol) in 1,4-dioxane (300 mL) was added 4M HCl in 1,4-dioxane (43.8 mL, 175 mmol). The reaction mixture was stirred
at room temperature for 4 hours. The reaction mixture was poured out into a beaker with DIPE (1 L). The suspension was stirred for 20 minutes and then the solvents were decanted off. The remaining precipitate was recrystallized in EtOH. The precipitate was filtered off, washed with DIPE and then dried in vacuo at 50 °C yielding compound 1a as salt with 2 equivalent of HCl (8.33 g, quantitative yield).

Example B11

Preparation of Compound 72 (via intermediate 156)

Step a:

Isobutyric anhydride (2.36 mL, 14.2 mmol) was added to a stirred solution of compound 22 (688.3 mg, 1.418 mmol) in pyridine (25 mL, 310.361 mmol) at rt. After addition the reaction mixture was stirred at 50 °C for 18 hours. The solvents were evaporated. The residue was co-evaporated with toluene. The residue was dissolved in DCM and purified over a Si0₂ column, type Grace Reveleris SRC, 40 g, Si 40, on a Armen Spot II Ultimate purification system using DCM and MeOH as eluens in a gradient starting from 100 % DCM for 5 column volumes and ending with 40 % MeOH and 60 % DCM over 30 column volumes. The desired fractions were combined and the solvents were evaporated yielding 0.94 g of intermediate 156.

Step b:

A solution of intermediate 156 (0.94 g, 1.372 mmol) and SOCl₂ (99.493 µE, 1.372 mmol) in MeOH (20 mL, 0.791 g/mL, 493.725 mmol) was stirred and heated at 110°C
using microwave irradiation for 5 hours. The solvents were evaporated. The residue
was dissolved in DCM and purified over a SiO₂ column, type Grace Reveleris SRC, 12
g. Si 40, on a Armen Spot II Ultimate purification system using DCM and MeOH as
euens in a gradient starting from 100 % DCM for 10 column volumes and ending with
20 % MeOH and 80% DCM over 30 column volumes. The fractions containing product
were combined and the solvents were evaporated yielding compound 72 (HCl) (0.66 g,
74 % yield).

Below compound was prepared by an analogous reaction protocol of example B11
using the appropriate starting materials (Table 22).

Table 22:

<table>
<thead>
<tr>
<th>Compound</th>
<th>Structure</th>
<th>Starting material</th>
</tr>
</thead>
<tbody>
<tr>
<td>73</td>
<td><img src="image" alt="Compound 73 Structure" /></td>
<td>Compound 2</td>
</tr>
<tr>
<td>89</td>
<td><img src="image" alt="Compound 89 Structure" /></td>
<td>Compound 1</td>
</tr>
</tbody>
</table>

Example B12

Preparation of Compound 74
To a solution of intermediate 160 (3.45g, 6.9 mmol) in MeOH (10mL) was added HCl/MeOH (4N, 10mL), and the mixture was stirred at room temperature for 1 hour. The mixture was lyophilized to give crude Compound 74 fraction 1 which was purified by prep-HPLC (Column: Phenomenex Synergi Max-RP 250*80mm 10 μm, Condition: water (0.05% ammonia hydroxide v/v)-ACN, Start B : 30%, End B : 60, Gradient Time(min): 22, FlowRate(ml/min): 120). The desired fractions were collected and lyophilized to give crude Compound 74 fraction 2 which was further purified by prep-HPLC (Column Phenomenex Gemini 150*25μm*10μm, Condition: gradient water (0.05% ammonia hydroxide v/v)-ACN. The desired fractions were collected and lyophilized to give Compound 74 (1383 mg, yield: 43.1%) as solid.

Salt forms of Compound 74 were prepared according to state of the art procedures, known to the skilled person (Table 44).

Table 44:

<table>
<thead>
<tr>
<th>Compound</th>
<th>Structure</th>
<th>Starting material</th>
</tr>
</thead>
<tbody>
<tr>
<td>116</td>
<td><img src="image1" alt="Structure 116" /></td>
<td>Compound 74 .HCl</td>
</tr>
<tr>
<td>117</td>
<td><img src="image2" alt="Structure 117" /></td>
<td>Compound 74 .HCOOH</td>
</tr>
</tbody>
</table>
A solution of intermediate 163 (680 mg, 1.04 mmol) in MeOH (q.s.) was dissolved in HCl/MeOH (4M, 15mL), stirred at room temperature for 2 hours. The mixture was basified with NH₃.H₂O to pH > 7. The solution was washed with H₂O (100 mL), extracted with ethyl acetate (150 mL x3). The combined organic layers were dried (Na₂SO₄), filtered and concentrated in vacuo to give the crude product as brown solid. The crude product was purified by prep-HPLC (Column: Waters Xbridge Prep OBD C18 150x30 mm, 5µm; Condition: gradient water (0.05% ammonia hydroxide v/v)-MeOH). The desired fractions were collected and lyophilized to give Compound 75 (129.8 mg, yield: 26.4%) as white solid.
Example B14

Preparation of Compound 76

The mixture of intermediate 767 (250 mg) and K₂CO₃ (185.3 mg, 1.34 mmol) in MeOH (3 ml) was stirred at 60°C for 1 h. The mixture was filtered and evaporated under vacuo to obtain the crude product. This was purified by preparative-HPLC (Column: Waters Xbridge Prep OBD C18 150x30 mm, 5 μη, Condition: gradient water (0.05% ammonia hydroxide v/v)-MeOH). The desired fractions were collected and the solvent was evaporated to give Compound 76 as a white solid (82.2 mg, 45.3 % yield).

Example B15

Preparation of Compound 77

The mixture of intermediate 169 (120 mg, -0.185 mmol) and K₂CO₃ (76.40 mg, 0.554 mmol) in methanol (3 ml) was stirred at 60°C for 1 h. The mixture was filtered and evaporated under vacuo to obtain a crude product. The crude product was purified by prep-HPLC (Column: Waters Xbridge Prep OBD C18 150x30 mm, 5 μη, Condition: gradient water (0.05% ammonia hydroxide v/v)-MeOH). The desired fractions were collected and the solvent was evaporated to give Compound 77 as a white solid (21.4 mg, 29.4 % yield).

Below Compounds were prepared by an analogous reaction protocol as was used for the preparation of compound 77 using the appropriate starting materials (Table 48).
Example B16

Preparation of Compound 78

The mixture of intermediate 171 (160 mg, -0.273 mmol) and K$_2$CO$_3$ (113.073 mg, 0.819 mmol) in methanol (3 ml) was stirred at 50°C for 1h. The mixture was filtered and evaporated under vacuo to obtain the crude product. This was purified by prep-HPLC (Column: Waters Xbridge Prep OBD C18 150x30 mm, 5 µm, Condition: gradient water (0.05% ammonia hydroxide v/v)-MeOH). The desired fractions were collected and the solvent was evaporated to give Compound 78 (87.2 mg, 75.3 % yield) as a white solid.

Example B17

Preparation of Compound 79
The mixture of intermediate 173 (250 mg, -0.241 mmol) and K$_2$CO$_3$ (99.6 mg, 0.72 mmol) in methanol (3 ml) was stirred at 50°C for 1h. The mixture was filtered and evaporated under vacuo to obtain the crude product. This was purified by preparative-HPLC (Column: Waters Xbridge Prep OBD C18 150x30 mm, 5 μm. Condition: gradient water (0.05% ammonia hydroxide v/v)-MeOH). The desired fractions were collected and the solvent was evaporated to give Compound 79 (96.1 mg, 94.5 % yield) as a white solid.

Below compound was prepared by an analogous reaction protocol of Compound 79 using the appropriate starting materials (Table 45).

<table>
<thead>
<tr>
<th>Compound</th>
<th>Structure</th>
<th>Starting material</th>
</tr>
</thead>
<tbody>
<tr>
<td>228</td>
<td><img src="structure228.png" alt="Structure" /></td>
<td>Intermediate 472</td>
</tr>
</tbody>
</table>

Example B18

Preparation of Compound 80
The mixture of intermediate 179 (350 mg) and K$_2$CO$_3$ (102 mg, 0.74 mmol) in methanol (3 mL) was stirred at 60°C for 1h. The mixture was filtered and evaporated under vacuo to obtain a crude product. The crude product was purified by prep-HPLC (Column: Waters Xbridge Prep OBD C18 150x30 mm, 5 µιη, Condition: gradient water (0.05% ammonia hydroxide v/v)-ACN). The desired fractions were collected and the solvent was evaporated to give Compound 80 (113.3 mg, 94.9 % yield) as a white solid.

Alternative Preparation of Compound 80

Intermediate 529 (21 g, 40.12 mmol) was dissolved in HCl/MeOH (250 mL). The mixture was stirred at room temperature for 2 hours. The solvent was concentrated in vacuum. Then H$_2$O (100 mL) was added. The pH was adjusted to around 9 by progressively adding aq. Na$_2$CO$_3$ (800 mL). The precipitate was filtered off to give crude product. The crude product was recrystallized from EtOH (250 mL) to give 11.4 g of Compound 80 as a white solid. The filtrate of the recrystallization was concentrated in vacuum. This residue was added to EtOH (50 mL) and refluxed for 3 hours. The reaction was cooled and the precipitate was filtered off to give product 2.2 g of Compound 80. The filtrate of the second recrystallization was concentrated in vacuum to give another 2.2 g of Compound 80.

Example B19

Preparation of Compound 81
The mixture of intermediate 184 (800 mg, 1.67 mmol) and HCl in methanol (15 ml) was stirred at r.t. for 2h. The mixture was neutralized with NH₄OH. The mixture was extracted by EtOAc (20mL x 3). The organic phase was evaporated and the crude product was purified by Prep-HPLC (gradient: water (10 mM NH₄HC0₃)-ACN). The combined solvent was evaporated to give Compound 81 (280 mg, 38% yield) as a white solid.

Example B20

Preparation of Compound 84

Intermediates 193 (110 mg, 0.23 mmol) in EtOH (3.5 ml) was stirred at r.t. HCl 1N (2.3 ml, 2.3 mmol) was added dropwise. Stirring was continued for 72h. Then the reaction mixture was treated with NH₃ 28% in water (0.235 ml, 3.5 mmol). The product started to precipitate. The precipitate was filtered off and was washed with EtOH / H₂O ratio 9 to 1 and dried yielding compound 84 (90 mg, 89% yield).

Example B21

Preparation of compound 162

A solution of intermediate 338 (520 mg, 0.96 mmol) in HCl/MeOH (4N, 7mL) and MeOH (2 ml.) was stirred at room temperature for 1h. The reaction was concentrated. The residue was dissolved in H₂O (3mL) and basified by aq.NH₃·H₂O. A precipitate was formed and collected. The solid was purified by prep-HPLC: conditions A: (water (0.05% ammonia hydroxide v/v)-B: ACN, Begin B 30% End B 60%). The desired fractions were collected and lyophilized to give the product (250mg). The product was
further purified by prep-SFC (Column OD (250 mm x 30mm, 10µm); Conditions A: 0.1% ammonia hydroxide v/v), B: EtOH; Begin B 35%, End B 35%; flow rate (ml/min) 60). The desired fractions were collected and lyophilized to give compound 162 (206 mg, 43% yield) as a solid.

Below compounds were prepared by an analogous reaction protocol as was used for the preparation of compound 162 using the appropriate starting materials (Table 46).

Table 46:

<table>
<thead>
<tr>
<th>Compound</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>163</td>
<td><img src="image1.png" alt="Image" /></td>
<td>Intermediate 353</td>
</tr>
<tr>
<td>164</td>
<td><img src="image2.png" alt="Image" /></td>
<td>Intermediate 354</td>
</tr>
<tr>
<td>165</td>
<td><img src="image3.png" alt="Image" /></td>
<td>Intermediate 355</td>
</tr>
<tr>
<td>166</td>
<td><img src="image4.png" alt="Image" /></td>
<td>Intermediate 356</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Starting materials</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>167</td>
<td><img src="image1" alt="Structure 167" /></td>
<td>Intermediate 357</td>
</tr>
<tr>
<td>168</td>
<td><img src="image2" alt="Structure 168" /></td>
<td>Intermediate 358</td>
</tr>
<tr>
<td>169</td>
<td><img src="image3" alt="Structure 169" /></td>
<td>Intermediate 359</td>
</tr>
<tr>
<td>170</td>
<td><img src="image4" alt="Structure 170" /></td>
<td>Intermediate 360</td>
</tr>
<tr>
<td>171</td>
<td><img src="image5" alt="Structure 171" /></td>
<td>Intermediate 361</td>
</tr>
<tr>
<td>172</td>
<td><img src="image6" alt="Structure 172" /></td>
<td>Intermediate 362</td>
</tr>
<tr>
<td>173</td>
<td><img src="image7" alt="Structure 173" /></td>
<td>Intermediate 401</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Starting materials</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>--------------------</td>
</tr>
<tr>
<td>174</td>
<td><img src="image174" alt="Structure Image 174" /></td>
<td>Intermediate 402</td>
</tr>
<tr>
<td>175</td>
<td><img src="image175" alt="Structure Image 175" /></td>
<td>Intermediate 417</td>
</tr>
<tr>
<td>176</td>
<td><img src="image176" alt="Structure Image 176" /></td>
<td>Intermediate 377</td>
</tr>
<tr>
<td>177</td>
<td><img src="image177" alt="Structure Image 177" /></td>
<td>Intermediate 378</td>
</tr>
<tr>
<td>178</td>
<td><img src="image178" alt="Structure Image 178" /></td>
<td>Intermediate 339</td>
</tr>
<tr>
<td>179</td>
<td><img src="image179" alt="Structure Image 179" /></td>
<td>Intermediate 340</td>
</tr>
<tr>
<td>180</td>
<td><img src="image180" alt="Structure Image 180" /></td>
<td>Intermediate 367</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Starting materials</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>--------------------</td>
</tr>
<tr>
<td>181</td>
<td><img src="image1.png" alt="Structure 181" /></td>
<td>Intermediate 368</td>
</tr>
<tr>
<td>182</td>
<td><img src="image2.png" alt="Structure 182" /></td>
<td>Intermediate 369</td>
</tr>
<tr>
<td>183</td>
<td><img src="image3.png" alt="Structure 183" /></td>
<td>Intermediate 341</td>
</tr>
<tr>
<td>184</td>
<td><img src="image4.png" alt="Structure 184" /></td>
<td>Intermediate 342</td>
</tr>
<tr>
<td>185</td>
<td><img src="image5.png" alt="Structure 185" /></td>
<td>Intermediate 403</td>
</tr>
<tr>
<td>186</td>
<td><img src="image6.png" alt="Structure 186" /></td>
<td>Intermediate 343</td>
</tr>
<tr>
<td>187</td>
<td><img src="image7.png" alt="Structure 187" /></td>
<td>Intermediate 365</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Starting materials</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>--------------------</td>
</tr>
<tr>
<td>188</td>
<td><img src="image1" alt="Structure 188" /></td>
<td>Intermediate 366</td>
</tr>
<tr>
<td>189</td>
<td><img src="image2" alt="Structure 189" /></td>
<td>Intermediate 404</td>
</tr>
<tr>
<td>190</td>
<td><img src="image3" alt="Structure 190" /></td>
<td>Intermediate 379</td>
</tr>
<tr>
<td>191</td>
<td><img src="image4" alt="Structure 191" /></td>
<td>Intermediate 375</td>
</tr>
<tr>
<td>192</td>
<td><img src="image5" alt="Structure 192" /></td>
<td>Intermediate 380</td>
</tr>
<tr>
<td>193</td>
<td><img src="image6" alt="Structure 193" /></td>
<td>Intermediate 381</td>
</tr>
<tr>
<td>194</td>
<td><img src="image7" alt="Structure 194" /></td>
<td>Intermediate 344</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Starting materials</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>--------------------</td>
</tr>
<tr>
<td>195</td>
<td><img src="image1" alt="Structure 195" /></td>
<td>Intermediate 371</td>
</tr>
<tr>
<td>196</td>
<td><img src="image2" alt="Structure 196" /></td>
<td>Intermediate 345</td>
</tr>
<tr>
<td>197</td>
<td><img src="image3" alt="Structure 197" /></td>
<td>Intermediate 346</td>
</tr>
<tr>
<td>198</td>
<td><img src="image4" alt="Structure 198" /></td>
<td>Intermediate 347</td>
</tr>
<tr>
<td>199</td>
<td><img src="image5" alt="Structure 199" /></td>
<td>Intermediate 372</td>
</tr>
<tr>
<td>200</td>
<td><img src="image6" alt="Structure 200" /></td>
<td>Intermediate 373</td>
</tr>
<tr>
<td>201</td>
<td><img src="image7" alt="Structure 201" /></td>
<td>Intermediate 348</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Starting materials</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>--------------------</td>
</tr>
<tr>
<td>202</td>
<td><img src="image" alt="Structure 202" /></td>
<td>Intermediate 349</td>
</tr>
<tr>
<td>203</td>
<td><img src="image" alt="Structure 203" /></td>
<td>Intermediate 350</td>
</tr>
<tr>
<td>204</td>
<td><img src="image" alt="Structure 204" /></td>
<td>Intermediate 374</td>
</tr>
<tr>
<td>205</td>
<td><img src="image" alt="Structure 205" /></td>
<td>Intermediate 376</td>
</tr>
<tr>
<td>206</td>
<td><img src="image" alt="Structure 206" /></td>
<td>Intermediate 351</td>
</tr>
<tr>
<td>208</td>
<td><img src="image" alt="Structure 208" /></td>
<td>Intermediate 385</td>
</tr>
<tr>
<td>209</td>
<td><img src="image" alt="Structure 209" /></td>
<td>Intermediate 405</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Starting materials</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>--------------------</td>
</tr>
<tr>
<td>210</td>
<td><img src="image1" alt="Structure 210" /></td>
<td>Intermediate 375</td>
</tr>
<tr>
<td>225</td>
<td><img src="image2" alt="Structure 225" /></td>
<td>Intermediate 465</td>
</tr>
<tr>
<td>226</td>
<td><img src="image3" alt="Structure 226" /></td>
<td>Intermediate 467</td>
</tr>
<tr>
<td>227</td>
<td><img src="image4" alt="Structure 227" /></td>
<td>Intermediate 470</td>
</tr>
<tr>
<td>229</td>
<td><img src="image5" alt="Structure 229" /></td>
<td>Intermediate 474</td>
</tr>
<tr>
<td>230</td>
<td><img src="image6" alt="Structure 230" /></td>
<td>Intermediate 475</td>
</tr>
<tr>
<td>231</td>
<td><img src="image7" alt="Structure 231" /></td>
<td>Intermediate 476</td>
</tr>
<tr>
<td>Compound</td>
<td>Structure</td>
<td>Starting materials</td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>--------------------</td>
</tr>
<tr>
<td>232</td>
<td><img src="image" alt="Structure 232" /></td>
<td>Intermediate 479</td>
</tr>
<tr>
<td>233</td>
<td><img src="image" alt="Structure 233" /></td>
<td>Intermediate 480</td>
</tr>
<tr>
<td>234</td>
<td><img src="image" alt="Structure 234" /></td>
<td>Intermediate 481</td>
</tr>
<tr>
<td>235</td>
<td><img src="image" alt="Structure 235" /></td>
<td>Intermediate 483</td>
</tr>
<tr>
<td>237</td>
<td><img src="image" alt="Structure 237" /></td>
<td>Intermediate 486</td>
</tr>
<tr>
<td>238</td>
<td><img src="image" alt="Structure 238" /></td>
<td>Intermediate 489</td>
</tr>
<tr>
<td>239</td>
<td><img src="image" alt="Structure 239" /></td>
<td>Intermediate 492</td>
</tr>
</tbody>
</table>
Example B22

Preparation of compound 163

A mixture of intermediate 353 (260 mg, 0.49 mmol) in HO/MeOH (4N, 1 mL) and MeOH (1 mL) was stirred at room temperature for 1 h. The reaction was concentrated. The residue was basified by NH₃.H₂O to pH>8. The residue was purified by HPLC: Column: Gemini 150 x 25 mm 5µm; conditions: A: water (0.05% ammonia hydroxide v/v), B: MeCN; at the beginning: A (89%) and B (11%), at the end: A (59%) and B (41%); Gradient Time (min) 10; 100% B Hold Time (min) 2; Flow Rate(ml/min) 25. The desired fractions were collected and concentrated. The residue was lyophilized to give compound 163 (93.4 mg, 48.6 % yield) as solid.

Example B23

Preparation of compound 185

A solution of intermediate 403 (600 mg, 1.28 mmol) in HCl/MeOH (4N, 2.7mL) and MeOH (1 mL) was stirred at room temperature for 4h. The reaction was concentrated. The residue was basified by NH₃.H₂O to pH>8. A precipitate was formed and collected by filtration. The precipitate was washed with water and MTBE. The precipitate was lyophilized to give compound 185 (345 mg, 61% yield) as solid.

Example B24
Preparation of **compound 187**

A solution of **intermediate 365** (250 mg, 0.54 mmol) in H\textsubscript{2}O/MeOH (4N, 1.52 mL) and MeOH (1 mL) was stirred at room temperature for 1h. The reaction was concentrated. The residue was basified by NH\textsubscript{3}.H\textsubscript{2}O to pH>8 and concentrated. The residue was purified by HPLC: column: Gemini 150 x 25mm, 5\mu m; conditions: A: water (0.05% ammonia hydroxide v/v), B: ACN); at the beginning: A (89%) and B (11%), at the end: A (59%) and B (41%); gradient time (min) 10; 100% B hold time (min) 2; flow rate(ml/min) 25. The desired fractions were collected and concentrated. The residue was lyophilized to give **compound 187** (29.4 mg, 13% yield) as a solid.

Example B 25

Preparation of **compound 188**

A solution of **intermediate 366** (410 mg, 0.76 mmol) in H\textsubscript{2}O/MeOH (4N, 7mL) and MeOH (2 mL) was stirred at room temperature for 1h. The reaction was concentrated. The residue was dissolved in H\textsubscript{2}O (3mL,) and basified by aq.NH\textsubscript{3}.H\textsubscript{2}O . A precipitate was formed and collected. The solid was purified by prep-HPLC (Phenomenex Gemini 150 x 25mm ,10\mu m; conditions: A: water (0.05% ammonia hydroxide v/v), B:ACN); at the beginning: A (70%) and B (30%), at the end: A (40%) and B (60%); gradient time(min) 10; 100% B hold time(min) 3; flow rate(ml/min) 25. The desired fractions were collected and lyophilized to give **compound 188** (131.3mg, 34.5%) as solid.
Example B26

Preparation of compound 211

Potassium carbonate (155 mg, 1.1 mmol) was added to intermediate 383 (0.3 g, 0.376 mmol) in CH3CN (10 ml). The mixture was stirred at room temperature for 3h. The mixture was evaporated under vacuo. The residue was purified by preparative-HPLC (Column: Waters Xbridge Prep OBD C18 150x30 mm 5μm; Condition: water (0.05% ammonia hydroxide v/v)-ACN, Begin: B 35%, End: B 65%, Gradient Time (min): 10, 100%B Hold Time (min): 3, FlowRate (ml/min): 25). The combined solvent was evaporated to give the product as a white solid. The product was purified by SEC separation (Column: OJ (250mm x 30mm, 10um), Condition; A: (0.1% ammonia hydroxide v/v) -B: EtOH, Begin: B 50%, End: B 50%, Flow Rate (ml/min): 80). The combined solvent was evaporated to give compound 211 (76mg, yield:39%) as a white solid.

Example B27

Preparation of compound 253

Compound 253 was prepared by an analogous reaction protocol as was used for the preparation of intermediate 382 described in A78 (Step 1) using the appropriate starting materials (Table 4 1).

Table 4 1:

<table>
<thead>
<tr>
<th>Compound</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>253</td>
<td><img src="" alt="Structure" /></td>
<td>Compound 2</td>
</tr>
</tbody>
</table>
Example B28

Preparation of compounds 207 and 208

HCl/MeOH (1mL, 4mol/L) was added into the mixture of intermediate 384 and intermediate 385 (200 mg) in MeOH (1mL) and stirred at room temperature for 30 min. The reaction mixture was added dropwise into aq. NH₃·H₂O (2 mL) and concentrated under vacuo to dryness to give the crude product. The crude product was purified by preparative high-performance liquid chromatography over Column: Phenomenex Gemini 150 x 25mm IOD; Condition: A: water (0.05% ammonia hydroxide v/v), B: MeCN; at the beginning: A (85%) and B (15%), at the end: A: (55%) and B (45%). The pure fractions were collected and the solvent was evaporated under vacuum. The residues were lyophilized to give compound 207 (32mg) and compound 208 (41 mg) as white solids.

Example B29

Preparation of compound 215

A mixture of intermediate 388 (1g, 0.67 mmol) and K₂CO₃ (1g, 7.25 mmol) in CH₂Cl₂ (10 mL) and dioxane (10 mL) was stirred at 50°C for 2 hours. The mixture was filtered and the filtrate was concentrated to give the crude product. The crude product was purified by preparative-HPLC (gradient elution: 0.05% NH₃·H₂O in CH₃OH / 0.05% NH₃·H₂O in H₂O; Column: Kromasil 150 x 25mm, 10µm) to obtain compound 215 (102 mg, 34%, yield) as a white solid.
Example B30

Preparation of compound 216

\[
\begin{align*}
\text{intermediate 390} & \xrightarrow{\text{K}_2\text{CO}_3/\text{MeOH}} \text{compound 216}
\end{align*}
\]

A mixture of intermediate 390 (300 mg, 0.60 mmol) and \(\text{K}_2\text{CO}_3\) (0.25 g, 1.80 mmol) in methanol (10 mL) was stirred at 50°C for 2 hours. The mixture was filtered and concentrated to give the crude product. The crude product was purified by preparative-HPLC (gradient elution: 0.05% \(\text{NH}_3\cdot\text{H}_2\text{O}\) in \(\text{CH}_3\text{OH}\) / 0.05% \(\text{NH}_3\cdot\text{H}_2\text{O}\) in \(\text{H}_2\text{O}\); column: Kromasil 150 x 25mm, 1Qum) to obtain compound 216 (37.9 mg, 15.5% yield) as a white solid.

Example B31

Preparation of compound 198

\[
\begin{align*}
\text{intermediate 347} & \xrightarrow{\text{HCl/MeOH}} \text{compound 198}
\end{align*}
\]

A mixture of intermediate 347 (1.2 g, 2.42 mmol) in \(\text{HQ/MeOH}\) (20 mL, 4M) was stirred at room temperature for 2 hours. The solvent was concentrated in vacuum. Then \(\text{H}_2\text{O}\) (50 ml) was added and the pH was adjusted to 9 by progressively adding solid \(\text{NaHCO}_3\). The solid was filtered and washed with \(\text{H}_2\text{O}\) (100 ml, x 6), methanol (100 mL x 2) and diisopropylether (100 mL x 2). The filtered cake was dried under vacuum to give compound 198 (273.7 mg, 24% yield) as white solid.

Example B32

Preparation of compound 199
A mixture of intermediate 372 (510 mg, 0.824 mmol) in HCl/MeOH (10 mL, 4M) was stirred at room temperature for 2 hours. The solvent was concentrated in vacuum. Then H2O (50 ml) was added and the pH was adjusted to 9 by progressively adding solid NaHCO3. Then ethyl acetate (50mL) was added. The organic layer was separated and the aqueous phase was extracted with ethyl acetate (50 mL x 2). The combined organic phase was dried with anhydrous Na2SO4, filtered and concentrated in vacuum to give crude product. The crude product was purified by preparative-HPLC (Column: Waters Xbridge Prep OBD C18 150 x 30 mm, 5µm, Conditions: A : water (0.05% ammonia hydroxide v/v)-B:ACN, Begin: B 13%, End: B 43%, Gradient Time(min): 10, 100% B Hold Time(min): 3, FlowRate (ml/min): 25) to obtain compound 199 (84.7 mg, 22% yield) as a white solid.

Example B33

Preparation of compound 218

To a solution of intermediate 232 (500 mg, 0.677 mmol, 1.0 eq) in DCM (15 mL) was added BBr3 (0.64 mL, 6.77 mmol, 10.0 eq) at -78°C under N2. The resulted mixture was stirred overnight at 20°C. The solid was filtered, rinsed with CH2Cl2 and collected to give the crude product. The residue was triturated with water, and the pH was adjusted to around 8 by progressively added solid K2CO3. The resulting solid was filtered through a funnel rinsed with water (20 mL x 5) and collected. The residue was purified by preparative-HPLC. (HPLC condition; A: water (0.05% ammonia hydroxide
Example B34

Preparation of compound 201

**Intermediate 348** (450 mg, 0.855 mmol) was dissolved in MeOH (15 mL), HCl/MeOH (4N, 15 mL) was added. The reaction mixture was stirred at room temperature for 2 hours. The solvent was removed by evaporation. The residue was triturated with EtOAc (100 mL) and saturated Na₂CO₃ (30 mL). The organic layer was separated and washed by brine (30 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by prep. HPLC (Waters Xbridge Prep OBD C₁₈ 150 x30 mm 5µm, conditions: A: water (0.05% NH₄OH v/v)-B: ACN, FlowRate: 25ml/min, gradient from B 35% to B 65%) to afford **compound 201** (148 mg, 35% yield) as a white solid.

Example B35

Preparation of compound 200

**Intermediate 373** (340 mg, 0.595 mmol) was dissolved in MeOH (50 mL) and 4N HCl/MeOH (10 mL) was added. The reaction mixture was stirred at room temperature for 2 hours. The solvent was removed by evaporation. The residue was triturated with EtOAc (100 mL) and saturated Na₂CO₃ (30 mL), the separated organic layer was
washed by brine (30 mL), dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by prep. HPLC (Waters Xbridge Prep OBD C18 150 x 30 mm 5µm, conditions; A: water (0.05% NH₃OH v/v)- B: ACN, FlowRate: 25ml/min, gradient from B 35% to B 65%) to afford the compound 200 (135 mg, 46% yield) as a white solid.

Example B36

Preparation of compound 204

A solution of intermediate 374 (350 mg, 0.73 mmol) in HCl/MeOH (4 M, 10 mL) was stirred at room temperature for 2 hours. The mixture was basified with NH₃·H₂O (20 mL) to pH > 7. The solution was washed with water (60 mL) and extracted with EtOAc (80 mL x 3). The combined organic layers were washed with brine (80 mL), dried (Na₂SC₄), filtered and concentrated by vacuum to give the crude product as brown solid. The crude product was purified by HPLC (Column: Waters Xbridge Prep OBD C18 150 x 30 mm 5µm; Conditions; A: water (0.05% ammonia hydroxide v/v)-B: ACN; Begin B : 25%; End B : 55%; Gradient Time(min): 10; 100% B Hold Time(min): 3; FlowRate(ml/min): 25) to give compound 204 (102.9 mg, 32% yield) as white solid.

Example B37

Preparation of compound 203

A solution of intermediate 350 (300 mg, 0.61 mmol) in HCl/CH₃OH(4 mol/L, 10 mL) was stirred at room temperature for 2 hours. The mixture was basified with NH₃·H₂O (8
mL) to pH > 7. The solution was treated with water (100 mL) and extracted with ethyl acetate (150 mL x 3). The combined organic layers were washed with brine (100 mL), dried (Na₂SO₄), filtered and concentrated by vacuum to give the crude product as a brown solid. The crude product was purified by HPLC (Column: Waters XBridge Prep OBD C18 150 x 30 mm, 5μm; Condition: A: water (0.05% ammonia hydroxide v/v)-B: ACN; Begin B: 25%; End B: 55%; Gradient Time(min): 10; 100% B Hold Time(min): 3; FlowRate(ml/min): 25) to give compound 203 (129.8 mg, 47% yield) as a white solid.

Example B38

Preparation of compound 202

A solution of intermediate 349 (350 mg, 0.734 mmol) in HCl/CH₃OH (4 M, 10 mL) was stirred at room temperature for 2 hours. The mixture was basified with NH₃·H₂O (10 mL) to pH > 7. The solution was washed with water (100 mL) and extracted with ethyl acetate (150 mL x 3). The combined organic layers were washed with brine (100 mL), dried (Na₂SO₄), filtered and concentrated by vacuum to give the crude product as a brown solid. The crude product was purified by HPLC to give compound 219 (149 mg, 46% yield) as white solid.

Example B39

Preparation of compound 219
To a solution of intermediate 422 (600 mg, 0.80 mmol) in DCM (11 mL) was added TFA (12 mL, 163 mmol) dropwise under N₂ at 0°C. The reaction mixture was stirred at 0°C for 30 minutes, then H₂O (3 mL) was added. The reaction mixture was stirred at room temperature overnight. The solvent was removed under vacuum. The residue was dissolved in water (30 mL) and the pH was adjusted to 8 and was then filtered. The solid was collected, dried under vacuum to give compound 219 (326 mg, 86.5% yield) as a white solid.

Example B40

Preparation of compound 220

![Diagram of intermediate 424 and compound 220]

To a solution of intermediate 424 (1 g, 1.20 mmol) in DCM (10 mL) was added TFA (10 mL, 135 mmol) dropwise under N₂ at 0°C. The reaction mixture was stirred at 0°C for 30 minutes, then H₂O (3 mL) was added. The reaction mixture was stirred at room temperature for 4 hours. The solvent was removed under vacuum. The residue was dissolved in MeOH (10 mL) and adjusted pH to 8, then filtered and the filtrate was concentrated to give the crude product. The crude product was purified by HPLC Column: DuraShell 150 x 25mm, 5µm; Conditions: A: water (0.05% NH₄OH v/v), B: MeOH; at the beginning: A (60%) and B (40%), at the end: A (30%) and B (70%); Gradient Time (min) 10; 100% B Hold Time (min) 3; Flow Rate (ml/min) 2.5 to give compound 220 (166 mg, 19% yield) as a white solid.

Example B42

Preparation of compound 221
The mixture of intermediate 426 (150 mg, 0.123 mmol) and potassium carbonate (51 mg, 0.369 mmol) in methanol (3 ml) was stirred at 60°C for 1h. The mixture was filtered and the filtrate was evaporated under vacuo to obtain the crude product as a solid. This residue was purified by preparative-HPLC (Column: Waters Xbridge Prep OBD C18 150 x 30 mm, 5μm, Condition; A: water (0.05% ammonia hydroxide v/v) - B: ACN, Begin: B 13%, End: B 43%, Gradient Time (min): 10, 100% B Hold Time (min): 3, FlowRate (ml/min): 25). The combined solvents were evaporated to give compound 221 (39mg) as a white solid.

C. Conversions of compounds

Example C1

Preparation of compound 217

To a solution of compound 2 (1.6 g, 2.88 mmol, 1.0 eq.), 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (0.72 g, 5.76 mmol, 2.0 eq) and K₂CO₃ (0.796 g, 5.76 mmol, 2.0 eq) in dioxane/H₂O ratio 10/1 (30 mL) was added Pd(dppf)Cl₂ (210 mg, 0.288 mmol, 0.1 eq). The resulting mixture was stirred at 90°C under N₂ for 16 hours. The resulting solid was filtered off. The filtrate was concentrated. The residue was triturated with water (30 ml) and DCM (30 ml) was added. A solid precipitated out of the reaction. The resulting solid was filtered to give the crude product. The residue was purified by column chromatography (gradient: petroleum ether/ethyl acetate/MeOH ratio 20/1/0 to 0/20/1). The product fractions were collected and the solvent was evaporated to give the product as solid. The product was purified by preparative-HPLC (HPLC condition:...
Example C2

Preparation of compound 212

To a solution of compound 2 (1 g, 1.8 mmol) in dioxane (40 ml) and H₂O (10 ml) was added potassium isopropyl trifluoroborate (3.19 mg, 2.16 mmol) and K₃PO₄ (764 mg, 3.6 mmol) at room temperature. 1,1'-bis(di-tert-butylphosphino)ferrocene palladium dichloride (58 mg, 0.09 mmol) was added to the above solution under nitrogen atmosphere. The reaction mixture was stirred at 80°C under nitrogen atmosphere overnight. The mixture was extracted with ethylacetate, the organic layers were combined and concentrated under vacuo to give the crude product. This crude product was purified by preparative-HPLC (gradient elution: 0.05% NH₃·H₂O in CH₃CN / 0.05% NH₃·H₂O in H₂O; Column: DuraShell 150 x 25 mm, 5 µm). The combined solvent was evaporated to give the desired product as a white solid of the product (300 mg, yield 35%). 100 mg of the product was purified by SEC separation (AD (250 mm x 30 mm, 10 µm)). The combined solvents were evaporated under vacuo to give the desired product as a white solid of compound 212 (71.9 mg).

Example C3

Preparation of compound 213

Pd/C (20 mg) was added into the mixture of compound 253 (200 mg, 0.429 mmol) in MeOH (20 ml). The mixture was hydrogenated at 25°C for 24 h under H₂ atmosphere. The mixture was filtered and evaporated under vacuo to obtain a crude product. It was purified by preparative-HPLC (gradient elution: 0.05% NH₃·H₂O in CH₃CN / 0.05%
NH₃·H₂O in H₂O; Column: Waters Xbridge Prep OBD C₁₈ 150 x 30 mm, 5 mm). The combined solvent was evaporated to give compound 213 as a white solid (132 mg, yield 73%).

Below compounds were prepared by an analogous reaction protocol as was used for the preparation of compound 213 using the appropriate starting materials (Table 47).

Table 47:

<table>
<thead>
<tr>
<th>compounds</th>
<th>Structure</th>
<th>Starting materials</th>
</tr>
</thead>
<tbody>
<tr>
<td>214</td>
<td>![Structure Image]</td>
<td>Compound 212</td>
</tr>
</tbody>
</table>

Analytical Part

NMR

For a number of compounds, ¹H NMR spectra were recorded on a Bruker DPX-360 operating at 360 MHz, on a Bruker Avance 600 operating at 600 MHz, on a Bruker Avance 400 operating at 400 MHz, or on a Varian 400MR spectrometer operating at 400MHz. As solvents CHLOROFORM-d (deuterated chloroform, CDCl₃), Methanol-J₄ or DMSO-J₆ (deuterated DMSO, dimethyl-d₆ sulfoxide) were used. Chemical shifts (δ) are reported in parts per million (ppm) relative to tetramethylsilane (TMS), which was used as internal standard.

Co. 217: ¹H NMR (400 MHz, DMSO-­J₆) δ ppm 2.44 (s, 3 H) 4.21 - 4.34 (m, 3 H) 4.34 - 4.43 (m, 1 H) 4.50 (q, J=5.7 Hz, 1 H) 5.37 (d, J=5.0 Hz, 1 H) 5.44 (d, J=6.3 Hz, 1 H) 6.17 (d, J=5.5 Hz, 1 H) 6.61 (d, J=3.8 Hz, 1 H) 7.01 (br s, 2 H) 7.27 (dd, J=8.8, 2.5 Hz, 1 H) 7.37 (d, J=3.8 Hz, 1 H) 7.41 (d, J=2.3 Hz, 1 H) 7.81 (d, J=9.0 Hz, 1 H) 8.05 (br s, 1 H) 8.07 (s, 1 H) 8.70 (d, J=2.0 Hz, 1 H).

Co. 218: ¹H NMR (400 MHz, DMSO-d₆) δ ppm 4.14 - 4.34 (m, 4 H) 4.48 (q, J=5.7 Hz, 1 H) 5.36 (d, J=5.0 Hz, 1 H) 5.44 (d, J=6.3 Hz, 1 H) 6.15 (d, J=5.5 Hz, 1 H) 6.33 (br s, 2 H) 6.58 (d, J=8.8 Hz, 1 H) 6.61 (d, J=3.8 Hz, 1 H) 6.83 (dd, J=8.7, 2.4 Hz, 1 H) 6.91 (d, J=2.3 Hz, 1 H) 7.02 (br s, 2 H) 7.35 (d, J=3.8 Hz, 1 H) 7.53 (d, J=8.8 Hz, 1 H) 7.79 (d, J=8.8 Hz, 1 H) 8.07 (s, 1 H).

Co. 74: ¹H NMR (600 MHz, DMSO-d₆) δ ppm 0.24 - 0.27 (m, 2 H) 0.45 - 0.48 (m, 2 H) 1.08 - 1.14 (m, 1 H) 1.52 (dt, J=12.4, 10.3 Hz, 1 H) 1.67 - 1.74 (m, 1 H) 1.84 - 1.92 (m, 1 H) 1.96 (ddt, J=13.0, 9.3, 6.4, 6.4 Hz, 1 H) 2.25 (dt, J=12.7, 7.9 Hz, 1 H) 2.65 -
2.72 (m, 1 H) 2.72 - 2.79 (m, 1 H) 3.26 (dd, J=6.5, 5.6 Hz, 2 H) 3.75 (q, J=4.9 Hz, 1 H) 4.21 (dt, J=7.6, 6.2 Hz, 1 H) 4.63 (d, J=4.8 Hz, 1 H) 4.77 (d, J=6.3 Hz, 1 H) 4.81 (dt, J=10.5, 8.0 Hz, 1 H) 6.55 (d, J=3.5 Hz, 1 H) 6.72 (d, J=8.9 Hz, 1 H) 6.91 (br s, 2 H) 6.99 - 7.03 (m, 2 H) 7.26 (d, J=3.5 Hz, 1 H) 7.33 (s, 1 H) 7.50 (d, J=8.1 Hz, 1 H) 7.76 (d, J=8.8 Hz, 1 H) 8.04 (s, 1 H).

Co. 129: H NMR (360 MHz, DMSO-d$_6$) δ ppm 1.53 (dt, J=12.3, 10.2 Hz, 1 H) 1.69 - 1.81 (m, 1 H) 1.82 - 1.93 (m, 1 H) 1.95 - 2.05 (m, 1 H) 2.25 (dt, J=12.4, 7.9 Hz, 1 H) 2.78 - 2.93 (m, 2 H) 3.76 (q, J=5.0 Hz, 1 H) 4.21 (q, J=5.9 Hz, 1 H) 4.66 (d, J=4.8 Hz, 1 H) 4.73 - 4.86 (m, 2 H) 6.55 (d, J=3.3 Hz, 1 H) 6.95 (br s, 2 H) 7.27 (d, J=3.7 Hz, 1 H) 7.59 (dd, J=8.4, 1.8 Hz, 1 H) 7.87 (s, 1 H) 7.91 (d, J=8.4 Hz, 1 H) 8.03 (s, 1 H) 8.68 (d, J=2.2 Hz, 1 H) 8.91 (d, J=2.6 Hz, 1 H).

Co. 130: H NMR (400 MHz, DMSO-d$_6$) δ ppm 4.22 - 4.39 (m, 3 H) 4.59 (q, J=5.0 Hz, 1 H) 5.49 (br d, J=4.5 Hz, 1 H) 5.60 (d, J=6.0 Hz, 1 H) 6.29 (d, J=5.5 Hz, 1 H) 6.64 (m, J=9.0 Hz, 2 H) 6.78 (d, J=3.8 Hz, 1 H) 6.90 (dd, J=8.7, 1.9 Hz, 1 H) 6.97 (d, J=1.5 Hz, 1 H) 7.58 (d, J=8.5 Hz, 1 H) 7.87 (d, J=9.0 Hz, 1 H) 7.97 (d, J=4.0 Hz, 1 H) 8.69 (s, 1 H).

Co. 176: H NMR (400 MHz, Methanol-d$_6$) δ ppm 2.32 - 2.45 (m, 1 H) 2.48 - 2.62 (m, 1 H) 2.65 - 2.83 (m, 2 H) 3.01 - 3.12 (m, 1 H) 3.45 (s, 3 H) 3.49 - 3.63 (m, 2 H) 3.69 (d, J=4.8 Hz, 3 H) 4.53 - 4.61 (m, 1 H) 5.05 - 5.11 (m, 1 H) 5.51 (d, J=4.8 Hz, 1 H) 5.60 (d, J=6.3 Hz, 1 H) 5.70 - 5.81 (m, 1 H) 7.47 (d, J=8.8 Hz, 1 H) 7.50 (d, J=3.8 Hz, 1 H) 7.73 (br q, J=5.0 Hz, 1 H) 7.84 (dd, J=8.0, 1.5 Hz, 1 H) 8.17 (br s, 1 H) 8.32 (d, J=8.0 Hz, 1 H) 8.53 (d, J=3.5 Hz, 1 H) 8.58 (d, J=8.8 Hz, 1 H) 9.43 (s, 1 H).

Co. 80: H NMR (600 MHz, DMSO-d$_6$) δ ppm 1.50 - 1.56 (m, 1 H) 1.68 - 1.75 (m, 1 H) 1.85 - 1.92 (m, 1 H) 1.96 (ddt, J=13.0, 9.0, 6.5, 6.5 Hz, 1 H) 2.25 (dt, J=12.7, 7.9 Hz, 1 H) 2.69 - 2.80 (m, 2 H) 3.76 (br t, J=4.7 Hz, 1 H) 4.21 (dd, J=7.6, 6.0 Hz, 1 H) 4.57 (br s, 1 H) 4.72 (br s, 1 H) 4.80 (dt, J=10.5, 7.9 Hz, 1 H) 6.50 (br s, 2 H) 6.59 (d, J=3.5 Hz, 1 H) 7.07 (br s, 2 H) 7.12 (dd, J=8.2, 1.6 Hz, 1 H) 7.29 (d, J=3.6 Hz, 1 H) 7.34 (s, 1 H) 7.58 (d, J=8.1 Hz, 1 H) 8.07 (s, 1 H) 8.31 (s, 1 H).

Co. 185: H NMR (400 MHz, DMSO-d$_6$) δ ppm 2.96 (br d, J=3.5 Hz, 3 H) 4.16 - 4.36 (m, 4 H) 4.44 - 4.55 (m, 1 H) 5.38 (br d, J=5.3 Hz, 1 H) 5.47 (br d, J=6.2 Hz, 1 H) 6.16 (d, J=5.7 Hz, 1 H) 6.63 (d, J=4.0 Hz, 1 H) 6.70 (br d, J=9.3 Hz, 1 H) 6.89 - 6.97 (m, 1 H) 7.05 - 7.23 (m, 3 H) 7.37 (d, J=3.5 Hz, 1 H) 7.63 (br d, J=9.3 Hz, 1 H) 7.84 - 7.95 (m, 1 H) 8.09 (s, 1 H).

Co. 75: H NMR (400 MHz, DMSO-d$_6$) δ ppm 1.45 - 1.59 (m, 1 H) 1.65 - 1.77 (m, 1 H) 1.83 - 2.02 (m, 2 H) 2.25 (dt, J=12.5, 7.9 Hz, 1 H) 2.63 - 2.83 (m, 2 H) 3.72 - 3.89 (m, 3 H) 4.16 - 4.24 (m, 1 H) 4.64 (d, J=4.8 Hz, 1 H) 4.77 (d, J=6.3 Hz, 1 H) 4.79 - 4.84 (m, 1 H) 6.22 (tt, J=56.7, 4.1 Hz, 1 H) 6.54 (d, J=3.5 Hz, 1 H) 6.78 (d, J=8.8 Hz, 1 H) 7.76 (d, J=8.8 Hz, 1 H) 8.04 (s, 1 H).
<table>
<thead>
<tr>
<th>δ ppm</th>
<th>J (Hz)</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.91</td>
<td>(br s, 2 H)</td>
<td>7.09 (dd, J = 8.2 Hz, 1 H)</td>
</tr>
<tr>
<td>7.26</td>
<td>(d, J = 3.5 Hz, 1 H)</td>
<td>7.36 (t, J = 4.9 Hz, 1 H)</td>
</tr>
<tr>
<td>7.34</td>
<td>(s, 1 H)</td>
<td>7.40 (br s, 1 H)</td>
</tr>
<tr>
<td>7.41</td>
<td>(4.16 - 4.25, 1 H)</td>
<td>6.54 (d, J = 3.5 Hz, 1 H)</td>
</tr>
<tr>
<td>7.77</td>
<td>(d, J = 8.4 Hz, 1 H)</td>
<td>7.37 (s, 1 H)</td>
</tr>
<tr>
<td>7.94</td>
<td>(br s, 2 H)</td>
<td>7.51 (d, J = 8.4 Hz, 1 H)</td>
</tr>
<tr>
<td>8.63</td>
<td>(s, 1 H)</td>
<td>7.95 (d, J = 4.0 Hz, 1 H)</td>
</tr>
</tbody>
</table>

Co. 81: H NMR (400 MHz, DMSO-d<sub>6</sub>) δ ppm: 1.42 - 1.60 (m, 1 H), 1.62 - 1.77 (m, 1 H) 1.81 - 2.00 (m, 2 H) 2.24 (dt, J = 12.7 Hz, 7.8 Hz, 1 H) 2.64 - 2.83 (m, 2 H) 3.70 - 3.79 (m, 1 H) 4.16 - 4.25 (m, 1 H) 4.62 (br d, J = 4.9 Hz, 1 H) 4.71 - 4.87 (m, 2 H) 6.54 (d, J = 3.5 Hz, 1 H) 6.65 (br s, 2 H) 6.90 (br s, 2 H) 7.12 (br d, J = 7.5 Hz, 1 H) 7.25 (d, J = 3.5 Hz, 1 H) 7.34 (s, 1 H) 7.58 (d, J = 8.4 Hz, 1 H) 8.03 (s, 1 H) 8.14 (s, 1 H).

Co. 151: H NMR (400 MHz, DMSO-d<sub>6</sub>) δ ppm: 1.45 - 1.57 (m, 1 H) 1.62 - 1.77 (m, 1 H) 1.82 - 2.01 (m, 2 H) 2.25 (dt, J = 12.4, 7.9 Hz, 1 H) 2.65 - 2.82 (m, 2 H) 3.75 (q, J = 4.8 Hz, 1 H) 4.20 (dt, J = 7.6, 6.2 Hz, 1 H) 4.26 - 4.39 (m, 2 H) 4.64 (d, J = 4.8 Hz, 1 H) 4.73 - 4.87 (m, 2 H) 6.54 (d, J = 3.5 Hz, 1 H) 6.82 (d, J = 8.8 Hz, 1 H) 6.91 (br s, 2 H) 7.12 (dd, J = 8.0, 1.5 Hz, 1 H) 7.26 (d, J = 3.5 Hz, 1 H) 7.42 (s, 1 H) 7.54 (br t, J = 6.4 Hz, 1 H) 7.59 (d, J = 8.0 Hz, 1 H) 7.91 (d, J = 8.9 Hz, 1 H) 8.03 (s, 1 H).

Co. 152: H NMR (400 MHz, DMSO-d<sub>6</sub>) δ ppm: 0.39 - 0.62 (m, 2 H) 0.67 - 0.84 (m, 2 H) 1.46 - 1.62 (m, 1 H) 1.64 - 1.78 (m, 1 H) 1.82 - 2.02 (m, 2 H) 2.25 (dt, J = 12.6, 8.0 Hz, 1 H) 2.63 - 2.83 (m, 3 H) 3.70 - 3.79 (m, 1 H) 4.15 - 4.25 (m, 1 H) 4.63 (d, J = 4.9 Hz, 1 H) 4.73 - 4.86 (m, 2 H) 6.54 (d, J = 3.5 Hz, 1 H) 6.75 (br d, J = 8.8 Hz, 1 H) 6.90 (br s, 2 H) 7.05 (dd, J = 8.2, 1.5 Hz, 1 H) 7.13 (br d, J = 2.6 Hz, 1 H) 7.26 (d, J = 3.5 Hz, 1 H) 7.37 (br s, 1 H) 7.54 (d, J = 7.9 Hz, 1 H) 7.84 (d, J = 8.8 Hz, 1 H) 8.03 (s, 1 H).

Co. 146: H NMR (400 MHz, DMSO-d<sub>6</sub>) δ ppm: 1.38 - 1.63 (m, 5 H) 1.65 - 1.75 (m, 3 H) 1.82 - 2.04 (m, 4 H) 2.25 (dt, J = 12.5, 7.9 Hz, 1 H) 2.63 - 2.80 (m, 2 H) 3.71 - 3.78 (m, 1 H) 4.14 - 4.25 (m, 1 H) 4.33 (dq, J = 13.6, 6.7 Hz, 1 H) 4.63 (d, J = 4.9 Hz, 1 H) 4.73 - 4.86 (m, 2 H) 6.54 (d, J = 3.1 Hz, 1 H) 6.66 (d, J = 8.8 Hz, 1 H) 6.76 - 6.97 (m, 3 H) 7.01 (dd, J = 7.9, 1.3 Hz, 1 H) 7.26 (d, J = 3.5 Hz, 1 H) 7.32 (s, 1 H) 7.49 (d, J = 8.4 Hz, 1 H) 7.74 (d, J = 8.8 Hz, 1 H) 8.03 (s, 1 H).

Co. 76: H NMR (400 MHz, DMSO-d<sub>6</sub>) δ ppm: 1.43 - 1.57 (m, 1 H) 1.62 - 1.76 (m, 1 H) 1.79 - 2.01 (m, 2 H) 2.18 - 2.29 (m, 1 H) 2.65 - 2.79 (m, 2 H) 3.70 - 3.78 (m, 1 H) 4.14 - 4.25 (m, 1 H) 4.63 (br d, J = 4.9 Hz, 1 H) 4.73 - 4.86 (m, 2 H) 6.42 (br s, 2 H) 6.54 (br d, J = 3.5 Hz, 1 H) 6.69 (br d, J = 8.8 Hz, 1 H) 6.92 (br s, 2 H) 7.05 (br d, J = 8.4 Hz, 1 H) 7.26 (br d, J = 3.5 Hz, 1 H) 7.28 (br s, 1 H) 7.54 (br d, J = 7.9 Hz, 1 H) 7.84 (br d, J = 8.8 Hz, 1 H) 8.02 (s, 1 H).

Co. 121: H NMR (400 MHz, DMSO-d<sub>6</sub>) δ ppm: 1.56 - 1.68 (m, 1 H) 1.69 - 1.82 (m, 1 H) 1.84 - 2.05 (m, 2 H) 2.24 - 2.37 (m, 1 H) 2.63 - 2.81 (m, 2 H) 2.88 (d, J = 4.4 Hz, 1 H) 3.73 - 3.81 (m, 1 H) 4.25 - 4.35 (m, 1 H) 4.73 (d, J = 4.4 Hz, 1 H) 4.86 (d, J = 6.6 Hz, 1 H) 4.93 - 5.04 (m, 1 H) 6.66 (d, J = 8.8 Hz, 1 H) 6.69 (d, J = 3.5 Hz, 1 H) 6.87 - 6.94 (m, 1 H) 7.03 (br dd, J = 7.9, 1.3 Hz, 1 H) 7.37 (s, 1 H) 7.51 (d, J = 8.4 Hz, 1 H) 7.77 (br d, J = 8.8 Hz, 1 H) 7.95 (d, J = 4.0 Hz, 1 H) 8.63 (s, 1 H).
H NMR (400 MHz, DMSO-\textsubscript{d\textregistered}6) δ ppm

1.48 - 1.58 (m, 1 H) 1.70 - 1.80 (m, 1 H) 1.82 - 1.94 (m, 1 H) 1.95 - 2.04 (m, 1 H) 2.25 (dt, J=12.5, 8.1 Hz, 1 H) 2.46 (s, 3 H) 2.75 - 2.90 (m, 2 H) 3.71 - 3.80 (m, 1 H) 4.20 (br dd, J=14.1, 6.2 Hz, 1 H) 4.65 (d, J=5.3 Hz, 1 H) 4.73 - 4.86 (m, 2 H) 6.54 (d, J=3.5 Hz, 1 H) 6.92 (br s, 2 H) 7.26 (d, J=3.5 Hz, 1 H) 7.47 (dd, J=8.4, 1.8 Hz, 1 H) 7.76 - 7.85 (m, 2 H) 8.02 (s, 1 H) 8.07 (br s, 1 H) 8.72 (d, J=2.2 Hz, 1 H).

OR (optical rotation)

Optical rotations were measured on a Perkin-Elmer 341 polarimeter with a sodium lamp (wavelength of light used is 589 nm (the sodium D line)). (T° means temperature).

<table>
<thead>
<tr>
<th>Co. Nr.</th>
<th>(\alpha_D) (°)</th>
<th>Wavelength (nm)</th>
<th>Concentration (w/v%)</th>
<th>Solvent</th>
<th>T (° C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>129</td>
<td>-8.6</td>
<td>589</td>
<td>0.3835</td>
<td>DMF</td>
<td>20</td>
</tr>
<tr>
<td>130</td>
<td>-84.95</td>
<td>589</td>
<td>0.3555</td>
<td>DMF</td>
<td>20</td>
</tr>
<tr>
<td>151</td>
<td>-11.15</td>
<td>589</td>
<td>0.5380</td>
<td>DMF</td>
<td>20</td>
</tr>
<tr>
<td>113</td>
<td>-8</td>
<td>589</td>
<td>0.5125</td>
<td>DMF</td>
<td>20</td>
</tr>
<tr>
<td>176</td>
<td>-20.63</td>
<td>589</td>
<td>0.2715</td>
<td>DMF</td>
<td>20</td>
</tr>
<tr>
<td>74</td>
<td>-11.97</td>
<td>589</td>
<td>0.3610</td>
<td>DMF</td>
<td>20</td>
</tr>
<tr>
<td>146</td>
<td>-10.19</td>
<td>589</td>
<td>0.5005</td>
<td>DMF</td>
<td>20</td>
</tr>
<tr>
<td>217</td>
<td>-92.69</td>
<td>589</td>
<td>0.5265</td>
<td>DMF</td>
<td>20</td>
</tr>
<tr>
<td>185</td>
<td>-88.93</td>
<td>589</td>
<td>0.5195</td>
<td>DMF</td>
<td>20</td>
</tr>
<tr>
<td>80</td>
<td>-1.88</td>
<td>589</td>
<td>0.5315</td>
<td>DMF</td>
<td>20</td>
</tr>
<tr>
<td>121</td>
<td>-18.82</td>
<td>589</td>
<td>0.3560</td>
<td>DMF</td>
<td>20</td>
</tr>
<tr>
<td>76</td>
<td>-3.37</td>
<td>589</td>
<td>0.2670</td>
<td>DMF</td>
<td>20</td>
</tr>
<tr>
<td>218</td>
<td>-79.03</td>
<td>589</td>
<td>0.3505</td>
<td>DMF</td>
<td>20</td>
</tr>
<tr>
<td>152</td>
<td>-8.19</td>
<td>589</td>
<td>0.5370</td>
<td>DMF</td>
<td>20</td>
</tr>
<tr>
<td>81</td>
<td>-2.48</td>
<td>589</td>
<td>0.3625</td>
<td>DMF</td>
<td>20</td>
</tr>
</tbody>
</table>
LCMS (Liquid chromatography/Mass spectrometry)

The High Performance Liquid Chromatography (HPLC) measurement was performed using a LC pump, a diode-array (DAD) or a UV detector and a column as specified in the respective methods. If necessary, additional detectors were included (see table of methods below).

Flow from the column was brought to the Mass Spectrometer (MS) which was configured with an atmospheric pressure ion source. It is within the knowledge of the skilled person to set the tune parameters (e.g. scanning range, dwell time...) in order to obtain ions allowing the identification of the compound's nominal monoisotopic molecular weight (MW). Data acquisition was performed with appropriate software.

Compounds are described by their experimental retention times (R<sub>t</sub>) and ions. If not specified differently in the table of data, the reported molecular ion corresponds to the [M+H]<sup>+</sup> (protonated molecule) and/or [M-H]<sup>-</sup> (deprotonated molecule). In case the compound was not directly ionizable the type of adduct is specified (i.e. [M+NH<sub>4</sub>]<sup>+</sup>, [M+HCOO]<sup>-</sup>, etc.). For molecules with multiple isotopic patterns (Br, Cl), the reported value is the one obtained for the lowest isotope mass. All results were obtained with experimental uncertainties that are commonly associated with the method used.


Table: LCMS Method codes (Flow expressed in mL/min; column temperature (T) in °C; Run time in minutes).
<table>
<thead>
<tr>
<th>Method code</th>
<th>Instrument</th>
<th>Column</th>
<th>Mobile phase</th>
<th>Gradient</th>
<th>Flow</th>
<th>Run time</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Waters: Acquity® UPLC® - DAD and SQD</td>
<td>Waters : BEH C18 (1.7μm, 2.1*50mm)</td>
<td>A: 10mM CH₃COONH₄ in 90% H₂O + 10% CH₃CN B: MeOH</td>
<td>From 95% A to 5% A in 1.3 min, held for 0.2 min, to 95% A in 0.2 min held for 0.1 min.</td>
<td>0.7</td>
<td>1.8</td>
</tr>
<tr>
<td>2</td>
<td>Waters: Acquity® UPLC® - DAD and SQD</td>
<td>Waters : BEH C18 (1.7μm, 2.1*50mm)</td>
<td>A: 10mM CH₃COONH₄ in 95% H₂O + 5% CH₃CN B: CH₃CN</td>
<td>From 95% A to 5% A in 1.3 min, held for 0.7 min.</td>
<td>0.8</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>Waters: Acquity® UPLC® - DAD and SQD</td>
<td>Waters : HSS T3 (1.8μm, 2.1*100mm)</td>
<td>A: 10mM CH₃COONH₄ in 95% H₂O + 5% CH₃CN B: CH₃CN</td>
<td>From 100% A to 5% A in 2.10min, to 0% A in 0.90min, to 5% A in 0.5min</td>
<td>0.7</td>
<td>3.5</td>
</tr>
<tr>
<td>4</td>
<td>Waters: Acquity® UPLC® - DAD and SQD</td>
<td>Waters : HSS T3 (1.8μm, 2.1*100mm)</td>
<td>A: 10mM CH₃COONH₄ in 95% H₂O + 5% CH₃CN B: CH₃CN</td>
<td>From 100% A to 5% A in 2.10min, to 0% A in 0.90min, to 5% A in 0.5min</td>
<td>0.7</td>
<td>3.5</td>
</tr>
<tr>
<td>5</td>
<td>Waters: Acquity® UPLC® - DAD and Quattro Micro™</td>
<td>Waters: BEH C18 (1.7μm, 2.1x100mm)</td>
<td>A: 95% CH₃COONH₄ 7mM / 5% CH₃CN, B: CH₃CN</td>
<td>84.2% A for 0.49min, to 10.5% A in 2.18min, held for 1.94min, back to 84.2% AB in 0.73min, held for 0.73min.</td>
<td>0.343</td>
<td>6.2</td>
</tr>
<tr>
<td>6</td>
<td>Agilent: 1100/1200-DAD and MSD</td>
<td>Waters: XBridgeTM Shield RP18 (5μm, 2.1x50mm)</td>
<td>A: NH₄OH 0.05% in water, B: CH₃CN</td>
<td>100% A for 1min, to 40% A in 4min, held for 2.5min, back to 100% A in 2min.</td>
<td>0.8</td>
<td>10.5</td>
</tr>
<tr>
<td>7</td>
<td>Agilent: 1200-DAD and MSD6110</td>
<td>Phenomenex: Luna-C18 (5μm, 2x50mm)</td>
<td>A: CF₃COOH 0.1% in water, B: CF₃COOH 0.05% in CH₃CN</td>
<td>100% A for 1min, to 40% A in 4min, to 15% A in 2.5min, back to 100% A in 2min.</td>
<td>0.8</td>
<td>10</td>
</tr>
<tr>
<td>8</td>
<td>Waters: Acquity® UPLC® - DAD and SQD</td>
<td>Waters : HSS T3 (1.8μm, 2.1*100mm)</td>
<td>A: 10mM CH₃COONH₄ in 95% H₂O + 5% CH₃CN B: CH₃CN</td>
<td>From 100% A to 5% A in 2.10min, to 0% A in 0.90min, to 5% A in 0.5min</td>
<td>0.7</td>
<td>3.5</td>
</tr>
</tbody>
</table>
Table: Co. No. means compound number; Retention time (R,) in min; n.d. means not determined.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.71</td>
<td>394</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>1a</td>
<td>0.60</td>
<td>394</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>2</td>
<td>1.41</td>
<td>472</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>3</td>
<td>2.00</td>
<td>520</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>4</td>
<td>0.98</td>
<td>462</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>5</td>
<td>0.66</td>
<td>394</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>6</td>
<td>0.70</td>
<td>394</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>7</td>
<td>0.76</td>
<td>394</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>8</td>
<td>0.77</td>
<td>394</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>9</td>
<td>2.31</td>
<td>393</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>10</td>
<td>0.74</td>
<td>394</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>11</td>
<td>0.65</td>
<td>394</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>12</td>
<td>0.62</td>
<td>394</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>13</td>
<td>0.66</td>
<td>394</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>14</td>
<td>0.96</td>
<td>395</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>15</td>
<td>1.02</td>
<td>395</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>16</td>
<td>0.44</td>
<td>395</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>17</td>
<td>0.58</td>
<td>395</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>18</td>
<td>0.55</td>
<td>410</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>19</td>
<td>0.91</td>
<td>424</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>0.89</td>
<td>428</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>21</td>
<td>0.83</td>
<td>408</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>22</td>
<td>1.51</td>
<td>462</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>23</td>
<td>0.88</td>
<td>437</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>24</td>
<td>0.80</td>
<td>412</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>25</td>
<td>1.39</td>
<td>428</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>26</td>
<td>0.79</td>
<td>424</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>27</td>
<td>0.97</td>
<td>462</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>28</td>
<td>0.66</td>
<td>453</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>29</td>
<td>0.47</td>
<td>434</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>30</td>
<td>0.69</td>
<td>483</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>31</td>
<td>0.50</td>
<td>464</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>32</td>
<td>1.91</td>
<td>408</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>33</td>
<td>1.36</td>
<td>428</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>34</td>
<td>0.91</td>
<td>447</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>35</td>
<td>1.11</td>
<td>462</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>36</td>
<td>0.69</td>
<td>458</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>37</td>
<td>0.96</td>
<td>462</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>38</td>
<td>0.86</td>
<td>462</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>39</td>
<td>2.00</td>
<td>408</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Co. No.</td>
<td>Rt</td>
<td>[M+H]+</td>
<td>LCMS Method</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-------</td>
<td>--------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>1.90</td>
<td>520</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>41</td>
<td>0.70</td>
<td>428</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>1.01</td>
<td>506</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>43</td>
<td>0.98</td>
<td>486</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>44</td>
<td>1.24</td>
<td>412</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>0.97</td>
<td>472</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>46</td>
<td>0.84</td>
<td>392</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>47</td>
<td>1.49</td>
<td>470</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>0.79</td>
<td>410</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>49</td>
<td>1.61</td>
<td>393</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>1.36</td>
<td>427</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>51</td>
<td>1.39</td>
<td>471</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>52</td>
<td>1.43</td>
<td>485</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>53</td>
<td>0.99</td>
<td>485</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>54</td>
<td>1.04</td>
<td>469</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>1.29</td>
<td>388</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>56</td>
<td>0.91</td>
<td>390</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>57</td>
<td>1.12</td>
<td>422</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>57a</td>
<td>1.44</td>
<td>424</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>1.77</td>
<td>424</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>59</td>
<td>1.45</td>
<td>426</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>60</td>
<td>0.69</td>
<td>394</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>61</td>
<td>0.76</td>
<td>390</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>62</td>
<td>0.81</td>
<td>392</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>63</td>
<td>1.97</td>
<td>388</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>64</td>
<td>0.82</td>
<td>392</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>65</td>
<td>0.76</td>
<td>392</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>66</td>
<td>1.24</td>
<td>376</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>67</td>
<td>0.79</td>
<td>408</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>68</td>
<td>0.82</td>
<td>408</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>69</td>
<td>0.50</td>
<td>395</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>70</td>
<td>0.74</td>
<td>419</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>71</td>
<td>0.95</td>
<td>487</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>72</td>
<td>1.22</td>
<td>602</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>73</td>
<td>1.17</td>
<td>612</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>74</td>
<td>0.80</td>
<td>459</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>75</td>
<td>4.23</td>
<td>469</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>76</td>
<td>3.65</td>
<td>405</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>77</td>
<td>0.90</td>
<td>390</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>78</td>
<td>2.77</td>
<td>419</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>79</td>
<td>3.59</td>
<td>420</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>80</td>
<td>2.99</td>
<td>483</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>81</td>
<td>3.08</td>
<td>439</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>245</td>
<td>3.06</td>
<td>437</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>246</td>
<td>3.41</td>
<td>451</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>85</td>
<td>3.50</td>
<td>392</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>175</td>
<td>3.52</td>
<td>438</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>82</td>
<td>1.24</td>
<td>408</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>83</td>
<td>1.26</td>
<td>408</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>54a</td>
<td>1.43</td>
<td>469</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>91</td>
<td>2.80</td>
<td>428</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>86</td>
<td>1.84</td>
<td>504</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>87</td>
<td>0.89</td>
<td>486</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>88</td>
<td>0.94</td>
<td>500</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>84</td>
<td>1.38</td>
<td>434</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>89</td>
<td>1.02</td>
<td>534</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>90</td>
<td>1.57</td>
<td>375</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>92</td>
<td>1.52</td>
<td>506</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>94</td>
<td>1.43</td>
<td>506</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>217</td>
<td>0.87</td>
<td>408</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>222</td>
<td>3.64</td>
<td>426</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>95</td>
<td>1.21</td>
<td>376</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>96</td>
<td>3.98</td>
<td>540</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>97</td>
<td>3.51</td>
<td>451</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>98</td>
<td>1.16</td>
<td>419</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>99</td>
<td>3.68</td>
<td>462</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>1.49</td>
<td>462</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>219</td>
<td>1.43</td>
<td>507</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>213</td>
<td>2.82</td>
<td>422</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>101</td>
<td>1.40</td>
<td>462</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>220</td>
<td>1.34</td>
<td>473</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>102</td>
<td>1.35</td>
<td>428</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>212</td>
<td>4.04</td>
<td>434</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>214</td>
<td>2.99</td>
<td>436</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>103</td>
<td>1.21</td>
<td>392</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>104</td>
<td>2.89</td>
<td>424</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>105</td>
<td>3.65</td>
<td>452</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>218</td>
<td>3.39</td>
<td>409</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>106</td>
<td>1.45</td>
<td>490</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>107</td>
<td>3.25</td>
<td>499</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>108</td>
<td>1.49</td>
<td>486</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>109</td>
<td>3.24</td>
<td>462</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>110</td>
<td>3.72</td>
<td>424</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>118</td>
<td>3.60</td>
<td>423</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>111</td>
<td>1.49</td>
<td>470</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>112</td>
<td>3.19</td>
<td>450</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>113</td>
<td>2.92</td>
<td>404</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>114</td>
<td>2.17</td>
<td>548</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Co. No.</td>
<td>Rt</td>
<td>[M+H]⁺</td>
<td>LCMS Method</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-----</td>
<td>--------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>115</td>
<td>2.90</td>
<td>478</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>116</td>
<td>0.79</td>
<td>459</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>117</td>
<td>1.60</td>
<td>459</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>118</td>
<td>1.60</td>
<td>459</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>119</td>
<td>1.60</td>
<td>459</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>120</td>
<td>2.75</td>
<td>438</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>121</td>
<td>1.71</td>
<td>438</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>122</td>
<td>2.97</td>
<td>420</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>123</td>
<td>3.82</td>
<td>406</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>124</td>
<td>2.53</td>
<td>529</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>189</td>
<td>3.16</td>
<td>451</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>166</td>
<td>3.01</td>
<td>444</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>125</td>
<td>3.10</td>
<td>418</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>126</td>
<td>2.98</td>
<td>419</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>127</td>
<td>3.14</td>
<td>550</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>128</td>
<td>3.55</td>
<td>440</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>171</td>
<td>2.55</td>
<td>514</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>164</td>
<td>2.93</td>
<td>404</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>129</td>
<td>1.58</td>
<td>468</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>130</td>
<td>3.13</td>
<td>428</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>131</td>
<td>2.01</td>
<td>552</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>132</td>
<td>3.44</td>
<td>533</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>176</td>
<td>3.01</td>
<td>418</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>190</td>
<td>3.02</td>
<td>458</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>172</td>
<td>3.42</td>
<td>480</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>193</td>
<td>2.35</td>
<td>528</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>133</td>
<td>3.29</td>
<td>426</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>134</td>
<td>2.58</td>
<td>407</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>167</td>
<td>2.87</td>
<td>392</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>135</td>
<td>1.74</td>
<td>531</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>136</td>
<td>3.20</td>
<td>442</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>187</td>
<td>1.36</td>
<td>424</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>137</td>
<td>2.89</td>
<td>421</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>169</td>
<td>3.83</td>
<td>406</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>138</td>
<td>3.82</td>
<td>480</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>191</td>
<td>3.79</td>
<td>476</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>139</td>
<td>3.13</td>
<td>461</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>165</td>
<td>2.55</td>
<td>516</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>140</td>
<td>1.81</td>
<td>482</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>192</td>
<td>3.77</td>
<td>406</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>168</td>
<td>3.20</td>
<td>446</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>186</td>
<td>2.78</td>
<td>423</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>163</td>
<td>3.48</td>
<td>394</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>177</td>
<td>2.54</td>
<td>530</td>
<td>11</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Co. No.</th>
<th>Rt</th>
<th>[M+H]⁺</th>
<th>LCMS Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>141</td>
<td>3.24</td>
<td>460</td>
<td>7</td>
</tr>
<tr>
<td>142</td>
<td>3.06</td>
<td>463</td>
<td>7</td>
</tr>
<tr>
<td>205</td>
<td>2.48</td>
<td>532</td>
<td>11</td>
</tr>
<tr>
<td>208</td>
<td>1.03</td>
<td>410</td>
<td>8</td>
</tr>
<tr>
<td>143</td>
<td>3.74</td>
<td>425</td>
<td>7</td>
</tr>
<tr>
<td>174</td>
<td>3.71</td>
<td>408</td>
<td>6</td>
</tr>
<tr>
<td>170</td>
<td>3.09</td>
<td>448</td>
<td>7</td>
</tr>
<tr>
<td>173</td>
<td>4.76</td>
<td>518</td>
<td>6</td>
</tr>
<tr>
<td>144</td>
<td>1.34</td>
<td>520</td>
<td>4</td>
</tr>
<tr>
<td>215</td>
<td>3.96</td>
<td>425</td>
<td>6</td>
</tr>
<tr>
<td>216</td>
<td>4.67</td>
<td>406</td>
<td>6</td>
</tr>
<tr>
<td>145</td>
<td>3.85</td>
<td>446</td>
<td>6</td>
</tr>
<tr>
<td>146</td>
<td>3.38</td>
<td>473</td>
<td>7</td>
</tr>
<tr>
<td>147</td>
<td>2.26</td>
<td>493</td>
<td>11</td>
</tr>
<tr>
<td>148</td>
<td>1.96</td>
<td>537</td>
<td>8</td>
</tr>
<tr>
<td>149</td>
<td>3.22</td>
<td>447</td>
<td>7</td>
</tr>
<tr>
<td>150</td>
<td>3.36</td>
<td>461</td>
<td>7</td>
</tr>
<tr>
<td>221</td>
<td>3.14</td>
<td>406</td>
<td>7</td>
</tr>
<tr>
<td>151</td>
<td>3.07</td>
<td>487</td>
<td>7</td>
</tr>
<tr>
<td>152</td>
<td>3.17</td>
<td>445</td>
<td>7</td>
</tr>
<tr>
<td>153</td>
<td>4.75</td>
<td>523</td>
<td>6</td>
</tr>
<tr>
<td>154</td>
<td>1.54</td>
<td>473</td>
<td>8</td>
</tr>
<tr>
<td>155</td>
<td>1.75</td>
<td>477</td>
<td>8</td>
</tr>
<tr>
<td>178</td>
<td>3.06</td>
<td>433</td>
<td>7</td>
</tr>
<tr>
<td>179</td>
<td>3.20</td>
<td>459</td>
<td>7</td>
</tr>
<tr>
<td>194</td>
<td>3.09</td>
<td>453</td>
<td>7</td>
</tr>
<tr>
<td>156</td>
<td>3.28</td>
<td>459</td>
<td>7</td>
</tr>
<tr>
<td>211</td>
<td>4.80</td>
<td>470</td>
<td>6</td>
</tr>
<tr>
<td>180</td>
<td>3.72</td>
<td>434</td>
<td>7</td>
</tr>
<tr>
<td>181</td>
<td>3.89</td>
<td>460</td>
<td>7</td>
</tr>
<tr>
<td>188</td>
<td>5.10</td>
<td>502</td>
<td>6</td>
</tr>
<tr>
<td>182</td>
<td>4.91</td>
<td>484</td>
<td>6</td>
</tr>
<tr>
<td>195</td>
<td>4.61</td>
<td>454</td>
<td>6</td>
</tr>
<tr>
<td>196</td>
<td>2.30</td>
<td>481</td>
<td>11</td>
</tr>
<tr>
<td>157</td>
<td>3.03</td>
<td>437</td>
<td>7</td>
</tr>
<tr>
<td>183</td>
<td>2.32</td>
<td>473</td>
<td>11</td>
</tr>
<tr>
<td>209</td>
<td>2.30</td>
<td>473</td>
<td>11</td>
</tr>
<tr>
<td>184</td>
<td>3.16</td>
<td>483</td>
<td>7</td>
</tr>
<tr>
<td>197</td>
<td>4.45</td>
<td>479</td>
<td>6</td>
</tr>
<tr>
<td>210</td>
<td>2.91</td>
<td>474</td>
<td>11</td>
</tr>
<tr>
<td>158</td>
<td>3.90</td>
<td>441</td>
<td>6</td>
</tr>
<tr>
<td>198</td>
<td>4.03</td>
<td>455</td>
<td>6</td>
</tr>
<tr>
<td>200</td>
<td>4.67</td>
<td>488</td>
<td>6</td>
</tr>
<tr>
<td>161</td>
<td>1.85</td>
<td>515</td>
<td>8</td>
</tr>
</tbody>
</table>
EXPERIMENTAL PROCEDURES

**in vitro assay (assay 1a and 1b)**

**Reagents.** PRMT5-MEP50 enzyme was purchased from Charles River (Argenta). The enzyme complex was produced in insect cells (Sf9) infected simultaneously with two baculoviruses. One virus expresses full length human PRMT5 with Flag-tag at N-terminus, the second virus expresses full length MEP50 with His6-TEV cleavage at N-terminus. The protein was affinity purified using anti-Flag (M2) beads eluted with 3xFLAG peptide, followed by His-Select eluted with 0.5M imidazole. Eluted protein was then dialysed against tris-buffered saline (TBS) (pH 8.0) containing 20% glycerol and 3mM dithiothreitol (DTT).

Full-length untagged human recombinant histone H2A (residues 1-130, Genbank Accession# NM_021052, MW = 14.1 kDa) expressed in E. coli was purchased from Reaction Biology Corporation, Cat# HMT-1 1-146. Reagents used for making reaction buffer or stopping reaction were purchased including Tris base (Sigma Cat# T-1503), NaCl (Sigma Cat# RGF-3270), MgCl2 (Sigma Cat # M0250), DTT (Invitrogen Cat# 15508-013) and Formic Acid (Riedel deHaen, Cat# 33015)

**High Throughput Mass Spectrometer Assay** PRMT5 catalyzes the sequential methylations of the terminal nitrogen atoms on the guanidine groups of arginine residues within proteins using co-substrate S-adenosyl-L-methionine (AdoMet, SAM), forming mono-methyl (MMA), symmetric-dimethyl arginine (sDMA) and S-adenosyl-
L-homocysteine (AdoHcy, SAH). The enzyme activity was determined by following the product SAH formation using high throughput mass spectrometry (Agilent Rapidfire 300 System coupled to a Sciex 4000 series QTrap® triple-quad MS/MS). The reaction buffer was 20 mM Tris-HCl, pH 8.5, 50 mM NaCl, 5 mM MgCl₂ and 1 mM DTT. The reaction activity was stopped using 1% formic acid (final concentration).

**Inhibition Studies.** The IC₅₀ Studies were performed using eleven point dosing series made for each compound by serially diluted 1:2 in dimethyl sulfoxide (DMSO), with point 12 being a DMSO control. Compounds were first spotted to plates, and followed by addition of 2 µM SAM and 0.6 µM H2A (histone H2A) solution mixture. The same volume of enzyme solution was added to initiate the enzymatic reactions. The final concentrations of the reaction are at 1 µM SAM, 0.3 µM H2A and 10 nM enzyme (assay 1a) or 1.25 nM enzyme (assay 1b). The reaction was incubated at 30 °C for 60 minutes (min) when 10 nM enzyme was used and for 120 min when 1.25 nM enzyme was used. Subsequently, the reaction was quenched by addition of formic acid to a final concentration of 1%. The inhibitions of SAH formation in the presence of compounds were calculated as a percentage of the control relative to the uninhibited reaction as a function of inhibitor concentration. The data were fit as follows:

\[ Y = \text{Bottom} + (\text{Top} - \text{Bottom})/(1+10^{\left((\log \text{IC}_{50} - \text{X})^{h}\right)}) \]

where IC₅₀ is the inhibitor concentration (same unit as X) at 50% inhibition and h is the Hill slope. Y is percent of inhibition, X is log of compound concentration. Bottom and Top are the plateaus in same units as Y.

**EXPERIMENTAL PROCEDURE PD assay (assay 2)**

**Reagents**

A549 cells (ATCC, Cat # CCL-185) were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Sigma, Cat #D5796), supplemented with 10% Fetal Calf Serum (FCS) (HyClone™, Cat #SV30 160.03), 100 mM Sodium Pyruvate (Sigma, Cat #S8636), 200 mM L-Glutamine (Sigma, Cat #G7513) and 50 mg/mL Gentamycin (Gibco, Cat #15750-037).

Reagents used for buffers were purchased: Dulbecco's phosphate buffered saline (DPBS) without Ca/Mg (Sigma, Cat #D8537), phosphate buffered saline (PBS) 10X (Roche, Cat #11 666 789 001), Formalin solution 10% (Sigma, HT50-1-128-4L), Methanol 100% (Sigma, Cat #32213-2.5L), Triton X-100 (Acros, Cat #215680010), Bovine Serum Albumin (BSA) (Sigma, Cat #A2153), Alexa fluor 488 goat anti-rabbit antibody (Life Technologies, Cat # A1 1034), HCS CellMask Deep Red Stain (Life Technologies, Cat #H32721), Hoechst Stain (Life Technologies, Cat #33258), Anti-dimethyl-Arginine, sym (SYM10) antibody (Millipore, 07-412).
Immunohistochemistry procedure

Cells were plated at 400 cells/40μL/well in 384 well black μ ρ clear bottom (Perkin Elmer) and overnight incubated at 37°C, 5% CO₂. The IC₅₀ Studies were performed using nine point dosing series ranging from 10 μM to 1 pM for each compound. 80 nL of the respective dilution of the compounds was added using the Labcyte POD 810 (Labcyte) reaching a final DMSO concentration of 0.2% in cell culture. After an incubation period of 48h at 37°C and 5% CO₂, cells were fixed in 10% formalin solution for 15 min at room temperature and 20 min in ice-cold methanol, after which they were washed 3x in DPBS. Subsequently, the cells were blocked for 1 h in blocking buffer (PBS + 1% BSA and 0.5% Triton X-100) and incubated overnight at 4°C with the SYM10 antibody diluted 1/2000 in blocking buffer. The cells were washed 3x with washing buffer (PBS + 0.1% Triton X-100) and incubated with the Alexa fluor 488 goat anti-rabbit antibody diluted 1/200 in blocking buffer for 1 h at room temperature. Subsequently, they were washed 3x with washing buffer and incubated for 30 min at room temperature with PBS containing a 1/5000 dilution of Hoechst Stain and a 1/5000 dilution of the HCS CellMask Deep Red Stain. After a final wash with PBS, the plates were imaged using the 10xW lens of the Opera® system (Perkin Elmer Life Sciences) using following settings (values in nm):

<table>
<thead>
<tr>
<th>laser</th>
<th>Filter camera</th>
<th>Primary dichrome</th>
<th>Detect dichrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>488</td>
<td>540/75</td>
<td>405/488/561/635</td>
<td>510</td>
</tr>
<tr>
<td>405</td>
<td>450/50</td>
<td>405/488/561/635</td>
<td>510</td>
</tr>
<tr>
<td>635</td>
<td>690/50</td>
<td>405/488/561/635</td>
<td>510</td>
</tr>
</tbody>
</table>

Analyses:

The inhibition of nuclear symmetric Arginine dimethylation in the presence of compounds (% effect) was calculated as the "median nuclear SYM10 intensity" / "median cytoplasmic SYM10 intensity", normalized by below equation:

\[
\text{normalized} = 100 - \frac{\text{raw-lowMedian}}{\text{highMedian-lowMedian}} * 100
\]

In the above equations, the following variable names are used:

<table>
<thead>
<tr>
<th>normalized</th>
<th>The normalized feature value</th>
</tr>
</thead>
<tbody>
<tr>
<td>raw</td>
<td>The raw feature value</td>
</tr>
<tr>
<td>lowMedian</td>
<td>The median of the raw values of the low control wells</td>
</tr>
<tr>
<td>highMedian</td>
<td>The median of the raw values of the high control wells</td>
</tr>
</tbody>
</table>
In the above equations, the following controls were used for normalization:

Low control: minimum level of symmetrically dimethylated Arginines (cells treated with reference compound at 10 µM).

High control: maximum level of symmetrically dimethylated Arginines (DMSO treated cells).

IC50 and pIC50 (-logIC50) values were calculated using the appropriate software.

The pIC50 values in the Table below are averaged values (Co. No. means compound number; n.d. means not determined).

<table>
<thead>
<tr>
<th>Co. No.</th>
<th>pIC50 Assay 1a</th>
<th>pIC50 Assay 1b</th>
<th>pIC50 Assay 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>5.7</td>
<td>5.3</td>
<td>&lt;5</td>
</tr>
<tr>
<td>1</td>
<td>7.8</td>
<td>7.9</td>
<td>7.1</td>
</tr>
<tr>
<td>1a</td>
<td>n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td>10</td>
<td>5.5</td>
<td>5.4</td>
<td>-5.15</td>
</tr>
<tr>
<td>6</td>
<td>5.5</td>
<td>5.3</td>
<td>&lt;5</td>
</tr>
<tr>
<td>11</td>
<td>5.5</td>
<td>5.1</td>
<td>&lt;5</td>
</tr>
<tr>
<td>12</td>
<td>5.8</td>
<td>5.4</td>
<td>&lt;5</td>
</tr>
<tr>
<td>8</td>
<td>5.2</td>
<td>4.9</td>
<td>&lt;5</td>
</tr>
<tr>
<td>7</td>
<td>5.9</td>
<td>5.6</td>
<td>-4.76</td>
</tr>
<tr>
<td>13</td>
<td>6.1</td>
<td>5.7</td>
<td>4.8</td>
</tr>
<tr>
<td>14</td>
<td>5.9</td>
<td>5.6</td>
<td>&lt;4.7</td>
</tr>
<tr>
<td>33</td>
<td>6.8</td>
<td>6.1</td>
<td>6.3</td>
</tr>
<tr>
<td>22</td>
<td>5.2</td>
<td>4.6</td>
<td>-4.75</td>
</tr>
<tr>
<td>2</td>
<td>8.1</td>
<td>7.6</td>
<td>7.4</td>
</tr>
<tr>
<td>15</td>
<td>6.0</td>
<td>n.d.</td>
<td>&lt;5.4</td>
</tr>
<tr>
<td>66</td>
<td>5.7</td>
<td>5.3</td>
<td>&lt;4.7</td>
</tr>
<tr>
<td>45</td>
<td>6.6</td>
<td>n.d.</td>
<td>6.2</td>
</tr>
<tr>
<td>44</td>
<td>7.2</td>
<td>6.9</td>
<td>6.6</td>
</tr>
<tr>
<td>25</td>
<td>7.9</td>
<td>7.4</td>
<td>6.9</td>
</tr>
<tr>
<td>9</td>
<td>5.5</td>
<td>n.d.</td>
<td>&lt;4.7</td>
</tr>
<tr>
<td>60</td>
<td>6.6</td>
<td>6.4</td>
<td>5.9</td>
</tr>
<tr>
<td>46</td>
<td>7.7</td>
<td>7.2</td>
<td>6.9</td>
</tr>
<tr>
<td>48</td>
<td>7.0</td>
<td>n.d.</td>
<td>6.4</td>
</tr>
<tr>
<td>68</td>
<td>5.6</td>
<td>&lt;4</td>
<td>-5.14</td>
</tr>
<tr>
<td>67</td>
<td>7.0</td>
<td>n.d.</td>
<td>6.5</td>
</tr>
<tr>
<td>17</td>
<td>6.0</td>
<td>5.8</td>
<td>5.1</td>
</tr>
<tr>
<td>245</td>
<td>5.7</td>
<td>5.5</td>
<td>&lt;4.7</td>
</tr>
<tr>
<td>49</td>
<td>8.4</td>
<td>8.0</td>
<td>8.0</td>
</tr>
<tr>
<td>16</td>
<td>6.6</td>
<td>5.9</td>
<td>5.3</td>
</tr>
<tr>
<td>61</td>
<td>6.4</td>
<td>6.0</td>
<td>-5.88</td>
</tr>
<tr>
<td>Co. No.</td>
<td>pIC\textsubscript{50} Assay 1a</td>
<td>pIC\textsubscript{50} Assay 1b</td>
<td>pIC\textsubscript{50} Assay 2</td>
</tr>
<tr>
<td>---------</td>
<td>----------------</td>
<td>----------------</td>
<td>----------------</td>
</tr>
<tr>
<td>26</td>
<td>7.2</td>
<td>6.7</td>
<td>~6.6</td>
</tr>
<tr>
<td>70</td>
<td>6.2</td>
<td>5.8</td>
<td>5.2</td>
</tr>
<tr>
<td>4</td>
<td>7.2</td>
<td>6.7</td>
<td>~6.21</td>
</tr>
<tr>
<td>42</td>
<td>7.3</td>
<td>6.9</td>
<td>6.5</td>
</tr>
<tr>
<td>41</td>
<td>5.2</td>
<td>5.0</td>
<td>&lt;5</td>
</tr>
<tr>
<td>43</td>
<td>7.1</td>
<td>6.7</td>
<td>6.5</td>
</tr>
<tr>
<td>37</td>
<td>6.0</td>
<td>6.2</td>
<td>5.3</td>
</tr>
<tr>
<td>82</td>
<td>6.7</td>
<td>6.3</td>
<td>5.9</td>
</tr>
<tr>
<td>83</td>
<td>7.4</td>
<td>6.9</td>
<td>6.7</td>
</tr>
<tr>
<td>54</td>
<td>7.8</td>
<td>7.8</td>
<td>7.5</td>
</tr>
<tr>
<td>54a</td>
<td>8.1</td>
<td>7.8</td>
<td>7.4</td>
</tr>
<tr>
<td>91</td>
<td>6.9</td>
<td>6.3</td>
<td>6.4</td>
</tr>
<tr>
<td>57a</td>
<td>7.5</td>
<td>7.3</td>
<td>7.2</td>
</tr>
<tr>
<td>47</td>
<td>7.6</td>
<td>7.2</td>
<td>7.3</td>
</tr>
<tr>
<td>86</td>
<td>5.6</td>
<td>6.0</td>
<td>5.3</td>
</tr>
<tr>
<td>72</td>
<td>&lt;5</td>
<td>&lt;4</td>
<td>&lt;5</td>
</tr>
<tr>
<td>50</td>
<td>8.0</td>
<td>8.1</td>
<td>7.6</td>
</tr>
<tr>
<td>38</td>
<td>6.7</td>
<td>6.4</td>
<td>6.1</td>
</tr>
<tr>
<td>52</td>
<td>7.2</td>
<td>6.8</td>
<td>6.4</td>
</tr>
<tr>
<td>87</td>
<td>6.3</td>
<td>6.0</td>
<td>5.8</td>
</tr>
<tr>
<td>88</td>
<td>&lt;5</td>
<td>5.1</td>
<td>&lt;5</td>
</tr>
<tr>
<td>53</td>
<td>7.4</td>
<td>7.3</td>
<td>7.3</td>
</tr>
<tr>
<td>73</td>
<td>&lt;5</td>
<td>&lt;4</td>
<td>7.0</td>
</tr>
<tr>
<td>84</td>
<td>7.8</td>
<td>7.1</td>
<td>6.7</td>
</tr>
<tr>
<td>89</td>
<td>&lt;5</td>
<td>4.5</td>
<td>7.2</td>
</tr>
<tr>
<td>90</td>
<td>7.0</td>
<td>6.2</td>
<td>&lt;5</td>
</tr>
<tr>
<td>57</td>
<td>7.5</td>
<td>n.d.</td>
<td>~6.82</td>
</tr>
<tr>
<td>92</td>
<td>7.2</td>
<td>n.d.</td>
<td>6.1</td>
</tr>
<tr>
<td>94</td>
<td>6.0</td>
<td>n.d.</td>
<td>~6</td>
</tr>
<tr>
<td>217</td>
<td>8.3</td>
<td>7.7</td>
<td>7.4</td>
</tr>
<tr>
<td>222</td>
<td>7.5</td>
<td>7.2</td>
<td>~6.76</td>
</tr>
<tr>
<td>95</td>
<td>6.5</td>
<td>6.3</td>
<td>&lt;5</td>
</tr>
<tr>
<td>59</td>
<td>7.6</td>
<td>7.1</td>
<td>6.9</td>
</tr>
<tr>
<td>96</td>
<td>6.7</td>
<td>6.3</td>
<td>6.7</td>
</tr>
<tr>
<td>97</td>
<td>&lt;5</td>
<td>4.8</td>
<td>&lt;5</td>
</tr>
<tr>
<td>58</td>
<td>7.9</td>
<td>7.7</td>
<td>7.4</td>
</tr>
<tr>
<td>98</td>
<td>6.2</td>
<td>5.8</td>
<td>5.0</td>
</tr>
<tr>
<td>99</td>
<td>&lt;5</td>
<td>&lt;4</td>
<td>&lt;5</td>
</tr>
<tr>
<td>100</td>
<td>6.9</td>
<td>6.7</td>
<td>6.1</td>
</tr>
<tr>
<td>219</td>
<td>5.4</td>
<td>&lt;4</td>
<td>5.1</td>
</tr>
<tr>
<td>213</td>
<td>8.1</td>
<td>7.8</td>
<td>7.2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Co. No.</th>
<th>pIC\textsubscript{50} Assay 1a</th>
<th>pIC\textsubscript{50} Assay 1b</th>
<th>pIC\textsubscript{50} Assay 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>101</td>
<td>6.0</td>
<td>6.1</td>
<td>5.7</td>
</tr>
<tr>
<td>220</td>
<td>6.5</td>
<td>6.3</td>
<td>5.6</td>
</tr>
<tr>
<td>102</td>
<td>7.0</td>
<td>6.3</td>
<td>&lt;5</td>
</tr>
<tr>
<td>212</td>
<td>7.7</td>
<td>7.3</td>
<td>6.7</td>
</tr>
<tr>
<td>214</td>
<td>7.5</td>
<td>7.0</td>
<td>6.4</td>
</tr>
<tr>
<td>103</td>
<td>6.4</td>
<td>5.9</td>
<td>5.1</td>
</tr>
<tr>
<td>104</td>
<td>5.3</td>
<td>4.8</td>
<td>&lt;5</td>
</tr>
<tr>
<td>105</td>
<td>6.8</td>
<td>6.0</td>
<td>5.6</td>
</tr>
<tr>
<td>218</td>
<td>8.6</td>
<td>8.3</td>
<td>8.3</td>
</tr>
<tr>
<td>106</td>
<td>7.2</td>
<td>6.8</td>
<td>6.4</td>
</tr>
<tr>
<td>107</td>
<td>8.9</td>
<td>8.4</td>
<td>8.4</td>
</tr>
<tr>
<td>108</td>
<td>7.4</td>
<td>7.0</td>
<td>7.2</td>
</tr>
<tr>
<td>109</td>
<td>6.9</td>
<td>6.7</td>
<td>6.0</td>
</tr>
<tr>
<td>110</td>
<td>8.7</td>
<td>8.8</td>
<td>9.3</td>
</tr>
<tr>
<td>185</td>
<td>8.4</td>
<td>8.1</td>
<td>7.3</td>
</tr>
<tr>
<td>111</td>
<td>7.9</td>
<td>7.4</td>
<td>7.2</td>
</tr>
<tr>
<td>112</td>
<td>7.3</td>
<td>6.7</td>
<td>6.4</td>
</tr>
<tr>
<td>113</td>
<td>8.3</td>
<td>8.0</td>
<td>8.3</td>
</tr>
<tr>
<td>114</td>
<td>7.8</td>
<td>7.6</td>
<td>7.9</td>
</tr>
<tr>
<td>115</td>
<td>8.0</td>
<td>8.3</td>
<td>~8.26</td>
</tr>
<tr>
<td>74</td>
<td>9.1</td>
<td>9.9</td>
<td>9.4</td>
</tr>
<tr>
<td>117</td>
<td>n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td>118</td>
<td>n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td>119</td>
<td>n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td>120</td>
<td>7.1</td>
<td>6.5</td>
<td>6.5</td>
</tr>
<tr>
<td>121</td>
<td>8.4</td>
<td>8.4</td>
<td>7.7</td>
</tr>
<tr>
<td>122</td>
<td>7.9</td>
<td>7.3</td>
<td>7.1</td>
</tr>
<tr>
<td>123</td>
<td>8.3</td>
<td>7.4</td>
<td>7.5</td>
</tr>
<tr>
<td>124</td>
<td>8.7</td>
<td>8.3</td>
<td>9.2</td>
</tr>
<tr>
<td>189</td>
<td>6.5</td>
<td>6.0</td>
<td>6.6</td>
</tr>
<tr>
<td>166</td>
<td>9.0</td>
<td>8.3</td>
<td>9.0</td>
</tr>
<tr>
<td>125</td>
<td>8.4</td>
<td>7.6</td>
<td>7.7</td>
</tr>
<tr>
<td>126</td>
<td>9.3</td>
<td>8.6</td>
<td>9.5</td>
</tr>
<tr>
<td>127</td>
<td>7.9</td>
<td>7.0</td>
<td>6.9</td>
</tr>
<tr>
<td>128</td>
<td>8.1</td>
<td>7.2</td>
<td>6.7</td>
</tr>
<tr>
<td>171</td>
<td>9.1</td>
<td>8.2</td>
<td>8.5</td>
</tr>
<tr>
<td>164</td>
<td>9.4</td>
<td>8.0</td>
<td>&gt;8.93</td>
</tr>
<tr>
<td>129</td>
<td>8.6</td>
<td>7.8</td>
<td>7.9</td>
</tr>
<tr>
<td>130</td>
<td>9.2</td>
<td>8.1</td>
<td>7.9</td>
</tr>
<tr>
<td>131</td>
<td>8.1</td>
<td>7.2</td>
<td>~7.18</td>
</tr>
<tr>
<td>Co. No.</td>
<td>pIC&lt;sub&gt;50&lt;/sub&gt; Assay 1a</td>
<td>pIC&lt;sub&gt;50&lt;/sub&gt; Assay 1b</td>
<td>pIC&lt;sub&gt;50&lt;/sub&gt; Assay 2</td>
</tr>
<tr>
<td>---------</td>
<td>----------------</td>
<td>----------------</td>
<td>----------------</td>
</tr>
<tr>
<td>132</td>
<td>9.1</td>
<td>8.6</td>
<td>8.6</td>
</tr>
<tr>
<td>76</td>
<td>9.6</td>
<td>n.d.</td>
<td>9.8</td>
</tr>
<tr>
<td>176</td>
<td>9.3</td>
<td>8.4</td>
<td>8.5</td>
</tr>
<tr>
<td>190</td>
<td>9.3</td>
<td>8.3</td>
<td>&lt;8.73</td>
</tr>
<tr>
<td>172</td>
<td>9.3</td>
<td>8.4</td>
<td>&gt;8.93</td>
</tr>
<tr>
<td>193</td>
<td>9.0</td>
<td>8.1</td>
<td>8.5</td>
</tr>
<tr>
<td>133</td>
<td>9.2</td>
<td>8.2</td>
<td>8.2</td>
</tr>
<tr>
<td>134</td>
<td>9.4</td>
<td>8.5</td>
<td>8.8</td>
</tr>
<tr>
<td>167</td>
<td>9.1</td>
<td>8.3</td>
<td>8.5</td>
</tr>
<tr>
<td>135</td>
<td>9.0</td>
<td>8.2</td>
<td>8.53</td>
</tr>
<tr>
<td>136</td>
<td>8.1</td>
<td>7.3</td>
<td>6.3</td>
</tr>
<tr>
<td>187</td>
<td>8.0</td>
<td>7.1</td>
<td>7.6</td>
</tr>
<tr>
<td>137</td>
<td>8.8</td>
<td>7.7</td>
<td>8.2</td>
</tr>
<tr>
<td>169</td>
<td>8.0</td>
<td>7.2</td>
<td>7.3</td>
</tr>
<tr>
<td>138</td>
<td>8.1</td>
<td>7.1</td>
<td>6.9</td>
</tr>
<tr>
<td>191</td>
<td>6.7</td>
<td>6.2</td>
<td>5.9</td>
</tr>
<tr>
<td>139</td>
<td>8.9</td>
<td>8.0</td>
<td>8.2</td>
</tr>
<tr>
<td>165</td>
<td>8.4</td>
<td>7.5</td>
<td>7.7</td>
</tr>
<tr>
<td>140</td>
<td>8.2</td>
<td>7.3</td>
<td>6.1</td>
</tr>
<tr>
<td>192</td>
<td>9.2</td>
<td>8.0</td>
<td>8.5</td>
</tr>
<tr>
<td>168</td>
<td>8.4</td>
<td>7.3</td>
<td>6.9</td>
</tr>
<tr>
<td>186</td>
<td>8.7</td>
<td>7.8</td>
<td>7.1</td>
</tr>
<tr>
<td>163</td>
<td>9.3</td>
<td>8.3</td>
<td>8.2</td>
</tr>
<tr>
<td>177</td>
<td>8.0</td>
<td>7.5</td>
<td>7.2</td>
</tr>
<tr>
<td>141</td>
<td>8.1</td>
<td>7.3</td>
<td>7.2</td>
</tr>
<tr>
<td>142</td>
<td>8.9</td>
<td>8.1</td>
<td>7.8</td>
</tr>
<tr>
<td>205</td>
<td>8.5</td>
<td>7.6</td>
<td>7.3</td>
</tr>
<tr>
<td>208</td>
<td>5.6</td>
<td>5.9</td>
<td>&lt;5</td>
</tr>
<tr>
<td>143</td>
<td>8.0</td>
<td>7.3</td>
<td>5.6</td>
</tr>
<tr>
<td>174</td>
<td>8.0</td>
<td>7.3</td>
<td>6.9</td>
</tr>
<tr>
<td>170</td>
<td>8.2</td>
<td>7.2</td>
<td>7.1</td>
</tr>
<tr>
<td>173</td>
<td>8.7</td>
<td>7.8</td>
<td>7.4</td>
</tr>
<tr>
<td>77</td>
<td>9.3</td>
<td>n.d.</td>
<td>&gt;8.93</td>
</tr>
<tr>
<td>78</td>
<td>8.9</td>
<td>n.d.</td>
<td>9.5</td>
</tr>
<tr>
<td>144</td>
<td>n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td>79</td>
<td>9.4</td>
<td>n.d.</td>
<td>&gt;8.93</td>
</tr>
<tr>
<td>215</td>
<td>8.1</td>
<td>7.4</td>
<td>5.9</td>
</tr>
<tr>
<td>216</td>
<td>9.0</td>
<td>8.1</td>
<td>8.0</td>
</tr>
<tr>
<td>145</td>
<td>7.8</td>
<td>7.1</td>
<td>7.1</td>
</tr>
<tr>
<td>146</td>
<td>9.6</td>
<td>8.6</td>
<td>&gt;8.93</td>
</tr>
<tr>
<td>147</td>
<td>6.6</td>
<td>6.6</td>
<td>7.5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Co. No.</th>
<th>pIC&lt;sub&gt;50&lt;/sub&gt; Assay 1a</th>
<th>pIC&lt;sub&gt;50&lt;/sub&gt; Assay 1b</th>
<th>pIC&lt;sub&gt;50&lt;/sub&gt; Assay 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>80</td>
<td>9.9</td>
<td>9.7</td>
<td>9.6</td>
</tr>
<tr>
<td>148</td>
<td>6.4</td>
<td>6.1</td>
<td>6.7</td>
</tr>
<tr>
<td>75</td>
<td>9.6</td>
<td>9.3</td>
<td>8.8</td>
</tr>
<tr>
<td>149</td>
<td>9.5</td>
<td>8.3</td>
<td>9.0</td>
</tr>
<tr>
<td>150</td>
<td>9.0</td>
<td>7.8</td>
<td>7.5</td>
</tr>
<tr>
<td>221</td>
<td>7.6</td>
<td>6.8</td>
<td>7.3</td>
</tr>
<tr>
<td>81</td>
<td>9.6</td>
<td>n.d.</td>
<td>9.7</td>
</tr>
<tr>
<td>151</td>
<td>9.1</td>
<td>7.8</td>
<td>8.3</td>
</tr>
<tr>
<td>152</td>
<td>9.3</td>
<td>8.4</td>
<td>&gt;8.93</td>
</tr>
<tr>
<td>153</td>
<td>n.d.</td>
<td>6.7</td>
<td>7.5</td>
</tr>
<tr>
<td>154</td>
<td>n.d.</td>
<td>9.5</td>
<td>8.6</td>
</tr>
<tr>
<td>155</td>
<td>n.d.</td>
<td>6.8</td>
<td>6.6</td>
</tr>
<tr>
<td>178</td>
<td>n.d.</td>
<td>9.1</td>
<td>8.0</td>
</tr>
<tr>
<td>179</td>
<td>n.d.</td>
<td>9.2</td>
<td>8.3</td>
</tr>
<tr>
<td>194</td>
<td>n.d.</td>
<td>9.2</td>
<td>8.8</td>
</tr>
<tr>
<td>156</td>
<td>n.d.</td>
<td>9.5</td>
<td>&gt;8.93</td>
</tr>
<tr>
<td>211</td>
<td>n.d.</td>
<td>8.5</td>
<td>&lt;5.59</td>
</tr>
<tr>
<td>180</td>
<td>n.d.</td>
<td>8.9</td>
<td>7.4</td>
</tr>
<tr>
<td>181</td>
<td>n.d.</td>
<td>8.9</td>
<td>7.4</td>
</tr>
<tr>
<td>188</td>
<td>n.d.</td>
<td>7.4</td>
<td>6.2</td>
</tr>
<tr>
<td>182</td>
<td>n.d.</td>
<td>8.2</td>
<td>6.5</td>
</tr>
<tr>
<td>195</td>
<td>n.d.</td>
<td>9.3</td>
<td>7.6</td>
</tr>
<tr>
<td>196</td>
<td>n.d.</td>
<td>8.7</td>
<td>7.0</td>
</tr>
<tr>
<td>157</td>
<td>n.d.</td>
<td>6.2</td>
<td>6.3</td>
</tr>
<tr>
<td>183</td>
<td>n.d.</td>
<td>9.3</td>
<td>8.2</td>
</tr>
<tr>
<td>209</td>
<td>n.d.</td>
<td>9.5</td>
<td>7.8</td>
</tr>
<tr>
<td>184</td>
<td>n.d.</td>
<td>8.7</td>
<td>7.2</td>
</tr>
<tr>
<td>197</td>
<td>n.d.</td>
<td>9.2</td>
<td>7.5</td>
</tr>
<tr>
<td>210</td>
<td>n.d.</td>
<td>8.6</td>
<td>6.9</td>
</tr>
<tr>
<td>158</td>
<td>n.d.</td>
<td>9.9</td>
<td>8.5</td>
</tr>
<tr>
<td>198</td>
<td>n.d.</td>
<td>8.4</td>
<td>7.2</td>
</tr>
<tr>
<td>200</td>
<td>n.d.</td>
<td>8.2</td>
<td>6.0</td>
</tr>
<tr>
<td>161</td>
<td>n.d.</td>
<td>8.8</td>
<td>7.4</td>
</tr>
<tr>
<td>202</td>
<td>n.d.</td>
<td>8.8</td>
<td>7.8</td>
</tr>
<tr>
<td>203</td>
<td>n.d.</td>
<td>&lt;5.6</td>
<td>5.2</td>
</tr>
<tr>
<td>162</td>
<td>n.d.</td>
<td>8.1</td>
<td>6.8</td>
</tr>
<tr>
<td>206</td>
<td>n.d.</td>
<td>8.8</td>
<td>7.6</td>
</tr>
<tr>
<td>201</td>
<td>n.d.</td>
<td>8.8</td>
<td>7.4</td>
</tr>
<tr>
<td>159</td>
<td>n.d.</td>
<td>9.9</td>
<td>&gt;8.93</td>
</tr>
<tr>
<td>204</td>
<td>n.d.</td>
<td>8.4</td>
<td>7.2</td>
</tr>
<tr>
<td>199</td>
<td>n.d.</td>
<td>7.4</td>
<td>6.6</td>
</tr>
</tbody>
</table>
5

Composition examples

"Active ingredient" (a.i.) as used throughout these examples relates to compounds of Formula (I), and pharmaceutically acceptable addition salts, and solvates thereof; in particular to any one of the exemplified compounds.

Typical examples of recipes for the formulation of the invention are as follows:

1. Tablets

<table>
<thead>
<tr>
<th>Active ingredient</th>
<th>5 to 50 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Di-calcium phosphate</td>
<td>20 mg</td>
</tr>
<tr>
<td>Lactose</td>
<td>30 mg</td>
</tr>
<tr>
<td>Talcum</td>
<td>10 mg</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>5 mg</td>
</tr>
<tr>
<td>Potato starch</td>
<td>ad 200 mg</td>
</tr>
</tbody>
</table>

2. Suspension

An aqueous suspension is prepared for oral administration so that each milliliter contains 1 to 5 mg of active ingredient, 50 mg of sodium carboxymethyl cellulose, 1 mg of sodium benzoate, 500 mg of sorbitol and water ad 1 ml.

3. Injectable
A parenteral composition is prepared by stirring 1.5% (weight/volume) of active ingredient in 0.9% NaCl solution or in 10% by volume propylene glycol in water.

4. Ointment

<table>
<thead>
<tr>
<th>Active ingredient</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stearyl alcohol</td>
<td>3 g</td>
</tr>
<tr>
<td>Lanoline</td>
<td>5 g</td>
</tr>
<tr>
<td>White petroleum</td>
<td>15 g</td>
</tr>
<tr>
<td>Water</td>
<td>ad 100 g</td>
</tr>
</tbody>
</table>

In this Example, active ingredient can be replaced with the same amount of any of the compounds according to the present invention, in particular by the same amount of any of the exemplified compounds.
Claims

1. A compound of Formula (I)

```
Ar — Z — Y
```

wherein

- $R^1$ represents hydrogen or $-\text{C}(=\text{O})\text{-C}_1\text{alkyl}$;
- $R^2$ represents hydrogen or $-\text{C}(=\text{O})\text{-C}_1\text{alkyl}$;
- $Y$ represents $-\text{O}$, $-\text{CH}_2\text{-}$ or $-\text{CF}_2\text{-}$;
- $Z$ represents $-\text{CH}_2\text{-}$, $-\text{X-}\text{CR}_{5a}\text{R}_{5b}$, $-\text{CR}_{5a}\text{=CR}_{5d}$, $-\text{CR}_{5a}\text{R}_{5b}\text{CR}_{5f}$, or $-\text{C}=\text{C}$;

and when $Y$ represents $-\text{CH}_2\text{-}$ or $-\text{CF}_2\text{-}$, then $Z$ can also represent $-\text{O}$ or $-\text{CR}_{5a}\text{R}_{5b}\text{X}$;

- $R_{5a}$, $R_{5b}$, $R_{5c}$, $R_{5d}$, $R_{5e}$, $R_{5f}$, $R_{5g}$ and $R_{5h}$ each independently represent hydrogen or $\text{Ci}_4\text{alkyl}$;
- $X$ represents $-\text{O}$, $-\text{S}$, or $-\text{NR}_{10a}$;

2. $R^{11}$ represents hydrogen, $\text{Ci}_4\text{alkyl}$, or $\text{Ci}_4\text{alkyl}$ substituted with one substituent selected from the group consisting of $-\text{OH}$, $-\text{O-}\text{Ci}_4\text{alkyl}$, $R^{12}$, $-\text{NH}_{2}$, $-\text{NH-}\text{Ci}_4\text{alkyl}$, and $-\text{N(Ci}_{14}\text{alkyl})_2$;

- $R^{12}$ represents a 4-, 5-, 6- or 7-membered heterocyclic ring containing one nitrogen atom and optionally one oxygen atom; said 4-, 5-, 6- or 7-membered heterocyclic ring being attached to the remainder of the molecule via a ring nitrogen atom;

3. $\text{Ar}$ represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;

4. $\text{Ar}$ is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, $-\text{OH}$, $-\text{NH}_{2}$, $-\text{NH-}\text{Ci}_4\text{alkyl}$, $-\text{N(Ci}_{14}\text{alkyl})_2$, $-\text{NHR}$, $-\text{NR}_{10a}\text{R}_{10b}$, cyano, $-\text{CF}_2$, $-\text{C}(=\text{O})\text{-NH}_{2}$, $-\text{C}(=\text{O})\text{-NH-}\text{C}_{14}\text{alkyl}$, $-\text{C}(=\text{O})\text{-Ci}_4\text{alkyl}$, $-\text{Ci}_4\text{alkyloxy}$, $-\text{C}(=\text{O})\text{-}\text{Ci}_4\text{alkyl}$, $-\text{C}_3\text{cycloalkyl}$, $-\text{C}_3=\text{C}_3\text{cycloalkyl}$, $-\text{NH-C}_3\text{cycloalkyl}$, $-\text{N(Ci}_{6}\text{cycloalkyl})_2$, $\text{C}_2\text{alkenyl}$, $\text{Ci}_4\text{alkyl}$ substituted with one $\text{Ci}_4\text{alkyloxy}$, and $\text{Ci}_4\text{alkyl}$ optionally substituted with one $-\text{NR}_{10a}\text{R}_{10b}$;

- $R^{10a}$ and $R^{10b}$ each independently represent hydrogen or $\text{Ci}_4\text{alkyl}$;
R\textsuperscript{10c} and R\textsuperscript{10d} each independently represent C\textsubscript{3-6}cycloalkyl; R\textsuperscript{13}; R\textsuperscript{14}; C\textsubscript{3-6}cycloalkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH and -0-C\textsubscript{4}alkyl; Ci\textsubscript{4}alkyl substituted with one, two or three substituents each independently selected from the group consisting of halo, -OH and -0-C\textsubscript{4}alkyl; or Ci\textsubscript{4}alkyl substituted with one substituent selected from the group consisting of C\textsubscript{3-6}cycloalkyl, R\textsuperscript{13} and R\textsuperscript{14};

R\textsuperscript{13} represents a 4- to 7-membered monocyclic aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(=0)\textsubscript{p} and N; or a 6- to 11-membered bicyclic fused aromatic ring containing one, two or three heteroatoms each independently selected from O, S, S(=0)\textsubscript{p} and N;

said 4- to 7-membered monocyclic aromatic ring or 6- to 11-membered bicyclic fused aromatic ring is optionally substituted with one or two substituents selected from the group consisting of Ci\textsubscript{4}alkyl;

p represents 1 or 2;

R\textsuperscript{14} represents phenyl optionally substituted with one, two or three substituents each independently selected from the group consisting of halo;

Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2), (a-3), (a-4) and (a-5):

\begin{align*}
\text{(a-1)} & \quad \text{(a-2)} & \quad \text{(a-3)} & \quad \text{(a-4)} & \quad \text{(a-5)} \\
R\textsuperscript{3a}, R\textsuperscript{3b}, R\textsuperscript{3c}, R\textsuperscript{3d} and R\textsuperscript{3e} each independently represent hydrogen, halo, -NR\textsuperscript{a}R\textsuperscript{b}, Ci\textsubscript{4}alkyl, C\textsubscript{2-4}alkenyl, C\textsubscript{3-6}cycloalkyl, -OH, or -0-Ci\textsubscript{4}alkyl; \\
R\textsuperscript{7a} represents hydrogen; \\
R\textsuperscript{7b} represents hydrogen, C\textsubscript{3-6}cycloalkyl, or Ci\textsubscript{4}alkyl; \\
R\textsuperscript{4a}, R\textsuperscript{4b}, R\textsuperscript{4c}, R\textsuperscript{4d}, R\textsuperscript{4e}, R\textsuperscript{4f} and R\textsuperscript{4g} each independently represent hydrogen, halo, -NR\textsuperscript{a}R\textsuperscript{b}, or Ci\textsubscript{4}alkyl; \\
R\textsuperscript{8a} and R\textsuperscript{8b} each independently represent hydrogen or Ci\textsubscript{4}alkyl;
\end{align*}
Q\textsuperscript{1} represents N or CR\textsuperscript{6a};
Q\textsuperscript{2} represents N or CR\textsuperscript{6b};
Q\textsuperscript{3} represents N or CR\textsuperscript{6c};
Q\textsuperscript{4} represents N or CR\textsuperscript{6d};
provided that maximum one of Q\textsuperscript{3} and Q\textsuperscript{4} represents N;
Q\textsuperscript{5} represents N or CR\textsuperscript{6e};
Q\textsuperscript{6} represents N or CR\textsuperscript{6f};
Q\textsuperscript{7} represents N or CR\textsuperscript{6g};
Q\textsuperscript{8} represents N or CR\textsuperscript{6h};
Q\textsuperscript{9} represents N or CR\textsuperscript{6i};
Q\textsuperscript{10} represents N or CR\textsuperscript{6j};
Q\textsuperscript{11} represents N or CR\textsuperscript{6k};

Q\textsuperscript{5} represents CR\textsuperscript{2d}; Q\textsuperscript{6} represents N; and Q\textsuperscript{7} represents CR\textsuperscript{4f}; or
Q\textsuperscript{5} represents CR\textsuperscript{3d}; Q\textsuperscript{6} represents CR\textsuperscript{4e}; and Q\textsuperscript{7} represents N; or
Q\textsuperscript{5} represents N; Q\textsuperscript{6} represents CR\textsuperscript{4f}; and Q\textsuperscript{7} represents CR\textsuperscript{4g}; or
Q\textsuperscript{5} represents N; Q\textsuperscript{6} represents CR\textsuperscript{4g}; and Q\textsuperscript{7} represents N; or
Q\textsuperscript{5} represents N; Q\textsuperscript{6} represents N; and Q\textsuperscript{7} represents CR\textsuperscript{4f}; or

R\textsuperscript{6a}, R\textsuperscript{6b}, R\textsuperscript{6c}, R\textsuperscript{6d}, R\textsuperscript{6e}, R\textsuperscript{6f}, R\textsuperscript{6g}, R\textsuperscript{6h}, R\textsuperscript{6i}, and R\textsuperscript{6j} each independently represent hydrogen, halogen, Ci\textsubscript{4}alkyl, -NR\textsuperscript{9a}R\textsuperscript{9b}, or Ci\textsubscript{4}alkyl substituted with one, two or three halo atoms;
R\textsuperscript{9a} and R\textsuperscript{9b} each independently represent hydrogen or Ci\textsubscript{4}alkyl;
or a pharmaceutically acceptable addition salt or a solvate thereof;

provided that the following compounds, and pharmaceutically acceptable addition salts, and solvates thereof are excluded:
2. The compound according to claim 1, wherein

Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings, wherein optionally 1 or 2 ring carbon atoms are replaced by a nitrogen atom; provided that when the nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system;

Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, -OH, -NH₂, -NH-C₄alkyl, -N(C₁₋₄alkyl)₂, cyano, -CF₃, -C(=0)-NH-C₄alkyl, -C(=0)-C₄alkyl, Cl₄alkyloxy, and Cl₄alkyl optionally substituted with one -NR₁⁰aR₁⁰b;

Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1), (a-2) and (a-3):

![Diagram](image)

R¹a, R³b and R⁴c each independently represent hydrogen, halo, -NR⁷aR⁷b, or -0-C₄alkyl;

R⁷b represents hydrogen or C₄alkyl;

R⁴a, R⁴b and R⁴c each independently represent hydrogen, halo, -NR⁸aR⁸b, or Cl₄alkyl;

Q⁴ represents N or CR⁶d;

Q² represents N or CR⁶b;

Q³ represents N or CR⁶c;

Q⁴ represents N or CR⁶d;

provided that maximum one of Q³ and Q⁴ represents N;
R^3a, R^3b, R^3c, R^3d, R^3e and R^3f each independently represent hydrogen, halogen, Ci_4 alkyl, -NR^9aR^9b, or Ci_4 alkyl substituted with one, two or three halo atoms.

3. The compound according to claim 1, wherein

Ar represents a 10-membered bicyclic aromatic ring system consisting of two fused 6-membered rings,

wherein at least 1 ring carbon atom of ring B is replaced by a nitrogen atom; wherein optionally 1 additional ring carbon atom of ring A or ring B is replaced by a nitrogen atom; provided that when a nitrogen atom replaces one of the two fused carbon atoms, a carbonyl group is present in said bicyclic aromatic ring system; Ar is optionally substituted with one, two, three or four substituents each independently selected from the group consisting of halo, -OH, -NH_2, -NH-Ci_4 alkyl, -N(Ci_4 alkyl)_2, -NHR^10d, -NR^10d-R^10e, cyano, -CF_3, -C(=0)-NH_2, -C(=0)-NH-Ci_4 alkyl, -C(=0)-Ci_4 alkyl, Ci_4 alkyloxy, -C(=0)-0-Ci_4 alkyl, C_3-C_6 cycloalkyl, -0-C_3-C_6 cycloalkyl, -NH-C_3-C_6 cycloalkyl, -N(C_3-C_6 cycloalkyl)_2, C_2,6 alkenyl, Ci_4 alkyl substituted with one Ci_4 alkyloxy, and Ci_4 alkyl optionally substituted with one -NR^10d-R^10e.

4. The compound according to claim 1, wherein

R^1 represents hydrogen or -C(=0)-Ci_4 alkyl;
R^2 represents hydrogen or -C(=O)-Ci_4 alkyl;
Y represents -O; Z represents -X-CR^5aR^5b;
R^5a and R^5b each independently represent hydrogen or Ci_4 alkyl;
X represents -0 -S, -NR^11; R" represents hydrogen;

Ar represents

Ar is optionally substituted with one or two substituents each independently selected from the group consisting of halo, -OH, -NH_2, -NH-Ci_4 alkyl, -N(Ci_4 alkyl)_2, cyano, -CF_3, -C(=O)-NH-Ci_4 alkyl, -C(=O)-Ci_4 alkyl, Ci_4 alkyloxy, and Ci_4 alkyl optionally substituted with one -NR^10d-R^10e;

R^10a and R^10b each independently represent hydrogen or Ci_4 alkyl;
Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1);
R\textsuperscript{a} represents hydrogen, halo, -NR\textsuperscript{a}R\textsuperscript{b}, or -0-Ci\textsubscript{4}alkyl;  
R\textsuperscript{b} represents hydrogen;  
R\textsuperscript{4}a represents hydrogen, halo, -NR\textsuperscript{a}R\textsuperscript{b}, or Ci\textsubscript{4}alkyl;  
R\textsuperscript{8}a and R\textsuperscript{8}b each independently represent hydrogen or Ci\textsubscript{4}alkyl;  
Q\textsuperscript{1} represents CR\textsuperscript{6}a;  
Q\textsuperscript{2} represents CR\textsuperscript{6}b;  
R\textsuperscript{6}a and R\textsuperscript{6}b each independently represent hydrogen, halogen, Ci\textsubscript{4}alkyl, -NR\textsuperscript{a}R\textsuperscript{b}, or Ci\textsubscript{4}alkyl substituted with one, two or three halo atoms;  
R\textsuperscript{3}a and R\textsuperscript{9}b each independently represent hydrogen or Ci\textsubscript{4}alkyl.

5. The compound according to claim 1, wherein  
R\textsuperscript{1} represents hydrogen;  
R\textsuperscript{2} represents hydrogen;  
Y represents -O- or -CH\textsubscript{2}-;  
Z represents -X-CR\textsuperscript{5}aR\textsuperscript{5}b, -CR\textsuperscript{5}aR\textsuperscript{5}b, or -CR\textsuperscript{5}aR\textsuperscript{5}b-X-;  
and when Y represents -CH\textsubscript{2}-, then Z can also represent -CR\textsuperscript{5}aR\textsuperscript{5}b-X-;  
R\textsuperscript{3}a, R\textsuperscript{3}b, R\textsuperscript{5}a, R\textsuperscript{5}b, R\textsuperscript{5}b, and R\textsuperscript{5}b represent hydrogen;  
X represents -0-;  
Ar represents

\[
\begin{array}{c}
\text{\textsuperscript{a}} \\
\text{\textsuperscript{\beta}} \\
\end{array}
\]

wherein Ar is optionally substituted in the position indicated by \(a\) with a substituent selected from the group consisting of -NH\textsubscript{2}, -NH-Ci\textsubscript{4}alkyl, and -NHR\textsuperscript{10d}; and wherein Ar is optionally substituted in the position indicated by \(\beta\) with a substituent selected from the group consisting of halo and CF\textsubscript{3};  
provided however that Ar is substituted in at least one of the positions indicated by a or \(\beta\);  
R\textsuperscript{10d} represents C\textsubscript{3-6}cycloalkyl; Ci\textsubscript{4}alkyl substituted with one, two or three halo substituents; or Ci\textsubscript{4}alkyl substituted with one C\textsubscript{3-6}cycloalkyl substituent;  
Het represents a bicyclic aromatic heterocyclic ring system selected from the group consisting of (a-1) and (a-4);  
R\textsuperscript{3}a and R\textsuperscript{3}d each independently represent hydrogen, halo, -NR\textsuperscript{7}aR\textsuperscript{7}b, Ci\textsubscript{4}alkyl, or -0-Ci\textsubscript{4}alkyl;  
R\textsuperscript{7}a represents hydrogen;  
R\textsuperscript{7}b represents hydrogen or Ci\textsubscript{4}alkyl;
R^{1a}, R^{4d} and R^{4f} each independently represent hydrogen or halo;
Q^1 represents CR^{6a};
Q^2 represents CR^{6b};
Q^8 represents CR^{6g};
Q^9 represents CR^{6h};
Q^5 represents CR^{3d}; Q^6 represents N; and Q^7 represents CR^{4f},
R^{6a}, R^{6b}, R^{6g}, and R^{6h} represent hydrogen;

6. The compound according to any one of claims 1 to 4, wherein R^1 and R^2 represent hydrogen.

7. The compound according to any one of claims 1 to 3 and claims 5 to 6, wherein Y represents -0-.

8. The compound according any one of claims 1 to 3 and claims 5 to 7, wherein Het represents a bicyclic aromatic heterocyclic ring system of Formula (a-1).

9. The compound according to claim 8, wherein
R^{3a} represents -NR^7aR^7b; and R^7a and R^7b represent hydrogen.

10. The compound according to any one of claims 1 to 9, wherein
Ar represents

\[
\begin{array}{c}
\text{N} \\
\text{Ar}
\end{array}
\]

wherein Ar is substituted in the position indicated by \( \beta \) with a halo substituent.

11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to any one of claims 1 to 10.

12. A compound as defined in any one of claims 1 to 10 for use as a medicament.

13. A compound as defined in any one of claims 1 to 10 for use in the treatment or prevention of a disease or condition selected from a blood disorder, metabolic disorders, autoimmune disorders, cancer, inflammatory diseases, cardiovascular
diseases, neurodegenerative diseases, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection, and lung injuries.

14. The compound according to claim 13 wherein the disease or condition is an autoimmune disorder, cancer, inflammatory disease, or a neurodegenerative disease.

15. The compound according to claim 14 wherein the disease or condition is cancer.
## INTERNATIONAL SEARCH REPORT

**PCT/EP2016/070097**

### A. CLASSIFICATION OF SUBJECT MATTER

- INV. C07D471/04
- A61K31/519
- A61K31/53

**ADD.**

According to International Patent Classification (IPC) onto both national classification and IPC

### B. FIELDS SEARCHED

- Minimum documentation searched (classification system followed by classification symbols)
  - C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

- EPO-Internal, WPI Data

### C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>wo 03/074083 AI (PFIZER [US]; BLOOM LAURA ANNE [US]; BORITZKI THORDORE JAMES [US]; KUN) 12 September 2003 (2003-09-12) page 1, line 20 - page 4, line 25 page 122 - page 148; examples 2(G) (18), 2(G) (42), 2(G) (50), 2(F) (6) claim 1</td>
<td>1-15</td>
</tr>
</tbody>
</table>

* Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

**X** Further documents are listed in the continuation of Box C.

**X** See patent family annex.

*"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

**"X"** document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

**"Y"** document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

**"A"** document member of the same patent family

**Date of the actual completion of the international search**

- 30 September 2016

**Date of mailing of the international search report**

- 12/10/2016

**Name and mailing address of the ISA**

- European Patent Office, P.B. 5818 Patentlaan 2
- NL - 2280 HV Rijswijk
- Tel. (+31-70) 340-2040
- Fax: (+31-70) 340-3016

**Authorized officer**

- Bi ssmi re, Stewart
### Category

<table>
<thead>
<tr>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wo 2014/100719 A2 (EPIZYME INC [US]) 26 June 2014 (2014-06-26) abstract claim 1</td>
<td>1-15</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>WO 03074083 A1</td>
<td>12-09-2003</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>WO 2014100719 A2</td>
<td>26-06-2014</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>